,title,publish_time,journal,url,abstract,doi,cord_uid,words
617,Identification of a Highly Conserved H1 Subtype-Specific Epitope with Diagnostic Potential in the Hemagglutinin Protein of Influenza A Virus,2011-08-19,PLoS One,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3158760/,"Subtype specificity of influenza A virus (IAV) is determined by its two surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA). For HA, 16 distinct subtypes (H1–H16) exist, while nine exist for NA. The epidemic strains of H1N1 IAV change frequently and cause annual seasonal epidemics as well as occasional pandemics, such as the notorious 1918 influenza pandemic. The recent introduction of pandemic A/H1N1 IAV (H1N1pdm virus) into humans re-emphasizes the public health concern about H1N1 IAV. Several studies have identified conserved epitopes within specific HA subtypes that can be used for diagnostics. However, immune specific epitopes in H1N1 IAV have not been completely assessed. In this study, linear epitopes on the H1N1pdm viral HA protein were identified by peptide scanning using libraries of overlapping peptides against convalescent sera from H1N1pdm patients. One epitope, P5 (aa 58–72) was found to be immunodominant in patients and to evoke high titer antibodies in mice. Multiple sequence alignments and in silico coverage analysis showed that this epitope is highly conserved in influenza H1 HA [with a coverage of 91.6% (9,860/10,767)] and almost completely absent in other subtypes [with a coverage of 3.3% (792/23,895)]. This previously unidentified linear epitope is located outside the five well-recognized antigenic sites in HA. A peptide ELISA method based on this epitope was developed and showed high correlation (χ(2) = 51.81, P<0.01, Pearson correlation coefficient R = 0.741) with a hemagglutination inhibition test. The highly conserved H1 subtype-specific immunodominant epitope may form the basis for developing novel assays for sero-diagnosis and active surveillance against H1N1 IAVs.",10.1371/journal.pone.0023374,ff2zadol,"['Subtype', 'specificity', 'of', 'influenza', 'A', 'virus', 'IAV', 'is', 'determined', 'by', 'its', 'two', 'surface', 'glycoproteins', 'hemagglutinin', 'HA', 'and', 'neuraminidase', 'NA', 'For', 'HA', '16', 'distinct', 'subtypes', 'H1', 'H16', 'exist', 'while', 'nine', 'exist', 'for', 'NA', 'The', 'epidemic', 'strains', 'of', 'H1N1', 'IAV', 'change', 'frequently', 'and', 'cause', 'annual', 'seasonal', 'epidemics', 'as', 'well', 'as', 'occasional', 'pandemics', 'such', 'as', 'the', 'notorious', '1918', 'influenza', 'pandemic', 'The', 'recent', 'introduction', 'of', 'pandemic', 'A', 'H1N1', 'IAV', 'H1N1pdm', 'virus', 'into', 'humans', 're', 'emphasizes', 'the', 'public', 'health', 'concern', 'about', 'H1N1', 'IAV', 'Several', 'studies', 'have', 'identified', 'conserved', 'epitopes', 'within', 'specific', 'HA', 'subtypes', 'that', 'can', 'be', 'used', 'for', 'diagnostics', 'However', 'immune', 'specific', 'epitopes', 'in', 'H1N1', 'IAV', 'have', 'not', 'been', 'completely', 'assessed', 'In', 'this', 'study', 'linear', 'epitopes', 'on', 'the', 'H1N1pdm', 'viral', 'HA', 'protein', 'were', 'identified', 'by', 'peptide', 'scanning', 'using', 'libraries', 'of', 'overlapping', 'peptides', 'against', 'convalescent', 'sera', 'from', 'H1N1pdm', 'patients', 'One', 'epitope', 'P5', 'aa', '58', '72', 'was', 'found', 'to', 'be', 'immunodominant', 'in', 'patients', 'and', 'to', 'evoke', 'high', 'titer', 'antibodies', 'in', 'mice', 'Multiple', 'sequence', 'alignments', 'and', 'in', 'silico', 'coverage', 'analysis', 'showed', 'that', 'this', 'epitope', 'is', 'highly', 'conserved', 'in', 'influenza', 'H1', 'HA', 'with', 'a', 'coverage', 'of', '91', '6', '9', '860', '10', '767', 'and', 'almost', 'completely', 'absent', 'in', 'other', 'subtypes', 'with', 'a', 'coverage', 'of', '3', '3', '792', '23', '895', 'This', 'previously', 'unidentified', 'linear', 'epitope', 'is', 'located', 'outside', 'the', 'five', 'well', 'recognized', 'antigenic', 'sites', 'in', 'HA', 'A', 'peptide', 'ELISA', 'method', 'based', 'on', 'this', 'epitope', 'was', 'developed', 'and', 'showed', 'high', 'correlation', 'χ', '2', '51', '81', 'P', '0', '01', 'Pearson', 'correlation', 'coefficient', 'R', '0', '741', 'with', 'a', 'hemagglutination', 'inhibition', 'test', 'The', 'highly', 'conserved', 'H1', 'subtype', 'specific', 'immunodominant', 'epitope', 'may', 'form', 'the', 'basis', 'for', 'developing', 'novel', 'assays', 'for', 'sero', 'diagnosis', 'and', 'active', 'surveillance', 'against', 'H1N1', 'IAVs', '']"
1221,Expression of Recombinant Antibodies,2013-07-29,Front Immunol,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3725456/,"Recombinant antibodies are highly specific detection probes in research, diagnostics, and have emerged over the last two decades as the fastest growing class of therapeutic proteins. Antibody generation has been dramatically accelerated by in vitro selection systems, particularly phage display. An increasing variety of recombinant production systems have been developed, ranging from Gram-negative and positive bacteria, yeasts and filamentous fungi, insect cell lines, mammalian cells to transgenic plants and animals. Currently, almost all therapeutic antibodies are still produced in mammalian cell lines in order to reduce the risk of immunogenicity due to altered, non-human glycosylation patterns. However, recent developments of glycosylation-engineered yeast, insect cell lines, and transgenic plants are promising to obtain antibodies with “human-like” post-translational modifications. Furthermore, smaller antibody fragments including bispecific antibodies without any glycosylation are successfully produced in bacteria and have advanced to clinical testing. The first therapeutic antibody products from a non-mammalian source can be expected in coming next years. In this review, we focus on current antibody production systems including their usability for different applications.",10.3389/fimmu.2013.00217,06o7pa3d,"['Recombinant', 'antibodies', 'are', 'highly', 'specific', 'detection', 'probes', 'in', 'research', 'diagnostics', 'and', 'have', 'emerged', 'over', 'the', 'last', 'two', 'decades', 'as', 'the', 'fastest', 'growing', 'class', 'of', 'therapeutic', 'proteins', 'Antibody', 'generation', 'has', 'been', 'dramatically', 'accelerated', 'by', 'in', 'vitro', 'selection', 'systems', 'particularly', 'phage', 'display', 'An', 'increasing', 'variety', 'of', 'recombinant', 'production', 'systems', 'have', 'been', 'developed', 'ranging', 'from', 'Gram', 'negative', 'and', 'positive', 'bacteria', 'yeasts', 'and', 'filamentous', 'fungi', 'insect', 'cell', 'lines', 'mammalian', 'cells', 'to', 'transgenic', 'plants', 'and', 'animals', 'Currently', 'almost', 'all', 'therapeutic', 'antibodies', 'are', 'still', 'produced', 'in', 'mammalian', 'cell', 'lines', 'in', 'order', 'to', 'reduce', 'the', 'risk', 'of', 'immunogenicity', 'due', 'to', 'altered', 'non', 'human', 'glycosylation', 'patterns', 'However', 'recent', 'developments', 'of', 'glycosylation', 'engineered', 'yeast', 'insect', 'cell', 'lines', 'and', 'transgenic', 'plants', 'are', 'promising', 'to', 'obtain', 'antibodies', 'with', 'human', 'like', 'post', 'translational', 'modifications', 'Furthermore', 'smaller', 'antibody', 'fragments', 'including', 'bispecific', 'antibodies', 'without', 'any', 'glycosylation', 'are', 'successfully', 'produced', 'in', 'bacteria', 'and', 'have', 'advanced', 'to', 'clinical', 'testing', 'The', 'first', 'therapeutic', 'antibody', 'products', 'from', 'a', 'non', 'mammalian', 'source', 'can', 'be', 'expected', 'in', 'coming', 'next', 'years', 'In', 'this', 'review', 'we', 'focus', 'on', 'current', 'antibody', 'production', 'systems', 'including', 'their', 'usability', 'for', 'different', 'applications', '']"
1998,Antibody Derived Peptides for Detection of Ebola Virus Glycoprotein,2015-10-21,PLoS One,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619498/,"BACKGROUND: Current Ebola virus (EBOV) detection methods are costly and impractical for epidemic scenarios. Different immune-based assays have been reported for the detection and quantification of Ebola virus (EBOV) proteins. In particular, several monoclonal antibodies (mAbs) have been described that bind the capsid glycoprotein (GP) of EBOV GP. However, the currently available platforms for the design and production of full-length mAbs are cumbersome and costly. The use of antibody fragments, rather than full-length antibodies, might represent a cost-effective alternative for the development of diagnostic and possibly even therapeutic alternatives for EBOV. METHODS/PRINCIPAL FINDINGS: We report the design and expression of three recombinant anti-GP mAb fragments in Escherichia coli cultures. These fragments contained the heavy and light variable portions of the three well-studied anti-GP full-length mAbs 13C6, 13F6, and KZ52, and are consequently named scFv-13C6, scFv-13F6, and Fab-KZ52, respectively. All three fragments exhibited specific anti-GP binding activity in ELISA experiments comparable to that of full-length anti-GP antibodies (i.e., the same order of magnitude) and they are easily and economically produced in bacterial cultures. CONCLUSION/SIGNIFICANCE: Antibody fragments might represent a useful, effective, and low cost alternative to full-length antibodies in Ebola related capture and diagnostics applications.",10.1371/journal.pone.0135859,m31mb2kr,"['BACKGROUND', 'Current', 'Ebola', 'virus', 'EBOV', 'detection', 'methods', 'are', 'costly', 'and', 'impractical', 'for', 'epidemic', 'scenarios', 'Different', 'immune', 'based', 'assays', 'have', 'been', 'reported', 'for', 'the', 'detection', 'and', 'quantification', 'of', 'Ebola', 'virus', 'EBOV', 'proteins', 'In', 'particular', 'several', 'monoclonal', 'antibodies', 'mAbs', 'have', 'been', 'described', 'that', 'bind', 'the', 'capsid', 'glycoprotein', 'GP', 'of', 'EBOV', 'GP', 'However', 'the', 'currently', 'available', 'platforms', 'for', 'the', 'design', 'and', 'production', 'of', 'full', 'length', 'mAbs', 'are', 'cumbersome', 'and', 'costly', 'The', 'use', 'of', 'antibody', 'fragments', 'rather', 'than', 'full', 'length', 'antibodies', 'might', 'represent', 'a', 'cost', 'effective', 'alternative', 'for', 'the', 'development', 'of', 'diagnostic', 'and', 'possibly', 'even', 'therapeutic', 'alternatives', 'for', 'EBOV', 'METHODS', 'PRINCIPAL', 'FINDINGS', 'We', 'report', 'the', 'design', 'and', 'expression', 'of', 'three', 'recombinant', 'anti', 'GP', 'mAb', 'fragments', 'in', 'Escherichia', 'coli', 'cultures', 'These', 'fragments', 'contained', 'the', 'heavy', 'and', 'light', 'variable', 'portions', 'of', 'the', 'three', 'well', 'studied', 'anti', 'GP', 'full', 'length', 'mAbs', '13C6', '13F6', 'and', 'KZ52', 'and', 'are', 'consequently', 'named', 'scFv', '13C6', 'scFv', '13F6', 'and', 'Fab', 'KZ52', 'respectively', 'All', 'three', 'fragments', 'exhibited', 'specific', 'anti', 'GP', 'binding', 'activity', 'in', 'ELISA', 'experiments', 'comparable', 'to', 'that', 'of', 'full', 'length', 'anti', 'GP', 'antibodies', 'i', 'e', 'the', 'same', 'order', 'of', 'magnitude', 'and', 'they', 'are', 'easily', 'and', 'economically', 'produced', 'in', 'bacterial', 'cultures', 'CONCLUSION', 'SIGNIFICANCE', 'Antibody', 'fragments', 'might', 'represent', 'a', 'useful', 'effective', 'and', 'low', 'cost', 'alternative', 'to', 'full', 'length', 'antibodies', 'in', 'Ebola', 'related', 'capture', 'and', 'diagnostics', 'applications', '']"
2123,Identification of Novel Immunogenic Proteins of Neisseria gonorrhoeae by Phage Display,2016-02-09,PLoS One,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747489/,"Neisseria gonorrhoeae is one of the most prevalent sexually transmitted diseases worldwide with more than 100 million new infections per year. A lack of intense research over the last decades and increasing resistances to the recommended antibiotics call for a better understanding of gonococcal infection, fast diagnostics and therapeutic measures against N. gonorrhoeae. Therefore, the aim of this work was to identify novel immunogenic proteins as a first step to advance those unresolved problems. For the identification of immunogenic proteins, pHORF oligopeptide phage display libraries of the entire N. gonorrhoeae genome were constructed. Several immunogenic oligopeptides were identified using polyclonal rabbit antibodies against N. gonorrhoeae. Corresponding full-length proteins of the identified oligopeptides were expressed and their immunogenic character was verified by ELISA. The immunogenic character of six proteins was identified for the first time. Additional 13 proteins were verified as immunogenic proteins in N. gonorrhoeae.",10.1371/journal.pone.0148986,pfjies16,"['Neisseria', 'gonorrhoeae', 'is', 'one', 'of', 'the', 'most', 'prevalent', 'sexually', 'transmitted', 'diseases', 'worldwide', 'with', 'more', 'than', '100', 'million', 'new', 'infections', 'per', 'year', 'A', 'lack', 'of', 'intense', 'research', 'over', 'the', 'last', 'decades', 'and', 'increasing', 'resistances', 'to', 'the', 'recommended', 'antibiotics', 'call', 'for', 'a', 'better', 'understanding', 'of', 'gonococcal', 'infection', 'fast', 'diagnostics', 'and', 'therapeutic', 'measures', 'against', 'N', 'gonorrhoeae', 'Therefore', 'the', 'aim', 'of', 'this', 'work', 'was', 'to', 'identify', 'novel', 'immunogenic', 'proteins', 'as', 'a', 'first', 'step', 'to', 'advance', 'those', 'unresolved', 'problems', 'For', 'the', 'identification', 'of', 'immunogenic', 'proteins', 'pHORF', 'oligopeptide', 'phage', 'display', 'libraries', 'of', 'the', 'entire', 'N', 'gonorrhoeae', 'genome', 'were', 'constructed', 'Several', 'immunogenic', 'oligopeptides', 'were', 'identified', 'using', 'polyclonal', 'rabbit', 'antibodies', 'against', 'N', 'gonorrhoeae', 'Corresponding', 'full', 'length', 'proteins', 'of', 'the', 'identified', 'oligopeptides', 'were', 'expressed', 'and', 'their', 'immunogenic', 'character', 'was', 'verified', 'by', 'ELISA', 'The', 'immunogenic', 'character', 'of', 'six', 'proteins', 'was', 'identified', 'for', 'the', 'first', 'time', 'Additional', '13', 'proteins', 'were', 'verified', 'as', 'immunogenic', 'proteins', 'in', 'N', 'gonorrhoeae', '']"
2655,Antibody Engineering for Pursuing a Healthier Future,2017-03-28,Front Microbiol,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368232/,"Since the development of antibody-production techniques, a number of immunoglobulins have been developed on a large scale using conventional methods. Hybridoma technology opened a new horizon in the production of antibodies against target antigens of infectious pathogens, malignant diseases including autoimmune disorders, and numerous potent toxins. However, these clinical humanized or chimeric murine antibodies have several limitations and complexities. Therefore, to overcome these difficulties, recent advances in genetic engineering techniques and phage display technique have allowed the production of highly specific recombinant antibodies. These engineered antibodies have been constructed in the hunt for novel therapeutic drugs equipped with enhanced immunoprotective abilities, such as engaging immune effector functions, effective development of fusion proteins, efficient tumor and tissue penetration, and high-affinity antibodies directed against conserved targets. Advanced antibody engineering techniques have extensive applications in the fields of immunology, biotechnology, diagnostics, and therapeutic medicines. However, there is limited knowledge regarding dynamic antibody development approaches. Therefore, this review extends beyond our understanding of conventional polyclonal and monoclonal antibodies. Furthermore, recent advances in antibody engineering techniques together with antibody fragments, display technologies, immunomodulation, and broad applications of antibodies are discussed to enhance innovative antibody production in pursuit of a healthier future for humans.",10.3389/fmicb.2017.00495,0fegsm1v,"['Since', 'the', 'development', 'of', 'antibody', 'production', 'techniques', 'a', 'number', 'of', 'immunoglobulins', 'have', 'been', 'developed', 'on', 'a', 'large', 'scale', 'using', 'conventional', 'methods', 'Hybridoma', 'technology', 'opened', 'a', 'new', 'horizon', 'in', 'the', 'production', 'of', 'antibodies', 'against', 'target', 'antigens', 'of', 'infectious', 'pathogens', 'malignant', 'diseases', 'including', 'autoimmune', 'disorders', 'and', 'numerous', 'potent', 'toxins', 'However', 'these', 'clinical', 'humanized', 'or', 'chimeric', 'murine', 'antibodies', 'have', 'several', 'limitations', 'and', 'complexities', 'Therefore', 'to', 'overcome', 'these', 'difficulties', 'recent', 'advances', 'in', 'genetic', 'engineering', 'techniques', 'and', 'phage', 'display', 'technique', 'have', 'allowed', 'the', 'production', 'of', 'highly', 'specific', 'recombinant', 'antibodies', 'These', 'engineered', 'antibodies', 'have', 'been', 'constructed', 'in', 'the', 'hunt', 'for', 'novel', 'therapeutic', 'drugs', 'equipped', 'with', 'enhanced', 'immunoprotective', 'abilities', 'such', 'as', 'engaging', 'immune', 'effector', 'functions', 'effective', 'development', 'of', 'fusion', 'proteins', 'efficient', 'tumor', 'and', 'tissue', 'penetration', 'and', 'high', 'affinity', 'antibodies', 'directed', 'against', 'conserved', 'targets', 'Advanced', 'antibody', 'engineering', 'techniques', 'have', 'extensive', 'applications', 'in', 'the', 'fields', 'of', 'immunology', 'biotechnology', 'diagnostics', 'and', 'therapeutic', 'medicines', 'However', 'there', 'is', 'limited', 'knowledge', 'regarding', 'dynamic', 'antibody', 'development', 'approaches', 'Therefore', 'this', 'review', 'extends', 'beyond', 'our', 'understanding', 'of', 'conventional', 'polyclonal', 'and', 'monoclonal', 'antibodies', 'Furthermore', 'recent', 'advances', 'in', 'antibody', 'engineering', 'techniques', 'together', 'with', 'antibody', 'fragments', 'display', 'technologies', 'immunomodulation', 'and', 'broad', 'applications', 'of', 'antibodies', 'are', 'discussed', 'to', 'enhance', 'innovative', 'antibody', 'production', 'in', 'pursuit', 'of', 'a', 'healthier', 'future', 'for', 'humans', '']"
4706,Diagnostic accuracy and utility of three dengue diagnostic tests for the diagnosis of acute dengue infection in Malaysia,2020-03-12,BMC Infect Dis,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069157/,"BACKGROUND: Dengue is an emerging infectious disease that infects up to 390 million people yearly. The growing demand of dengue diagnostics especially in low-resource settings gave rise to many rapid diagnostic tests (RDT). This study evaluated the accuracy and utility of ViroTrack Dengue Acute - a new biosensors-based dengue NS1 RDT, SD Bioline Dengue Duo NS1/IgM/IgG combo - a commercially available RDT, and SD Dengue NS1 Ag enzyme-linked immunosorbent assay (ELISA), for the diagnosis of acute dengue infection. METHODS: This prospective cross-sectional study consecutively recruited 494 patients with suspected dengue from a health clinic in Malaysia. Both RDTs were performed onsite. The evaluated ELISA and reference tests were performed in a virology laboratory. The reference tests comprised of a reverse transcription-polymerase chain reaction and three ELISAs for the detection of dengue NS1 antigen, IgM and IgG antibodies, respectively. The diagnostic performance of evaluated tests was computed using STATA version 12. RESULTS: The sensitivity and specificity of ViroTrack were 62.3% (95%CI 55.6–68.7) and 95.0% (95%CI 91.7–97.3), versus 66.5% (95%CI 60.0–72.6) and 95.4% (95%CI 92.1–97.6) for SD NS1 ELISA, and 52.4% (95%CI 45.7–59.1) and 97.7% (95%CI 95.1–99.2) for NS1 component of SD Bioline, respectively. The combination of the latter with its IgM and IgG components were able to increase test sensitivity to 82.4% (95%CI 76.8–87.1) with corresponding decrease in specificity to 87.4% (95%CI 82.8–91.2). Although a positive test on any of the NS1 assays would increase the probability of dengue to above 90% in a patient, a negative result would only reduce this probability to 23.0–29.3%. In contrast, this probability of false negative diagnosis would be further reduced to 14.7% (95%CI 11.4–18.6) if SD Bioline NS1/IgM/IgG combo was negative. CONCLUSIONS: The performance of ViroTrack Dengue Acute was comparable to SD Dengue NS1 Ag ELISA. Addition of serology components to SD Bioline Dengue Duo significantly improved its sensitivity and reduced its false negative rate such that it missed the fewest dengue patients, making it a better point-of-care diagnostic tool. New RDT like ViroTrack Dengue Acute may be a potential alternative to existing RDT if its combination with serology components is proven better in future studies.",10.1186/s12879-020-4911-5,r50atew9,"['BACKGROUND', 'Dengue', 'is', 'an', 'emerging', 'infectious', 'disease', 'that', 'infects', 'up', 'to', '390', 'million', 'people', 'yearly', 'The', 'growing', 'demand', 'of', 'dengue', 'diagnostics', 'especially', 'in', 'low', 'resource', 'settings', 'gave', 'rise', 'to', 'many', 'rapid', 'diagnostic', 'tests', 'RDT', 'This', 'study', 'evaluated', 'the', 'accuracy', 'and', 'utility', 'of', 'ViroTrack', 'Dengue', 'Acute', 'a', 'new', 'biosensors', 'based', 'dengue', 'NS1', 'RDT', 'SD', 'Bioline', 'Dengue', 'Duo', 'NS1', 'IgM', 'IgG', 'combo', 'a', 'commercially', 'available', 'RDT', 'and', 'SD', 'Dengue', 'NS1', 'Ag', 'enzyme', 'linked', 'immunosorbent', 'assay', 'ELISA', 'for', 'the', 'diagnosis', 'of', 'acute', 'dengue', 'infection', 'METHODS', 'This', 'prospective', 'cross', 'sectional', 'study', 'consecutively', 'recruited', '494', 'patients', 'with', 'suspected', 'dengue', 'from', 'a', 'health', 'clinic', 'in', 'Malaysia', 'Both', 'RDTs', 'were', 'performed', 'onsite', 'The', 'evaluated', 'ELISA', 'and', 'reference', 'tests', 'were', 'performed', 'in', 'a', 'virology', 'laboratory', 'The', 'reference', 'tests', 'comprised', 'of', 'a', 'reverse', 'transcription', 'polymerase', 'chain', 'reaction', 'and', 'three', 'ELISAs', 'for', 'the', 'detection', 'of', 'dengue', 'NS1', 'antigen', 'IgM', 'and', 'IgG', 'antibodies', 'respectively', 'The', 'diagnostic', 'performance', 'of', 'evaluated', 'tests', 'was', 'computed', 'using', 'STATA', 'version', '12', 'RESULTS', 'The', 'sensitivity', 'and', 'specificity', 'of', 'ViroTrack', 'were', '62', '3', '95', 'CI', '55', '6', '68', '7', 'and', '95', '0', '95', 'CI', '91', '7', '97', '3', 'versus', '66', '5', '95', 'CI', '60', '0', '72', '6', 'and', '95', '4', '95', 'CI', '92', '1', '97', '6', 'for', 'SD', 'NS1', 'ELISA', 'and', '52', '4', '95', 'CI', '45', '7', '59', '1', 'and', '97', '7', '95', 'CI', '95', '1', '99', '2', 'for', 'NS1', 'component', 'of', 'SD', 'Bioline', 'respectively', 'The', 'combination', 'of', 'the', 'latter', 'with', 'its', 'IgM', 'and', 'IgG', 'components', 'were', 'able', 'to', 'increase', 'test', 'sensitivity', 'to', '82', '4', '95', 'CI', '76', '8', '87', '1', 'with', 'corresponding', 'decrease', 'in', 'specificity', 'to', '87', '4', '95', 'CI', '82', '8', '91', '2', 'Although', 'a', 'positive', 'test', 'on', 'any', 'of', 'the', 'NS1', 'assays', 'would', 'increase', 'the', 'probability', 'of', 'dengue', 'to', 'above', '90', 'in', 'a', 'patient', 'a', 'negative', 'result', 'would', 'only', 'reduce', 'this', 'probability', 'to', '23', '0', '29', '3', 'In', 'contrast', 'this', 'probability', 'of', 'false', 'negative', 'diagnosis', 'would', 'be', 'further', 'reduced', 'to', '14', '7', '95', 'CI', '11', '4', '18', '6', 'if', 'SD', 'Bioline', 'NS1', 'IgM', 'IgG', 'combo', 'was', 'negative', 'CONCLUSIONS', 'The', 'performance', 'of', 'ViroTrack', 'Dengue', 'Acute', 'was', 'comparable', 'to', 'SD', 'Dengue', 'NS1', 'Ag', 'ELISA', 'Addition', 'of', 'serology', 'components', 'to', 'SD', 'Bioline', 'Dengue', 'Duo', 'significantly', 'improved', 'its', 'sensitivity', 'and', 'reduced', 'its', 'false', 'negative', 'rate', 'such', 'that', 'it', 'missed', 'the', 'fewest', 'dengue', 'patients', 'making', 'it', 'a', 'better', 'point', 'of', 'care', 'diagnostic', 'tool', 'New', 'RDT', 'like', 'ViroTrack', 'Dengue', 'Acute', 'may', 'be', 'a', 'potential', 'alternative', 'to', 'existing', 'RDT', 'if', 'its', 'combination', 'with', 'serology', 'components', 'is', 'proven', 'better', 'in', 'future', 'studies', '']"
4820,Automated analytical microarrays: a critical review,2008-05-27,Anal Bioanal Chem,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7080066/,"Microarrays provide a powerful analytical tool for the simultaneous detection of multiple analytes in a single experiment. The specific affinity reaction of nucleic acids (hybridization) and antibodies towards antigens is the most common bioanalytical method for generating multiplexed quantitative results. Nucleic acid-based analysis is restricted to the detection of cells and viruses. Antibodies are more universal biomolecular receptors that selectively bind small molecules such as pesticides, small toxins, and pharmaceuticals and to biopolymers (e.g. toxins, allergens) and complex biological structures like bacterial cells and viruses. By producing an appropriate antibody, the corresponding antigenic analyte can be detected on a multiplexed immunoanalytical microarray. Food and water analysis along with clinical diagnostics constitute potential application fields for multiplexed analysis. Diverse fluorescence, chemiluminescence, electrochemical, and label-free microarray readout systems have been developed in the last decade. Some of them are constructed as flow-through microarrays by combination with a fluidic system. Microarrays have the potential to become widely accepted as a system for analytical applications, provided that robust and validated results on fully automated platforms are successfully generated. This review gives an overview of the current research on microarrays with the focus on automated systems and quantitative multiplexed applications. [Figure: see text]",10.1007/s00216-008-2039-3,5lk0mts4,"['Microarrays', 'provide', 'a', 'powerful', 'analytical', 'tool', 'for', 'the', 'simultaneous', 'detection', 'of', 'multiple', 'analytes', 'in', 'a', 'single', 'experiment', 'The', 'specific', 'affinity', 'reaction', 'of', 'nucleic', 'acids', 'hybridization', 'and', 'antibodies', 'towards', 'antigens', 'is', 'the', 'most', 'common', 'bioanalytical', 'method', 'for', 'generating', 'multiplexed', 'quantitative', 'results', 'Nucleic', 'acid', 'based', 'analysis', 'is', 'restricted', 'to', 'the', 'detection', 'of', 'cells', 'and', 'viruses', 'Antibodies', 'are', 'more', 'universal', 'biomolecular', 'receptors', 'that', 'selectively', 'bind', 'small', 'molecules', 'such', 'as', 'pesticides', 'small', 'toxins', 'and', 'pharmaceuticals', 'and', 'to', 'biopolymers', 'e', 'g', 'toxins', 'allergens', 'and', 'complex', 'biological', 'structures', 'like', 'bacterial', 'cells', 'and', 'viruses', 'By', 'producing', 'an', 'appropriate', 'antibody', 'the', 'corresponding', 'antigenic', 'analyte', 'can', 'be', 'detected', 'on', 'a', 'multiplexed', 'immunoanalytical', 'microarray', 'Food', 'and', 'water', 'analysis', 'along', 'with', 'clinical', 'diagnostics', 'constitute', 'potential', 'application', 'fields', 'for', 'multiplexed', 'analysis', 'Diverse', 'fluorescence', 'chemiluminescence', 'electrochemical', 'and', 'label', 'free', 'microarray', 'readout', 'systems', 'have', 'been', 'developed', 'in', 'the', 'last', 'decade', 'Some', 'of', 'them', 'are', 'constructed', 'as', 'flow', 'through', 'microarrays', 'by', 'combination', 'with', 'a', 'fluidic', 'system', 'Microarrays', 'have', 'the', 'potential', 'to', 'become', 'widely', 'accepted', 'as', 'a', 'system', 'for', 'analytical', 'applications', 'provided', 'that', 'robust', 'and', 'validated', 'results', 'on', 'fully', 'automated', 'platforms', 'are', 'successfully', 'generated', 'This', 'review', 'gives', 'an', 'overview', 'of', 'the', 'current', 'research', 'on', 'microarrays', 'with', 'the', 'focus', 'on', 'automated', 'systems', 'and', 'quantitative', 'multiplexed', 'applications', 'Figure', 'see', 'text', '']"
5730,Antibody epitope repertoire analysis enables rapid antigen discovery and multiplex serology,2020-03-24,Sci Rep,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7093460/,"The detection of pathogen-specific antibodies remains a cornerstone of clinical diagnostics. Yet, many test exhibit undesirable performance or are completely lacking. Given this, we developed serum epitope repertoire analysis (SERA), a method to rapidly discover conserved, pathogen-specific antigens and their epitopes, and applied it to develop an assay for Chagas disease caused by the protozoan parasite Trypanosoma cruzi. Antibody binding peptide motifs were identified from 28 Chagas repertoires using a bacterial display random 12-mer peptide library and next-generation sequencing (NGS). Thirty-three motifs were selected and mapped to candidate Chagas antigens. In a blinded validation set (n = 72), 30/30 Chagas were positive, 30/30 non-Chagas were negative, and 1/12 Leishmania sp. was positive. After unblinding, a Leishmania cross-reactive epitope was identified and removed from the panel. The Chagas assay exhibited 100% sensitivity (30/30) and specificity (90/90) in a second blinded validation set including individuals with other parasitic infections. Amongst additional epitope repertoires with unknown Chagas serostatus, assay specificity was 99.8% (998/1000). Thus, the Chagas assay achieved a combined sensitivity and specificity equivalent or superior to diagnostic algorithms that rely on three separate tests to achieve high specificity. NGS-based serology via SERA provides an effective approach to discover antigenic epitopes and develop high performance multiplex serological assays.",10.1038/s41598-020-62256-9,equnyib7,"['The', 'detection', 'of', 'pathogen', 'specific', 'antibodies', 'remains', 'a', 'cornerstone', 'of', 'clinical', 'diagnostics', 'Yet', 'many', 'test', 'exhibit', 'undesirable', 'performance', 'or', 'are', 'completely', 'lacking', 'Given', 'this', 'we', 'developed', 'serum', 'epitope', 'repertoire', 'analysis', 'SERA', 'a', 'method', 'to', 'rapidly', 'discover', 'conserved', 'pathogen', 'specific', 'antigens', 'and', 'their', 'epitopes', 'and', 'applied', 'it', 'to', 'develop', 'an', 'assay', 'for', 'Chagas', 'disease', 'caused', 'by', 'the', 'protozoan', 'parasite', 'Trypanosoma', 'cruzi', 'Antibody', 'binding', 'peptide', 'motifs', 'were', 'identified', 'from', '28', 'Chagas', 'repertoires', 'using', 'a', 'bacterial', 'display', 'random', '12', 'mer', 'peptide', 'library', 'and', 'next', 'generation', 'sequencing', 'NGS', 'Thirty', 'three', 'motifs', 'were', 'selected', 'and', 'mapped', 'to', 'candidate', 'Chagas', 'antigens', 'In', 'a', 'blinded', 'validation', 'set', 'n', '72', '30', '30', 'Chagas', 'were', 'positive', '30', '30', 'non', 'Chagas', 'were', 'negative', 'and', '1', '12', 'Leishmania', 'sp', 'was', 'positive', 'After', 'unblinding', 'a', 'Leishmania', 'cross', 'reactive', 'epitope', 'was', 'identified', 'and', 'removed', 'from', 'the', 'panel', 'The', 'Chagas', 'assay', 'exhibited', '100', 'sensitivity', '30', '30', 'and', 'specificity', '90', '90', 'in', 'a', 'second', 'blinded', 'validation', 'set', 'including', 'individuals', 'with', 'other', 'parasitic', 'infections', 'Amongst', 'additional', 'epitope', 'repertoires', 'with', 'unknown', 'Chagas', 'serostatus', 'assay', 'specificity', 'was', '99', '8', '998', '1000', 'Thus', 'the', 'Chagas', 'assay', 'achieved', 'a', 'combined', 'sensitivity', 'and', 'specificity', 'equivalent', 'or', 'superior', 'to', 'diagnostic', 'algorithms', 'that', 'rely', 'on', 'three', 'separate', 'tests', 'to', 'achieve', 'high', 'specificity', 'NGS', 'based', 'serology', 'via', 'SERA', 'provides', 'an', 'effective', 'approach', 'to', 'discover', 'antigenic', 'epitopes', 'and', 'develop', 'high', 'performance', 'multiplex', 'serological', 'assays', '']"
6172,Verbreitung von Hantavirusinfektionen in Deutschland,2004,Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095999/,"Hantaviruses belong to the group of “emerging” viruses. Pathogenic European hantaviruses can cause a human disease designated “hemorrhagic fever with renal syndrome” of varying severity. In general, diagnostics of hantavirus infections are based on immunofluorescence assays using virus-infected cells or enzyme immunoassays and Western blot tests using recombinant nucleocapsid proteins. For highly sensitive detection of hantavirus-specific antibodies in the enzyme immunoassay, a homologous hantavirus nucleocapsid protein is needed as a diagnostic antigen. Serological typing of hantavirus infections can be obtained by neutralization assays, which in certain cases require the use of late convalescent sera. The seroprevalence in the normal German population is about 1%. In professionally exposed risk groups, e. g., forest workers, a seroprevalence higher than that in the normal population was observed. Endemic regions for hantavirus infections are located mainly in Baden-Württemberg. In the years 2001–2003 an annual number of about 200 clinically apparent hantavirus infections were registered in Germany. Neutralization assays detected almost exclusively human infections caused by Puumala and Dobrava viruses, only very rarely by Tula virus. Until this day in Germany mainly mild to moderate courses of human hantavirus infections have been documented. Besides infections caused by “German” hantaviruses, up to 10% of the clinically apparent hantavirus infections registered annually in Germany are caused by infections imported from other countries, mainly from Europe. So far only very limited molecular genetic data about the circulating hantaviruses in Germany are available. Additional investigations are needed to get a more precise picture about the distribution of hantaviruses in Germany and to calculate the resulting risk for the human population.",10.1007/s00103-004-0858-8,gfir11bf,"['Hantaviruses', 'belong', 'to', 'the', 'group', 'of', 'emerging', 'viruses', 'Pathogenic', 'European', 'hantaviruses', 'can', 'cause', 'a', 'human', 'disease', 'designated', 'hemorrhagic', 'fever', 'with', 'renal', 'syndrome', 'of', 'varying', 'severity', 'In', 'general', 'diagnostics', 'of', 'hantavirus', 'infections', 'are', 'based', 'on', 'immunofluorescence', 'assays', 'using', 'virus', 'infected', 'cells', 'or', 'enzyme', 'immunoassays', 'and', 'Western', 'blot', 'tests', 'using', 'recombinant', 'nucleocapsid', 'proteins', 'For', 'highly', 'sensitive', 'detection', 'of', 'hantavirus', 'specific', 'antibodies', 'in', 'the', 'enzyme', 'immunoassay', 'a', 'homologous', 'hantavirus', 'nucleocapsid', 'protein', 'is', 'needed', 'as', 'a', 'diagnostic', 'antigen', 'Serological', 'typing', 'of', 'hantavirus', 'infections', 'can', 'be', 'obtained', 'by', 'neutralization', 'assays', 'which', 'in', 'certain', 'cases', 'require', 'the', 'use', 'of', 'late', 'convalescent', 'sera', 'The', 'seroprevalence', 'in', 'the', 'normal', 'German', 'population', 'is', 'about', '1', 'In', 'professionally', 'exposed', 'risk', 'groups', 'e', 'g', 'forest', 'workers', 'a', 'seroprevalence', 'higher', 'than', 'that', 'in', 'the', 'normal', 'population', 'was', 'observed', 'Endemic', 'regions', 'for', 'hantavirus', 'infections', 'are', 'located', 'mainly', 'in', 'Baden', 'Württemberg', 'In', 'the', 'years', '2001', '2003', 'an', 'annual', 'number', 'of', 'about', '200', 'clinically', 'apparent', 'hantavirus', 'infections', 'were', 'registered', 'in', 'Germany', 'Neutralization', 'assays', 'detected', 'almost', 'exclusively', 'human', 'infections', 'caused', 'by', 'Puumala', 'and', 'Dobrava', 'viruses', 'only', 'very', 'rarely', 'by', 'Tula', 'virus', 'Until', 'this', 'day', 'in', 'Germany', 'mainly', 'mild', 'to', 'moderate', 'courses', 'of', 'human', 'hantavirus', 'infections', 'have', 'been', 'documented', 'Besides', 'infections', 'caused', 'by', 'German', 'hantaviruses', 'up', 'to', '10', 'of', 'the', 'clinically', 'apparent', 'hantavirus', 'infections', 'registered', 'annually', 'in', 'Germany', 'are', 'caused', 'by', 'infections', 'imported', 'from', 'other', 'countries', 'mainly', 'from', 'Europe', 'So', 'far', 'only', 'very', 'limited', 'molecular', 'genetic', 'data', 'about', 'the', 'circulating', 'hantaviruses', 'in', 'Germany', 'are', 'available', 'Additional', 'investigations', 'are', 'needed', 'to', 'get', 'a', 'more', 'precise', 'picture', 'about', 'the', 'distribution', 'of', 'hantaviruses', 'in', 'Germany', 'and', 'to', 'calculate', 'the', 'resulting', 'risk', 'for', 'the', 'human', 'population', '']"
7020,Endemic Mycoses: What’s New About Old Diseases?,2016-03-18,Curr Clin Microbiol Rep,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102464/,"Infections with geographically constrained dimorphic fungi cause the endemic mycoses, which include blastomycosis, coccidioidomycosis, emmonsiosis, histoplasmosis, paracoccidioidomycosis, sporotrichosis, and penicilliosis. In the last 5 years, our understanding of the epidemiology, diagnostics, and to a lesser extent management of these diseases has advanced. Specifically, the application of molecular techniques for genotyping fungal pathogens has resulted in the recognition of cryptic species within several genera, including Blastomyces, and Paracoccidioides; the reclassification of Penicillium marneffei, the agent of penicilliosis, to the genus Talaromyces; and the global emergence of dimorphic fungi of the genus Emmonsia, cause disease in immunocompromised persons. New and refined diagnostic tests are available based on the detection of circulating antigens and antibodies, mass spectrometry, and targeted gene amplification. In contrast, the development of new therapeutic options remains stalled, although isavuconazole may hold promise. Finally, advances have been made in the prospect of viable vaccines for preventing animal and human disease.",10.1007/s40588-016-0034-6,hrsk5l73,"['Infections', 'with', 'geographically', 'constrained', 'dimorphic', 'fungi', 'cause', 'the', 'endemic', 'mycoses', 'which', 'include', 'blastomycosis', 'coccidioidomycosis', 'emmonsiosis', 'histoplasmosis', 'paracoccidioidomycosis', 'sporotrichosis', 'and', 'penicilliosis', 'In', 'the', 'last', '5', 'years', 'our', 'understanding', 'of', 'the', 'epidemiology', 'diagnostics', 'and', 'to', 'a', 'lesser', 'extent', 'management', 'of', 'these', 'diseases', 'has', 'advanced', 'Specifically', 'the', 'application', 'of', 'molecular', 'techniques', 'for', 'genotyping', 'fungal', 'pathogens', 'has', 'resulted', 'in', 'the', 'recognition', 'of', 'cryptic', 'species', 'within', 'several', 'genera', 'including', 'Blastomyces', 'and', 'Paracoccidioides', 'the', 'reclassification', 'of', 'Penicillium', 'marneffei', 'the', 'agent', 'of', 'penicilliosis', 'to', 'the', 'genus', 'Talaromyces', 'and', 'the', 'global', 'emergence', 'of', 'dimorphic', 'fungi', 'of', 'the', 'genus', 'Emmonsia', 'cause', 'disease', 'in', 'immunocompromised', 'persons', 'New', 'and', 'refined', 'diagnostic', 'tests', 'are', 'available', 'based', 'on', 'the', 'detection', 'of', 'circulating', 'antigens', 'and', 'antibodies', 'mass', 'spectrometry', 'and', 'targeted', 'gene', 'amplification', 'In', 'contrast', 'the', 'development', 'of', 'new', 'therapeutic', 'options', 'remains', 'stalled', 'although', 'isavuconazole', 'may', 'hold', 'promise', 'Finally', 'advances', 'have', 'been', 'made', 'in', 'the', 'prospect', 'of', 'viable', 'vaccines', 'for', 'preventing', 'animal', 'and', 'human', 'disease', '']"
8803,Application of monoclonal antibodies in animal production: A review,2003-10-02,Livest,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7131807/,"The hybridoma technology for production of monoclonal antibodies circumvents many of the constraints associated with the use of conventional antisera, and consequently broadens the areas of application of antibodies in animal sciences. In the present review, the potential usefulness of monoclonal antibodies in animal production - with emphasis on reproduction - is discussed, including the inherent limitations of the current technology and the improvements that can be foreseen within the next few years. Because of their unique specificity and the fact that they can be produced in virtually unlimited quantities, monoclonal antibodies are an important tool in diagnostics. However, the use of these antibodies does not always guarantee absolute specificity, and the low affinity of many monoclonal antibodies will impose a number of limitations on their use. Monoclonal antibodies can also be used to optimize physiological processes such as growth and reproduction. For this, homologous antibodies will probably offer several advantages over their murine counterparts in terms of effectiveness for passive immunization. Some success has already been achieved in the development of monoclonal antibodies from livestock species. Finally, it is shown that monoclonal antibodies are becoming extremely powerful research tools.",10.1016/0301-6226(88)90032-2,ye0tvnnf,"['The', 'hybridoma', 'technology', 'for', 'production', 'of', 'monoclonal', 'antibodies', 'circumvents', 'many', 'of', 'the', 'constraints', 'associated', 'with', 'the', 'use', 'of', 'conventional', 'antisera', 'and', 'consequently', 'broadens', 'the', 'areas', 'of', 'application', 'of', 'antibodies', 'in', 'animal', 'sciences', 'In', 'the', 'present', 'review', 'the', 'potential', 'usefulness', 'of', 'monoclonal', 'antibodies', 'in', 'animal', 'production', 'with', 'emphasis', 'on', 'reproduction', 'is', 'discussed', 'including', 'the', 'inherent', 'limitations', 'of', 'the', 'current', 'technology', 'and', 'the', 'improvements', 'that', 'can', 'be', 'foreseen', 'within', 'the', 'next', 'few', 'years', 'Because', 'of', 'their', 'unique', 'specificity', 'and', 'the', 'fact', 'that', 'they', 'can', 'be', 'produced', 'in', 'virtually', 'unlimited', 'quantities', 'monoclonal', 'antibodies', 'are', 'an', 'important', 'tool', 'in', 'diagnostics', 'However', 'the', 'use', 'of', 'these', 'antibodies', 'does', 'not', 'always', 'guarantee', 'absolute', 'specificity', 'and', 'the', 'low', 'affinity', 'of', 'many', 'monoclonal', 'antibodies', 'will', 'impose', 'a', 'number', 'of', 'limitations', 'on', 'their', 'use', 'Monoclonal', 'antibodies', 'can', 'also', 'be', 'used', 'to', 'optimize', 'physiological', 'processes', 'such', 'as', 'growth', 'and', 'reproduction', 'For', 'this', 'homologous', 'antibodies', 'will', 'probably', 'offer', 'several', 'advantages', 'over', 'their', 'murine', 'counterparts', 'in', 'terms', 'of', 'effectiveness', 'for', 'passive', 'immunization', 'Some', 'success', 'has', 'already', 'been', 'achieved', 'in', 'the', 'development', 'of', 'monoclonal', 'antibodies', 'from', 'livestock', 'species', 'Finally', 'it', 'is', 'shown', 'that', 'monoclonal', 'antibodies', 'are', 'becoming', 'extremely', 'powerful', 'research', 'tools', '']"
15784,"Genomics, Other “Omic” Technologies, Personalized Medicine, and Additional Biotechnology-Related Techniques",2013-08-27,Pharmaceutical Biotechnology,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7122419/,"The products resulting for biotechnologies continue to grow at an exponential rate, and the expectations are that an even greater percentage of drug development will be in the area of the biologics. In 2011, worldwide there were over 800 new biotech drugs and treatments in development including 23 antisense, 64 cell therapy, 50 gene therapy, 300 monoclonal antibodies, 78 recombinant proteins, and 298 vaccines (PhRMA 2012). Pharmaceutical biotechnology techniques are at the core of most methodologies used today for drug discovery and development of both biologics and small molecules. While recombinant DNA technology and hybridoma techniques were the major methods utilized in pharmaceutical biotechnology through most of its historical timeline, our ever-widening understanding of human cellular function and disease processes and a wealth of additional and innovative biotechnologies have been, and will continue to be, developed in order to harvest the information found in the human genome. These technological advances will provide a better understanding of the relationship between genetics and biological function, unravel the underlying causes of disease, explore the association of genomic variation and drug response, enhance pharmaceutical research, and fuel the discovery and development of new and novel biopharmaceuticals. These revolutionary technologies and additional biotechnology-related techniques are improving the very competitive and costly process of drug development of new medicinal agents, diagnostics, and medical devices. Some of the technologies and techniques described in this chapter are both well established and commonly used applications of biotechnology producing potential therapeutic products now in development including clinical trials. New techniques are emerging at a rapid and unprecedented pace and their full impact on the future of molecular medicine has yet to be imagined.",10.1007/978-1-4614-6486-0_8,j8bdb3qy,"['The', 'products', 'resulting', 'for', 'biotechnologies', 'continue', 'to', 'grow', 'at', 'an', 'exponential', 'rate', 'and', 'the', 'expectations', 'are', 'that', 'an', 'even', 'greater', 'percentage', 'of', 'drug', 'development', 'will', 'be', 'in', 'the', 'area', 'of', 'the', 'biologics', 'In', '2011', 'worldwide', 'there', 'were', 'over', '800', 'new', 'biotech', 'drugs', 'and', 'treatments', 'in', 'development', 'including', '23', 'antisense', '64', 'cell', 'therapy', '50', 'gene', 'therapy', '300', 'monoclonal', 'antibodies', '78', 'recombinant', 'proteins', 'and', '298', 'vaccines', 'PhRMA', '2012', 'Pharmaceutical', 'biotechnology', 'techniques', 'are', 'at', 'the', 'core', 'of', 'most', 'methodologies', 'used', 'today', 'for', 'drug', 'discovery', 'and', 'development', 'of', 'both', 'biologics', 'and', 'small', 'molecules', 'While', 'recombinant', 'DNA', 'technology', 'and', 'hybridoma', 'techniques', 'were', 'the', 'major', 'methods', 'utilized', 'in', 'pharmaceutical', 'biotechnology', 'through', 'most', 'of', 'its', 'historical', 'timeline', 'our', 'ever', 'widening', 'understanding', 'of', 'human', 'cellular', 'function', 'and', 'disease', 'processes', 'and', 'a', 'wealth', 'of', 'additional', 'and', 'innovative', 'biotechnologies', 'have', 'been', 'and', 'will', 'continue', 'to', 'be', 'developed', 'in', 'order', 'to', 'harvest', 'the', 'information', 'found', 'in', 'the', 'human', 'genome', 'These', 'technological', 'advances', 'will', 'provide', 'a', 'better', 'understanding', 'of', 'the', 'relationship', 'between', 'genetics', 'and', 'biological', 'function', 'unravel', 'the', 'underlying', 'causes', 'of', 'disease', 'explore', 'the', 'association', 'of', 'genomic', 'variation', 'and', 'drug', 'response', 'enhance', 'pharmaceutical', 'research', 'and', 'fuel', 'the', 'discovery', 'and', 'development', 'of', 'new', 'and', 'novel', 'biopharmaceuticals', 'These', 'revolutionary', 'technologies', 'and', 'additional', 'biotechnology', 'related', 'techniques', 'are', 'improving', 'the', 'very', 'competitive', 'and', 'costly', 'process', 'of', 'drug', 'development', 'of', 'new', 'medicinal', 'agents', 'diagnostics', 'and', 'medical', 'devices', 'Some', 'of', 'the', 'technologies', 'and', 'techniques', 'described', 'in', 'this', 'chapter', 'are', 'both', 'well', 'established', 'and', 'commonly', 'used', 'applications', 'of', 'biotechnology', 'producing', 'potential', 'therapeutic', 'products', 'now', 'in', 'development', 'including', 'clinical', 'trials', 'New', 'techniques', 'are', 'emerging', 'at', 'a', 'rapid', 'and', 'unprecedented', 'pace', 'and', 'their', 'full', 'impact', 'on', 'the', 'future', 'of', 'molecular', 'medicine', 'has', 'yet', 'to', 'be', 'imagined', '']"
20244,Current and Future Applications of Monoclonal Antibodies against Bacteria in Veterinary Medicine,2014-06-27,Monoclonal Antibodies Against Bacteria,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7155467/,"This chapter discusses the current and future applications of monoclonal antibodies against bacteria in veterinary medicine. It discusses the existing applications of monoclonal antibodies, including the use of pilus-specific monoclonal antibodies for passive immunization of calves and piglets against enteropathogenic E. coli (EPEC) infections as well as the development of rapid diagnostic test kits for field diagnosis of EPEC infections. The potential applications of monoclonal antibodies for passive immunization against a variety of veterinary pathogens are passive immunization against Moraxella bovis (pinkeye), Bacteroides nodosus (foot rot), EPEC enterotoxin (enteric colibacillosis), Pasteurella haemolytica (pneumonic pasteurellosis), and Streptococcus equi (strangles). Three main areas of application for monoclonal antibodies against bacterial antigens in veterinary medicine are passive immunization, improved immunodiagnostics, and immunotherapy. Monoclonal antibodies, because of their specificity, unlimited availability, and high titer, represent excellent passive immunizing agents. However, their potential usefulness in preventing infection must be evaluated on a case-by-case basis.",10.1016/b978-0-12-463003-1.50018-6,hxph2xid,"['This', 'chapter', 'discusses', 'the', 'current', 'and', 'future', 'applications', 'of', 'monoclonal', 'antibodies', 'against', 'bacteria', 'in', 'veterinary', 'medicine', 'It', 'discusses', 'the', 'existing', 'applications', 'of', 'monoclonal', 'antibodies', 'including', 'the', 'use', 'of', 'pilus', 'specific', 'monoclonal', 'antibodies', 'for', 'passive', 'immunization', 'of', 'calves', 'and', 'piglets', 'against', 'enteropathogenic', 'E', 'coli', 'EPEC', 'infections', 'as', 'well', 'as', 'the', 'development', 'of', 'rapid', 'diagnostic', 'test', 'kits', 'for', 'field', 'diagnosis', 'of', 'EPEC', 'infections', 'The', 'potential', 'applications', 'of', 'monoclonal', 'antibodies', 'for', 'passive', 'immunization', 'against', 'a', 'variety', 'of', 'veterinary', 'pathogens', 'are', 'passive', 'immunization', 'against', 'Moraxella', 'bovis', 'pinkeye', 'Bacteroides', 'nodosus', 'foot', 'rot', 'EPEC', 'enterotoxin', 'enteric', 'colibacillosis', 'Pasteurella', 'haemolytica', 'pneumonic', 'pasteurellosis', 'and', 'Streptococcus', 'equi', 'strangles', 'Three', 'main', 'areas', 'of', 'application', 'for', 'monoclonal', 'antibodies', 'against', 'bacterial', 'antigens', 'in', 'veterinary', 'medicine', 'are', 'passive', 'immunization', 'improved', 'immunodiagnostics', 'and', 'immunotherapy', 'Monoclonal', 'antibodies', 'because', 'of', 'their', 'specificity', 'unlimited', 'availability', 'and', 'high', 'titer', 'represent', 'excellent', 'passive', 'immunizing', 'agents', 'However', 'their', 'potential', 'usefulness', 'in', 'preventing', 'infection', 'must', 'be', 'evaluated', 'on', 'a', 'case', 'by', 'case', 'basis', '']"
23666,Built‐in RNA‐mediated chaperone (chaperna) for antigen folding tailored to immunized hosts,2020-05-02,Biotechnol Bioeng,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262357/,"High‐quality antibody (Ab) production depends on the availability of immunologically relevant antigens. We present a potentially universal platform for generating soluble antigens from bacterial hosts, tailored to immunized animals for Ab production. A novel RNA‐dependent chaperone, in which the target antigen is genetically fused with an RNA‐interacting domain (RID) docking tag derived from the immunized host, promotes the solubility and robust folding of the target antigen. We selected the N‐terminal tRNA‐binding domain of lysyl‐tRNA synthetase (LysRS) as the RID for fusion with viral proteins and demonstrated the expression of the RID fusion proteins in their soluble and native conformations; immunization predominantly elicited Ab responses to the target antigen, whereas the “self” RID tag remained nonimmunogenic. Differential immunogenicity of the fusion proteins greatly enriched and simplified the screening of hybridoma clones of monoclonal antibodies (mAbs), enabling specific and sensitive serodiagnosis of MERS‐CoV infection. Moreover, mAbs against the consensus influenza hemagglutinin stalk domain enabled a novel assay for trivalent seasonal influenza vaccines. The Fc‐mediated effector function was demonstrated, which could be harnessed for the design of next‐generation “universal” influenza vaccines. The nonimmunogenic built‐in antigen folding module tailored to a repertoire of immunized animal hosts will drive immunochemical diagnostics, therapeutics, and designer vaccines.",10.1002/bit.27355,ln2v50b7,"['High', 'quality', 'antibody', 'Ab', 'production', 'depends', 'on', 'the', 'availability', 'of', 'immunologically', 'relevant', 'antigens', 'We', 'present', 'a', 'potentially', 'universal', 'platform', 'for', 'generating', 'soluble', 'antigens', 'from', 'bacterial', 'hosts', 'tailored', 'to', 'immunized', 'animals', 'for', 'Ab', 'production', 'A', 'novel', 'RNA', 'dependent', 'chaperone', 'in', 'which', 'the', 'target', 'antigen', 'is', 'genetically', 'fused', 'with', 'an', 'RNA', 'interacting', 'domain', 'RID', 'docking', 'tag', 'derived', 'from', 'the', 'immunized', 'host', 'promotes', 'the', 'solubility', 'and', 'robust', 'folding', 'of', 'the', 'target', 'antigen', 'We', 'selected', 'the', 'N', 'terminal', 'tRNA', 'binding', 'domain', 'of', 'lysyl', 'tRNA', 'synthetase', 'LysRS', 'as', 'the', 'RID', 'for', 'fusion', 'with', 'viral', 'proteins', 'and', 'demonstrated', 'the', 'expression', 'of', 'the', 'RID', 'fusion', 'proteins', 'in', 'their', 'soluble', 'and', 'native', 'conformations', 'immunization', 'predominantly', 'elicited', 'Ab', 'responses', 'to', 'the', 'target', 'antigen', 'whereas', 'the', 'self', 'RID', 'tag', 'remained', 'nonimmunogenic', 'Differential', 'immunogenicity', 'of', 'the', 'fusion', 'proteins', 'greatly', 'enriched', 'and', 'simplified', 'the', 'screening', 'of', 'hybridoma', 'clones', 'of', 'monoclonal', 'antibodies', 'mAbs', 'enabling', 'specific', 'and', 'sensitive', 'serodiagnosis', 'of', 'MERS', 'CoV', 'infection', 'Moreover', 'mAbs', 'against', 'the', 'consensus', 'influenza', 'hemagglutinin', 'stalk', 'domain', 'enabled', 'a', 'novel', 'assay', 'for', 'trivalent', 'seasonal', 'influenza', 'vaccines', 'The', 'Fc', 'mediated', 'effector', 'function', 'was', 'demonstrated', 'which', 'could', 'be', 'harnessed', 'for', 'the', 'design', 'of', 'next', 'generation', 'universal', 'influenza', 'vaccines', 'The', 'nonimmunogenic', 'built', 'in', 'antigen', 'folding', 'module', 'tailored', 'to', 'a', 'repertoire', 'of', 'immunized', 'animal', 'hosts', 'will', 'drive', 'immunochemical', 'diagnostics', 'therapeutics', 'and', 'designer', 'vaccines', '']"
33401,Current laboratory diagnostics of coronavirus disease 2019 (COVID-19).,2020-05-11,Acta bio-medica : Atenei Parmensis,https://doi.org/10.23750/abm.v91i2.9548; https://www.ncbi.nlm.nih.gov/pubmed/32420937/,"Laboratory medicine provides an almost irreplaceable contribution to the diagnostic reasoning and managed care of most human pathologies. The novel coronavirus disease 2019 (COVID-19) is not an exception to this paradigm. Although the relatively recent emergence does not allow to draw definitive conclusions on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) diagnostics, some standpoints can be conveyed. First and foremost, it seems now clear that we will be living together with this virus for quite a long time, so that our vigilance and responsiveness against the emergence of new local outbreaks shall be maintained at the highest possible levels. The etiological diagnosis of COVID-19 is, and will remain for the foreseeable future, deeply based on direct identification of viral RNA by means of molecular biology techniques in biological materials, especially upper and lower respiratory tract specimens. Whether other materials, such as blood, urine, stools, saliva and throat washing, will become valid alternatives has not been unequivocally defined so far. As concerns serological testing, promising information can be garnered from preliminary investigations, showing that the vast majority of COVID-19 patients seem to develop a sustained immune response against the virus, characterized especially by emergence of anti-SARS-CoV-2 IgG and IgA, 1 to 2 weeks after the onset of fever and/or respiratory symptoms. Whether these antibodies will have persistent neutralizing activity against the virus is still to be elucidated on individual and general basis. The availability of rapid tests for detecting either viral antigens or anti-SARS-CoV-2 antibodies are a potentially viable opportunity for purposes of epidemiologic surveillance, though more information is needed on accuracy and reliability of these portable immunoassays.",10.23750/abm.v91i2.9548,r2rnnsfh,"['Laboratory', 'medicine', 'provides', 'an', 'almost', 'irreplaceable', 'contribution', 'to', 'the', 'diagnostic', 'reasoning', 'and', 'managed', 'care', 'of', 'most', 'human', 'pathologies', 'The', 'novel', 'coronavirus', 'disease', '2019', 'COVID', '19', 'is', 'not', 'an', 'exception', 'to', 'this', 'paradigm', 'Although', 'the', 'relatively', 'recent', 'emergence', 'does', 'not', 'allow', 'to', 'draw', 'definitive', 'conclusions', 'on', 'severe', 'acute', 'respiratory', 'syndrome', 'coronavirus', '2', 'SARS', 'CoV', '2', 'diagnostics', 'some', 'standpoints', 'can', 'be', 'conveyed', 'First', 'and', 'foremost', 'it', 'seems', 'now', 'clear', 'that', 'we', 'will', 'be', 'living', 'together', 'with', 'this', 'virus', 'for', 'quite', 'a', 'long', 'time', 'so', 'that', 'our', 'vigilance', 'and', 'responsiveness', 'against', 'the', 'emergence', 'of', 'new', 'local', 'outbreaks', 'shall', 'be', 'maintained', 'at', 'the', 'highest', 'possible', 'levels', 'The', 'etiological', 'diagnosis', 'of', 'COVID', '19', 'is', 'and', 'will', 'remain', 'for', 'the', 'foreseeable', 'future', 'deeply', 'based', 'on', 'direct', 'identification', 'of', 'viral', 'RNA', 'by', 'means', 'of', 'molecular', 'biology', 'techniques', 'in', 'biological', 'materials', 'especially', 'upper', 'and', 'lower', 'respiratory', 'tract', 'specimens', 'Whether', 'other', 'materials', 'such', 'as', 'blood', 'urine', 'stools', 'saliva', 'and', 'throat', 'washing', 'will', 'become', 'valid', 'alternatives', 'has', 'not', 'been', 'unequivocally', 'defined', 'so', 'far', 'As', 'concerns', 'serological', 'testing', 'promising', 'information', 'can', 'be', 'garnered', 'from', 'preliminary', 'investigations', 'showing', 'that', 'the', 'vast', 'majority', 'of', 'COVID', '19', 'patients', 'seem', 'to', 'develop', 'a', 'sustained', 'immune', 'response', 'against', 'the', 'virus', 'characterized', 'especially', 'by', 'emergence', 'of', 'anti', 'SARS', 'CoV', '2', 'IgG', 'and', 'IgA', '1', 'to', '2', 'weeks', 'after', 'the', 'onset', 'of', 'fever', 'and', 'or', 'respiratory', 'symptoms', 'Whether', 'these', 'antibodies', 'will', 'have', 'persistent', 'neutralizing', 'activity', 'against', 'the', 'virus', 'is', 'still', 'to', 'be', 'elucidated', 'on', 'individual', 'and', 'general', 'basis', 'The', 'availability', 'of', 'rapid', 'tests', 'for', 'detecting', 'either', 'viral', 'antigens', 'or', 'anti', 'SARS', 'CoV', '2', 'antibodies', 'are', 'a', 'potentially', 'viable', 'opportunity', 'for', 'purposes', 'of', 'epidemiologic', 'surveillance', 'though', 'more', 'information', 'is', 'needed', 'on', 'accuracy', 'and', 'reliability', 'of', 'these', 'portable', 'immunoassays', '']"
34391,Autoantibodies in cancer: prognostic biomarkers and immune activation.,2011,Expert review of proteomics,https://doi.org/10.1586/epr.11.48; https://www.ncbi.nlm.nih.gov/pubmed/21999829/,"The development of proteomic technologies that display a wide variety of antigenic structures has led to the identification of autoantibodies to cancer-derived tumor antigens. These autoantibodies have been detected in sera from patients with multiple cancer types, and are being evaluated as biomarkers for early cancer detection. It is not known whether these antibodies also contribute to active immune surveillance or even tumorigenicity of developing tumors. Here, we review which tumor antigen-specific antibodies are prognostic biomarkers of cancer outcome, and emerging proteomic methods for the isolation and cloning of these antibodies for potential molecular diagnostics and therapeutics.",10.1586/epr.11.48,5oldlm6t,"['The', 'development', 'of', 'proteomic', 'technologies', 'that', 'display', 'a', 'wide', 'variety', 'of', 'antigenic', 'structures', 'has', 'led', 'to', 'the', 'identification', 'of', 'autoantibodies', 'to', 'cancer', 'derived', 'tumor', 'antigens', 'These', 'autoantibodies', 'have', 'been', 'detected', 'in', 'sera', 'from', 'patients', 'with', 'multiple', 'cancer', 'types', 'and', 'are', 'being', 'evaluated', 'as', 'biomarkers', 'for', 'early', 'cancer', 'detection', 'It', 'is', 'not', 'known', 'whether', 'these', 'antibodies', 'also', 'contribute', 'to', 'active', 'immune', 'surveillance', 'or', 'even', 'tumorigenicity', 'of', 'developing', 'tumors', 'Here', 'we', 'review', 'which', 'tumor', 'antigen', 'specific', 'antibodies', 'are', 'prognostic', 'biomarkers', 'of', 'cancer', 'outcome', 'and', 'emerging', 'proteomic', 'methods', 'for', 'the', 'isolation', 'and', 'cloning', 'of', 'these', 'antibodies', 'for', 'potential', 'molecular', 'diagnostics', 'and', 'therapeutics', '']"
43827,Achieving molecular diagnostics for Lyme disease.,2013,Expert review of molecular diagnostics,https://doi.org/10.1586/14737159.2013.850418; https://www.ncbi.nlm.nih.gov/pubmed/24151851/,"Early Lyme disease is often difficult to diagnose. Left untreated, symptoms can last for many years leading to chronic health problems. Serological tests for the presence of antibodies that react to Borrelia burgdorferi antigens are generally used to support a clinical diagnosis. Due to the biologically delayed antibody response, serology is negative in many patients in the initial 3 weeks after infection and a single test cannot be used to demonstrate active disease, although certain specialized tests provide strong correlation. Because of these limitations there exists a need for better diagnostics for Lyme disease that can detect Borrelia genomic material at the onset of symptoms.",10.1586/14737159.2013.850418,u31i00w6,"['Early', 'Lyme', 'disease', 'is', 'often', 'difficult', 'to', 'diagnose', 'Left', 'untreated', 'symptoms', 'can', 'last', 'for', 'many', 'years', 'leading', 'to', 'chronic', 'health', 'problems', 'Serological', 'tests', 'for', 'the', 'presence', 'of', 'antibodies', 'that', 'react', 'to', 'Borrelia', 'burgdorferi', 'antigens', 'are', 'generally', 'used', 'to', 'support', 'a', 'clinical', 'diagnosis', 'Due', 'to', 'the', 'biologically', 'delayed', 'antibody', 'response', 'serology', 'is', 'negative', 'in', 'many', 'patients', 'in', 'the', 'initial', '3', 'weeks', 'after', 'infection', 'and', 'a', 'single', 'test', 'cannot', 'be', 'used', 'to', 'demonstrate', 'active', 'disease', 'although', 'certain', 'specialized', 'tests', 'provide', 'strong', 'correlation', 'Because', 'of', 'these', 'limitations', 'there', 'exists', 'a', 'need', 'for', 'better', 'diagnostics', 'for', 'Lyme', 'disease', 'that', 'can', 'detect', 'Borrelia', 'genomic', 'material', 'at', 'the', 'onset', 'of', 'symptoms', '']"
44349,Markers of Borna disease virus infection in cats with staggering disease.,2012,Journal of feline medicine and surgery,https://doi.org/10.1177/1098612x12446638; https://www.ncbi.nlm.nih.gov/pubmed/22553310/,"Borna disease virus (BDV) is a RNA-virus causing neurological disorders in a wide range of mammals. In cats, BDV infection may cause staggering disease. Presently, staggering disease is a tentative clinical diagnosis, only confirmed at necropsy. In this study, cats with staggering disease were investigated to study markers of BDV infection aiming for improvement of current diagnostics. Nineteen cats fulfilled the inclusion criteria based on neurological signs and pathological findings. In 17/19 cats, BDV infection markers (BDV-specific antibodies and/or BDV-RNA) were found, and antibodies in serum (13/16, 81%) were the most common marker. BDV-RNA was found in 11/19 cats (58%). In a reference population without neurological signs, 4/25 cats were seropositive (16%). The clinical history and neurological signs in combination with presence of BDV infection markers, where serology and rRT-PCR on blood can be helpful tools, improve the diagnostic accuracy in the living cat.",10.1177/1098612x12446638,vw6t0alg,"['Borna', 'disease', 'virus', 'BDV', 'is', 'a', 'RNA', 'virus', 'causing', 'neurological', 'disorders', 'in', 'a', 'wide', 'range', 'of', 'mammals', 'In', 'cats', 'BDV', 'infection', 'may', 'cause', 'staggering', 'disease', 'Presently', 'staggering', 'disease', 'is', 'a', 'tentative', 'clinical', 'diagnosis', 'only', 'confirmed', 'at', 'necropsy', 'In', 'this', 'study', 'cats', 'with', 'staggering', 'disease', 'were', 'investigated', 'to', 'study', 'markers', 'of', 'BDV', 'infection', 'aiming', 'for', 'improvement', 'of', 'current', 'diagnostics', 'Nineteen', 'cats', 'fulfilled', 'the', 'inclusion', 'criteria', 'based', 'on', 'neurological', 'signs', 'and', 'pathological', 'findings', 'In', '17', '19', 'cats', 'BDV', 'infection', 'markers', 'BDV', 'specific', 'antibodies', 'and', 'or', 'BDV', 'RNA', 'were', 'found', 'and', 'antibodies', 'in', 'serum', '13', '16', '81', 'were', 'the', 'most', 'common', 'marker', 'BDV', 'RNA', 'was', 'found', 'in', '11', '19', 'cats', '58', 'In', 'a', 'reference', 'population', 'without', 'neurological', 'signs', '4', '25', 'cats', 'were', 'seropositive', '16', 'The', 'clinical', 'history', 'and', 'neurological', 'signs', 'in', 'combination', 'with', 'presence', 'of', 'BDV', 'infection', 'markers', 'where', 'serology', 'and', 'rRT', 'PCR', 'on', 'blood', 'can', 'be', 'helpful', 'tools', 'improve', 'the', 'diagnostic', 'accuracy', 'in', 'the', 'living', 'cat', '']"
47640,Recombinant protein-based viral disease diagnostics in veterinary medicine.,2010,Expert review of molecular diagnostics,https://doi.org/10.1586/erm.10.61; https://www.ncbi.nlm.nih.gov/pubmed/20843198/,"Identification of pathogens or antibody response to pathogens in human and animals modulates the treatment strategies for naive population and subsequent infections. Diseases can be controlled and even eradicated based on the epidemiology and effective prophylaxis, which often depends on development of efficient diagnostics. In addition, combating newly emerging diseases in human as well as animal healthcare is challenging and is dependent on developing safe and efficient diagnostics. Detection of antibodies directed against specific antigens has been the method of choice for documenting prior infection. Other than zoonosis, development of inexpensive vaccines and diagnostics is a unique problem in animal healthcare. The advent of recombinant DNA technology and its application in the biotechnology industry has revolutionized animal healthcare. The use of recombinant DNA technology in animal disease diagnosis has improved the rapidity, specificity and sensitivity of various diagnostic assays. This is because of the absence of host cellular proteins in the recombinant derived antigen preparations that dramatically decrease the rate of false-positive reactions. Various recombinant products are used for disease diagnosis in veterinary medicine and this article discusses recombinant-based viral disease diagnostics currently used for detection of pathogens in livestock and poultry.",10.1586/erm.10.61,ierl283y,"['Identification', 'of', 'pathogens', 'or', 'antibody', 'response', 'to', 'pathogens', 'in', 'human', 'and', 'animals', 'modulates', 'the', 'treatment', 'strategies', 'for', 'naive', 'population', 'and', 'subsequent', 'infections', 'Diseases', 'can', 'be', 'controlled', 'and', 'even', 'eradicated', 'based', 'on', 'the', 'epidemiology', 'and', 'effective', 'prophylaxis', 'which', 'often', 'depends', 'on', 'development', 'of', 'efficient', 'diagnostics', 'In', 'addition', 'combating', 'newly', 'emerging', 'diseases', 'in', 'human', 'as', 'well', 'as', 'animal', 'healthcare', 'is', 'challenging', 'and', 'is', 'dependent', 'on', 'developing', 'safe', 'and', 'efficient', 'diagnostics', 'Detection', 'of', 'antibodies', 'directed', 'against', 'specific', 'antigens', 'has', 'been', 'the', 'method', 'of', 'choice', 'for', 'documenting', 'prior', 'infection', 'Other', 'than', 'zoonosis', 'development', 'of', 'inexpensive', 'vaccines', 'and', 'diagnostics', 'is', 'a', 'unique', 'problem', 'in', 'animal', 'healthcare', 'The', 'advent', 'of', 'recombinant', 'DNA', 'technology', 'and', 'its', 'application', 'in', 'the', 'biotechnology', 'industry', 'has', 'revolutionized', 'animal', 'healthcare', 'The', 'use', 'of', 'recombinant', 'DNA', 'technology', 'in', 'animal', 'disease', 'diagnosis', 'has', 'improved', 'the', 'rapidity', 'specificity', 'and', 'sensitivity', 'of', 'various', 'diagnostic', 'assays', 'This', 'is', 'because', 'of', 'the', 'absence', 'of', 'host', 'cellular', 'proteins', 'in', 'the', 'recombinant', 'derived', 'antigen', 'preparations', 'that', 'dramatically', 'decrease', 'the', 'rate', 'of', 'false', 'positive', 'reactions', 'Various', 'recombinant', 'products', 'are', 'used', 'for', 'disease', 'diagnosis', 'in', 'veterinary', 'medicine', 'and', 'this', 'article', 'discusses', 'recombinant', 'based', 'viral', 'disease', 'diagnostics', 'currently', 'used', 'for', 'detection', 'of', 'pathogens', 'in', 'livestock', 'and', 'poultry', '']"
49504,Navigating the Pandemic Response Life Cycle: Molecular Diagnostics and Immunoassays in the Context of COVID-19 Management.,2020-04-29,IEEE reviews in biomedical engineering,https://doi.org/10.1109/rbme.2020.2991444; https://www.ncbi.nlm.nih.gov/pubmed/32356761/,"Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To counter COVID-19 spreading, an infrastructure to provide rapid and thorough molecular diagnostics and serology testing is the cornerstone of outbreak and pandemic management. We hereby review the clinical insights with regard to using molecular tests and immunoassays in the context of COVID-19 management life cycle: the preventive phase, the preparedness phase, the response phase and the recovery phase. The spatial and temporal distribution of viral RNA, antigens and antibodies during human infection is summarized to provide a biological foundation for accurate detection of the disease. We shared the lessons learned and the obstacles encountered during real world high-volume screening programs. Clinical needs are discussed to identify existing technology gaps in these tests. Leverage technologies, such as engineered polymerases, isothermal amplification, and direct amplification from complex matrices may improve the productivity of current infrastructure, while emerging technologies like CRISPR diagnostics, visual end point detection, and PCR free methods for nucleic acid sensing may lead to at-home tests. The lessons learned, and innovations spurred from the COVID-19 pandemic could upgrade our global public health infrastructure to better combat potential outbreaks in the future.",10.1109/rbme.2020.2991444,6wlbl0wg,"['Coronavirus', 'disease', '2019', 'COVID', '19', 'is', 'an', 'infectious', 'disease', 'caused', 'by', 'severe', 'acute', 'respiratory', 'syndrome', 'coronavirus', '2', 'SARS', 'CoV', '2', 'To', 'counter', 'COVID', '19', 'spreading', 'an', 'infrastructure', 'to', 'provide', 'rapid', 'and', 'thorough', 'molecular', 'diagnostics', 'and', 'serology', 'testing', 'is', 'the', 'cornerstone', 'of', 'outbreak', 'and', 'pandemic', 'management', 'We', 'hereby', 'review', 'the', 'clinical', 'insights', 'with', 'regard', 'to', 'using', 'molecular', 'tests', 'and', 'immunoassays', 'in', 'the', 'context', 'of', 'COVID', '19', 'management', 'life', 'cycle', 'the', 'preventive', 'phase', 'the', 'preparedness', 'phase', 'the', 'response', 'phase', 'and', 'the', 'recovery', 'phase', 'The', 'spatial', 'and', 'temporal', 'distribution', 'of', 'viral', 'RNA', 'antigens', 'and', 'antibodies', 'during', 'human', 'infection', 'is', 'summarized', 'to', 'provide', 'a', 'biological', 'foundation', 'for', 'accurate', 'detection', 'of', 'the', 'disease', 'We', 'shared', 'the', 'lessons', 'learned', 'and', 'the', 'obstacles', 'encountered', 'during', 'real', 'world', 'high', 'volume', 'screening', 'programs', 'Clinical', 'needs', 'are', 'discussed', 'to', 'identify', 'existing', 'technology', 'gaps', 'in', 'these', 'tests', 'Leverage', 'technologies', 'such', 'as', 'engineered', 'polymerases', 'isothermal', 'amplification', 'and', 'direct', 'amplification', 'from', 'complex', 'matrices', 'may', 'improve', 'the', 'productivity', 'of', 'current', 'infrastructure', 'while', 'emerging', 'technologies', 'like', 'CRISPR', 'diagnostics', 'visual', 'end', 'point', 'detection', 'and', 'PCR', 'free', 'methods', 'for', 'nucleic', 'acid', 'sensing', 'may', 'lead', 'to', 'at', 'home', 'tests', 'The', 'lessons', 'learned', 'and', 'innovations', 'spurred', 'from', 'the', 'COVID', '19', 'pandemic', 'could', 'upgrade', 'our', 'global', 'public', 'health', 'infrastructure', 'to', 'better', 'combat', 'potential', 'outbreaks', 'in', 'the', 'future', '']"
56177,Stability engineering of anti-EGFR scFv antibodies by rational design of a lambda-to-kappa swap of the VL framework using a structure-guided approach.,2015,mAbs,https://doi.org/10.1080/19420862.2015.1088618; https://www.ncbi.nlm.nih.gov/pubmed/26337947/,"Phage-display technology facilitates rapid selection of antigen-specific single-chain variable fragment (scFv) antibodies from large recombinant libraries. ScFv antibodies, composed of a VH and VL domain, are readily engineered into multimeric formats for the development of diagnostics and targeted therapies. However, the recombinant nature of the selection strategy can result in VH and VL domains with sub-optimal biophysical properties, such as reduced thermodynamic stability and enhanced aggregation propensity, which lead to poor production and limited application. We found that the C10 anti-epidermal growth factor receptor (EGFR) scFv, and its affinity mutant, P2224, exhibit weak production from E. coli. Interestingly, these scFv contain a fusion of lambda3 and lambda1 V-region (LV3 and LV1) genes, most likely the result of a PCR aberration during library construction. To enhance the biophysical properties of these scFvs, we utilized a structure-based approach to replace and redesign the pre-existing framework of the VL domain to one that best pairs with the existing VH. We describe a method to exchange lambda sequences with a more stable kappa3 framework (KV3) within the VL domain that incorporates the original lambda DE-loop. The resulting scFvs, C10KV3_LV1DE and P2224KV3_LV1DE, are more thermodynamically stable and easier to produce from bacterial culture. Additionally, C10KV3_LV1DE and P2224KV3_LV1DE retain binding affinity to EGFR, suggesting that such a dramatic framework swap does not significantly affect scFv binding. We provide here a novel strategy for redesigning the light chain of problematic scFvs to enhance their stability and therapeutic applicability.",10.1080/19420862.2015.1088618,6lsageb9,"['Phage', 'display', 'technology', 'facilitates', 'rapid', 'selection', 'of', 'antigen', 'specific', 'single', 'chain', 'variable', 'fragment', 'scFv', 'antibodies', 'from', 'large', 'recombinant', 'libraries', 'ScFv', 'antibodies', 'composed', 'of', 'a', 'VH', 'and', 'VL', 'domain', 'are', 'readily', 'engineered', 'into', 'multimeric', 'formats', 'for', 'the', 'development', 'of', 'diagnostics', 'and', 'targeted', 'therapies', 'However', 'the', 'recombinant', 'nature', 'of', 'the', 'selection', 'strategy', 'can', 'result', 'in', 'VH', 'and', 'VL', 'domains', 'with', 'sub', 'optimal', 'biophysical', 'properties', 'such', 'as', 'reduced', 'thermodynamic', 'stability', 'and', 'enhanced', 'aggregation', 'propensity', 'which', 'lead', 'to', 'poor', 'production', 'and', 'limited', 'application', 'We', 'found', 'that', 'the', 'C10', 'anti', 'epidermal', 'growth', 'factor', 'receptor', 'EGFR', 'scFv', 'and', 'its', 'affinity', 'mutant', 'P2224', 'exhibit', 'weak', 'production', 'from', 'E', 'coli', 'Interestingly', 'these', 'scFv', 'contain', 'a', 'fusion', 'of', 'lambda3', 'and', 'lambda1', 'V', 'region', 'LV3', 'and', 'LV1', 'genes', 'most', 'likely', 'the', 'result', 'of', 'a', 'PCR', 'aberration', 'during', 'library', 'construction', 'To', 'enhance', 'the', 'biophysical', 'properties', 'of', 'these', 'scFvs', 'we', 'utilized', 'a', 'structure', 'based', 'approach', 'to', 'replace', 'and', 'redesign', 'the', 'pre', 'existing', 'framework', 'of', 'the', 'VL', 'domain', 'to', 'one', 'that', 'best', 'pairs', 'with', 'the', 'existing', 'VH', 'We', 'describe', 'a', 'method', 'to', 'exchange', 'lambda', 'sequences', 'with', 'a', 'more', 'stable', 'kappa3', 'framework', 'KV3', 'within', 'the', 'VL', 'domain', 'that', 'incorporates', 'the', 'original', 'lambda', 'DE', 'loop', 'The', 'resulting', 'scFvs', 'C10KV3', 'LV1DE', 'and', 'P2224KV3', 'LV1DE', 'are', 'more', 'thermodynamically', 'stable', 'and', 'easier', 'to', 'produce', 'from', 'bacterial', 'culture', 'Additionally', 'C10KV3', 'LV1DE', 'and', 'P2224KV3', 'LV1DE', 'retain', 'binding', 'affinity', 'to', 'EGFR', 'suggesting', 'that', 'such', 'a', 'dramatic', 'framework', 'swap', 'does', 'not', 'significantly', 'affect', 'scFv', 'binding', 'We', 'provide', 'here', 'a', 'novel', 'strategy', 'for', 'redesigning', 'the', 'light', 'chain', 'of', 'problematic', 'scFvs', 'to', 'enhance', 'their', 'stability', 'and', 'therapeutic', 'applicability', '']"
71608,Evaluation of antibody testing for SARS-Cov-2 using ELISA and lateral flow immunoassays,2020-04-20,,https://doi.org/10.1101/2020.04.15.20066407,"Background: The SARS-CoV-2 pandemic caused >1 million infections during January-March 2020. There is an urgent need for robust antibody detection approaches to support diagnostics, vaccine development, safe individual release from quarantine and population lock-down exit strategies. The early promise of lateral flow immunoassay (LFIA) devices has been questioned following concerns about sensitivity and specificity. Methods: We used a panel of plasma samples designated SARS-CoV-2 positive (from SARS-CoV-2 RT-PCR-positive individuals; n=40) and negative (samples banked in the UK prior to December-2019 (n=142)). We tested plasma for SARS-Cov-2 IgM and IgG antibodies by ELISA and using nine different commercially available LFIA devices. Results: ELISA detected SARS-CoV-2 IgM or IgG in 34/40 individuals with an RT-PCR-confirmed diagnosis of SARS-CoV-2 infection (sensitivity 85%, 95%CI 70-94%), vs 0/50 pre-pandemic controls (specificity 100% [95%CI 93-100%]). IgG levels were detected in 31/31 RT-PCR-positive individuals tested ≥10 days after symptom onset (sensitivity 100%, 95%CI 89-100%). IgG titres rose during the 3 weeks post symptom onset and began to fall by 8 weeks, but remained above the detection threshold. Point estimates for the sensitivity of LFIA devices ranged from 55-70% versus RT-PCR and 65-85% versus ELISA, with specificity 95-100% and 93-100% respectively. Within the limits of the study size, the performance of most LFIA devices was similar. Conclusions: The performance of current LFIA devices is inadequate for most individual patient applications. ELISA can be calibrated to be specific for detecting and quantifying SARS-CoV-2 IgM and IgG and is highly sensitive for IgG from 10 days following symptoms onset.",10.1101/2020.04.15.20066407,5trox1i5,"['Background', 'The', 'SARS', 'CoV', '2', 'pandemic', 'caused', '1', 'million', 'infections', 'during', 'January', 'March', '2020', 'There', 'is', 'an', 'urgent', 'need', 'for', 'robust', 'antibody', 'detection', 'approaches', 'to', 'support', 'diagnostics', 'vaccine', 'development', 'safe', 'individual', 'release', 'from', 'quarantine', 'and', 'population', 'lock', 'down', 'exit', 'strategies', 'The', 'early', 'promise', 'of', 'lateral', 'flow', 'immunoassay', 'LFIA', 'devices', 'has', 'been', 'questioned', 'following', 'concerns', 'about', 'sensitivity', 'and', 'specificity', 'Methods', 'We', 'used', 'a', 'panel', 'of', 'plasma', 'samples', 'designated', 'SARS', 'CoV', '2', 'positive', 'from', 'SARS', 'CoV', '2', 'RT', 'PCR', 'positive', 'individuals', 'n', '40', 'and', 'negative', 'samples', 'banked', 'in', 'the', 'UK', 'prior', 'to', 'December', '2019', 'n', '142', 'We', 'tested', 'plasma', 'for', 'SARS', 'Cov', '2', 'IgM', 'and', 'IgG', 'antibodies', 'by', 'ELISA', 'and', 'using', 'nine', 'different', 'commercially', 'available', 'LFIA', 'devices', 'Results', 'ELISA', 'detected', 'SARS', 'CoV', '2', 'IgM', 'or', 'IgG', 'in', '34', '40', 'individuals', 'with', 'an', 'RT', 'PCR', 'confirmed', 'diagnosis', 'of', 'SARS', 'CoV', '2', 'infection', 'sensitivity', '85', '95', 'CI', '70', '94', 'vs', '0', '50', 'pre', 'pandemic', 'controls', 'specificity', '100', '95', 'CI', '93', '100', 'IgG', 'levels', 'were', 'detected', 'in', '31', '31', 'RT', 'PCR', 'positive', 'individuals', 'tested', '10', 'days', 'after', 'symptom', 'onset', 'sensitivity', '100', '95', 'CI', '89', '100', 'IgG', 'titres', 'rose', 'during', 'the', '3', 'weeks', 'post', 'symptom', 'onset', 'and', 'began', 'to', 'fall', 'by', '8', 'weeks', 'but', 'remained', 'above', 'the', 'detection', 'threshold', 'Point', 'estimates', 'for', 'the', 'sensitivity', 'of', 'LFIA', 'devices', 'ranged', 'from', '55', '70', 'versus', 'RT', 'PCR', 'and', '65', '85', 'versus', 'ELISA', 'with', 'specificity', '95', '100', 'and', '93', '100', 'respectively', 'Within', 'the', 'limits', 'of', 'the', 'study', 'size', 'the', 'performance', 'of', 'most', 'LFIA', 'devices', 'was', 'similar', 'Conclusions', 'The', 'performance', 'of', 'current', 'LFIA', 'devices', 'is', 'inadequate', 'for', 'most', 'individual', 'patient', 'applications', 'ELISA', 'can', 'be', 'calibrated', 'to', 'be', 'specific', 'for', 'detecting', 'and', 'quantifying', 'SARS', 'CoV', '2', 'IgM', 'and', 'IgG', 'and', 'is', 'highly', 'sensitive', 'for', 'IgG', 'from', '10', 'days', 'following', 'symptoms', 'onset', '']"
72639,Development and potential usefulness of the COVID-19 Ag Respi-Strip diagnostic assay in a pandemic context.,2020-04-29,,http://medrxiv.org/cgi/content/short/2020.04.24.20077776v1?rss=1,"Introduction: COVID-19 Ag Respi-Strip, an immunochromatographic (ICT) assay for the rapid detection of SARS-CoV-2 antigen on nasopharyngeal specimen, has been developed to identify positive COVID-19 patients allowing prompt clinical and quarantine decisions. In this Original Research article, we describe the conception, the analytical and clinical performances as well as the risk management of implementing the COVID-19 Ag Respi-Strip in a diagnostic decision algorithm. Materials and Methods: Development of the COVID-19 Ag Respi-Strip resulted in a ready-to-use ICT assay based on a membrane technology with colloidal gold nanoparticles using monoclonal antibodies directed against the SARS-CoV and SARS-CoV-2 highly conserved nucleoprotein antigen. Four hundred observations were recorded for the analytical performance study and thirty tests were analysed for the cross-reactivity study. The clinical performance study was performed in a retrospective multi-centric evaluation on aliquots of 328 nasopharyngeal samples. COVID-19 Ag Respi-Strip results were compared with qRT-PCR as golden standard for COVID-19 diagnostics. Results: In the analytical performance study, the reproducibility showed a between-observer disagreement of 1.7%, a robustness of 98%, an overall satisfying user friendliness and no cross-reactivity with other virus-infected nasopharyngeal samples. In the clinical performance study performed in three different clinical laboratories we found an overall sensitivity and specificity of 57.6% and 99.5% respectively with an accuracy of 82.6%. The cut-off of the assay was found at Ct<22. User-friendliness analysis and risk management assessment through Ishikawa diagram demonstrate that COVID-19 Ag Respi-Strip may be implemented in clinical laboratories according to biosafety recommendations. Conclusion: The COVID-19 Ag Respi-Strip represents a promising rapid SARS-CoV-2 antigen assay for the first-line diagnosis of COVID-19 in 15 minutes. Its role in the proposed diagnostic algorithm is complementary to the currently-used molecular techniques.",10.1101/2020.04.24.20077776,812st0np,"['Introduction', 'COVID', '19', 'Ag', 'Respi', 'Strip', 'an', 'immunochromatographic', 'ICT', 'assay', 'for', 'the', 'rapid', 'detection', 'of', 'SARS', 'CoV', '2', 'antigen', 'on', 'nasopharyngeal', 'specimen', 'has', 'been', 'developed', 'to', 'identify', 'positive', 'COVID', '19', 'patients', 'allowing', 'prompt', 'clinical', 'and', 'quarantine', 'decisions', 'In', 'this', 'Original', 'Research', 'article', 'we', 'describe', 'the', 'conception', 'the', 'analytical', 'and', 'clinical', 'performances', 'as', 'well', 'as', 'the', 'risk', 'management', 'of', 'implementing', 'the', 'COVID', '19', 'Ag', 'Respi', 'Strip', 'in', 'a', 'diagnostic', 'decision', 'algorithm', 'Materials', 'and', 'Methods', 'Development', 'of', 'the', 'COVID', '19', 'Ag', 'Respi', 'Strip', 'resulted', 'in', 'a', 'ready', 'to', 'use', 'ICT', 'assay', 'based', 'on', 'a', 'membrane', 'technology', 'with', 'colloidal', 'gold', 'nanoparticles', 'using', 'monoclonal', 'antibodies', 'directed', 'against', 'the', 'SARS', 'CoV', 'and', 'SARS', 'CoV', '2', 'highly', 'conserved', 'nucleoprotein', 'antigen', 'Four', 'hundred', 'observations', 'were', 'recorded', 'for', 'the', 'analytical', 'performance', 'study', 'and', 'thirty', 'tests', 'were', 'analysed', 'for', 'the', 'cross', 'reactivity', 'study', 'The', 'clinical', 'performance', 'study', 'was', 'performed', 'in', 'a', 'retrospective', 'multi', 'centric', 'evaluation', 'on', 'aliquots', 'of', '328', 'nasopharyngeal', 'samples', 'COVID', '19', 'Ag', 'Respi', 'Strip', 'results', 'were', 'compared', 'with', 'qRT', 'PCR', 'as', 'golden', 'standard', 'for', 'COVID', '19', 'diagnostics', 'Results', 'In', 'the', 'analytical', 'performance', 'study', 'the', 'reproducibility', 'showed', 'a', 'between', 'observer', 'disagreement', 'of', '1', '7', 'a', 'robustness', 'of', '98', 'an', 'overall', 'satisfying', 'user', 'friendliness', 'and', 'no', 'cross', 'reactivity', 'with', 'other', 'virus', 'infected', 'nasopharyngeal', 'samples', 'In', 'the', 'clinical', 'performance', 'study', 'performed', 'in', 'three', 'different', 'clinical', 'laboratories', 'we', 'found', 'an', 'overall', 'sensitivity', 'and', 'specificity', 'of', '57', '6', 'and', '99', '5', 'respectively', 'with', 'an', 'accuracy', 'of', '82', '6', 'The', 'cut', 'off', 'of', 'the', 'assay', 'was', 'found', 'at', 'Ct', '22', 'User', 'friendliness', 'analysis', 'and', 'risk', 'management', 'assessment', 'through', 'Ishikawa', 'diagram', 'demonstrate', 'that', 'COVID', '19', 'Ag', 'Respi', 'Strip', 'may', 'be', 'implemented', 'in', 'clinical', 'laboratories', 'according', 'to', 'biosafety', 'recommendations', 'Conclusion', 'The', 'COVID', '19', 'Ag', 'Respi', 'Strip', 'represents', 'a', 'promising', 'rapid', 'SARS', 'CoV', '2', 'antigen', 'assay', 'for', 'the', 'first', 'line', 'diagnosis', 'of', 'COVID', '19', 'in', '15', 'minutes', 'Its', 'role', 'in', 'the', 'proposed', 'diagnostic', 'algorithm', 'is', 'complementary', 'to', 'the', 'currently', 'used', 'molecular', 'techniques', '']"
73021,The UCSC SARS-CoV-2 Genome Browser,2020-05-04,bioRxiv,https://doi.org/10.1101/2020.05.04.075945,"Background Researchers are generating molecular data pertaining to the SARS-CoV-2 RNA genome and its proteins at an unprecedented rate during the COVID-19 pandemic. As a result, there is a critical need for rapid and continuously updated access to the latest molecular data in a format in which all data can be quickly cross-referenced and compared. We adapted our genome browser visualization tool to the viral genome for this purpose. Molecular data, curated from published studies or from database submissions, are mapped to the viral genome and grouped together into “annotation tracks” where they can be visualized along the linear map of the viral genome sequence and programmatically downloaded in standard format for analysis. Results The UCSC Genome Browser for SARS-CoV-2 (https://genome.ucsc.edu/covid19.html) provides continuously updated access to the mutations in the many thousands of SARS-CoV-2 genomes deposited in GISAID and the international nucleotide sequencing databases, displayed alongside phylogenetic trees. These data are augmented with alignments of bat, pangolin, and other animal and human coronavirus genomes, including per-base evolutionary rate analysis. All available annotations are cross-referenced on the virus genome, including those from major databases (PDB, RFAM, IEDB, UniProt) as well as up-to-date individual results from preprints. Annotated data include predicted and validated immune epitopes, promising antibodies, RT-PCR and sequencing primers, CRISPR guides (from research, diagnostics, vaccines, and therapies), and points of interaction between human and viral genes. As a community resource, any user can add manual annotations which are quality checked and shared publicly on the browser the next day. Conclusions We invite all investigators to contribute additional data and annotations to this resource to accelerate research and development activities globally. Contact us at genome-www@soe.ucsc.edu with data suggestions or requests for support for adding data. Rapid sharing of data will accelerate SARS-CoV-2 research, especially when researchers take time to integrate their data with those from other labs on a widely-used community browser platform with standardized machine-readable data formats, such as the SARS-CoV-2 Genome Browser.",10.1101/2020.05.04.075945,gmk4qo4i,"['Background', 'Researchers', 'are', 'generating', 'molecular', 'data', 'pertaining', 'to', 'the', 'SARS', 'CoV', '2', 'RNA', 'genome', 'and', 'its', 'proteins', 'at', 'an', 'unprecedented', 'rate', 'during', 'the', 'COVID', '19', 'pandemic', 'As', 'a', 'result', 'there', 'is', 'a', 'critical', 'need', 'for', 'rapid', 'and', 'continuously', 'updated', 'access', 'to', 'the', 'latest', 'molecular', 'data', 'in', 'a', 'format', 'in', 'which', 'all', 'data', 'can', 'be', 'quickly', 'cross', 'referenced', 'and', 'compared', 'We', 'adapted', 'our', 'genome', 'browser', 'visualization', 'tool', 'to', 'the', 'viral', 'genome', 'for', 'this', 'purpose', 'Molecular', 'data', 'curated', 'from', 'published', 'studies', 'or', 'from', 'database', 'submissions', 'are', 'mapped', 'to', 'the', 'viral', 'genome', 'and', 'grouped', 'together', 'into', 'annotation', 'tracks', 'where', 'they', 'can', 'be', 'visualized', 'along', 'the', 'linear', 'map', 'of', 'the', 'viral', 'genome', 'sequence', 'and', 'programmatically', 'downloaded', 'in', 'standard', 'format', 'for', 'analysis', 'Results', 'The', 'UCSC', 'Genome', 'Browser', 'for', 'SARS', 'CoV', '2', 'https', 'genome', 'ucsc', 'edu', 'covid19', 'html', 'provides', 'continuously', 'updated', 'access', 'to', 'the', 'mutations', 'in', 'the', 'many', 'thousands', 'of', 'SARS', 'CoV', '2', 'genomes', 'deposited', 'in', 'GISAID', 'and', 'the', 'international', 'nucleotide', 'sequencing', 'databases', 'displayed', 'alongside', 'phylogenetic', 'trees', 'These', 'data', 'are', 'augmented', 'with', 'alignments', 'of', 'bat', 'pangolin', 'and', 'other', 'animal', 'and', 'human', 'coronavirus', 'genomes', 'including', 'per', 'base', 'evolutionary', 'rate', 'analysis', 'All', 'available', 'annotations', 'are', 'cross', 'referenced', 'on', 'the', 'virus', 'genome', 'including', 'those', 'from', 'major', 'databases', 'PDB', 'RFAM', 'IEDB', 'UniProt', 'as', 'well', 'as', 'up', 'to', 'date', 'individual', 'results', 'from', 'preprints', 'Annotated', 'data', 'include', 'predicted', 'and', 'validated', 'immune', 'epitopes', 'promising', 'antibodies', 'RT', 'PCR', 'and', 'sequencing', 'primers', 'CRISPR', 'guides', 'from', 'research', 'diagnostics', 'vaccines', 'and', 'therapies', 'and', 'points', 'of', 'interaction', 'between', 'human', 'and', 'viral', 'genes', 'As', 'a', 'community', 'resource', 'any', 'user', 'can', 'add', 'manual', 'annotations', 'which', 'are', 'quality', 'checked', 'and', 'shared', 'publicly', 'on', 'the', 'browser', 'the', 'next', 'day', 'Conclusions', 'We', 'invite', 'all', 'investigators', 'to', 'contribute', 'additional', 'data', 'and', 'annotations', 'to', 'this', 'resource', 'to', 'accelerate', 'research', 'and', 'development', 'activities', 'globally', 'Contact', 'us', 'at', 'genome', 'www', 'soe', 'ucsc', 'edu', 'with', 'data', 'suggestions', 'or', 'requests', 'for', 'support', 'for', 'adding', 'data', 'Rapid', 'sharing', 'of', 'data', 'will', 'accelerate', 'SARS', 'CoV', '2', 'research', 'especially', 'when', 'researchers', 'take', 'time', 'to', 'integrate', 'their', 'data', 'with', 'those', 'from', 'other', 'labs', 'on', 'a', 'widely', 'used', 'community', 'browser', 'platform', 'with', 'standardized', 'machine', 'readable', 'data', 'formats', 'such', 'as', 'the', 'SARS', 'CoV', '2', 'Genome', 'Browser', '']"
73070,Diagnostic accuracy of six commercial SARS-CoV-2 IgG/total antibody assays and identification of SARS-CoV-2 neutralizing antibodies in convalescent sera,2020-06-17,,http://medrxiv.org/cgi/content/short/2020.06.15.20131672v1?rss=1,"The reliable detection of immunoglobulin G (IgG) or total antibodies directed against the novel severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) is important for clinical diagnostics and epidemiological studies. Here, we compare the diagnostic accuracy of six commercially available SARS-CoV-2 IgG (Abbott SARS-CoV-2 IgG; Diasorin Liaison SARS-CoV-2 S1/2 IgG; Epitope EDI Novel Coronavirus COVID-19 IgG ELISA Kit; Euroimmun Anti-SARS-CoV-2 ELISA (IgG); Mikrogen recomWell SARS-CoV-2 IgG) or total SARS-CoV-2 antibody assays (Roche Elecsys Anti-SARS-CoV-2). The test sensitivities were analyzed with a set of 34 sera obtained from 26 patients after PCR-confirmed SARS-CoV-2 infection and varied from 76.9% (Euroimmun) to 96.2% (Abbott). The majority of assay results were confirmed in a laboratory-developed plaque reduction neutralization test and by a SARS-CoV-2 IgG-specific line assay including measurement of generally low IgG avidities (Mikrogen recomLine Coronavirus IgG [Aviditaet], prototype). Moreover, 100 stored sera collected during summer 2018 (N = 50) and winter season 2018/2019 (N = 50) were included to demonstrate test specificities. These varied from 96.0% (DiaSorin) to 100% (Epitope EDI). A subset of sera were retested with a lateral flow test (STANDARD Q COVID-19 IgM/IgG Duo) and a considerably lower sensitivity was noted. Overall, the diagnostic accuracy of the six SARS-CoV-2 IgG/total antibody assays was good and varied from 92.9% (Euroimmun) to 98.4% (Abbott). Due to the different specificities, results of commercially available SARS-CoV-2 antibody tests should be interpreted with caution. A high proportion of antibody-positive patient sera demonstrated neutralizing capacity against SARS-CoV-2.",10.1101/2020.06.15.20131672,tbr2ynx0,"['The', 'reliable', 'detection', 'of', 'immunoglobulin', 'G', 'IgG', 'or', 'total', 'antibodies', 'directed', 'against', 'the', 'novel', 'severe', 'acute', 'respiratory', 'syndrome', 'coronavirus', 'type', '2', 'SARS', 'CoV', '2', 'is', 'important', 'for', 'clinical', 'diagnostics', 'and', 'epidemiological', 'studies', 'Here', 'we', 'compare', 'the', 'diagnostic', 'accuracy', 'of', 'six', 'commercially', 'available', 'SARS', 'CoV', '2', 'IgG', 'Abbott', 'SARS', 'CoV', '2', 'IgG', 'Diasorin', 'Liaison', 'SARS', 'CoV', '2', 'S1', '2', 'IgG', 'Epitope', 'EDI', 'Novel', 'Coronavirus', 'COVID', '19', 'IgG', 'ELISA', 'Kit', 'Euroimmun', 'Anti', 'SARS', 'CoV', '2', 'ELISA', 'IgG', 'Mikrogen', 'recomWell', 'SARS', 'CoV', '2', 'IgG', 'or', 'total', 'SARS', 'CoV', '2', 'antibody', 'assays', 'Roche', 'Elecsys', 'Anti', 'SARS', 'CoV', '2', 'The', 'test', 'sensitivities', 'were', 'analyzed', 'with', 'a', 'set', 'of', '34', 'sera', 'obtained', 'from', '26', 'patients', 'after', 'PCR', 'confirmed', 'SARS', 'CoV', '2', 'infection', 'and', 'varied', 'from', '76', '9', 'Euroimmun', 'to', '96', '2', 'Abbott', 'The', 'majority', 'of', 'assay', 'results', 'were', 'confirmed', 'in', 'a', 'laboratory', 'developed', 'plaque', 'reduction', 'neutralization', 'test', 'and', 'by', 'a', 'SARS', 'CoV', '2', 'IgG', 'specific', 'line', 'assay', 'including', 'measurement', 'of', 'generally', 'low', 'IgG', 'avidities', 'Mikrogen', 'recomLine', 'Coronavirus', 'IgG', 'Aviditaet', 'prototype', 'Moreover', '100', 'stored', 'sera', 'collected', 'during', 'summer', '2018', 'N', '50', 'and', 'winter', 'season', '2018', '2019', 'N', '50', 'were', 'included', 'to', 'demonstrate', 'test', 'specificities', 'These', 'varied', 'from', '96', '0', 'DiaSorin', 'to', '100', 'Epitope', 'EDI', 'A', 'subset', 'of', 'sera', 'were', 'retested', 'with', 'a', 'lateral', 'flow', 'test', 'STANDARD', 'Q', 'COVID', '19', 'IgM', 'IgG', 'Duo', 'and', 'a', 'considerably', 'lower', 'sensitivity', 'was', 'noted', 'Overall', 'the', 'diagnostic', 'accuracy', 'of', 'the', 'six', 'SARS', 'CoV', '2', 'IgG', 'total', 'antibody', 'assays', 'was', 'good', 'and', 'varied', 'from', '92', '9', 'Euroimmun', 'to', '98', '4', 'Abbott', 'Due', 'to', 'the', 'different', 'specificities', 'results', 'of', 'commercially', 'available', 'SARS', 'CoV', '2', 'antibody', 'tests', 'should', 'be', 'interpreted', 'with', 'caution', 'A', 'high', 'proportion', 'of', 'antibody', 'positive', 'patient', 'sera', 'demonstrated', 'neutralizing', 'capacity', 'against', 'SARS', 'CoV', '2', '']"
73546,SARS-CoV-2 antibody responses determine disease severity in COVID-19 infected individuals,2020-07-29,,http://medrxiv.org/cgi/content/short/2020.07.27.20162321v1?rss=1,"Globally, the COVID-19 pandemic has had extreme consequences for the healthcare system and calls for diagnostic tools to monitor and understand the transmission, pathogenesis and epidemiology, as well as to evaluate future vaccination strategies. Here we have developed novel flexible ELISA-based assays for specific detection of SARS-CoV-2 antibodies against the receptor-binding domain (RBD): An antigen sandwich-ELISA relevant for large population screening and three isotype-specific assays for in-depth diagnostics. Their performance was evaluated in a cohort of 350 convalescent participants with previous COVID-19 infection, ranging from asymptomatic to critical cases. We mapped the antibody responses to different areas on protein N and S and showed that the IgM, A and G antibody responses against RBD are significantly correlated to the disease severity. These assays-and the data generated from them-are highly relevant for diagnostics and prognostics and contribute to the understanding of long-term COVID-19 immunity.",10.1101/2020.07.27.20162321,lbmbp9ca,"['Globally', 'the', 'COVID', '19', 'pandemic', 'has', 'had', 'extreme', 'consequences', 'for', 'the', 'healthcare', 'system', 'and', 'calls', 'for', 'diagnostic', 'tools', 'to', 'monitor', 'and', 'understand', 'the', 'transmission', 'pathogenesis', 'and', 'epidemiology', 'as', 'well', 'as', 'to', 'evaluate', 'future', 'vaccination', 'strategies', 'Here', 'we', 'have', 'developed', 'novel', 'flexible', 'ELISA', 'based', 'assays', 'for', 'specific', 'detection', 'of', 'SARS', 'CoV', '2', 'antibodies', 'against', 'the', 'receptor', 'binding', 'domain', 'RBD', 'An', 'antigen', 'sandwich', 'ELISA', 'relevant', 'for', 'large', 'population', 'screening', 'and', 'three', 'isotype', 'specific', 'assays', 'for', 'in', 'depth', 'diagnostics', 'Their', 'performance', 'was', 'evaluated', 'in', 'a', 'cohort', 'of', '350', 'convalescent', 'participants', 'with', 'previous', 'COVID', '19', 'infection', 'ranging', 'from', 'asymptomatic', 'to', 'critical', 'cases', 'We', 'mapped', 'the', 'antibody', 'responses', 'to', 'different', 'areas', 'on', 'protein', 'N', 'and', 'S', 'and', 'showed', 'that', 'the', 'IgM', 'A', 'and', 'G', 'antibody', 'responses', 'against', 'RBD', 'are', 'significantly', 'correlated', 'to', 'the', 'disease', 'severity', 'These', 'assays', 'and', 'the', 'data', 'generated', 'from', 'them', 'are', 'highly', 'relevant', 'for', 'diagnostics', 'and', 'prognostics', 'and', 'contribute', 'to', 'the', 'understanding', 'of', 'long', 'term', 'COVID', '19', 'immunity', '']"
75514,"Distinct systems serology features in children, elderly and COVID patients",2020-05-18,,http://medrxiv.org/cgi/content/short/2020.05.11.20098459v1?rss=1,"SARS-CoV-2, the pandemic coronavirus that causes COVID-19, has infected millions worldwide, causing unparalleled social and economic disruptions. COVID-19 results in higher pathogenicity and mortality in the elderly compared to children. Examining baseline SARS-CoV-2 cross-reactive coronavirus immunological responses, induced by circulating human coronaviruses, is critical to understand such divergent clinical outcomes. The cross-reactivity of coronavirus antibody responses of healthy children (n=89), adults (n=98), elderly (n=57), and COVID-19 patients (n=19) were analysed by systems serology. While moderate levels of cross-reactive SARS-CoV-2 IgG, IgM, and IgA were detected in healthy individuals, we identified serological signatures associated with SARS-CoV-2 antigen-specific Fc{gamma} receptor binding, which accurately distinguished COVID-19 patients from healthy individuals and suggested that SARS-CoV-2 induces qualitative changes to antibody Fc upon infection, enhancing Fc{gamma} receptor engagement. Vastly different serological signatures were observed between healthy children and elderly, with markedly higher cross-reactive SARS-CoV-2 IgA and IgG observed in elderly, whereas children displayed elevated SARS-CoV-2 IgM, including receptor binding domain-specific IgM with higher avidity. These results suggest that less-experienced humoral immunity associated with higher IgM, as observed in children, may have the potential to induce more potent antibodies upon SARS-CoV-2 infection. These key insights will inform COVID-19 vaccination strategies, improved serological diagnostics and therapeutics.",10.1101/2020.05.11.20098459,8nbmrjrw,"['SARS', 'CoV', '2', 'the', 'pandemic', 'coronavirus', 'that', 'causes', 'COVID', '19', 'has', 'infected', 'millions', 'worldwide', 'causing', 'unparalleled', 'social', 'and', 'economic', 'disruptions', 'COVID', '19', 'results', 'in', 'higher', 'pathogenicity', 'and', 'mortality', 'in', 'the', 'elderly', 'compared', 'to', 'children', 'Examining', 'baseline', 'SARS', 'CoV', '2', 'cross', 'reactive', 'coronavirus', 'immunological', 'responses', 'induced', 'by', 'circulating', 'human', 'coronaviruses', 'is', 'critical', 'to', 'understand', 'such', 'divergent', 'clinical', 'outcomes', 'The', 'cross', 'reactivity', 'of', 'coronavirus', 'antibody', 'responses', 'of', 'healthy', 'children', 'n', '89', 'adults', 'n', '98', 'elderly', 'n', '57', 'and', 'COVID', '19', 'patients', 'n', '19', 'were', 'analysed', 'by', 'systems', 'serology', 'While', 'moderate', 'levels', 'of', 'cross', 'reactive', 'SARS', 'CoV', '2', 'IgG', 'IgM', 'and', 'IgA', 'were', 'detected', 'in', 'healthy', 'individuals', 'we', 'identified', 'serological', 'signatures', 'associated', 'with', 'SARS', 'CoV', '2', 'antigen', 'specific', 'Fc', 'gamma', 'receptor', 'binding', 'which', 'accurately', 'distinguished', 'COVID', '19', 'patients', 'from', 'healthy', 'individuals', 'and', 'suggested', 'that', 'SARS', 'CoV', '2', 'induces', 'qualitative', 'changes', 'to', 'antibody', 'Fc', 'upon', 'infection', 'enhancing', 'Fc', 'gamma', 'receptor', 'engagement', 'Vastly', 'different', 'serological', 'signatures', 'were', 'observed', 'between', 'healthy', 'children', 'and', 'elderly', 'with', 'markedly', 'higher', 'cross', 'reactive', 'SARS', 'CoV', '2', 'IgA', 'and', 'IgG', 'observed', 'in', 'elderly', 'whereas', 'children', 'displayed', 'elevated', 'SARS', 'CoV', '2', 'IgM', 'including', 'receptor', 'binding', 'domain', 'specific', 'IgM', 'with', 'higher', 'avidity', 'These', 'results', 'suggest', 'that', 'less', 'experienced', 'humoral', 'immunity', 'associated', 'with', 'higher', 'IgM', 'as', 'observed', 'in', 'children', 'may', 'have', 'the', 'potential', 'to', 'induce', 'more', 'potent', 'antibodies', 'upon', 'SARS', 'CoV', '2', 'infection', 'These', 'key', 'insights', 'will', 'inform', 'COVID', '19', 'vaccination', 'strategies', 'improved', 'serological', 'diagnostics', 'and', 'therapeutics', '']"
75708,SARS-CoV-2 assays to detect functional antibody responses that block ACE2 recognition in vaccinated animals and infected patients,2020-06-18,bioRxiv,https://doi.org/10.1101/2020.06.17.158527,"SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) has caused a global pandemic of COVID-19 resulting in cases of mild to severe respiratory distress and significant mortality. The global outbreak of this novel coronavirus has now infected >8 million people worldwide with >2 million cases in the US (June 17th, 2020). There is an urgent need for vaccines and therapeutics to combat the spread of this coronavirus. Similarly, the development of diagnostic and research tools to determine infection and vaccine efficacy are critically needed. Molecular assays have been developed to determine viral genetic material present in patients. Serological assays have been developed to determine humoral responses to the spike protein or receptor binding domain (RBD). Detection of functional antibodies can be accomplished through neutralization of live SARS-CoV2 virus, but requires significant expertise, an infectible stable cell line, a specialized BioSafety Level 3 (BSL-3) facility. As large numbers of people return from quarantine, it is critical to have rapid diagnostics that can be widely adopted and employed to assess functional antibody levels in the returning workforce. This type of surrogate neutralization diagnostic can also be used to assess humoral immune responses induced in patients from the large number of vaccine and immunotherapy trials currently on-going. Here we describe a rapid serological diagnostic assay for determining antibody receptor blocking and demonstrate the broad utility of the assay by measuring the antibody functionality of sera from small animals and non-human primates immunized with an experimental SARS-CoV-2 vaccine and using sera from infected patients.",10.1101/2020.06.17.158527,qpbgq5d8,"['SARS', 'CoV', '2', 'Severe', 'Acute', 'Respiratory', 'Syndrome', 'Coronavirus', '2', 'has', 'caused', 'a', 'global', 'pandemic', 'of', 'COVID', '19', 'resulting', 'in', 'cases', 'of', 'mild', 'to', 'severe', 'respiratory', 'distress', 'and', 'significant', 'mortality', 'The', 'global', 'outbreak', 'of', 'this', 'novel', 'coronavirus', 'has', 'now', 'infected', '8', 'million', 'people', 'worldwide', 'with', '2', 'million', 'cases', 'in', 'the', 'US', 'June', '17th', '2020', 'There', 'is', 'an', 'urgent', 'need', 'for', 'vaccines', 'and', 'therapeutics', 'to', 'combat', 'the', 'spread', 'of', 'this', 'coronavirus', 'Similarly', 'the', 'development', 'of', 'diagnostic', 'and', 'research', 'tools', 'to', 'determine', 'infection', 'and', 'vaccine', 'efficacy', 'are', 'critically', 'needed', 'Molecular', 'assays', 'have', 'been', 'developed', 'to', 'determine', 'viral', 'genetic', 'material', 'present', 'in', 'patients', 'Serological', 'assays', 'have', 'been', 'developed', 'to', 'determine', 'humoral', 'responses', 'to', 'the', 'spike', 'protein', 'or', 'receptor', 'binding', 'domain', 'RBD', 'Detection', 'of', 'functional', 'antibodies', 'can', 'be', 'accomplished', 'through', 'neutralization', 'of', 'live', 'SARS', 'CoV2', 'virus', 'but', 'requires', 'significant', 'expertise', 'an', 'infectible', 'stable', 'cell', 'line', 'a', 'specialized', 'BioSafety', 'Level', '3', 'BSL', '3', 'facility', 'As', 'large', 'numbers', 'of', 'people', 'return', 'from', 'quarantine', 'it', 'is', 'critical', 'to', 'have', 'rapid', 'diagnostics', 'that', 'can', 'be', 'widely', 'adopted', 'and', 'employed', 'to', 'assess', 'functional', 'antibody', 'levels', 'in', 'the', 'returning', 'workforce', 'This', 'type', 'of', 'surrogate', 'neutralization', 'diagnostic', 'can', 'also', 'be', 'used', 'to', 'assess', 'humoral', 'immune', 'responses', 'induced', 'in', 'patients', 'from', 'the', 'large', 'number', 'of', 'vaccine', 'and', 'immunotherapy', 'trials', 'currently', 'on', 'going', 'Here', 'we', 'describe', 'a', 'rapid', 'serological', 'diagnostic', 'assay', 'for', 'determining', 'antibody', 'receptor', 'blocking', 'and', 'demonstrate', 'the', 'broad', 'utility', 'of', 'the', 'assay', 'by', 'measuring', 'the', 'antibody', 'functionality', 'of', 'sera', 'from', 'small', 'animals', 'and', 'non', 'human', 'primates', 'immunized', 'with', 'an', 'experimental', 'SARS', 'CoV', '2', 'vaccine', 'and', 'using', 'sera', 'from', 'infected', 'patients', '']"
76158,Multi-site Validation of a SARS-CoV-2 IgG/IgM Rapid Antibody Detection Kit,2020-05-26,,http://medrxiv.org/cgi/content/short/2020.05.25.20112227v1?rss=1,"Deaths from coronavirus disease (COVID-19) have exceeded 300,000 persons globally, calling for rapid development of mobile diagnostics that can assay widespread prevalence and infection rates. Data provided in this study supports the utility of a newly-designed lateral flow immunoassay (LFA) for detecting SARS-CoV-2 IgM and IgG antibodies. We employed a clinical cohort of 1,892 SARS-CoV-2 patients and controls, including individuals diagnosed by RT-qPCR at Yale New Haven Hospital, The First Affiliated Hospital of Anhui Medical University, the Chinese Center for Disease Control and Prevention of Hefei City (Hefei CDC), Anhui Province (Anhui Province CDC), and Fuyang City (Fuyang CDC). The LFA studied here detects SARS-CoV-2 IgM and IgG antibodies with a specificity of 97.9-100% for IgM, 99.7-100% for IgG, and sensitivities ranging from 94.1-100% for patients >14-days post symptom onset. Sensitivity decreases in patients <14-days post symptom onset, which is likely due to lower IgG/IgM antibody levels in this population. Finally, we developed a visual intensity reporting system that we believe will be suitable for laboratory and point-of-care settings, and will provide granular information about antibody levels. Overall our results support the widespread utility of this and other LFAs in assessing population-level epidemiological statistics.",10.1101/2020.05.25.20112227,lqed8b0b,"['Deaths', 'from', 'coronavirus', 'disease', 'COVID', '19', 'have', 'exceeded', '300', '000', 'persons', 'globally', 'calling', 'for', 'rapid', 'development', 'of', 'mobile', 'diagnostics', 'that', 'can', 'assay', 'widespread', 'prevalence', 'and', 'infection', 'rates', 'Data', 'provided', 'in', 'this', 'study', 'supports', 'the', 'utility', 'of', 'a', 'newly', 'designed', 'lateral', 'flow', 'immunoassay', 'LFA', 'for', 'detecting', 'SARS', 'CoV', '2', 'IgM', 'and', 'IgG', 'antibodies', 'We', 'employed', 'a', 'clinical', 'cohort', 'of', '1', '892', 'SARS', 'CoV', '2', 'patients', 'and', 'controls', 'including', 'individuals', 'diagnosed', 'by', 'RT', 'qPCR', 'at', 'Yale', 'New', 'Haven', 'Hospital', 'The', 'First', 'Affiliated', 'Hospital', 'of', 'Anhui', 'Medical', 'University', 'the', 'Chinese', 'Center', 'for', 'Disease', 'Control', 'and', 'Prevention', 'of', 'Hefei', 'City', 'Hefei', 'CDC', 'Anhui', 'Province', 'Anhui', 'Province', 'CDC', 'and', 'Fuyang', 'City', 'Fuyang', 'CDC', 'The', 'LFA', 'studied', 'here', 'detects', 'SARS', 'CoV', '2', 'IgM', 'and', 'IgG', 'antibodies', 'with', 'a', 'specificity', 'of', '97', '9', '100', 'for', 'IgM', '99', '7', '100', 'for', 'IgG', 'and', 'sensitivities', 'ranging', 'from', '94', '1', '100', 'for', 'patients', '14', 'days', 'post', 'symptom', 'onset', 'Sensitivity', 'decreases', 'in', 'patients', '14', 'days', 'post', 'symptom', 'onset', 'which', 'is', 'likely', 'due', 'to', 'lower', 'IgG', 'IgM', 'antibody', 'levels', 'in', 'this', 'population', 'Finally', 'we', 'developed', 'a', 'visual', 'intensity', 'reporting', 'system', 'that', 'we', 'believe', 'will', 'be', 'suitable', 'for', 'laboratory', 'and', 'point', 'of', 'care', 'settings', 'and', 'will', 'provide', 'granular', 'information', 'about', 'antibody', 'levels', 'Overall', 'our', 'results', 'support', 'the', 'widespread', 'utility', 'of', 'this', 'and', 'other', 'LFAs', 'in', 'assessing', 'population', 'level', 'epidemiological', 'statistics', '']"
76548,Antibody Profiling and Prevalence in the US population during the SARS-CoV2 Pandemic,2020-05-05,,http://medrxiv.org/cgi/content/short/2020.04.29.20085068v1?rss=1,"ABSTRACT Background: Antibody diagnostics play an important role in disease detection and can potentially aid in monitoring of the immune responses to see if an individual has developed immunity. Developing high throughput diagnostics which does not involve handling of infectious material becomes imperative in the case of pandemics such as the recent outbreak of SARS-CoV2. Methods: A protein microarray technology was used to detect the plurality of antibody response to four novel antigens namely S1 glycoprotein, Receptor binding domain (RBD), S2 glycoprotein and Nucleoprotein of the novel coronavirus named SARS-CoV2 using serum samples. A DBS card was additionally used to compare its performance with a venipuncture-based serum separator tube (SST) draw. Results: The three main subclasses of antibodies IgM, IgA and IgG were analyzed to see the variations in immune responses in the affected population and compared to their microbial RT-PCR based NP swab results. The clinical sensitivity and specificity were determined to be 98.1% and 98.6%. In the matrix comparison study, which would enable patients to test without risk of transmitting the virus, DBS matched with higher than 98% accuracy to a venipuncture-based SST collection. Conclusion: Multiplex testing enables higher sensitivity and specificity which is essential while establishing exposure on a population scale. This flexible platform along with a discrete collection methodology would be crucial and broadly useful to scale up testing in current and future pandemics. Minimum sample volume that can be collected using DBS cards can be processed in this multiplex pillar plate format enabling the capacity to provide the reliability of high throughput analyzers while having the ease of collection similar to rapid tests. Keywords: COVID19, SARS-CoV2, Antibody, Multiplex, serology, biomarker, immune modulation, prevalence, high sensitivity, high specificity, Dried blood spot, pandemic, venipuncture",10.1101/2020.04.29.20085068,8uu10t4p,"['ABSTRACT', 'Background', 'Antibody', 'diagnostics', 'play', 'an', 'important', 'role', 'in', 'disease', 'detection', 'and', 'can', 'potentially', 'aid', 'in', 'monitoring', 'of', 'the', 'immune', 'responses', 'to', 'see', 'if', 'an', 'individual', 'has', 'developed', 'immunity', 'Developing', 'high', 'throughput', 'diagnostics', 'which', 'does', 'not', 'involve', 'handling', 'of', 'infectious', 'material', 'becomes', 'imperative', 'in', 'the', 'case', 'of', 'pandemics', 'such', 'as', 'the', 'recent', 'outbreak', 'of', 'SARS', 'CoV2', 'Methods', 'A', 'protein', 'microarray', 'technology', 'was', 'used', 'to', 'detect', 'the', 'plurality', 'of', 'antibody', 'response', 'to', 'four', 'novel', 'antigens', 'namely', 'S1', 'glycoprotein', 'Receptor', 'binding', 'domain', 'RBD', 'S2', 'glycoprotein', 'and', 'Nucleoprotein', 'of', 'the', 'novel', 'coronavirus', 'named', 'SARS', 'CoV2', 'using', 'serum', 'samples', 'A', 'DBS', 'card', 'was', 'additionally', 'used', 'to', 'compare', 'its', 'performance', 'with', 'a', 'venipuncture', 'based', 'serum', 'separator', 'tube', 'SST', 'draw', 'Results', 'The', 'three', 'main', 'subclasses', 'of', 'antibodies', 'IgM', 'IgA', 'and', 'IgG', 'were', 'analyzed', 'to', 'see', 'the', 'variations', 'in', 'immune', 'responses', 'in', 'the', 'affected', 'population', 'and', 'compared', 'to', 'their', 'microbial', 'RT', 'PCR', 'based', 'NP', 'swab', 'results', 'The', 'clinical', 'sensitivity', 'and', 'specificity', 'were', 'determined', 'to', 'be', '98', '1', 'and', '98', '6', 'In', 'the', 'matrix', 'comparison', 'study', 'which', 'would', 'enable', 'patients', 'to', 'test', 'without', 'risk', 'of', 'transmitting', 'the', 'virus', 'DBS', 'matched', 'with', 'higher', 'than', '98', 'accuracy', 'to', 'a', 'venipuncture', 'based', 'SST', 'collection', 'Conclusion', 'Multiplex', 'testing', 'enables', 'higher', 'sensitivity', 'and', 'specificity', 'which', 'is', 'essential', 'while', 'establishing', 'exposure', 'on', 'a', 'population', 'scale', 'This', 'flexible', 'platform', 'along', 'with', 'a', 'discrete', 'collection', 'methodology', 'would', 'be', 'crucial', 'and', 'broadly', 'useful', 'to', 'scale', 'up', 'testing', 'in', 'current', 'and', 'future', 'pandemics', 'Minimum', 'sample', 'volume', 'that', 'can', 'be', 'collected', 'using', 'DBS', 'cards', 'can', 'be', 'processed', 'in', 'this', 'multiplex', 'pillar', 'plate', 'format', 'enabling', 'the', 'capacity', 'to', 'provide', 'the', 'reliability', 'of', 'high', 'throughput', 'analyzers', 'while', 'having', 'the', 'ease', 'of', 'collection', 'similar', 'to', 'rapid', 'tests', 'Keywords', 'COVID19', 'SARS', 'CoV2', 'Antibody', 'Multiplex', 'serology', 'biomarker', 'immune', 'modulation', 'prevalence', 'high', 'sensitivity', 'high', 'specificity', 'Dried', 'blood', 'spot', 'pandemic', 'venipuncture']"
77228,A novel in-cell ELISA assay allows rapid and automated quantification of SARS-CoV-2 to analyse neutralizing antibodies and antiviral compounds,2020-06-05,bioRxiv,https://doi.org/10.1101/2020.06.05.135806,"The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently the most pressing medical and socioeconomic challenge. Constituting important correlates of protection, determination of virus-neutralizing antibodies (NAbs) is indispensable for convalescent plasma selection, vaccine candidate evaluation, and immunity certificates. In contrast to standard serology ELISAs, plaque reduction neutralization tests (PRNTs) are laborious, time-consuming, expensive, and restricted to specialized laboratories. To replace microscopic counting-based SARS-CoV-2 PRNTs by a novel assay exempt from genetically modified viruses, which are inapplicable in most diagnostics departments, we established a simple, rapid, and automated SARS-CoV-2 neutralization assay employing an in-cell ELISA (icELISA) approach. After optimization of various parameters such as virus-specific antibodies, cell lines, virus doses, and duration of infection, SARS-CoV-2-infected cells became amenable as direct antigen source for quantitative icELISA. Using commercially available nucleocapsid protein-specific antibodies, viral infection could easily be quantified in human and highly permissive Vero E6 cells by icELISA. Antiviral agents such as human sera containing NAbs or antiviral interferons dose-dependently reduced the SARS-CoV-2-specific signal. Applying increased infectious doses, the icNT was superior to PRNT in discriminating convalescent sera with high from those with intermediate neutralizing capacities. The SARS-CoV-2 icELISA test allows rapid (<48h in total, read-out in seconds) and automated quantification of virus infection in cell culture to evaluate the efficacy of NAbs as well as antiviral drugs, using reagents and equipment present in most routine diagnostics departments. We propose the icELISA and the icNT for COVID-19 research and diagnostics.",10.1101/2020.06.05.135806,grs1zpag,"['The', 'coronavirus', 'disease', '2019', 'COVID', '19', 'caused', 'by', 'the', 'severe', 'acute', 'respiratory', 'syndrome', 'coronavirus', '2', 'SARS', 'CoV', '2', 'is', 'currently', 'the', 'most', 'pressing', 'medical', 'and', 'socioeconomic', 'challenge', 'Constituting', 'important', 'correlates', 'of', 'protection', 'determination', 'of', 'virus', 'neutralizing', 'antibodies', 'NAbs', 'is', 'indispensable', 'for', 'convalescent', 'plasma', 'selection', 'vaccine', 'candidate', 'evaluation', 'and', 'immunity', 'certificates', 'In', 'contrast', 'to', 'standard', 'serology', 'ELISAs', 'plaque', 'reduction', 'neutralization', 'tests', 'PRNTs', 'are', 'laborious', 'time', 'consuming', 'expensive', 'and', 'restricted', 'to', 'specialized', 'laboratories', 'To', 'replace', 'microscopic', 'counting', 'based', 'SARS', 'CoV', '2', 'PRNTs', 'by', 'a', 'novel', 'assay', 'exempt', 'from', 'genetically', 'modified', 'viruses', 'which', 'are', 'inapplicable', 'in', 'most', 'diagnostics', 'departments', 'we', 'established', 'a', 'simple', 'rapid', 'and', 'automated', 'SARS', 'CoV', '2', 'neutralization', 'assay', 'employing', 'an', 'in', 'cell', 'ELISA', 'icELISA', 'approach', 'After', 'optimization', 'of', 'various', 'parameters', 'such', 'as', 'virus', 'specific', 'antibodies', 'cell', 'lines', 'virus', 'doses', 'and', 'duration', 'of', 'infection', 'SARS', 'CoV', '2', 'infected', 'cells', 'became', 'amenable', 'as', 'direct', 'antigen', 'source', 'for', 'quantitative', 'icELISA', 'Using', 'commercially', 'available', 'nucleocapsid', 'protein', 'specific', 'antibodies', 'viral', 'infection', 'could', 'easily', 'be', 'quantified', 'in', 'human', 'and', 'highly', 'permissive', 'Vero', 'E6', 'cells', 'by', 'icELISA', 'Antiviral', 'agents', 'such', 'as', 'human', 'sera', 'containing', 'NAbs', 'or', 'antiviral', 'interferons', 'dose', 'dependently', 'reduced', 'the', 'SARS', 'CoV', '2', 'specific', 'signal', 'Applying', 'increased', 'infectious', 'doses', 'the', 'icNT', 'was', 'superior', 'to', 'PRNT', 'in', 'discriminating', 'convalescent', 'sera', 'with', 'high', 'from', 'those', 'with', 'intermediate', 'neutralizing', 'capacities', 'The', 'SARS', 'CoV', '2', 'icELISA', 'test', 'allows', 'rapid', '48h', 'in', 'total', 'read', 'out', 'in', 'seconds', 'and', 'automated', 'quantification', 'of', 'virus', 'infection', 'in', 'cell', 'culture', 'to', 'evaluate', 'the', 'efficacy', 'of', 'NAbs', 'as', 'well', 'as', 'antiviral', 'drugs', 'using', 'reagents', 'and', 'equipment', 'present', 'in', 'most', 'routine', 'diagnostics', 'departments', 'We', 'propose', 'the', 'icELISA', 'and', 'the', 'icNT', 'for', 'COVID', '19', 'research', 'and', 'diagnostics', '']"
80025,Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation,2020-05-22,,http://medrxiv.org/cgi/content/short/2020.05.18.20101618v1?rss=1,"There is an urgent need for reliable high-throughput serological assays for the management of the ongoing COVID-19 pandemic. Preferably, the performance of serological tests for a novel virus should be determined with clinical specimens against a gold standard, i.e. virus neutralisation. We evaluated specificity and sensitivity of six commercial immunoassays for the detection of SARS-CoV-2 IgG, IgA and IgM antibodies, including four automated assays [Abbott SARS-COV-2 IgG (CE marked), Diasorin Liaison SARS-CoV-2 S1/S2 IgG (research use only), and Euroimmun SARS-CoV-2 IgG and IgA (CE marked)], and two rapid lateral flow (immunocromatographic) tests [Acro Biotech 2019-nCoV IgG/IgM (CE marked) and Xiamen Biotime Biotechnology SARS-CoV-2 IgG/IgM (CE marked)] in comparison with a microneutralisation test (MNT). Two specimen panels from serum samples sent to Helsinki University Hospital Laboratory (HUSLAB) were compiled: the patient panel included sera from PCR confirmed COVID-19 patients, and the negative panel included sera sent for screening of autoimmune diseases and respiratory virus antibodies in 2018 and 2019. The MNT was carried out for all COVID-19 samples (70 serum samples, 62 individuals) and for 53 samples from the negative panel. Forty-one out of 62 COVID-19 patients showed neutralising antibodies with median of 11 days (range 3-51) after onset of symptoms. The specificity and sensitivity values of the commercial tests against MNT, respectively, were as follows: 95.1%/80.5% (Abbott Architect SARS-CoV-2 IgG), 94.9%/43.8% (Diasorin Liaison SARS-CoV-2 IgG), 68.3%/87.8% (Euroimmun SARS-CoV-2 IgA), 86.6%/70.7% (Euroimmun SARS-CoV-2 IgG), 74.4%/56.1% (Acro 2019-nCoV IgG), 69.5%/46.3% (Acro 2019-nCoV IgM), 97.5%/71.9% (Xiamen Biotime SARS-CoV-2 IgG), and 88.8%/81.3% (Xiamen Biotime SARS-CoV-2 IgM). This study shows variable performance values. Laboratories should carefully consider their testing process, such as a two-tier approach, in order to optimize the overall performance of SARS-CoV-2 serodiagnostics.",10.1101/2020.05.18.20101618,hb2bpyag,"['There', 'is', 'an', 'urgent', 'need', 'for', 'reliable', 'high', 'throughput', 'serological', 'assays', 'for', 'the', 'management', 'of', 'the', 'ongoing', 'COVID', '19', 'pandemic', 'Preferably', 'the', 'performance', 'of', 'serological', 'tests', 'for', 'a', 'novel', 'virus', 'should', 'be', 'determined', 'with', 'clinical', 'specimens', 'against', 'a', 'gold', 'standard', 'i', 'e', 'virus', 'neutralisation', 'We', 'evaluated', 'specificity', 'and', 'sensitivity', 'of', 'six', 'commercial', 'immunoassays', 'for', 'the', 'detection', 'of', 'SARS', 'CoV', '2', 'IgG', 'IgA', 'and', 'IgM', 'antibodies', 'including', 'four', 'automated', 'assays', 'Abbott', 'SARS', 'COV', '2', 'IgG', 'CE', 'marked', 'Diasorin', 'Liaison', 'SARS', 'CoV', '2', 'S1', 'S2', 'IgG', 'research', 'use', 'only', 'and', 'Euroimmun', 'SARS', 'CoV', '2', 'IgG', 'and', 'IgA', 'CE', 'marked', 'and', 'two', 'rapid', 'lateral', 'flow', 'immunocromatographic', 'tests', 'Acro', 'Biotech', '2019', 'nCoV', 'IgG', 'IgM', 'CE', 'marked', 'and', 'Xiamen', 'Biotime', 'Biotechnology', 'SARS', 'CoV', '2', 'IgG', 'IgM', 'CE', 'marked', 'in', 'comparison', 'with', 'a', 'microneutralisation', 'test', 'MNT', 'Two', 'specimen', 'panels', 'from', 'serum', 'samples', 'sent', 'to', 'Helsinki', 'University', 'Hospital', 'Laboratory', 'HUSLAB', 'were', 'compiled', 'the', 'patient', 'panel', 'included', 'sera', 'from', 'PCR', 'confirmed', 'COVID', '19', 'patients', 'and', 'the', 'negative', 'panel', 'included', 'sera', 'sent', 'for', 'screening', 'of', 'autoimmune', 'diseases', 'and', 'respiratory', 'virus', 'antibodies', 'in', '2018', 'and', '2019', 'The', 'MNT', 'was', 'carried', 'out', 'for', 'all', 'COVID', '19', 'samples', '70', 'serum', 'samples', '62', 'individuals', 'and', 'for', '53', 'samples', 'from', 'the', 'negative', 'panel', 'Forty', 'one', 'out', 'of', '62', 'COVID', '19', 'patients', 'showed', 'neutralising', 'antibodies', 'with', 'median', 'of', '11', 'days', 'range', '3', '51', 'after', 'onset', 'of', 'symptoms', 'The', 'specificity', 'and', 'sensitivity', 'values', 'of', 'the', 'commercial', 'tests', 'against', 'MNT', 'respectively', 'were', 'as', 'follows', '95', '1', '80', '5', 'Abbott', 'Architect', 'SARS', 'CoV', '2', 'IgG', '94', '9', '43', '8', 'Diasorin', 'Liaison', 'SARS', 'CoV', '2', 'IgG', '68', '3', '87', '8', 'Euroimmun', 'SARS', 'CoV', '2', 'IgA', '86', '6', '70', '7', 'Euroimmun', 'SARS', 'CoV', '2', 'IgG', '74', '4', '56', '1', 'Acro', '2019', 'nCoV', 'IgG', '69', '5', '46', '3', 'Acro', '2019', 'nCoV', 'IgM', '97', '5', '71', '9', 'Xiamen', 'Biotime', 'SARS', 'CoV', '2', 'IgG', 'and', '88', '8', '81', '3', 'Xiamen', 'Biotime', 'SARS', 'CoV', '2', 'IgM', 'This', 'study', 'shows', 'variable', 'performance', 'values', 'Laboratories', 'should', 'carefully', 'consider', 'their', 'testing', 'process', 'such', 'as', 'a', 'two', 'tier', 'approach', 'in', 'order', 'to', 'optimize', 'the', 'overall', 'performance', 'of', 'SARS', 'CoV', '2', 'serodiagnostics', '']"
81941,Production systems for recombinant antibodies.,2008,Frontiers in bioscience : a journal and virtual library,https://www.ncbi.nlm.nih.gov/pubmed/18508530/,"Recombinant antibodies are the fastest growing class of therapeutic proteins. Furthermore, antibodies are key detection reagents in research and diagnostics. The increasing demand for antibodies with regards to amount and quality resulted in the development of a variety of recombinant production systems employing gram-negative and gram-positive bacteria, yeast and filamentous fungi, insect cell lines as well as mammalian cell lines. More recently, antibodies were also successfully produced in transgenic plants and animals. Currently, the production of recombinant antibodies for therapy is performed in mammalian cell lines to reduce the risk of immunogenicity caused by non-human post-translational modifications, in particular glycosylation. However, novel strategies already allow human-like glycosylation patterns in yeast, insect cell lines and transgenic plants. Furthermore, therapeutic strategies not requiring glycosylation of the Fc portion have been conceived, most prominently using bispecific antibodies or scFv fusion proteins, which can be produced in bacteria. Here, we review all current antibody production systems considering their advantages and limitations with respect to intended applications.",,a6ewlox0,"['Recombinant', 'antibodies', 'are', 'the', 'fastest', 'growing', 'class', 'of', 'therapeutic', 'proteins', 'Furthermore', 'antibodies', 'are', 'key', 'detection', 'reagents', 'in', 'research', 'and', 'diagnostics', 'The', 'increasing', 'demand', 'for', 'antibodies', 'with', 'regards', 'to', 'amount', 'and', 'quality', 'resulted', 'in', 'the', 'development', 'of', 'a', 'variety', 'of', 'recombinant', 'production', 'systems', 'employing', 'gram', 'negative', 'and', 'gram', 'positive', 'bacteria', 'yeast', 'and', 'filamentous', 'fungi', 'insect', 'cell', 'lines', 'as', 'well', 'as', 'mammalian', 'cell', 'lines', 'More', 'recently', 'antibodies', 'were', 'also', 'successfully', 'produced', 'in', 'transgenic', 'plants', 'and', 'animals', 'Currently', 'the', 'production', 'of', 'recombinant', 'antibodies', 'for', 'therapy', 'is', 'performed', 'in', 'mammalian', 'cell', 'lines', 'to', 'reduce', 'the', 'risk', 'of', 'immunogenicity', 'caused', 'by', 'non', 'human', 'post', 'translational', 'modifications', 'in', 'particular', 'glycosylation', 'However', 'novel', 'strategies', 'already', 'allow', 'human', 'like', 'glycosylation', 'patterns', 'in', 'yeast', 'insect', 'cell', 'lines', 'and', 'transgenic', 'plants', 'Furthermore', 'therapeutic', 'strategies', 'not', 'requiring', 'glycosylation', 'of', 'the', 'Fc', 'portion', 'have', 'been', 'conceived', 'most', 'prominently', 'using', 'bispecific', 'antibodies', 'or', 'scFv', 'fusion', 'proteins', 'which', 'can', 'be', 'produced', 'in', 'bacteria', 'Here', 'we', 'review', 'all', 'current', 'antibody', 'production', 'systems', 'considering', 'their', 'advantages', 'and', 'limitations', 'with', 'respect', 'to', 'intended', 'applications', '']"
82294,Verification of a specific reaction between an airborne antigen and an immobilized antibody at a gas-solid interface.,2009,Analytical sciences : the international journal of the Japan Society for Analytical Chemistry,https://www.ncbi.nlm.nih.gov/pubmed/19745537/,"With a specific and strong molecular-recognition capability cultivated in humoral acquired immunity, an antibody has been extensively utilized in various applications, such as diagnostics and therapy. However, so far most of its uses have been limited to be in the liquid phase. In view of its potential uses, such as a gas-phase biosensor or a high-performance air filter, we have tried to verify a previously undescribed binding reaction between protein antigens and corresponding antibodies immobilized on a solid surface by using fluorescence resonance energy transfer between the two. Our data showed that the antibody on a solid surface specifically reacted with a protein antigen supplied from the gas phase under the normal ambient condition. Also discovered was that the reaction occurred even faster than that in the liquid phase under several assay conditions.",,d737uzwk,"['With', 'a', 'specific', 'and', 'strong', 'molecular', 'recognition', 'capability', 'cultivated', 'in', 'humoral', 'acquired', 'immunity', 'an', 'antibody', 'has', 'been', 'extensively', 'utilized', 'in', 'various', 'applications', 'such', 'as', 'diagnostics', 'and', 'therapy', 'However', 'so', 'far', 'most', 'of', 'its', 'uses', 'have', 'been', 'limited', 'to', 'be', 'in', 'the', 'liquid', 'phase', 'In', 'view', 'of', 'its', 'potential', 'uses', 'such', 'as', 'a', 'gas', 'phase', 'biosensor', 'or', 'a', 'high', 'performance', 'air', 'filter', 'we', 'have', 'tried', 'to', 'verify', 'a', 'previously', 'undescribed', 'binding', 'reaction', 'between', 'protein', 'antigens', 'and', 'corresponding', 'antibodies', 'immobilized', 'on', 'a', 'solid', 'surface', 'by', 'using', 'fluorescence', 'resonance', 'energy', 'transfer', 'between', 'the', 'two', 'Our', 'data', 'showed', 'that', 'the', 'antibody', 'on', 'a', 'solid', 'surface', 'specifically', 'reacted', 'with', 'a', 'protein', 'antigen', 'supplied', 'from', 'the', 'gas', 'phase', 'under', 'the', 'normal', 'ambient', 'condition', 'Also', 'discovered', 'was', 'that', 'the', 'reaction', 'occurred', 'even', 'faster', 'than', 'that', 'in', 'the', 'liquid', 'phase', 'under', 'several', 'assay', 'conditions', '']"
82654,Nucleocapsid protein-based enzyme-linked immunosorbent assay for detection and differentiation of antibodies against European and North American porcine reproductive and respiratory syndrome virus.,2002,Clinical and diagnostic laboratory immunology,https://www.ncbi.nlm.nih.gov/pubmed/12414748/,"Two types of porcine reproductive and respiratory syndrome virus (PRRSV) have been reported, the European type (EU PRRSV) and the North American type (US PRRSV). We developed a dual enzyme-linked immunosorbent assay (ELISA) for the simultaneous detection and differentiation of serum antibodies directed against either of the two PRRSV types. This tandem PRRS ELISA is based on affinity-purified recombinant nucleocapsid protein expressed in Escherichia coli. Sensitivity and specificity were assessed by using the IDEXX HerdChek PRRS ELISA and the indirect immunofluorescence assay as reference tests. A total of 1571 sera originating from the United States, Europe, and two PRRS-free countries, i.e., Switzerland and New Zealand, were used for validation of the tandem PRRS ELISA. The new test performed at least as well as the reference tests in regard to sensitivity (0.94 for the US PRRS ELISA and 0.93 for the EU PRRS ELISA) and specificity (0.96 for the US PRRS ELISA and 0.99 for the EU PRRS ELISA). Positive sera were correctly differentiated in 582 of 591 cases, indicating a high differentiation capability of this dual ELISA. The robustness and repeatability of the test were assessed and found to be appropriate for diagnostic applications. Taken together, the data indicate that the tandem PRRS ELISA described here is the first differentiation ELISA for PRRSV serology based on recombinant antigen. It is convenient with respect to antigen production, and it is reliable, economical, and highly sensitive and specific. Thus, it is considered to be a powerful tool for routine diagnostics, epidemiological surveys, and outbreak investigations.",,lr9gb0sb,"['Two', 'types', 'of', 'porcine', 'reproductive', 'and', 'respiratory', 'syndrome', 'virus', 'PRRSV', 'have', 'been', 'reported', 'the', 'European', 'type', 'EU', 'PRRSV', 'and', 'the', 'North', 'American', 'type', 'US', 'PRRSV', 'We', 'developed', 'a', 'dual', 'enzyme', 'linked', 'immunosorbent', 'assay', 'ELISA', 'for', 'the', 'simultaneous', 'detection', 'and', 'differentiation', 'of', 'serum', 'antibodies', 'directed', 'against', 'either', 'of', 'the', 'two', 'PRRSV', 'types', 'This', 'tandem', 'PRRS', 'ELISA', 'is', 'based', 'on', 'affinity', 'purified', 'recombinant', 'nucleocapsid', 'protein', 'expressed', 'in', 'Escherichia', 'coli', 'Sensitivity', 'and', 'specificity', 'were', 'assessed', 'by', 'using', 'the', 'IDEXX', 'HerdChek', 'PRRS', 'ELISA', 'and', 'the', 'indirect', 'immunofluorescence', 'assay', 'as', 'reference', 'tests', 'A', 'total', 'of', '1571', 'sera', 'originating', 'from', 'the', 'United', 'States', 'Europe', 'and', 'two', 'PRRS', 'free', 'countries', 'i', 'e', 'Switzerland', 'and', 'New', 'Zealand', 'were', 'used', 'for', 'validation', 'of', 'the', 'tandem', 'PRRS', 'ELISA', 'The', 'new', 'test', 'performed', 'at', 'least', 'as', 'well', 'as', 'the', 'reference', 'tests', 'in', 'regard', 'to', 'sensitivity', '0', '94', 'for', 'the', 'US', 'PRRS', 'ELISA', 'and', '0', '93', 'for', 'the', 'EU', 'PRRS', 'ELISA', 'and', 'specificity', '0', '96', 'for', 'the', 'US', 'PRRS', 'ELISA', 'and', '0', '99', 'for', 'the', 'EU', 'PRRS', 'ELISA', 'Positive', 'sera', 'were', 'correctly', 'differentiated', 'in', '582', 'of', '591', 'cases', 'indicating', 'a', 'high', 'differentiation', 'capability', 'of', 'this', 'dual', 'ELISA', 'The', 'robustness', 'and', 'repeatability', 'of', 'the', 'test', 'were', 'assessed', 'and', 'found', 'to', 'be', 'appropriate', 'for', 'diagnostic', 'applications', 'Taken', 'together', 'the', 'data', 'indicate', 'that', 'the', 'tandem', 'PRRS', 'ELISA', 'described', 'here', 'is', 'the', 'first', 'differentiation', 'ELISA', 'for', 'PRRSV', 'serology', 'based', 'on', 'recombinant', 'antigen', 'It', 'is', 'convenient', 'with', 'respect', 'to', 'antigen', 'production', 'and', 'it', 'is', 'reliable', 'economical', 'and', 'highly', 'sensitive', 'and', 'specific', 'Thus', 'it', 'is', 'considered', 'to', 'be', 'a', 'powerful', 'tool', 'for', 'routine', 'diagnostics', 'epidemiological', 'surveys', 'and', 'outbreak', 'investigations', '']"
82843,Molecular targets for diagnostics and therapeutics of severe acute respiratory syndrome (SARS-CoV).,2008,"Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques",https://www.ncbi.nlm.nih.gov/pubmed/19203466/,"PURPOSE The large number of deaths in a short period of time due to the spread of severe acute respiratory syndrome (SARS) infection led to the unparalleled collaborative efforts world wide to determine and characterize the new coronavirus (SARS-CoV). The full genome sequence was determined within weeks of the first outbreak by the Canadian group with international collaboration. As per the World Health Organization (WHO), the continual lack of a rapid laboratory test to aid the early diagnosis of suspected cases of SARS makes this area a priority for future research. To prevent deaths in the future, early diagnosis and therapy of this infectious disease is of paramount importance. METHODS This review describes the specific molecular targets for diagnostics and therapeutics of viral infection. RESULTS The three major diagnostic methods available for SARS includes viral RNA detection by reverse transcription polymerase chain reaction (RT-PCR), virus induced antibodies by immunofluorescence assay (IFA) or by enzyme linked immunosorbant assay (ELISA) of nucleocapsid protein (NP). The spike glycoprotein of SARS-CoV is the major inducer of neutralizing antibodies. The receptor binding domain (RBD) in the S1 region of the spike glycoprotein contains multiple conformational epitopes that induces highly potent neutralizing antibodies. The genetically engineered attenuated form of the virus or viral vector vaccine encoding for the SARS-CoV spike glycoprotein has been shown to elicit protective immunity in vaccinated animals. CONCLUSION NP is the preferred target for routine detection of SARS-CoV infection by ELISA which is an economical method compared to other methods. The RBD of the spike glycoprotein is both a functional domain for cell receptor binding and also a major neutralizing determinant of SARS-CoV. The progress in evaluating a therapeutic or vaccine would depend on the avail ability of clinically relevant animal model.",,qxiyo47f,"['PURPOSE', 'The', 'large', 'number', 'of', 'deaths', 'in', 'a', 'short', 'period', 'of', 'time', 'due', 'to', 'the', 'spread', 'of', 'severe', 'acute', 'respiratory', 'syndrome', 'SARS', 'infection', 'led', 'to', 'the', 'unparalleled', 'collaborative', 'efforts', 'world', 'wide', 'to', 'determine', 'and', 'characterize', 'the', 'new', 'coronavirus', 'SARS', 'CoV', 'The', 'full', 'genome', 'sequence', 'was', 'determined', 'within', 'weeks', 'of', 'the', 'first', 'outbreak', 'by', 'the', 'Canadian', 'group', 'with', 'international', 'collaboration', 'As', 'per', 'the', 'World', 'Health', 'Organization', 'WHO', 'the', 'continual', 'lack', 'of', 'a', 'rapid', 'laboratory', 'test', 'to', 'aid', 'the', 'early', 'diagnosis', 'of', 'suspected', 'cases', 'of', 'SARS', 'makes', 'this', 'area', 'a', 'priority', 'for', 'future', 'research', 'To', 'prevent', 'deaths', 'in', 'the', 'future', 'early', 'diagnosis', 'and', 'therapy', 'of', 'this', 'infectious', 'disease', 'is', 'of', 'paramount', 'importance', 'METHODS', 'This', 'review', 'describes', 'the', 'specific', 'molecular', 'targets', 'for', 'diagnostics', 'and', 'therapeutics', 'of', 'viral', 'infection', 'RESULTS', 'The', 'three', 'major', 'diagnostic', 'methods', 'available', 'for', 'SARS', 'includes', 'viral', 'RNA', 'detection', 'by', 'reverse', 'transcription', 'polymerase', 'chain', 'reaction', 'RT', 'PCR', 'virus', 'induced', 'antibodies', 'by', 'immunofluorescence', 'assay', 'IFA', 'or', 'by', 'enzyme', 'linked', 'immunosorbant', 'assay', 'ELISA', 'of', 'nucleocapsid', 'protein', 'NP', 'The', 'spike', 'glycoprotein', 'of', 'SARS', 'CoV', 'is', 'the', 'major', 'inducer', 'of', 'neutralizing', 'antibodies', 'The', 'receptor', 'binding', 'domain', 'RBD', 'in', 'the', 'S1', 'region', 'of', 'the', 'spike', 'glycoprotein', 'contains', 'multiple', 'conformational', 'epitopes', 'that', 'induces', 'highly', 'potent', 'neutralizing', 'antibodies', 'The', 'genetically', 'engineered', 'attenuated', 'form', 'of', 'the', 'virus', 'or', 'viral', 'vector', 'vaccine', 'encoding', 'for', 'the', 'SARS', 'CoV', 'spike', 'glycoprotein', 'has', 'been', 'shown', 'to', 'elicit', 'protective', 'immunity', 'in', 'vaccinated', 'animals', 'CONCLUSION', 'NP', 'is', 'the', 'preferred', 'target', 'for', 'routine', 'detection', 'of', 'SARS', 'CoV', 'infection', 'by', 'ELISA', 'which', 'is', 'an', 'economical', 'method', 'compared', 'to', 'other', 'methods', 'The', 'RBD', 'of', 'the', 'spike', 'glycoprotein', 'is', 'both', 'a', 'functional', 'domain', 'for', 'cell', 'receptor', 'binding', 'and', 'also', 'a', 'major', 'neutralizing', 'determinant', 'of', 'SARS', 'CoV', 'The', 'progress', 'in', 'evaluating', 'a', 'therapeutic', 'or', 'vaccine', 'would', 'depend', 'on', 'the', 'avail', 'ability', 'of', 'clinically', 'relevant', 'animal', 'model', '']"
83692,[Construction and screening of SARS-CoV S protein-specific phage displayed antigen library].,2013,Bing du xue bao = Chinese journal of virology,https://www.ncbi.nlm.nih.gov/pubmed/23905471/,"The aim of this study is to construct a SARS-CoV S protein-specific phage displayed antigen library for the epitope characterization of anti-S monoclonal antibodies (mAbs). First, the full-length gene of SARS-S protein was PCR amplified, purified and then digested with DNase I to obtain DNA fragments in the size range of 50-500 bp. The resulting fragments were blunt-end ligated to the modified phage display vector pComb3XSS. The reactions were electrotransformed into XL1-Blue and infected with VCSM13 helper phage. The SARS-CoV S protein-specific phage displayed antigen library was biopanned and screened against two anti-S mAbs, S-M1 and S-M2. The results showed that we successfully constructed the phage displayed antigen library with a size of 5.7 x 10(6). After three-rounds of biopanning, 14 positive phage clones for S-M1 and 15 for S-M2 were respectively identified. Sequence analyses revealed the possible epitopes of two mAbs. Therefore, the S protein-specific phage displayed antigen library provides a crucial platform for the epitope characterization of anti-S antibodies and it is highly valuable for development of SARS vaccines and diagnostics.",,rmjvb8v6,"['The', 'aim', 'of', 'this', 'study', 'is', 'to', 'construct', 'a', 'SARS', 'CoV', 'S', 'protein', 'specific', 'phage', 'displayed', 'antigen', 'library', 'for', 'the', 'epitope', 'characterization', 'of', 'anti', 'S', 'monoclonal', 'antibodies', 'mAbs', 'First', 'the', 'full', 'length', 'gene', 'of', 'SARS', 'S', 'protein', 'was', 'PCR', 'amplified', 'purified', 'and', 'then', 'digested', 'with', 'DNase', 'I', 'to', 'obtain', 'DNA', 'fragments', 'in', 'the', 'size', 'range', 'of', '50', '500', 'bp', 'The', 'resulting', 'fragments', 'were', 'blunt', 'end', 'ligated', 'to', 'the', 'modified', 'phage', 'display', 'vector', 'pComb3XSS', 'The', 'reactions', 'were', 'electrotransformed', 'into', 'XL1', 'Blue', 'and', 'infected', 'with', 'VCSM13', 'helper', 'phage', 'The', 'SARS', 'CoV', 'S', 'protein', 'specific', 'phage', 'displayed', 'antigen', 'library', 'was', 'biopanned', 'and', 'screened', 'against', 'two', 'anti', 'S', 'mAbs', 'S', 'M1', 'and', 'S', 'M2', 'The', 'results', 'showed', 'that', 'we', 'successfully', 'constructed', 'the', 'phage', 'displayed', 'antigen', 'library', 'with', 'a', 'size', 'of', '5', '7', 'x', '10', '6', 'After', 'three', 'rounds', 'of', 'biopanning', '14', 'positive', 'phage', 'clones', 'for', 'S', 'M1', 'and', '15', 'for', 'S', 'M2', 'were', 'respectively', 'identified', 'Sequence', 'analyses', 'revealed', 'the', 'possible', 'epitopes', 'of', 'two', 'mAbs', 'Therefore', 'the', 'S', 'protein', 'specific', 'phage', 'displayed', 'antigen', 'library', 'provides', 'a', 'crucial', 'platform', 'for', 'the', 'epitope', 'characterization', 'of', 'anti', 'S', 'antibodies', 'and', 'it', 'is', 'highly', 'valuable', 'for', 'development', 'of', 'SARS', 'vaccines', 'and', 'diagnostics', '']"
88005,[Rapid point-of-care serology testing for sars-cov-2].,2020-05-27,Lakartidningen,https://www.ncbi.nlm.nih.gov/pubmed/32463475/,"Increasing evidence indicates immunity against severe acute respiratory syndrome coronavirus 2 (sars-cov-2) after covid-19, but it remains unclear for how long the protection remains. Serology testing seems to have a higher sensitivity than molecular diagnostics from 8 days after onset of symtoms, and should be part of risk assessment and epidemiological studies of COVID-19. The performance of commercial serological point-of-care (POC) lateral flow tests are highly manufacturer-dependant. Low sensitivity increases the risk of false negative results and could result in unnecessary quarantine of test persons with developed antibodies. Low specificity increases the risk of false positive results and could lead to false assumptions of immunity. Carefully selected serological POC tests for sars-cov-2 can be used in large scale testing but should only be used by licensed medical staff able to understand their limitations and interpret the results.",,91872v0l,"['Increasing', 'evidence', 'indicates', 'immunity', 'against', 'severe', 'acute', 'respiratory', 'syndrome', 'coronavirus', '2', 'sars', 'cov', '2', 'after', 'covid', '19', 'but', 'it', 'remains', 'unclear', 'for', 'how', 'long', 'the', 'protection', 'remains', 'Serology', 'testing', 'seems', 'to', 'have', 'a', 'higher', 'sensitivity', 'than', 'molecular', 'diagnostics', 'from', '8', 'days', 'after', 'onset', 'of', 'symtoms', 'and', 'should', 'be', 'part', 'of', 'risk', 'assessment', 'and', 'epidemiological', 'studies', 'of', 'COVID', '19', 'The', 'performance', 'of', 'commercial', 'serological', 'point', 'of', 'care', 'POC', 'lateral', 'flow', 'tests', 'are', 'highly', 'manufacturer', 'dependant', 'Low', 'sensitivity', 'increases', 'the', 'risk', 'of', 'false', 'negative', 'results', 'and', 'could', 'result', 'in', 'unnecessary', 'quarantine', 'of', 'test', 'persons', 'with', 'developed', 'antibodies', 'Low', 'specificity', 'increases', 'the', 'risk', 'of', 'false', 'positive', 'results', 'and', 'could', 'lead', 'to', 'false', 'assumptions', 'of', 'immunity', 'Carefully', 'selected', 'serological', 'POC', 'tests', 'for', 'sars', 'cov', '2', 'can', 'be', 'used', 'in', 'large', 'scale', 'testing', 'but', 'should', 'only', 'be', 'used', 'by', 'licensed', 'medical', 'staff', 'able', 'to', 'understand', 'their', 'limitations', 'and', 'interpret', 'the', 'results', '']"
88793,Development of recombinant nucleoprotein-based diagnostic systems for Lassa fever.,2007,Clinical and vaccine immunology : CVI,https://www.ncbi.nlm.nih.gov/pubmed/17634509/,"Diagnostic systems for Lassa fever (LF), a viral hemorrhagic fever caused by Lassa virus (LASV), such as enzyme immunoassays for the detection of LASV antibodies and LASV antigens, were developed using the recombinant nucleoprotein (rNP) of LASV (LASV-rNP). The LASV-rNP was expressed in a recombinant baculovirus system. LASV-rNP was used as an antigen in the detection of LASV-antibodies and as an immunogen for the production of monoclonal antibodies. The LASV-rNP was also expressed in HeLa cells by transfection with the expression vector encoding cDNA of the LASV-NP gene. An immunoglobulin G enzyme-linked immunosorbent assay (ELISA) using LASV-rNP and an indirect immunofluorescence assay using LASV-rNP-expressing HeLa cells were confirmed to have high sensitivity and specificity in the detection of LASV-antibodies. A novel monoclonal antibody to LASV-rNP, monoclonal antibody 4A5, was established. A sandwich antigen capture (Ag-capture) ELISA using the monoclonal antibody and an anti-LASV-rNP rabbit serum as capture and detection antibodies, respectively, was then developed. Authentic LASV nucleoprotein in serum samples collected from hamsters experimentally infected with LASV was detected by the Ag-capture ELISA. The Ag-capture ELISA specifically detected LASV-rNP but not the rNPs of lymphocytic choriomeningitis virus or Junin virus. The sensitivity of the Ag-capture ELISA in detecting LASV antigens was comparable to that of reverse transcription-PCR in detecting LASV RNA. These LASV rNP-based diagnostics were confirmed to be useful in the diagnosis of LF even in institutes without a high containment laboratory, since the antigens can be prepared without manipulation of the infectious viruses.",,izg86lim,"['Diagnostic', 'systems', 'for', 'Lassa', 'fever', 'LF', 'a', 'viral', 'hemorrhagic', 'fever', 'caused', 'by', 'Lassa', 'virus', 'LASV', 'such', 'as', 'enzyme', 'immunoassays', 'for', 'the', 'detection', 'of', 'LASV', 'antibodies', 'and', 'LASV', 'antigens', 'were', 'developed', 'using', 'the', 'recombinant', 'nucleoprotein', 'rNP', 'of', 'LASV', 'LASV', 'rNP', 'The', 'LASV', 'rNP', 'was', 'expressed', 'in', 'a', 'recombinant', 'baculovirus', 'system', 'LASV', 'rNP', 'was', 'used', 'as', 'an', 'antigen', 'in', 'the', 'detection', 'of', 'LASV', 'antibodies', 'and', 'as', 'an', 'immunogen', 'for', 'the', 'production', 'of', 'monoclonal', 'antibodies', 'The', 'LASV', 'rNP', 'was', 'also', 'expressed', 'in', 'HeLa', 'cells', 'by', 'transfection', 'with', 'the', 'expression', 'vector', 'encoding', 'cDNA', 'of', 'the', 'LASV', 'NP', 'gene', 'An', 'immunoglobulin', 'G', 'enzyme', 'linked', 'immunosorbent', 'assay', 'ELISA', 'using', 'LASV', 'rNP', 'and', 'an', 'indirect', 'immunofluorescence', 'assay', 'using', 'LASV', 'rNP', 'expressing', 'HeLa', 'cells', 'were', 'confirmed', 'to', 'have', 'high', 'sensitivity', 'and', 'specificity', 'in', 'the', 'detection', 'of', 'LASV', 'antibodies', 'A', 'novel', 'monoclonal', 'antibody', 'to', 'LASV', 'rNP', 'monoclonal', 'antibody', '4A5', 'was', 'established', 'A', 'sandwich', 'antigen', 'capture', 'Ag', 'capture', 'ELISA', 'using', 'the', 'monoclonal', 'antibody', 'and', 'an', 'anti', 'LASV', 'rNP', 'rabbit', 'serum', 'as', 'capture', 'and', 'detection', 'antibodies', 'respectively', 'was', 'then', 'developed', 'Authentic', 'LASV', 'nucleoprotein', 'in', 'serum', 'samples', 'collected', 'from', 'hamsters', 'experimentally', 'infected', 'with', 'LASV', 'was', 'detected', 'by', 'the', 'Ag', 'capture', 'ELISA', 'The', 'Ag', 'capture', 'ELISA', 'specifically', 'detected', 'LASV', 'rNP', 'but', 'not', 'the', 'rNPs', 'of', 'lymphocytic', 'choriomeningitis', 'virus', 'or', 'Junin', 'virus', 'The', 'sensitivity', 'of', 'the', 'Ag', 'capture', 'ELISA', 'in', 'detecting', 'LASV', 'antigens', 'was', 'comparable', 'to', 'that', 'of', 'reverse', 'transcription', 'PCR', 'in', 'detecting', 'LASV', 'RNA', 'These', 'LASV', 'rNP', 'based', 'diagnostics', 'were', 'confirmed', 'to', 'be', 'useful', 'in', 'the', 'diagnosis', 'of', 'LF', 'even', 'in', 'institutes', 'without', 'a', 'high', 'containment', 'laboratory', 'since', 'the', 'antigens', 'can', 'be', 'prepared', 'without', 'manipulation', 'of', 'the', 'infectious', 'viruses', '']"
93219,Evaluation of the EDI enzyme linked immunosorbent assays for the detection of SARS-CoV-2 IgM and IgG antibodies in human plasma,2020,Clin Chim Acta,,"BACKGROUND: Besides SARS-CoV-2 RT-PCR testing, serological testing is emerging as additional option in COVID-19 diagnostics. Aim of this study was to evaluate novel immunoassays for detection of SARS-CoV-2 antibodies in human plasma. METHODS: Using EDITM Novel Coronavirus COVID-19 Enzyme Linked Immunosorbent Assays (ELISAs), we measured SARS-CoV-2 IgM and IgG antibodies in 64 SARS-CoV-2 RT-PCR confirmed COVID-19 patients with serial blood samples (n = 104) collected at different time points from symptom onset. Blood samples from 200 healthy blood donors and 256 intensive care unit (ICU) patients collected before the COVID-19 outbreak were also used. RESULTS: The positivity rates in the COVID-19 patients were 5.9% for IgM and 2.9% for IgG &#8804; 5 days after symptom onset; Between day 5 and day 10 the positivity rates were 37.1% for IgM and 37.1% for IgG and rose to 76.4% for IgM and 82.4% for IgG after > 10-15 days. After 15-22 days the ""true"" positivity rates were 94.4% for IgM and 100% for IgG. The ""false"" positivity rates were 0.5% for IgM and 1.0% for IgG in the healthy blood donors, 1.6% for IgM and 1.2% for IgG in ICU patients. CONCLUSIONS: This study shows high ""true"" vs. low ""false"" positivity rates for the EDITM SARS-CoV-2 IgM and IgG ELISAs.",,zvj00qjj,"['BACKGROUND', 'Besides', 'SARS', 'CoV', '2', 'RT', 'PCR', 'testing', 'serological', 'testing', 'is', 'emerging', 'as', 'additional', 'option', 'in', 'COVID', '19', 'diagnostics', 'Aim', 'of', 'this', 'study', 'was', 'to', 'evaluate', 'novel', 'immunoassays', 'for', 'detection', 'of', 'SARS', 'CoV', '2', 'antibodies', 'in', 'human', 'plasma', 'METHODS', 'Using', 'EDITM', 'Novel', 'Coronavirus', 'COVID', '19', 'Enzyme', 'Linked', 'Immunosorbent', 'Assays', 'ELISAs', 'we', 'measured', 'SARS', 'CoV', '2', 'IgM', 'and', 'IgG', 'antibodies', 'in', '64', 'SARS', 'CoV', '2', 'RT', 'PCR', 'confirmed', 'COVID', '19', 'patients', 'with', 'serial', 'blood', 'samples', 'n', '104', 'collected', 'at', 'different', 'time', 'points', 'from', 'symptom', 'onset', 'Blood', 'samples', 'from', '200', 'healthy', 'blood', 'donors', 'and', '256', 'intensive', 'care', 'unit', 'ICU', 'patients', 'collected', 'before', 'the', 'COVID', '19', 'outbreak', 'were', 'also', 'used', 'RESULTS', 'The', 'positivity', 'rates', 'in', 'the', 'COVID', '19', 'patients', 'were', '5', '9', 'for', 'IgM', 'and', '2', '9', 'for', 'IgG', '8804', '5', 'days', 'after', 'symptom', 'onset', 'Between', 'day', '5', 'and', 'day', '10', 'the', 'positivity', 'rates', 'were', '37', '1', 'for', 'IgM', 'and', '37', '1', 'for', 'IgG', 'and', 'rose', 'to', '76', '4', 'for', 'IgM', 'and', '82', '4', 'for', 'IgG', 'after', '10', '15', 'days', 'After', '15', '22', 'days', 'the', 'true', 'positivity', 'rates', 'were', '94', '4', 'for', 'IgM', 'and', '100', 'for', 'IgG', 'The', 'false', 'positivity', 'rates', 'were', '0', '5', 'for', 'IgM', 'and', '1', '0', 'for', 'IgG', 'in', 'the', 'healthy', 'blood', 'donors', '1', '6', 'for', 'IgM', 'and', '1', '2', 'for', 'IgG', 'in', 'ICU', 'patients', 'CONCLUSIONS', 'This', 'study', 'shows', 'high', 'true', 'vs', 'low', 'false', 'positivity', 'rates', 'for', 'the', 'EDITM', 'SARS', 'CoV', '2', 'IgM', 'and', 'IgG', 'ELISAs', '']"
95608,Diagnostic accuracy of an automated chemiluminescent immunoassay for anti-SARS-CoV-2 IgM and IgG antibodies: an Italian experience,2020,J. med. virol,,"A pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been spreading throughout the world. Though molecular diagnostic tests are the gold standard for COVID-19, serological testing is emerging as a potential surveillance tool, in addition to its complementary role in COVID-19 diagnostics. Indubitably quantitative serological testing provides greater advantages than qualitative tests but today there is still little known about serological diagnostics and what the most appropriate role quantitative tests might play. Sixty-one COVID-19 patients and 64 patients from a control group were tested by iFlash1800 CLIA analyzer for anti-SARS CoV-2 antibodies IgM and IgG. All COVID-19 patients were hospitalized in San Giovanni di Dio Hospital (Florence, Italy) and had a positive oro/nasopharyngeal swab reverse-transcription polymerase chain reaction result. The highest sensitivity with a very good specificity performance was reached at a cutoff value of 10.0 AU/mL for IgM and of 7.1 for IgG antibodies, hence near to the manufacturer's cutoff values of 10 AU/mL for both isotypes. The receiver operating characteristic curves showed area under the curve values of 0.918 and 0.980 for anti-SARS CoV-2 antibodies IgM and IgG, respectively. iFlash1800 CLIA analyzer has shown highly accurate results for the anti-SARS-CoV-2 antibodies profile and can be considered an excellent tool for COVID-19 diagnostics.",,1dbeh8q7,"['A', 'pandemic', 'of', 'coronavirus', 'disease', '2019', 'COVID', '19', 'caused', 'by', 'severe', 'acute', 'respiratory', 'syndrome', 'coronavirus', '2', 'SARS', 'CoV', '2', 'has', 'been', 'spreading', 'throughout', 'the', 'world', 'Though', 'molecular', 'diagnostic', 'tests', 'are', 'the', 'gold', 'standard', 'for', 'COVID', '19', 'serological', 'testing', 'is', 'emerging', 'as', 'a', 'potential', 'surveillance', 'tool', 'in', 'addition', 'to', 'its', 'complementary', 'role', 'in', 'COVID', '19', 'diagnostics', 'Indubitably', 'quantitative', 'serological', 'testing', 'provides', 'greater', 'advantages', 'than', 'qualitative', 'tests', 'but', 'today', 'there', 'is', 'still', 'little', 'known', 'about', 'serological', 'diagnostics', 'and', 'what', 'the', 'most', 'appropriate', 'role', 'quantitative', 'tests', 'might', 'play', 'Sixty', 'one', 'COVID', '19', 'patients', 'and', '64', 'patients', 'from', 'a', 'control', 'group', 'were', 'tested', 'by', 'iFlash1800', 'CLIA', 'analyzer', 'for', 'anti', 'SARS', 'CoV', '2', 'antibodies', 'IgM', 'and', 'IgG', 'All', 'COVID', '19', 'patients', 'were', 'hospitalized', 'in', 'San', 'Giovanni', 'di', 'Dio', 'Hospital', 'Florence', 'Italy', 'and', 'had', 'a', 'positive', 'oro', 'nasopharyngeal', 'swab', 'reverse', 'transcription', 'polymerase', 'chain', 'reaction', 'result', 'The', 'highest', 'sensitivity', 'with', 'a', 'very', 'good', 'specificity', 'performance', 'was', 'reached', 'at', 'a', 'cutoff', 'value', 'of', '10', '0', 'AU', 'mL', 'for', 'IgM', 'and', 'of', '7', '1', 'for', 'IgG', 'antibodies', 'hence', 'near', 'to', 'the', 'manufacturer', 's', 'cutoff', 'values', 'of', '10', 'AU', 'mL', 'for', 'both', 'isotypes', 'The', 'receiver', 'operating', 'characteristic', 'curves', 'showed', 'area', 'under', 'the', 'curve', 'values', 'of', '0', '918', 'and', '0', '980', 'for', 'anti', 'SARS', 'CoV', '2', 'antibodies', 'IgM', 'and', 'IgG', 'respectively', 'iFlash1800', 'CLIA', 'analyzer', 'has', 'shown', 'highly', 'accurate', 'results', 'for', 'the', 'anti', 'SARS', 'CoV', '2', 'antibodies', 'profile', 'and', 'can', 'be', 'considered', 'an', 'excellent', 'tool', 'for', 'COVID', '19', 'diagnostics', '']"
98529,Current laboratory diagnostics of coronavirus disease 2019 (COVID-19),2020,Acta Biomed,,"Laboratory medicine provides an almost irreplaceable contribution to the diagnostic reasoning and managed care of most human pathologies. The novel coronavirus disease 2019 (COVID-19) is not an exception to this paradigm. Although the relatively recent emergence does not allow to draw definitive conclusions on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) diagnostics, some standpoints can be conveyed. First and foremost, it seems now clear that we will be living together with this virus for quite a long time, so that our vigilance and responsiveness against the emergence of new local outbreaks shall be maintained at the highest possible levels. The etiological diagnosis of COVID-19 is, and will remain for the foreseeable future, deeply based on direct identification of viral RNA by means of molecular biology techniques in biological materials, especially upper and lower respiratory tract specimens. Whether other materials, such as blood, urine, stools, saliva and throat washing, will become valid alternatives has not been unequivocally defined so far. As concerns serological testing, promising information can be garnered from preliminary investigations, showing that the vast majority of COVID-19 patients seem to develop a sustained immune response against the virus, characterized especially by emergence of anti-SARS-CoV-2 IgG and IgA, 1 to 2 weeks after the onset of fever and/or respiratory symptoms. Whether these antibodies will have persistent neutralizing activity against the virus is still to be elucidated on individual and general basis. The availability of rapid tests for detecting either viral antigens or anti-SARS-CoV-2 antibodies are a potentially viable opportunity for purposes of epidemiologic surveillance, though more information is needed on accuracy and reliability of these portable immunoassays.",,3y47oszt,"['Laboratory', 'medicine', 'provides', 'an', 'almost', 'irreplaceable', 'contribution', 'to', 'the', 'diagnostic', 'reasoning', 'and', 'managed', 'care', 'of', 'most', 'human', 'pathologies', 'The', 'novel', 'coronavirus', 'disease', '2019', 'COVID', '19', 'is', 'not', 'an', 'exception', 'to', 'this', 'paradigm', 'Although', 'the', 'relatively', 'recent', 'emergence', 'does', 'not', 'allow', 'to', 'draw', 'definitive', 'conclusions', 'on', 'severe', 'acute', 'respiratory', 'syndrome', 'coronavirus', '2', 'SARS', 'CoV', '2', 'diagnostics', 'some', 'standpoints', 'can', 'be', 'conveyed', 'First', 'and', 'foremost', 'it', 'seems', 'now', 'clear', 'that', 'we', 'will', 'be', 'living', 'together', 'with', 'this', 'virus', 'for', 'quite', 'a', 'long', 'time', 'so', 'that', 'our', 'vigilance', 'and', 'responsiveness', 'against', 'the', 'emergence', 'of', 'new', 'local', 'outbreaks', 'shall', 'be', 'maintained', 'at', 'the', 'highest', 'possible', 'levels', 'The', 'etiological', 'diagnosis', 'of', 'COVID', '19', 'is', 'and', 'will', 'remain', 'for', 'the', 'foreseeable', 'future', 'deeply', 'based', 'on', 'direct', 'identification', 'of', 'viral', 'RNA', 'by', 'means', 'of', 'molecular', 'biology', 'techniques', 'in', 'biological', 'materials', 'especially', 'upper', 'and', 'lower', 'respiratory', 'tract', 'specimens', 'Whether', 'other', 'materials', 'such', 'as', 'blood', 'urine', 'stools', 'saliva', 'and', 'throat', 'washing', 'will', 'become', 'valid', 'alternatives', 'has', 'not', 'been', 'unequivocally', 'defined', 'so', 'far', 'As', 'concerns', 'serological', 'testing', 'promising', 'information', 'can', 'be', 'garnered', 'from', 'preliminary', 'investigations', 'showing', 'that', 'the', 'vast', 'majority', 'of', 'COVID', '19', 'patients', 'seem', 'to', 'develop', 'a', 'sustained', 'immune', 'response', 'against', 'the', 'virus', 'characterized', 'especially', 'by', 'emergence', 'of', 'anti', 'SARS', 'CoV', '2', 'IgG', 'and', 'IgA', '1', 'to', '2', 'weeks', 'after', 'the', 'onset', 'of', 'fever', 'and', 'or', 'respiratory', 'symptoms', 'Whether', 'these', 'antibodies', 'will', 'have', 'persistent', 'neutralizing', 'activity', 'against', 'the', 'virus', 'is', 'still', 'to', 'be', 'elucidated', 'on', 'individual', 'and', 'general', 'basis', 'The', 'availability', 'of', 'rapid', 'tests', 'for', 'detecting', 'either', 'viral', 'antigens', 'or', 'anti', 'SARS', 'CoV', '2', 'antibodies', 'are', 'a', 'potentially', 'viable', 'opportunity', 'for', 'purposes', 'of', 'epidemiologic', 'surveillance', 'though', 'more', 'information', 'is', 'needed', 'on', 'accuracy', 'and', 'reliability', 'of', 'these', 'portable', 'immunoassays', '']"
98530,Current laboratory diagnostics of coronavirus disease 2019 (COVID-19),2020,Acta Biomed,,"Laboratory medicine provides an almost irreplaceable contribution to the diagnostic reasoning and managed care of most human pathologies. The novel coronavirus disease 2019 (COVID-19) is not an exception to this paradigm. Although the relatively recent emergence does not allow to draw definitive conclusions on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) diagnostics, some standpoints can be conveyed. First and foremost, it seems now clear that we will be living together with this virus for quite a long time, so that our vigilance and responsiveness against the emergence of new local outbreaks shall be maintained at the highest possible levels. The etiological diagnosis of COVID-19 is, and will remain for the foreseeable future, deeply based on direct identification of viral RNA by means of molecular biology techniques in biological materials, especially upper and lower respiratory tract specimens. Whether other materials, such as blood, urine, stools, saliva and throat washing, will become valid alternatives has not been unequivocally defined so far. As concerns serological testing, promising information can be garnered from preliminary investigations, showing that the vast majority of COVID-19 patients seem to develop a sustained immune response against the virus, characterized especially by emergence of anti-SARS-CoV-2 IgG and IgA, 1 to 2 weeks after the onset of fever and/or respiratory symptoms. Whether these antibodies will have persistent neutralizing activity against the virus is still to be elucidated on individual and general basis. The availability of rapid tests for detecting either viral antigens or anti-SARS-CoV-2 antibodies are a potentially viable opportunity for purposes of epidemiologic surveillance, though more information is needed on accuracy and reliability of these portable immunoassays.",,40tgyur8,"['Laboratory', 'medicine', 'provides', 'an', 'almost', 'irreplaceable', 'contribution', 'to', 'the', 'diagnostic', 'reasoning', 'and', 'managed', 'care', 'of', 'most', 'human', 'pathologies', 'The', 'novel', 'coronavirus', 'disease', '2019', 'COVID', '19', 'is', 'not', 'an', 'exception', 'to', 'this', 'paradigm', 'Although', 'the', 'relatively', 'recent', 'emergence', 'does', 'not', 'allow', 'to', 'draw', 'definitive', 'conclusions', 'on', 'severe', 'acute', 'respiratory', 'syndrome', 'coronavirus', '2', 'SARS', 'CoV', '2', 'diagnostics', 'some', 'standpoints', 'can', 'be', 'conveyed', 'First', 'and', 'foremost', 'it', 'seems', 'now', 'clear', 'that', 'we', 'will', 'be', 'living', 'together', 'with', 'this', 'virus', 'for', 'quite', 'a', 'long', 'time', 'so', 'that', 'our', 'vigilance', 'and', 'responsiveness', 'against', 'the', 'emergence', 'of', 'new', 'local', 'outbreaks', 'shall', 'be', 'maintained', 'at', 'the', 'highest', 'possible', 'levels', 'The', 'etiological', 'diagnosis', 'of', 'COVID', '19', 'is', 'and', 'will', 'remain', 'for', 'the', 'foreseeable', 'future', 'deeply', 'based', 'on', 'direct', 'identification', 'of', 'viral', 'RNA', 'by', 'means', 'of', 'molecular', 'biology', 'techniques', 'in', 'biological', 'materials', 'especially', 'upper', 'and', 'lower', 'respiratory', 'tract', 'specimens', 'Whether', 'other', 'materials', 'such', 'as', 'blood', 'urine', 'stools', 'saliva', 'and', 'throat', 'washing', 'will', 'become', 'valid', 'alternatives', 'has', 'not', 'been', 'unequivocally', 'defined', 'so', 'far', 'As', 'concerns', 'serological', 'testing', 'promising', 'information', 'can', 'be', 'garnered', 'from', 'preliminary', 'investigations', 'showing', 'that', 'the', 'vast', 'majority', 'of', 'COVID', '19', 'patients', 'seem', 'to', 'develop', 'a', 'sustained', 'immune', 'response', 'against', 'the', 'virus', 'characterized', 'especially', 'by', 'emergence', 'of', 'anti', 'SARS', 'CoV', '2', 'IgG', 'and', 'IgA', '1', 'to', '2', 'weeks', 'after', 'the', 'onset', 'of', 'fever', 'and', 'or', 'respiratory', 'symptoms', 'Whether', 'these', 'antibodies', 'will', 'have', 'persistent', 'neutralizing', 'activity', 'against', 'the', 'virus', 'is', 'still', 'to', 'be', 'elucidated', 'on', 'individual', 'and', 'general', 'basis', 'The', 'availability', 'of', 'rapid', 'tests', 'for', 'detecting', 'either', 'viral', 'antigens', 'or', 'anti', 'SARS', 'CoV', '2', 'antibodies', 'are', 'a', 'potentially', 'viable', 'opportunity', 'for', 'purposes', 'of', 'epidemiologic', 'surveillance', 'though', 'more', 'information', 'is', 'needed', 'on', 'accuracy', 'and', 'reliability', 'of', 'these', 'portable', 'immunoassays', '']"
99409,Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and avidity,2020,Emerg Microbes Infect,,"Coronaviruses cause severe human viral diseases including SARS, MERS and COVID-19. Most recently SARS-CoV-2 virus (causing COVID-19) has led to a pandemic with no successful therapeutics. The SARS-CoV-2 infection relies on trimeric spike (S) proteins to facilitate virus entry into host cells by binding to ACE2 receptor on host cell membranes. Therefore, blocking this interaction with antibodies are promising agents against SARS-CoV-2. Here we describe using humanized llama antibody VHHs against SARS-CoV-2 that would overcome the limitations associated with polyclonal and monoclonal combination therapies. From two llama VHH libraries, unique humanized VHHs that bind to S protein and block the S/ACE2 interaction were identified. Furthermore, pairwise combination of VHHs showed synergistic blocking. Multi-specific antibodies with enhanced affinity and avidity, and improved S/ACE2 blocking are currently being developed using an in-silico approach that also fuses VHHs to Fc domains. Importantly, our current bi-specific antibody shows potent S/ACE2 blocking (KD - 0.25 nM, IC100 â¼ 36.7 nM, IC95 â¼ 12.2 nM, IC50 â¼ 1 nM) which is significantly better than individual monoclonal VHH-Fcs. Overall, this design would equip the VHH-Fcs multiple mechanisms of actions against SARS-CoV-2. Thus, we aim to contribute to the battle against COVID-19 by developing therapeutic antibodies as well as diagnostics.",,qbyz4uz5,"['Coronaviruses', 'cause', 'severe', 'human', 'viral', 'diseases', 'including', 'SARS', 'MERS', 'and', 'COVID', '19', 'Most', 'recently', 'SARS', 'CoV', '2', 'virus', 'causing', 'COVID', '19', 'has', 'led', 'to', 'a', 'pandemic', 'with', 'no', 'successful', 'therapeutics', 'The', 'SARS', 'CoV', '2', 'infection', 'relies', 'on', 'trimeric', 'spike', 'S', 'proteins', 'to', 'facilitate', 'virus', 'entry', 'into', 'host', 'cells', 'by', 'binding', 'to', 'ACE2', 'receptor', 'on', 'host', 'cell', 'membranes', 'Therefore', 'blocking', 'this', 'interaction', 'with', 'antibodies', 'are', 'promising', 'agents', 'against', 'SARS', 'CoV', '2', 'Here', 'we', 'describe', 'using', 'humanized', 'llama', 'antibody', 'VHHs', 'against', 'SARS', 'CoV', '2', 'that', 'would', 'overcome', 'the', 'limitations', 'associated', 'with', 'polyclonal', 'and', 'monoclonal', 'combination', 'therapies', 'From', 'two', 'llama', 'VHH', 'libraries', 'unique', 'humanized', 'VHHs', 'that', 'bind', 'to', 'S', 'protein', 'and', 'block', 'the', 'S', 'ACE2', 'interaction', 'were', 'identified', 'Furthermore', 'pairwise', 'combination', 'of', 'VHHs', 'showed', 'synergistic', 'blocking', 'Multi', 'specific', 'antibodies', 'with', 'enhanced', 'affinity', 'and', 'avidity', 'and', 'improved', 'S', 'ACE2', 'blocking', 'are', 'currently', 'being', 'developed', 'using', 'an', 'in', 'silico', 'approach', 'that', 'also', 'fuses', 'VHHs', 'to', 'Fc', 'domains', 'Importantly', 'our', 'current', 'bi', 'specific', 'antibody', 'shows', 'potent', 'S', 'ACE2', 'blocking', 'KD', '0', '25', 'nM', 'IC100', 'â', '¼', '36', '7', 'nM', 'IC95', 'â', '¼', '12', '2', 'nM', 'IC50', 'â', '¼', '1', 'nM', 'which', 'is', 'significantly', 'better', 'than', 'individual', 'monoclonal', 'VHH', 'Fcs', 'Overall', 'this', 'design', 'would', 'equip', 'the', 'VHH', 'Fcs', 'multiple', 'mechanisms', 'of', 'actions', 'against', 'SARS', 'CoV', '2', 'Thus', 'we', 'aim', 'to', 'contribute', 'to', 'the', 'battle', 'against', 'COVID', '19', 'by', 'developing', 'therapeutic', 'antibodies', 'as', 'well', 'as', 'diagnostics', '']"
99675,SARS-CoV-2 testing in infertile patients: different recommendations in Europe and America,2020,J. assist. reprod. genet,,"The incorporation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing into patient care algorithms has been proposed to mitigate risk. However, the two main professional societies for human reproduction (ESHRE and ASRM) appear divergent on their clinical utility and whether they should be adopted. In this opinion paper, we review the currently available tests and discuss the strengths and weaknesses of the proposed clinical care pathways. Nucleic acid amplification tests are the cornerstone of SARS-CoV-2 testing but test results are largely influenced by viral load, sample site, specimen collection method, and specimen shipment technique, such that a negative result in a symptomatic patient cannot be relied upon. Serological assays for SARS-CoV-2 antibodies exhibit a temporal increase in sensitivity and specificity after symptom onset irrespective of the assay used, with sensitivity estimates ranging from 0 to 50% with the first 3 days of symptoms, to 83 to 88% at 10 days, increasing to almost 100% at &#8805; 14 days. These inherent constraints in diagnostics would suggest that at present there is inadequate evidence to utilize SARS-CoV-2 testing to stratify fertility patients and reliably inform clinical decision-making. The failure to appreciate the characteristics and limitations of the diagnostic tests may lead to disastrous consequences for the patient and the multidisciplinary team looking after them.",,z1ad5uc2,"['The', 'incorporation', 'of', 'severe', 'acute', 'respiratory', 'syndrome', 'coronavirus', '2', 'SARS', 'CoV', '2', 'testing', 'into', 'patient', 'care', 'algorithms', 'has', 'been', 'proposed', 'to', 'mitigate', 'risk', 'However', 'the', 'two', 'main', 'professional', 'societies', 'for', 'human', 'reproduction', 'ESHRE', 'and', 'ASRM', 'appear', 'divergent', 'on', 'their', 'clinical', 'utility', 'and', 'whether', 'they', 'should', 'be', 'adopted', 'In', 'this', 'opinion', 'paper', 'we', 'review', 'the', 'currently', 'available', 'tests', 'and', 'discuss', 'the', 'strengths', 'and', 'weaknesses', 'of', 'the', 'proposed', 'clinical', 'care', 'pathways', 'Nucleic', 'acid', 'amplification', 'tests', 'are', 'the', 'cornerstone', 'of', 'SARS', 'CoV', '2', 'testing', 'but', 'test', 'results', 'are', 'largely', 'influenced', 'by', 'viral', 'load', 'sample', 'site', 'specimen', 'collection', 'method', 'and', 'specimen', 'shipment', 'technique', 'such', 'that', 'a', 'negative', 'result', 'in', 'a', 'symptomatic', 'patient', 'cannot', 'be', 'relied', 'upon', 'Serological', 'assays', 'for', 'SARS', 'CoV', '2', 'antibodies', 'exhibit', 'a', 'temporal', 'increase', 'in', 'sensitivity', 'and', 'specificity', 'after', 'symptom', 'onset', 'irrespective', 'of', 'the', 'assay', 'used', 'with', 'sensitivity', 'estimates', 'ranging', 'from', '0', 'to', '50', 'with', 'the', 'first', '3', 'days', 'of', 'symptoms', 'to', '83', 'to', '88', 'at', '10', 'days', 'increasing', 'to', 'almost', '100', 'at', '8805', '14', 'days', 'These', 'inherent', 'constraints', 'in', 'diagnostics', 'would', 'suggest', 'that', 'at', 'present', 'there', 'is', 'inadequate', 'evidence', 'to', 'utilize', 'SARS', 'CoV', '2', 'testing', 'to', 'stratify', 'fertility', 'patients', 'and', 'reliably', 'inform', 'clinical', 'decision', 'making', 'The', 'failure', 'to', 'appreciate', 'the', 'characteristics', 'and', 'limitations', 'of', 'the', 'diagnostic', 'tests', 'may', 'lead', 'to', 'disastrous', 'consequences', 'for', 'the', 'patient', 'and', 'the', 'multidisciplinary', 'team', 'looking', 'after', 'them', '']"
106232,SARS-CoV-2 antibody testing-questions to be asked,2020,J Allergy Clin Immunol,,"Severe acute respiratory syndrome coronavirus 2 infection and development of coronavirus disease 2019 presents a major health care challenge of global dimensions. Laboratory diagnostics of infected patients, and the assessment of immunity against severe acute respiratory syndrome coronavirus 2, presents a major cornerstone in handling the pandemic. Currently, there is an increase in demand for antibody testing and a large number of tests are already marketed or are in the late stage of development. However, the interpretation of test results depends on many variables and factors, including sensitivity, specificity, potential cross-reactivity and cross-protectivity, the diagnostic value of antibodies of different isotypes, and the use of antibody testing in identification of acutely ill patients or in epidemiological settings. In this article, the recently established COVID-19 Task Force of the German Society for Clinical Chemistry and Laboratory Medicine (DGKL) addresses these issues on the basis of currently available data sets in this rapidly moving field.",,laobflfb,"['Severe', 'acute', 'respiratory', 'syndrome', 'coronavirus', '2', 'infection', 'and', 'development', 'of', 'coronavirus', 'disease', '2019', 'presents', 'a', 'major', 'health', 'care', 'challenge', 'of', 'global', 'dimensions', 'Laboratory', 'diagnostics', 'of', 'infected', 'patients', 'and', 'the', 'assessment', 'of', 'immunity', 'against', 'severe', 'acute', 'respiratory', 'syndrome', 'coronavirus', '2', 'presents', 'a', 'major', 'cornerstone', 'in', 'handling', 'the', 'pandemic', 'Currently', 'there', 'is', 'an', 'increase', 'in', 'demand', 'for', 'antibody', 'testing', 'and', 'a', 'large', 'number', 'of', 'tests', 'are', 'already', 'marketed', 'or', 'are', 'in', 'the', 'late', 'stage', 'of', 'development', 'However', 'the', 'interpretation', 'of', 'test', 'results', 'depends', 'on', 'many', 'variables', 'and', 'factors', 'including', 'sensitivity', 'specificity', 'potential', 'cross', 'reactivity', 'and', 'cross', 'protectivity', 'the', 'diagnostic', 'value', 'of', 'antibodies', 'of', 'different', 'isotypes', 'and', 'the', 'use', 'of', 'antibody', 'testing', 'in', 'identification', 'of', 'acutely', 'ill', 'patients', 'or', 'in', 'epidemiological', 'settings', 'In', 'this', 'article', 'the', 'recently', 'established', 'COVID', '19', 'Task', 'Force', 'of', 'the', 'German', 'Society', 'for', 'Clinical', 'Chemistry', 'and', 'Laboratory', 'Medicine', 'DGKL', 'addresses', 'these', 'issues', 'on', 'the', 'basis', 'of', 'currently', 'available', 'data', 'sets', 'in', 'this', 'rapidly', 'moving', 'field', '']"
106520,Biochemical characterization of SARS-CoV-2 nucleocapsid protein,2020,Biochem Biophys Res Commun,,"The nucleocapsid (N) protein is an important antigen for coronavirus, which participate in RNA package and virus particle release. In this study, we expressed the N protein of SARS-CoV-2 and characterized its biochemical properties. Static light scattering, size exclusive chromatography, and small-angle X-ray scattering (SAXS) showed that the purified N protein is largely a dimer in solution. CD spectra showed that it has a high percentage of disordered region at room temperature while it was best structured at 55 °C, suggesting its structural dynamics. Fluorescence polarization assay showed it has non-specific nucleic acid binding capability, which raised a concern in using it as a diagnostic marker. Immunoblot assays confirmed the presence of IgA, IgM and IgG antibodies against N antigen in COVID-19 infection patients' sera, proving the importance of this antigen in host immunity and diagnostics.",,5v06k96c,"['The', 'nucleocapsid', 'N', 'protein', 'is', 'an', 'important', 'antigen', 'for', 'coronavirus', 'which', 'participate', 'in', 'RNA', 'package', 'and', 'virus', 'particle', 'release', 'In', 'this', 'study', 'we', 'expressed', 'the', 'N', 'protein', 'of', 'SARS', 'CoV', '2', 'and', 'characterized', 'its', 'biochemical', 'properties', 'Static', 'light', 'scattering', 'size', 'exclusive', 'chromatography', 'and', 'small', 'angle', 'X', 'ray', 'scattering', 'SAXS', 'showed', 'that', 'the', 'purified', 'N', 'protein', 'is', 'largely', 'a', 'dimer', 'in', 'solution', 'CD', 'spectra', 'showed', 'that', 'it', 'has', 'a', 'high', 'percentage', 'of', 'disordered', 'region', 'at', 'room', 'temperature', 'while', 'it', 'was', 'best', 'structured', 'at', '55', 'C', 'suggesting', 'its', 'structural', 'dynamics', 'Fluorescence', 'polarization', 'assay', 'showed', 'it', 'has', 'non', 'specific', 'nucleic', 'acid', 'binding', 'capability', 'which', 'raised', 'a', 'concern', 'in', 'using', 'it', 'as', 'a', 'diagnostic', 'marker', 'Immunoblot', 'assays', 'confirmed', 'the', 'presence', 'of', 'IgA', 'IgM', 'and', 'IgG', 'antibodies', 'against', 'N', 'antigen', 'in', 'COVID', '19', 'infection', 'patients', 'sera', 'proving', 'the', 'importance', 'of', 'this', 'antigen', 'in', 'host', 'immunity', 'and', 'diagnostics', '']"
107580,Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients,2020,Nat Commun,,"Given the ongoing SARS-CoV-2 pandemic, identification of immunogenic targets against the coronavirus spike glycoprotein will provide crucial advances towards the development of sensitive diagnostic tools and potential vaccine candidate targets. In this study, using pools of overlapping linear B-cell peptides, we report two IgG immunodominant regions on SARS-CoV-2 spike glycoprotein that are recognised by sera from COVID-19 convalescent patients. Notably, one is specific to SARS-CoV-2, which is located in close proximity to the receptor binding domain. The other region, which is localised at the fusion peptide, could potentially function as a pan-SARS target. Functionally, antibody depletion assays demonstrate that antibodies targeting these immunodominant regions significantly alter virus neutralisation capacities. Taken together, identification and validation of these neutralising B-cell epitopes will provide insights towards the design of diagnostics and vaccine candidates against this high priority coronavirus.",,budjcbej,"['Given', 'the', 'ongoing', 'SARS', 'CoV', '2', 'pandemic', 'identification', 'of', 'immunogenic', 'targets', 'against', 'the', 'coronavirus', 'spike', 'glycoprotein', 'will', 'provide', 'crucial', 'advances', 'towards', 'the', 'development', 'of', 'sensitive', 'diagnostic', 'tools', 'and', 'potential', 'vaccine', 'candidate', 'targets', 'In', 'this', 'study', 'using', 'pools', 'of', 'overlapping', 'linear', 'B', 'cell', 'peptides', 'we', 'report', 'two', 'IgG', 'immunodominant', 'regions', 'on', 'SARS', 'CoV', '2', 'spike', 'glycoprotein', 'that', 'are', 'recognised', 'by', 'sera', 'from', 'COVID', '19', 'convalescent', 'patients', 'Notably', 'one', 'is', 'specific', 'to', 'SARS', 'CoV', '2', 'which', 'is', 'located', 'in', 'close', 'proximity', 'to', 'the', 'receptor', 'binding', 'domain', 'The', 'other', 'region', 'which', 'is', 'localised', 'at', 'the', 'fusion', 'peptide', 'could', 'potentially', 'function', 'as', 'a', 'pan', 'SARS', 'target', 'Functionally', 'antibody', 'depletion', 'assays', 'demonstrate', 'that', 'antibodies', 'targeting', 'these', 'immunodominant', 'regions', 'significantly', 'alter', 'virus', 'neutralisation', 'capacities', 'Taken', 'together', 'identification', 'and', 'validation', 'of', 'these', 'neutralising', 'B', 'cell', 'epitopes', 'will', 'provide', 'insights', 'towards', 'the', 'design', 'of', 'diagnostics', 'and', 'vaccine', 'candidates', 'against', 'this', 'high', 'priority', 'coronavirus', '']"
113701,Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation,2020,Science,,"The outbreak of a novel coronavirus (2019-nCoV) represents a pandemic threat that has been declared a public health emergency of international concern. The CoV spike (S) glycoprotein is a key target for vaccines, therapeutic antibodies, and diagnostics. To facilitate medical countermeasure development, we determined a 3.5-angstrom-resolution cryo-electron microscopy structure of the 2019-nCoV S trimer in the prefusion conformation. The predominant state of the trimer has one of the three receptor-binding domains (RBDs) rotated up in a receptor-accessible conformation. We also provide biophysical and structural evidence that the 2019-nCoV S protein binds angiotensin-converting enzyme 2 (ACE2) with higher affinity than does severe acute respiratory syndrome (SARS)-CoV S. Additionally, we tested several published SARS-CoV RBD-specific monoclonal antibodies and found that they do not have appreciable binding to 2019-nCoV S, suggesting that antibody cross-reactivity may be limited between the two RBDs. The structure of 2019-nCoV S should enable the rapid development and evaluation of medical countermeasures to address the ongoing public health crisis.",,2b5hue2r,"['The', 'outbreak', 'of', 'a', 'novel', 'coronavirus', '2019', 'nCoV', 'represents', 'a', 'pandemic', 'threat', 'that', 'has', 'been', 'declared', 'a', 'public', 'health', 'emergency', 'of', 'international', 'concern', 'The', 'CoV', 'spike', 'S', 'glycoprotein', 'is', 'a', 'key', 'target', 'for', 'vaccines', 'therapeutic', 'antibodies', 'and', 'diagnostics', 'To', 'facilitate', 'medical', 'countermeasure', 'development', 'we', 'determined', 'a', '3', '5', 'angstrom', 'resolution', 'cryo', 'electron', 'microscopy', 'structure', 'of', 'the', '2019', 'nCoV', 'S', 'trimer', 'in', 'the', 'prefusion', 'conformation', 'The', 'predominant', 'state', 'of', 'the', 'trimer', 'has', 'one', 'of', 'the', 'three', 'receptor', 'binding', 'domains', 'RBDs', 'rotated', 'up', 'in', 'a', 'receptor', 'accessible', 'conformation', 'We', 'also', 'provide', 'biophysical', 'and', 'structural', 'evidence', 'that', 'the', '2019', 'nCoV', 'S', 'protein', 'binds', 'angiotensin', 'converting', 'enzyme', '2', 'ACE2', 'with', 'higher', 'affinity', 'than', 'does', 'severe', 'acute', 'respiratory', 'syndrome', 'SARS', 'CoV', 'S', 'Additionally', 'we', 'tested', 'several', 'published', 'SARS', 'CoV', 'RBD', 'specific', 'monoclonal', 'antibodies', 'and', 'found', 'that', 'they', 'do', 'not', 'have', 'appreciable', 'binding', 'to', '2019', 'nCoV', 'S', 'suggesting', 'that', 'antibody', 'cross', 'reactivity', 'may', 'be', 'limited', 'between', 'the', 'two', 'RBDs', 'The', 'structure', 'of', '2019', 'nCoV', 'S', 'should', 'enable', 'the', 'rapid', 'development', 'and', 'evaluation', 'of', 'medical', 'countermeasures', 'to', 'address', 'the', 'ongoing', 'public', 'health', 'crisis', '']"
113702,Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation,2020,Science,,"The outbreak of a novel coronavirus (2019-nCoV) represents a pandemic threat that has been declared a public health emergency of international concern. The CoV spike (S) glycoprotein is a key target for vaccines, therapeutic antibodies, and diagnostics. To facilitate medical countermeasure development, we determined a 3.5-angstrom-resolution cryo-electron microscopy structure of the 2019-nCoV S trimer in the prefusion conformation. The predominant state of the trimer has one of the three receptor-binding domains (RBDs) rotated up in a receptor-accessible conformation. We also provide biophysical and structural evidence that the 2019-nCoV S protein binds angiotensin-converting enzyme 2 (ACE2) with higher affinity than does severe acute respiratory syndrome (SARS)-CoV S. Additionally, we tested several published SARS-CoV RBD-specific monoclonal antibodies and found that they do not have appreciable binding to 2019-nCoV S, suggesting that antibody cross-reactivity may be limited between the two RBDs. The structure of 2019-nCoV S should enable the rapid development and evaluation of medical countermeasures to address the ongoing public health crisis.",,sb297tzj,"['The', 'outbreak', 'of', 'a', 'novel', 'coronavirus', '2019', 'nCoV', 'represents', 'a', 'pandemic', 'threat', 'that', 'has', 'been', 'declared', 'a', 'public', 'health', 'emergency', 'of', 'international', 'concern', 'The', 'CoV', 'spike', 'S', 'glycoprotein', 'is', 'a', 'key', 'target', 'for', 'vaccines', 'therapeutic', 'antibodies', 'and', 'diagnostics', 'To', 'facilitate', 'medical', 'countermeasure', 'development', 'we', 'determined', 'a', '3', '5', 'angstrom', 'resolution', 'cryo', 'electron', 'microscopy', 'structure', 'of', 'the', '2019', 'nCoV', 'S', 'trimer', 'in', 'the', 'prefusion', 'conformation', 'The', 'predominant', 'state', 'of', 'the', 'trimer', 'has', 'one', 'of', 'the', 'three', 'receptor', 'binding', 'domains', 'RBDs', 'rotated', 'up', 'in', 'a', 'receptor', 'accessible', 'conformation', 'We', 'also', 'provide', 'biophysical', 'and', 'structural', 'evidence', 'that', 'the', '2019', 'nCoV', 'S', 'protein', 'binds', 'angiotensin', 'converting', 'enzyme', '2', 'ACE2', 'with', 'higher', 'affinity', 'than', 'does', 'severe', 'acute', 'respiratory', 'syndrome', 'SARS', 'CoV', 'S', 'Additionally', 'we', 'tested', 'several', 'published', 'SARS', 'CoV', 'RBD', 'specific', 'monoclonal', 'antibodies', 'and', 'found', 'that', 'they', 'do', 'not', 'have', 'appreciable', 'binding', 'to', '2019', 'nCoV', 'S', 'suggesting', 'that', 'antibody', 'cross', 'reactivity', 'may', 'be', 'limited', 'between', 'the', 'two', 'RBDs', 'The', 'structure', 'of', '2019', 'nCoV', 'S', 'should', 'enable', 'the', 'rapid', 'development', 'and', 'evaluation', 'of', 'medical', 'countermeasures', 'to', 'address', 'the', 'ongoing', 'public', 'health', 'crisis', '']"
116783,Navigating the Pandemic Response Life Cycle: Molecular Diagnostics and Immunoassays in the Context of COVID-19 Management,2020,IEEE reviews in biomedical engineering (Online),,"Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To counter COVID-19 spreading, an infrastructure to provide rapid and thorough molecular diagnostics and serology testing is the cornerstone of outbreak and pandemic management. We hereby review the clinical insights with regard to using molecular tests and immunoassays in the context of COVID-19 management life cycle: the preventive phase, the preparedness phase, the response phase and the recovery phase. The spatial and temporal distribution of viral RNA, antigens and antibodies during human infection is summarized to provide a biological foundation for accurate detection of the disease. We shared the lessons learned and the obstacles encountered during real world high-volume screening programs. Clinical needs are discussed to identify existing technology gaps in these tests. Leverage technologies, such as engineered polymerases, isothermal amplification, and direct amplification from complex matrices may improve the productivity of current infrastructure, while emerging technologies like CRISPR diagnostics, visual end point detection, and PCR free methods for nucleic acid sensing may lead to at-home tests. The lessons learned, and innovations spurred from the COVID-19 pandemic could upgrade our global public health infrastructure to better combat potential outbreaks in the future.",,kawhus2f,"['Coronavirus', 'disease', '2019', 'COVID', '19', 'is', 'an', 'infectious', 'disease', 'caused', 'by', 'severe', 'acute', 'respiratory', 'syndrome', 'coronavirus', '2', 'SARS', 'CoV', '2', 'To', 'counter', 'COVID', '19', 'spreading', 'an', 'infrastructure', 'to', 'provide', 'rapid', 'and', 'thorough', 'molecular', 'diagnostics', 'and', 'serology', 'testing', 'is', 'the', 'cornerstone', 'of', 'outbreak', 'and', 'pandemic', 'management', 'We', 'hereby', 'review', 'the', 'clinical', 'insights', 'with', 'regard', 'to', 'using', 'molecular', 'tests', 'and', 'immunoassays', 'in', 'the', 'context', 'of', 'COVID', '19', 'management', 'life', 'cycle', 'the', 'preventive', 'phase', 'the', 'preparedness', 'phase', 'the', 'response', 'phase', 'and', 'the', 'recovery', 'phase', 'The', 'spatial', 'and', 'temporal', 'distribution', 'of', 'viral', 'RNA', 'antigens', 'and', 'antibodies', 'during', 'human', 'infection', 'is', 'summarized', 'to', 'provide', 'a', 'biological', 'foundation', 'for', 'accurate', 'detection', 'of', 'the', 'disease', 'We', 'shared', 'the', 'lessons', 'learned', 'and', 'the', 'obstacles', 'encountered', 'during', 'real', 'world', 'high', 'volume', 'screening', 'programs', 'Clinical', 'needs', 'are', 'discussed', 'to', 'identify', 'existing', 'technology', 'gaps', 'in', 'these', 'tests', 'Leverage', 'technologies', 'such', 'as', 'engineered', 'polymerases', 'isothermal', 'amplification', 'and', 'direct', 'amplification', 'from', 'complex', 'matrices', 'may', 'improve', 'the', 'productivity', 'of', 'current', 'infrastructure', 'while', 'emerging', 'technologies', 'like', 'CRISPR', 'diagnostics', 'visual', 'end', 'point', 'detection', 'and', 'PCR', 'free', 'methods', 'for', 'nucleic', 'acid', 'sensing', 'may', 'lead', 'to', 'at', 'home', 'tests', 'The', 'lessons', 'learned', 'and', 'innovations', 'spurred', 'from', 'the', 'COVID', '19', 'pandemic', 'could', 'upgrade', 'our', 'global', 'public', 'health', 'infrastructure', 'to', 'better', 'combat', 'potential', 'outbreaks', 'in', 'the', 'future', '']"
116784,Navigating the Pandemic Response Life Cycle: Molecular Diagnostics and Immunoassays in the Context of COVID-19 Management,2020,,,"Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To counter COVID-19 spreading, an infrastructure to provide rapid and thorough molecular diagnostics and serology testing is the cornerstone of outbreak and pandemic management. We hereby review the clinical insights with regard to using molecular tests and immunoassays in the context of COVID-19 management life cycle: the preventive phase, the preparedness phase, the response phase and the recovery phase. The spatial and temporal distribution of viral RNA, antigens and antibodies during human infection is summarized to provide a biological foundation for accurate detection of the disease. We shared the lessons learned and the obstacles encountered during real world high-volume screening programs. Clinical needs are discussed to identify existing technology gaps in these tests. Leverage technologies, such as engineered polymerases, isothermal amplification, and direct amplification from complex matrices may improve the productivity of current infrastructure, while emerging technologies like CRISPR diagnostics, visual end point detection, and PCR free methods for nucleic acid sensing may lead to at-home tests. The lessons learned, and innovations spurred from the COVID-19 pandemic could upgrade our global public health infrastructure to better combat potential outbreaks in the future.",,ye44fr72,"['Coronavirus', 'disease', '2019', 'COVID', '19', 'is', 'an', 'infectious', 'disease', 'caused', 'by', 'severe', 'acute', 'respiratory', 'syndrome', 'coronavirus', '2', 'SARS', 'CoV', '2', 'To', 'counter', 'COVID', '19', 'spreading', 'an', 'infrastructure', 'to', 'provide', 'rapid', 'and', 'thorough', 'molecular', 'diagnostics', 'and', 'serology', 'testing', 'is', 'the', 'cornerstone', 'of', 'outbreak', 'and', 'pandemic', 'management', 'We', 'hereby', 'review', 'the', 'clinical', 'insights', 'with', 'regard', 'to', 'using', 'molecular', 'tests', 'and', 'immunoassays', 'in', 'the', 'context', 'of', 'COVID', '19', 'management', 'life', 'cycle', 'the', 'preventive', 'phase', 'the', 'preparedness', 'phase', 'the', 'response', 'phase', 'and', 'the', 'recovery', 'phase', 'The', 'spatial', 'and', 'temporal', 'distribution', 'of', 'viral', 'RNA', 'antigens', 'and', 'antibodies', 'during', 'human', 'infection', 'is', 'summarized', 'to', 'provide', 'a', 'biological', 'foundation', 'for', 'accurate', 'detection', 'of', 'the', 'disease', 'We', 'shared', 'the', 'lessons', 'learned', 'and', 'the', 'obstacles', 'encountered', 'during', 'real', 'world', 'high', 'volume', 'screening', 'programs', 'Clinical', 'needs', 'are', 'discussed', 'to', 'identify', 'existing', 'technology', 'gaps', 'in', 'these', 'tests', 'Leverage', 'technologies', 'such', 'as', 'engineered', 'polymerases', 'isothermal', 'amplification', 'and', 'direct', 'amplification', 'from', 'complex', 'matrices', 'may', 'improve', 'the', 'productivity', 'of', 'current', 'infrastructure', 'while', 'emerging', 'technologies', 'like', 'CRISPR', 'diagnostics', 'visual', 'end', 'point', 'detection', 'and', 'PCR', 'free', 'methods', 'for', 'nucleic', 'acid', 'sensing', 'may', 'lead', 'to', 'at', 'home', 'tests', 'The', 'lessons', 'learned', 'and', 'innovations', 'spurred', 'from', 'the', 'COVID', '19', 'pandemic', 'could', 'upgrade', 'our', 'global', 'public', 'health', 'infrastructure', 'to', 'better', 'combat', 'potential', 'outbreaks', 'in', 'the', 'future', '']"
119302,Rapid point-of-care serology testing for sars-cov-2/ Snabbtest for covid-19-antikroppar bor utforas av utbildad personal,2020,Lakartidningen,,"Increasing evidence indicates immunity against severe acute respiratory syndrome coronavirus 2 (sars-cov-2) after covid-19, but it remains unclear for how long the protection remains Serology testing seems to have a higher sensitivity than molecular diagnostics from 8 days after onset of symtoms, and should be part of risk assessment and epidemiological studies of COVID-19 The performance of commercial serological point-of-care (POC) lateral flow tests are highly manufacturer-dependant Low sensitivity increases the risk of false negative results and could result in unnecessary quarantine of test persons with developed antibodies Low specificity increases the risk of false positive results and could lead to false assumptions of immunity Carefully selected serological POC tests for sars-cov-2 can be used in large scale testing but should only be used by licensed medical staff able to understand their limitations and interpret the results",,m60w5dnl,"['Increasing', 'evidence', 'indicates', 'immunity', 'against', 'severe', 'acute', 'respiratory', 'syndrome', 'coronavirus', '2', 'sars', 'cov', '2', 'after', 'covid', '19', 'but', 'it', 'remains', 'unclear', 'for', 'how', 'long', 'the', 'protection', 'remains', 'Serology', 'testing', 'seems', 'to', 'have', 'a', 'higher', 'sensitivity', 'than', 'molecular', 'diagnostics', 'from', '8', 'days', 'after', 'onset', 'of', 'symtoms', 'and', 'should', 'be', 'part', 'of', 'risk', 'assessment', 'and', 'epidemiological', 'studies', 'of', 'COVID', '19', 'The', 'performance', 'of', 'commercial', 'serological', 'point', 'of', 'care', 'POC', 'lateral', 'flow', 'tests', 'are', 'highly', 'manufacturer', 'dependant', 'Low', 'sensitivity', 'increases', 'the', 'risk', 'of', 'false', 'negative', 'results', 'and', 'could', 'result', 'in', 'unnecessary', 'quarantine', 'of', 'test', 'persons', 'with', 'developed', 'antibodies', 'Low', 'specificity', 'increases', 'the', 'risk', 'of', 'false', 'positive', 'results', 'and', 'could', 'lead', 'to', 'false', 'assumptions', 'of', 'immunity', 'Carefully', 'selected', 'serological', 'POC', 'tests', 'for', 'sars', 'cov', '2', 'can', 'be', 'used', 'in', 'large', 'scale', 'testing', 'but', 'should', 'only', 'be', 'used', 'by', 'licensed', 'medical', 'staff', 'able', 'to', 'understand', 'their', 'limitations', 'and', 'interpret', 'the', 'results']"
127400,An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment,2020,Nat Commun,,"The world is entering a new era of the COVID-19 pandemic in which there is an increasing call for reliable antibody testing. To support decision making on the deployment of serology for either population screening or diagnostics, we present a detailed comparison of serological COVID-19 assays. We show that among the selected assays there is a wide diversity in assay performance in different scenarios and when correlated to virus neutralizing antibodies. The Wantai ELISA detecting total immunoglobulins against the receptor binding domain of SARS CoV-2, has the best overall characteristics to detect functional antibodies in different stages and severity of disease, including the potential to set a cut-off indicating the presence of protective antibodies. The large variety of available serological assays requires proper assay validation before deciding on deployment of assays for specific applications.",,cv2dg9tg,"['The', 'world', 'is', 'entering', 'a', 'new', 'era', 'of', 'the', 'COVID', '19', 'pandemic', 'in', 'which', 'there', 'is', 'an', 'increasing', 'call', 'for', 'reliable', 'antibody', 'testing', 'To', 'support', 'decision', 'making', 'on', 'the', 'deployment', 'of', 'serology', 'for', 'either', 'population', 'screening', 'or', 'diagnostics', 'we', 'present', 'a', 'detailed', 'comparison', 'of', 'serological', 'COVID', '19', 'assays', 'We', 'show', 'that', 'among', 'the', 'selected', 'assays', 'there', 'is', 'a', 'wide', 'diversity', 'in', 'assay', 'performance', 'in', 'different', 'scenarios', 'and', 'when', 'correlated', 'to', 'virus', 'neutralizing', 'antibodies', 'The', 'Wantai', 'ELISA', 'detecting', 'total', 'immunoglobulins', 'against', 'the', 'receptor', 'binding', 'domain', 'of', 'SARS', 'CoV', '2', 'has', 'the', 'best', 'overall', 'characteristics', 'to', 'detect', 'functional', 'antibodies', 'in', 'different', 'stages', 'and', 'severity', 'of', 'disease', 'including', 'the', 'potential', 'to', 'set', 'a', 'cut', 'off', 'indicating', 'the', 'presence', 'of', 'protective', 'antibodies', 'The', 'large', 'variety', 'of', 'available', 'serological', 'assays', 'requires', 'proper', 'assay', 'validation', 'before', 'deciding', 'on', 'deployment', 'of', 'assays', 'for', 'specific', 'applications', '']"
129482,SARS-CoV-2-IgG response is different in COVID-19 outpatients and asymptomatic contact persons,2020,J Clin Virol,,"Commercially available immunoassays have been developed for sensitive and specific detection of antibodies against SARS-CoV-2. While a fast and reliable IgG response has been reported for samples from hospitalized COVID-19 patients, less is known about ambulatory patients. We evaluated the SARS-CoV-2-IgG response by the Anti-SARS-CoV-2-ELISA IgG (Euroimmun) in a defined cohort of SARS-CoV-2-PCR-confirmed outpatients and asymptomatic contact persons including 137 serum samples from PCR-confirmed outpatients (n = 111) and asymptomatic but PCR-positive contact persons (n = 26) sent to our laboratory as part of routine diagnostics for determination of SARS-CoV-2-IgG. Overall positivity rate for SARS-CoV-2-IgG was 81.1 % in outpatients (irrespective of sampling before or after day 21 after onset of symptoms) but significantly lower in asymptomatic contact persons (15.4 %, p < 0.0001). In contact persons without symptoms the ct values of the PCR assays were significantly higher (5-7 threshold cycles) than in outpatients, and ct values were significantly negative correlated to the SARS-CoV-2-IgG ratio, suggesting a lower viral load as a possible explanation for lower rate of seropositivity. In summary, our study shows that serological response to SARS-CoV-2 in outpatients including asymptomatic persons is less pronounced than in hospitalized patients. Further controlled studies are urgently needed to determine serological response in outpatients and asymptomatic persons since this is the main target population for seroepidemiological investigations.",,pvkw12w4,"['Commercially', 'available', 'immunoassays', 'have', 'been', 'developed', 'for', 'sensitive', 'and', 'specific', 'detection', 'of', 'antibodies', 'against', 'SARS', 'CoV', '2', 'While', 'a', 'fast', 'and', 'reliable', 'IgG', 'response', 'has', 'been', 'reported', 'for', 'samples', 'from', 'hospitalized', 'COVID', '19', 'patients', 'less', 'is', 'known', 'about', 'ambulatory', 'patients', 'We', 'evaluated', 'the', 'SARS', 'CoV', '2', 'IgG', 'response', 'by', 'the', 'Anti', 'SARS', 'CoV', '2', 'ELISA', 'IgG', 'Euroimmun', 'in', 'a', 'defined', 'cohort', 'of', 'SARS', 'CoV', '2', 'PCR', 'confirmed', 'outpatients', 'and', 'asymptomatic', 'contact', 'persons', 'including', '137', 'serum', 'samples', 'from', 'PCR', 'confirmed', 'outpatients', 'n', '111', 'and', 'asymptomatic', 'but', 'PCR', 'positive', 'contact', 'persons', 'n', '26', 'sent', 'to', 'our', 'laboratory', 'as', 'part', 'of', 'routine', 'diagnostics', 'for', 'determination', 'of', 'SARS', 'CoV', '2', 'IgG', 'Overall', 'positivity', 'rate', 'for', 'SARS', 'CoV', '2', 'IgG', 'was', '81', '1', 'in', 'outpatients', 'irrespective', 'of', 'sampling', 'before', 'or', 'after', 'day', '21', 'after', 'onset', 'of', 'symptoms', 'but', 'significantly', 'lower', 'in', 'asymptomatic', 'contact', 'persons', '15', '4', 'p', '0', '0001', 'In', 'contact', 'persons', 'without', 'symptoms', 'the', 'ct', 'values', 'of', 'the', 'PCR', 'assays', 'were', 'significantly', 'higher', '5', '7', 'threshold', 'cycles', 'than', 'in', 'outpatients', 'and', 'ct', 'values', 'were', 'significantly', 'negative', 'correlated', 'to', 'the', 'SARS', 'CoV', '2', 'IgG', 'ratio', 'suggesting', 'a', 'lower', 'viral', 'load', 'as', 'a', 'possible', 'explanation', 'for', 'lower', 'rate', 'of', 'seropositivity', 'In', 'summary', 'our', 'study', 'shows', 'that', 'serological', 'response', 'to', 'SARS', 'CoV', '2', 'in', 'outpatients', 'including', 'asymptomatic', 'persons', 'is', 'less', 'pronounced', 'than', 'in', 'hospitalized', 'patients', 'Further', 'controlled', 'studies', 'are', 'urgently', 'needed', 'to', 'determine', 'serological', 'response', 'in', 'outpatients', 'and', 'asymptomatic', 'persons', 'since', 'this', 'is', 'the', 'main', 'target', 'population', 'for', 'seroepidemiological', 'investigations', '']"
133754,Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation,2020,J Clin Virol,,"There is an urgent need for reliable high-throughput serological assays for the management of the ongoing COVID-19 pandemic. Preferably, the performance of serological tests for a novel virus should be determined with clinical specimens against a gold standard, i.e. virus neutralisation. We compared the performance of six commercial immunoassays for the detection of SARS-COV-2 IgG, IgA and IgM antibodies, including four automated assays [Abbott SARS-COV-2 IgG (CE marked), Diasorin Liaison® SARS-COV-2 S1/S2 IgG (research use only, RUO), and Euroimmun SARS-COV-2 IgG and IgA (CE marked)], and two rapid lateral flow (immunocromatographic) tests [Acro Biotech 2019-nCoV IgG/IgM (CE marked) and Xiamen Biotime Biotechnology SARS-COV-2 IgG/IgM (CE marked)] with a microneutralisation test (MNT). Two specimen panels from serum samples sent to Helsinki University Hospital Laboratory (HUSLAB) were compiled: the patient panel (N=70) included sera from PCR confirmed COVID-19 patients, and the negative panel (N=81) included sera sent for screening of autoimmune diseases and respiratory virus antibodies in 2018 and 2019. The MNT was carried out for all COVID-19 samples (70 serum samples, 62 individuals) and for 53 samples from the negative panel. Forty-one out of 62 COVID-19 patients showed neutralising antibodies.The specificity and sensitivity values of the commercial tests against MNT, respectively, were as follows: 95.1 %/80.5 % (Abbott Architect SARS-CoV-2 IgG), 94.9 %/43.8 % (Diasorin Liaison SARS-CoV-2 IgG; RUO), 68.3 %/87.8 % (Euroimmun SARS-CoV-2 IgA), 86.6 %/70.7 % (Euroimmun SARS-CoV-2 IgG), 74.4 %/56.1 % (Acro 2019-nCoV IgG), 69.5 %/46.3 % (Acro 2019-nCoV IgM), 97.5 %/71.9 % (Xiamen Biotime SARS-CoV-2 IgG), and 88.8 %/81.3 % (Xiamen Biotime SARS-CoV-2 IgM). This study shows variable performance values. Laboratories should carefully consider their testing process, such as a two-tier approach, in order to optimize the overall performance of SARS- CoV-2 serodiagnostics.",,4n7ax0gg,"['There', 'is', 'an', 'urgent', 'need', 'for', 'reliable', 'high', 'throughput', 'serological', 'assays', 'for', 'the', 'management', 'of', 'the', 'ongoing', 'COVID', '19', 'pandemic', 'Preferably', 'the', 'performance', 'of', 'serological', 'tests', 'for', 'a', 'novel', 'virus', 'should', 'be', 'determined', 'with', 'clinical', 'specimens', 'against', 'a', 'gold', 'standard', 'i', 'e', 'virus', 'neutralisation', 'We', 'compared', 'the', 'performance', 'of', 'six', 'commercial', 'immunoassays', 'for', 'the', 'detection', 'of', 'SARS', 'COV', '2', 'IgG', 'IgA', 'and', 'IgM', 'antibodies', 'including', 'four', 'automated', 'assays', 'Abbott', 'SARS', 'COV', '2', 'IgG', 'CE', 'marked', 'Diasorin', 'Liaison', 'SARS', 'COV', '2', 'S1', 'S2', 'IgG', 'research', 'use', 'only', 'RUO', 'and', 'Euroimmun', 'SARS', 'COV', '2', 'IgG', 'and', 'IgA', 'CE', 'marked', 'and', 'two', 'rapid', 'lateral', 'flow', 'immunocromatographic', 'tests', 'Acro', 'Biotech', '2019', 'nCoV', 'IgG', 'IgM', 'CE', 'marked', 'and', 'Xiamen', 'Biotime', 'Biotechnology', 'SARS', 'COV', '2', 'IgG', 'IgM', 'CE', 'marked', 'with', 'a', 'microneutralisation', 'test', 'MNT', 'Two', 'specimen', 'panels', 'from', 'serum', 'samples', 'sent', 'to', 'Helsinki', 'University', 'Hospital', 'Laboratory', 'HUSLAB', 'were', 'compiled', 'the', 'patient', 'panel', 'N', '70', 'included', 'sera', 'from', 'PCR', 'confirmed', 'COVID', '19', 'patients', 'and', 'the', 'negative', 'panel', 'N', '81', 'included', 'sera', 'sent', 'for', 'screening', 'of', 'autoimmune', 'diseases', 'and', 'respiratory', 'virus', 'antibodies', 'in', '2018', 'and', '2019', 'The', 'MNT', 'was', 'carried', 'out', 'for', 'all', 'COVID', '19', 'samples', '70', 'serum', 'samples', '62', 'individuals', 'and', 'for', '53', 'samples', 'from', 'the', 'negative', 'panel', 'Forty', 'one', 'out', 'of', '62', 'COVID', '19', 'patients', 'showed', 'neutralising', 'antibodies', 'The', 'specificity', 'and', 'sensitivity', 'values', 'of', 'the', 'commercial', 'tests', 'against', 'MNT', 'respectively', 'were', 'as', 'follows', '95', '1', '80', '5', 'Abbott', 'Architect', 'SARS', 'CoV', '2', 'IgG', '94', '9', '43', '8', 'Diasorin', 'Liaison', 'SARS', 'CoV', '2', 'IgG', 'RUO', '68', '3', '87', '8', 'Euroimmun', 'SARS', 'CoV', '2', 'IgA', '86', '6', '70', '7', 'Euroimmun', 'SARS', 'CoV', '2', 'IgG', '74', '4', '56', '1', 'Acro', '2019', 'nCoV', 'IgG', '69', '5', '46', '3', 'Acro', '2019', 'nCoV', 'IgM', '97', '5', '71', '9', 'Xiamen', 'Biotime', 'SARS', 'CoV', '2', 'IgG', 'and', '88', '8', '81', '3', 'Xiamen', 'Biotime', 'SARS', 'CoV', '2', 'IgM', 'This', 'study', 'shows', 'variable', 'performance', 'values', 'Laboratories', 'should', 'carefully', 'consider', 'their', 'testing', 'process', 'such', 'as', 'a', 'two', 'tier', 'approach', 'in', 'order', 'to', 'optimize', 'the', 'overall', 'performance', 'of', 'SARS', 'CoV', '2', 'serodiagnostics', '']"
133861,"The Strategic Alliance between Clinical and Molecular Science in the War against SARS-CoV-2, with the Rapid-Diagnostics Test as an Indispensable Weapon for Front Line Doctors",2020,,,"Our work concerns the actual problem of spread of SARS- CoV-2 outbreak which requires fast and correct as possible answer. In current scenario, the need of rapid answer put away the imperative of proper methodology. We focus on the serogical immunoassay for diagnosis of Covid-19 as an important weapon not only for diagnostic purpose, but also for epidemiologic one. The right equilibrium between high speed, low cost and accuracy is obtained with easy-to-use decentralized point-of-care test as the colloidal gold-based immunochromatographic strip assay which detects IgM and IgG antibodies directed against SARS-CoV-2. As our aim is to evaluate the efficacy of Covid-19 rapid tests and of serological assays in real-life settings, we designed a research protocol aimed to establish how to use correctly these diagnostics, taking into account the different possible clinical and epidemiological scenarios.",,xaw3t7tf,"['Our', 'work', 'concerns', 'the', 'actual', 'problem', 'of', 'spread', 'of', 'SARS', 'CoV', '2', 'outbreak', 'which', 'requires', 'fast', 'and', 'correct', 'as', 'possible', 'answer', 'In', 'current', 'scenario', 'the', 'need', 'of', 'rapid', 'answer', 'put', 'away', 'the', 'imperative', 'of', 'proper', 'methodology', 'We', 'focus', 'on', 'the', 'serogical', 'immunoassay', 'for', 'diagnosis', 'of', 'Covid', '19', 'as', 'an', 'important', 'weapon', 'not', 'only', 'for', 'diagnostic', 'purpose', 'but', 'also', 'for', 'epidemiologic', 'one', 'The', 'right', 'equilibrium', 'between', 'high', 'speed', 'low', 'cost', 'and', 'accuracy', 'is', 'obtained', 'with', 'easy', 'to', 'use', 'decentralized', 'point', 'of', 'care', 'test', 'as', 'the', 'colloidal', 'gold', 'based', 'immunochromatographic', 'strip', 'assay', 'which', 'detects', 'IgM', 'and', 'IgG', 'antibodies', 'directed', 'against', 'SARS', 'CoV', '2', 'As', 'our', 'aim', 'is', 'to', 'evaluate', 'the', 'efficacy', 'of', 'Covid', '19', 'rapid', 'tests', 'and', 'of', 'serological', 'assays', 'in', 'real', 'life', 'settings', 'we', 'designed', 'a', 'research', 'protocol', 'aimed', 'to', 'establish', 'how', 'to', 'use', 'correctly', 'these', 'diagnostics', 'taking', 'into', 'account', 'the', 'different', 'possible', 'clinical', 'and', 'epidemiological', 'scenarios', '']"
142220,Aptasensors for viral diagnostics,2015-12-31,TrAC Trends in Analytical Chemistry,https://api.elsevier.com/content/article/pii/S0165993615002435; https://www.sciencedirect.com/science/article/pii/S0165993615002435; https://doi.org/10.1016/j.trac.2015.05.012; https://www.ncbi.nlm.nih.gov/pubmed/32287539/,"Abstract Novel viral diagnostic tools need to be affordable, fast, accurate and easy to use with sensitivity and specificity equivalent or superior to current standards. At present, viral diagnostics are based on direct detection of viral components or indirect detection by measuring antibodies generated in response to viral infection. While sensitivity of detection and quantification are still important challenges, we expect major advances from new assay formats and synthetic binding molecules, such as aptamers. Compared to traditional antibody-based detection, aptamers could provide faster adaptation to continuously evolving virus strains and higher discriminating capacity between specific virus serotypes. Aptamers are very stable and easily modifiable, so are ideal molecules for detection and chemical sensing applications. Here, we review the use of aptasensors for detection of viral pathogens and consider the feasibility of aptasensors to become standard devices for point-of-care diagnostics of viruses.",10.1016/j.trac.2015.05.012,o4z6xthw,"['Abstract', 'Novel', 'viral', 'diagnostic', 'tools', 'need', 'to', 'be', 'affordable', 'fast', 'accurate', 'and', 'easy', 'to', 'use', 'with', 'sensitivity', 'and', 'specificity', 'equivalent', 'or', 'superior', 'to', 'current', 'standards', 'At', 'present', 'viral', 'diagnostics', 'are', 'based', 'on', 'direct', 'detection', 'of', 'viral', 'components', 'or', 'indirect', 'detection', 'by', 'measuring', 'antibodies', 'generated', 'in', 'response', 'to', 'viral', 'infection', 'While', 'sensitivity', 'of', 'detection', 'and', 'quantification', 'are', 'still', 'important', 'challenges', 'we', 'expect', 'major', 'advances', 'from', 'new', 'assay', 'formats', 'and', 'synthetic', 'binding', 'molecules', 'such', 'as', 'aptamers', 'Compared', 'to', 'traditional', 'antibody', 'based', 'detection', 'aptamers', 'could', 'provide', 'faster', 'adaptation', 'to', 'continuously', 'evolving', 'virus', 'strains', 'and', 'higher', 'discriminating', 'capacity', 'between', 'specific', 'virus', 'serotypes', 'Aptamers', 'are', 'very', 'stable', 'and', 'easily', 'modifiable', 'so', 'are', 'ideal', 'molecules', 'for', 'detection', 'and', 'chemical', 'sensing', 'applications', 'Here', 'we', 'review', 'the', 'use', 'of', 'aptasensors', 'for', 'detection', 'of', 'viral', 'pathogens', 'and', 'consider', 'the', 'feasibility', 'of', 'aptasensors', 'to', 'become', 'standard', 'devices', 'for', 'point', 'of', 'care', 'diagnostics', 'of', 'viruses', '']"
143488,Generation of Recombinant Antibodies Against Toxins and Viruses by Phage Display for Diagnostics and Therapy,2016-04-13,Protein Targeting Compounds,https://www.ncbi.nlm.nih.gov/pubmed/27236552/; https://doi.org/10.1007/978-3-319-32805-8_4,"Antibody phage display is an in vitro technology to generate recombinant antibodies. In particular for pathogens like viruses or toxins, antibody phage display is an alternative to hybridoma technology, since it circumvents the limitations of the immune system. Phage display allows the generation of human antibodies from naive antibody gene libraries when either immunized patients are not available or immunization is not ethically feasible. This technology also allows the construction of immune libraries to select in vivo affinity matured antibodies if immunized patients or animals are available. In this review, we describe the generation of human and human-like antibodies from naive antibody gene libraries and antibodies from immune antibody gene libraries. Furthermore, we give an overview about phage display derived recombinant antibodies against viruses and toxins for diagnostics and therapy.",10.1007/978-3-319-32805-8_4,wwuscmai,"['Antibody', 'phage', 'display', 'is', 'an', 'in', 'vitro', 'technology', 'to', 'generate', 'recombinant', 'antibodies', 'In', 'particular', 'for', 'pathogens', 'like', 'viruses', 'or', 'toxins', 'antibody', 'phage', 'display', 'is', 'an', 'alternative', 'to', 'hybridoma', 'technology', 'since', 'it', 'circumvents', 'the', 'limitations', 'of', 'the', 'immune', 'system', 'Phage', 'display', 'allows', 'the', 'generation', 'of', 'human', 'antibodies', 'from', 'naive', 'antibody', 'gene', 'libraries', 'when', 'either', 'immunized', 'patients', 'are', 'not', 'available', 'or', 'immunization', 'is', 'not', 'ethically', 'feasible', 'This', 'technology', 'also', 'allows', 'the', 'construction', 'of', 'immune', 'libraries', 'to', 'select', 'in', 'vivo', 'affinity', 'matured', 'antibodies', 'if', 'immunized', 'patients', 'or', 'animals', 'are', 'available', 'In', 'this', 'review', 'we', 'describe', 'the', 'generation', 'of', 'human', 'and', 'human', 'like', 'antibodies', 'from', 'naive', 'antibody', 'gene', 'libraries', 'and', 'antibodies', 'from', 'immune', 'antibody', 'gene', 'libraries', 'Furthermore', 'we', 'give', 'an', 'overview', 'about', 'phage', 'display', 'derived', 'recombinant', 'antibodies', 'against', 'viruses', 'and', 'toxins', 'for', 'diagnostics', 'and', 'therapy', '']"
144496,Biochemical characterization of SARS-CoV-2 nucleocapsid protein,2020-04-30,Biochem Biophys Res Commun,https://doi.org/10.1016/j.bbrc.2020.04.136; https://www.sciencedirect.com/science/article/pii/S0006291X20308767?v=s5; https://www.ncbi.nlm.nih.gov/pubmed/32416961/; https://api.elsevier.com/content/article/pii/S0006291X20308767,"The nucleocapsid (N) protein is an important antigen for coronavirus, which participate in RNA package and virus particle release. In this study, we expressed the N protein of SARS-CoV-2 and characterized its biochemical properties. Static light scattering, size exclusive chromatography, and small-angle X-ray scattering (SAXS) showed that the purified N protein is largely a dimer in solution. CD spectra showed that it has a high percentage of disordered region at room temperature while it was best structured at 55 °C, suggesting its structural dynamics. Fluorescence polarization assay showed it has non-specific nucleic acid binding capability, which raised a concern in using it as a diagnostic marker. Immunoblot assays confirmed the presence of IgA, IgM and IgG antibodies against N antigen in COVID-19 infection patients' sera, proving the importance of this antigen in host immunity and diagnostics.",10.1016/j.bbrc.2020.04.136,8qcy0nl1,"['The', 'nucleocapsid', 'N', 'protein', 'is', 'an', 'important', 'antigen', 'for', 'coronavirus', 'which', 'participate', 'in', 'RNA', 'package', 'and', 'virus', 'particle', 'release', 'In', 'this', 'study', 'we', 'expressed', 'the', 'N', 'protein', 'of', 'SARS', 'CoV', '2', 'and', 'characterized', 'its', 'biochemical', 'properties', 'Static', 'light', 'scattering', 'size', 'exclusive', 'chromatography', 'and', 'small', 'angle', 'X', 'ray', 'scattering', 'SAXS', 'showed', 'that', 'the', 'purified', 'N', 'protein', 'is', 'largely', 'a', 'dimer', 'in', 'solution', 'CD', 'spectra', 'showed', 'that', 'it', 'has', 'a', 'high', 'percentage', 'of', 'disordered', 'region', 'at', 'room', 'temperature', 'while', 'it', 'was', 'best', 'structured', 'at', '55', 'C', 'suggesting', 'its', 'structural', 'dynamics', 'Fluorescence', 'polarization', 'assay', 'showed', 'it', 'has', 'non', 'specific', 'nucleic', 'acid', 'binding', 'capability', 'which', 'raised', 'a', 'concern', 'in', 'using', 'it', 'as', 'a', 'diagnostic', 'marker', 'Immunoblot', 'assays', 'confirmed', 'the', 'presence', 'of', 'IgA', 'IgM', 'and', 'IgG', 'antibodies', 'against', 'N', 'antigen', 'in', 'COVID', '19', 'infection', 'patients', 'sera', 'proving', 'the', 'importance', 'of', 'this', 'antigen', 'in', 'host', 'immunity', 'and', 'diagnostics', '']"
145215,Pathogenicity and immunogenicity of a new strain of porcine epidemic diarrhea virus containing a novel deletion in the N gene,2019-11-15,Vet Microbiol,https://www.sciencedirect.com/science/article/pii/S0378113519307497; https://api.elsevier.com/content/article/pii/S0378113519307497; https://www.ncbi.nlm.nih.gov/pubmed/31902508/; https://doi.org/10.1016/j.vetmic.2019.108511,"Since late 2010, highly virulent PEDV G2-genotype strains have emerged globally extracting heavy losses on the pork industries of numerous countries. We investigated the characteristics of a field strain of PEDV (PEDV strain SH) isolated from a piglet with severe diarrhea on a farm in Shanghai China. Whole genome sequencing and analysis revealed that the SH strain belonged to subtype G2b and has a unique 12-aa deletion (aa 399–410) including the antigenic epitope NEP-1C9 (aa 398–406) of the N protein. PEDV SH strain is highly pathogenic to challenged newborn piglets, resulting in 100 % morbidity and mortality. Pathological examination revealed significant villus atrophy in the jejuna of infected piglets. Mice inoculated with inactivated PEDV SH produced antibodies against the N protein, but no antibodies against the deletions. These results illustrated that deletion of the NEP-1C9 epitope had no effect on the immunogenicity or pathogenicity of PEDV, providing evidence of the necessity to monitor the genetic diversity of the virus. Our study also contributes to development of candidate for vaccines and diagnostics that could differentiate pigs seropositive due to vaccination by conventional strains from wild virus infection.",10.1016/j.vetmic.2019.108511,4jrsws4e,"['Since', 'late', '2010', 'highly', 'virulent', 'PEDV', 'G2', 'genotype', 'strains', 'have', 'emerged', 'globally', 'extracting', 'heavy', 'losses', 'on', 'the', 'pork', 'industries', 'of', 'numerous', 'countries', 'We', 'investigated', 'the', 'characteristics', 'of', 'a', 'field', 'strain', 'of', 'PEDV', 'PEDV', 'strain', 'SH', 'isolated', 'from', 'a', 'piglet', 'with', 'severe', 'diarrhea', 'on', 'a', 'farm', 'in', 'Shanghai', 'China', 'Whole', 'genome', 'sequencing', 'and', 'analysis', 'revealed', 'that', 'the', 'SH', 'strain', 'belonged', 'to', 'subtype', 'G2b', 'and', 'has', 'a', 'unique', '12', 'aa', 'deletion', 'aa', '399', '410', 'including', 'the', 'antigenic', 'epitope', 'NEP', '1C9', 'aa', '398', '406', 'of', 'the', 'N', 'protein', 'PEDV', 'SH', 'strain', 'is', 'highly', 'pathogenic', 'to', 'challenged', 'newborn', 'piglets', 'resulting', 'in', '100', 'morbidity', 'and', 'mortality', 'Pathological', 'examination', 'revealed', 'significant', 'villus', 'atrophy', 'in', 'the', 'jejuna', 'of', 'infected', 'piglets', 'Mice', 'inoculated', 'with', 'inactivated', 'PEDV', 'SH', 'produced', 'antibodies', 'against', 'the', 'N', 'protein', 'but', 'no', 'antibodies', 'against', 'the', 'deletions', 'These', 'results', 'illustrated', 'that', 'deletion', 'of', 'the', 'NEP', '1C9', 'epitope', 'had', 'no', 'effect', 'on', 'the', 'immunogenicity', 'or', 'pathogenicity', 'of', 'PEDV', 'providing', 'evidence', 'of', 'the', 'necessity', 'to', 'monitor', 'the', 'genetic', 'diversity', 'of', 'the', 'virus', 'Our', 'study', 'also', 'contributes', 'to', 'development', 'of', 'candidate', 'for', 'vaccines', 'and', 'diagnostics', 'that', 'could', 'differentiate', 'pigs', 'seropositive', 'due', 'to', 'vaccination', 'by', 'conventional', 'strains', 'from', 'wild', 'virus', 'infection', '']"
146632,Super induction of dengue virus NS1 protein in E. coli,2009-07-31,Protein Expression and Purification,https://doi.org/10.1016/j.pep.2009.02.003; https://www.sciencedirect.com/science/article/pii/S1046592809000333; https://api.elsevier.com/content/article/pii/S1046592809000333; https://www.ncbi.nlm.nih.gov/pubmed/19232392/,"Abstract The non-structural protein 1 (NS1) of dengue virus is a useful target for diagnostics of dengue infection since the protein is abundantly circulating in blood during the acute phase of the disease. Prior work has established that secreted NS1 levels in plasma correlates with viremia levels and hence can also be used to diagnose patients at the risk for developing dengue hemorrhagic fever. Thus detection of non-structural dengue antigens may be of benefit for an early rapid diagnosis of dengue infection due to its long half life in the blood. Here we describe a simple and efficient method for the expression of NS1 in Escherichia coli, which could potentially be used to develop monoclonal and bispecific antibodies for point of care diagnostics. E. coli codon optimized synthetic full-length NS1 gene of dengue serotype 1 (DEN-1) was successfully cloned and expressed in very high-level as inclusion bodies. The NS1 protein was successfully affinity purified and refolded as a recombinant NS1 (rNS1) protein in E. coli and yield was 230–250mg/L of bacterial culture. The rNS1 protein was used to immunize mice for hybridoma development. The polyclonal antiserum from animals immunized with this rNS1 protein was found to specifically recognize the rNS1, thus demonstrating the immunogenic nature of the protein. The rNS1 protein purified from E. coli could be useful for developing a sensitive serum diagnostic assay to monitor dengue outbreaks.",10.1016/j.pep.2009.02.003,k8ob9wbe,"['Abstract', 'The', 'non', 'structural', 'protein', '1', 'NS1', 'of', 'dengue', 'virus', 'is', 'a', 'useful', 'target', 'for', 'diagnostics', 'of', 'dengue', 'infection', 'since', 'the', 'protein', 'is', 'abundantly', 'circulating', 'in', 'blood', 'during', 'the', 'acute', 'phase', 'of', 'the', 'disease', 'Prior', 'work', 'has', 'established', 'that', 'secreted', 'NS1', 'levels', 'in', 'plasma', 'correlates', 'with', 'viremia', 'levels', 'and', 'hence', 'can', 'also', 'be', 'used', 'to', 'diagnose', 'patients', 'at', 'the', 'risk', 'for', 'developing', 'dengue', 'hemorrhagic', 'fever', 'Thus', 'detection', 'of', 'non', 'structural', 'dengue', 'antigens', 'may', 'be', 'of', 'benefit', 'for', 'an', 'early', 'rapid', 'diagnosis', 'of', 'dengue', 'infection', 'due', 'to', 'its', 'long', 'half', 'life', 'in', 'the', 'blood', 'Here', 'we', 'describe', 'a', 'simple', 'and', 'efficient', 'method', 'for', 'the', 'expression', 'of', 'NS1', 'in', 'Escherichia', 'coli', 'which', 'could', 'potentially', 'be', 'used', 'to', 'develop', 'monoclonal', 'and', 'bispecific', 'antibodies', 'for', 'point', 'of', 'care', 'diagnostics', 'E', 'coli', 'codon', 'optimized', 'synthetic', 'full', 'length', 'NS1', 'gene', 'of', 'dengue', 'serotype', '1', 'DEN', '1', 'was', 'successfully', 'cloned', 'and', 'expressed', 'in', 'very', 'high', 'level', 'as', 'inclusion', 'bodies', 'The', 'NS1', 'protein', 'was', 'successfully', 'affinity', 'purified', 'and', 'refolded', 'as', 'a', 'recombinant', 'NS1', 'rNS1', 'protein', 'in', 'E', 'coli', 'and', 'yield', 'was', '230', '250mg', 'L', 'of', 'bacterial', 'culture', 'The', 'rNS1', 'protein', 'was', 'used', 'to', 'immunize', 'mice', 'for', 'hybridoma', 'development', 'The', 'polyclonal', 'antiserum', 'from', 'animals', 'immunized', 'with', 'this', 'rNS1', 'protein', 'was', 'found', 'to', 'specifically', 'recognize', 'the', 'rNS1', 'thus', 'demonstrating', 'the', 'immunogenic', 'nature', 'of', 'the', 'protein', 'The', 'rNS1', 'protein', 'purified', 'from', 'E', 'coli', 'could', 'be', 'useful', 'for', 'developing', 'a', 'sensitive', 'serum', 'diagnostic', 'assay', 'to', 'monitor', 'dengue', 'outbreaks', '']"
146829,SARS-CoV-2 testing in infertile patients: different recommendations in Europe and America,2020-07-17,J Assist Reprod Genet,https://doi.org/10.1007/s10815-020-01887-3; https://www.ncbi.nlm.nih.gov/pubmed/32681280/,"The incorporation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing into patient care algorithms has been proposed to mitigate risk. However, the two main professional societies for human reproduction (ESHRE and ASRM) appear divergent on their clinical utility and whether they should be adopted. In this opinion paper, we review the currently available tests and discuss the strengths and weaknesses of the proposed clinical care pathways. Nucleic acid amplification tests are the cornerstone of SARS-CoV-2 testing but test results are largely influenced by viral load, sample site, specimen collection method, and specimen shipment technique, such that a negative result in a symptomatic patient cannot be relied upon. Serological assays for SARS-CoV-2 antibodies exhibit a temporal increase in sensitivity and specificity after symptom onset irrespective of the assay used, with sensitivity estimates ranging from 0 to 50% with the first 3 days of symptoms, to 83 to 88% at 10 days, increasing to almost 100% at ≥ 14 days. These inherent constraints in diagnostics would suggest that at present there is inadequate evidence to utilize SARS-CoV-2 testing to stratify fertility patients and reliably inform clinical decision-making. The failure to appreciate the characteristics and limitations of the diagnostic tests may lead to disastrous consequences for the patient and the multidisciplinary team looking after them.",10.1007/s10815-020-01887-3,qwuivy99,"['The', 'incorporation', 'of', 'severe', 'acute', 'respiratory', 'syndrome', 'coronavirus', '2', 'SARS', 'CoV', '2', 'testing', 'into', 'patient', 'care', 'algorithms', 'has', 'been', 'proposed', 'to', 'mitigate', 'risk', 'However', 'the', 'two', 'main', 'professional', 'societies', 'for', 'human', 'reproduction', 'ESHRE', 'and', 'ASRM', 'appear', 'divergent', 'on', 'their', 'clinical', 'utility', 'and', 'whether', 'they', 'should', 'be', 'adopted', 'In', 'this', 'opinion', 'paper', 'we', 'review', 'the', 'currently', 'available', 'tests', 'and', 'discuss', 'the', 'strengths', 'and', 'weaknesses', 'of', 'the', 'proposed', 'clinical', 'care', 'pathways', 'Nucleic', 'acid', 'amplification', 'tests', 'are', 'the', 'cornerstone', 'of', 'SARS', 'CoV', '2', 'testing', 'but', 'test', 'results', 'are', 'largely', 'influenced', 'by', 'viral', 'load', 'sample', 'site', 'specimen', 'collection', 'method', 'and', 'specimen', 'shipment', 'technique', 'such', 'that', 'a', 'negative', 'result', 'in', 'a', 'symptomatic', 'patient', 'cannot', 'be', 'relied', 'upon', 'Serological', 'assays', 'for', 'SARS', 'CoV', '2', 'antibodies', 'exhibit', 'a', 'temporal', 'increase', 'in', 'sensitivity', 'and', 'specificity', 'after', 'symptom', 'onset', 'irrespective', 'of', 'the', 'assay', 'used', 'with', 'sensitivity', 'estimates', 'ranging', 'from', '0', 'to', '50', 'with', 'the', 'first', '3', 'days', 'of', 'symptoms', 'to', '83', 'to', '88', 'at', '10', 'days', 'increasing', 'to', 'almost', '100', 'at', '14', 'days', 'These', 'inherent', 'constraints', 'in', 'diagnostics', 'would', 'suggest', 'that', 'at', 'present', 'there', 'is', 'inadequate', 'evidence', 'to', 'utilize', 'SARS', 'CoV', '2', 'testing', 'to', 'stratify', 'fertility', 'patients', 'and', 'reliably', 'inform', 'clinical', 'decision', 'making', 'The', 'failure', 'to', 'appreciate', 'the', 'characteristics', 'and', 'limitations', 'of', 'the', 'diagnostic', 'tests', 'may', 'lead', 'to', 'disastrous', 'consequences', 'for', 'the', 'patient', 'and', 'the', 'multidisciplinary', 'team', 'looking', 'after', 'them', '']"
146845,An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment,2020-07-06,Nat Commun,https://www.ncbi.nlm.nih.gov/pubmed/32632160/; https://doi.org/10.1038/s41467-020-17317-y,"The world is entering a new era of the COVID-19 pandemic in which there is an increasing call for reliable antibody testing. To support decision making on the deployment of serology for either population screening or diagnostics, we present a detailed comparison of serological COVID-19 assays. We show that among the selected assays there is a wide diversity in assay performance in different scenarios and when correlated to virus neutralizing antibodies. The Wantai ELISA detecting total immunoglobulins against the receptor binding domain of SARS CoV-2, has the best overall characteristics to detect functional antibodies in different stages and severity of disease, including the potential to set a cut-off indicating the presence of protective antibodies. The large variety of available serological assays requires proper assay validation before deciding on deployment of assays for specific applications.",10.1038/s41467-020-17317-y,jeedo5mc,"['The', 'world', 'is', 'entering', 'a', 'new', 'era', 'of', 'the', 'COVID', '19', 'pandemic', 'in', 'which', 'there', 'is', 'an', 'increasing', 'call', 'for', 'reliable', 'antibody', 'testing', 'To', 'support', 'decision', 'making', 'on', 'the', 'deployment', 'of', 'serology', 'for', 'either', 'population', 'screening', 'or', 'diagnostics', 'we', 'present', 'a', 'detailed', 'comparison', 'of', 'serological', 'COVID', '19', 'assays', 'We', 'show', 'that', 'among', 'the', 'selected', 'assays', 'there', 'is', 'a', 'wide', 'diversity', 'in', 'assay', 'performance', 'in', 'different', 'scenarios', 'and', 'when', 'correlated', 'to', 'virus', 'neutralizing', 'antibodies', 'The', 'Wantai', 'ELISA', 'detecting', 'total', 'immunoglobulins', 'against', 'the', 'receptor', 'binding', 'domain', 'of', 'SARS', 'CoV', '2', 'has', 'the', 'best', 'overall', 'characteristics', 'to', 'detect', 'functional', 'antibodies', 'in', 'different', 'stages', 'and', 'severity', 'of', 'disease', 'including', 'the', 'potential', 'to', 'set', 'a', 'cut', 'off', 'indicating', 'the', 'presence', 'of', 'protective', 'antibodies', 'The', 'large', 'variety', 'of', 'available', 'serological', 'assays', 'requires', 'proper', 'assay', 'validation', 'before', 'deciding', 'on', 'deployment', 'of', 'assays', 'for', 'specific', 'applications', '']"
147447,Functional peptide microarrays for specific and sensitive antibody diagnostics,2006-02-03,Proteomics,https://www.ncbi.nlm.nih.gov/pubmed/16456884/,"Peptide microarrays displaying biologically active small synthetic peptides in a high‐density format provide an attractive technology to probe complex samples for the presence and/or function of protein analytes. We present a new approach for manufacturing functional peptide microarrays for molecular immune diagnostics. Our method relies on the efficiency of site‐specific solution‐phase coupling of biotinylated synthetic peptides to NeutrAvidin (NA) and localized microdispensing of peptide‐NA‐complexes onto activated glass surfaces. Antibodies are captured in a sandwich manner between surface immobilized peptide probes and fluorescence‐labeled secondary antibodies. Our work includes a total of 54 peptides derived from immunodominant linear epitopes of the T7 phage capsid protein, Herpes simplex virus glycoprotein D, c‐myc protein, and three domains of the Human coronavirus polymerase polyprotein and their cognate mAbs. By using spacer molecules of different type and length for NA‐mediated peptide presentation, we show that the incorporation of a minimum spacer length is imperative for antibody binding, whereas the peptide immobilization direction has only secondary importance for antibody affinity and binding. We further demonstrate that the peptide array is capable of detecting low‐picomolar concentrations of mAbs in buffered solutions and diluted human serum with high specificity.",10.1002/pmic.200500343,lntwhz05,"['Peptide', 'microarrays', 'displaying', 'biologically', 'active', 'small', 'synthetic', 'peptides', 'in', 'a', 'high', 'density', 'format', 'provide', 'an', 'attractive', 'technology', 'to', 'probe', 'complex', 'samples', 'for', 'the', 'presence', 'and', 'or', 'function', 'of', 'protein', 'analytes', 'We', 'present', 'a', 'new', 'approach', 'for', 'manufacturing', 'functional', 'peptide', 'microarrays', 'for', 'molecular', 'immune', 'diagnostics', 'Our', 'method', 'relies', 'on', 'the', 'efficiency', 'of', 'site', 'specific', 'solution', 'phase', 'coupling', 'of', 'biotinylated', 'synthetic', 'peptides', 'to', 'NeutrAvidin', 'NA', 'and', 'localized', 'microdispensing', 'of', 'peptide', 'NA', 'complexes', 'onto', 'activated', 'glass', 'surfaces', 'Antibodies', 'are', 'captured', 'in', 'a', 'sandwich', 'manner', 'between', 'surface', 'immobilized', 'peptide', 'probes', 'and', 'fluorescence', 'labeled', 'secondary', 'antibodies', 'Our', 'work', 'includes', 'a', 'total', 'of', '54', 'peptides', 'derived', 'from', 'immunodominant', 'linear', 'epitopes', 'of', 'the', 'T7', 'phage', 'capsid', 'protein', 'Herpes', 'simplex', 'virus', 'glycoprotein', 'D', 'c', 'myc', 'protein', 'and', 'three', 'domains', 'of', 'the', 'Human', 'coronavirus', 'polymerase', 'polyprotein', 'and', 'their', 'cognate', 'mAbs', 'By', 'using', 'spacer', 'molecules', 'of', 'different', 'type', 'and', 'length', 'for', 'NA', 'mediated', 'peptide', 'presentation', 'we', 'show', 'that', 'the', 'incorporation', 'of', 'a', 'minimum', 'spacer', 'length', 'is', 'imperative', 'for', 'antibody', 'binding', 'whereas', 'the', 'peptide', 'immobilization', 'direction', 'has', 'only', 'secondary', 'importance', 'for', 'antibody', 'affinity', 'and', 'binding', 'We', 'further', 'demonstrate', 'that', 'the', 'peptide', 'array', 'is', 'capable', 'of', 'detecting', 'low', 'picomolar', 'concentrations', 'of', 'mAbs', 'in', 'buffered', 'solutions', 'and', 'diluted', 'human', 'serum', 'with', 'high', 'specificity', '']"
148114,Diagnostic Techniques: Serological and Molecular Approaches☆,2015-12-31,Reference Module in Biomedical Sciences,https://api.elsevier.com/content/article/pii/B9780128012383025587; https://www.sciencedirect.com/science/article/pii/B9780128012383025587,"Abstract Virus laboratory diagnostics has an increasingly important role in modern patient care. Virological methods are needed to investigate the etiology of acute viral infection or the reactivation of a latent infection, as well as to follow virus load in antiviral treatments. Serological assays are also used for screening of blood products for the risk of certain chronic infections, evaluation of the immune status, and need for prophylactic treatments in connection with organ transplantations. For diagnostic purposes the following approaches can be used: demonstration of presence of infectious virus or its structural components directly from a patient's specimens or investigation of specific antibody response in serum specimens. Amplification techniques, most commonly polymerase chain reaction (PCR) is currently the workhorse of nucleic acid testing for the detection and quantitation of virus genomes. Virus isolation is used to demonstrate infectious virus in a patient's specimens, whereas virus antigens are investigated by antigen detection assays. Serological diagnosis is based on either the demonstration of the presence of virus-specific IgM antibodies or a significant increase in the levels and/or avidity of specific IgG antibodies. Immunoassays are the most commonly used serological assays. Point-of-care tests (POC tests), for antigens, antibodies, and also nucleic acids are also becoming more and more common in diagnostic use. In order to reach the best diagnostic efficiency for each patient it is important to select the most suitable method using the right sample collected at the right time.",10.1016/b978-0-12-801238-3.02558-7,2u16otbf,"['Abstract', 'Virus', 'laboratory', 'diagnostics', 'has', 'an', 'increasingly', 'important', 'role', 'in', 'modern', 'patient', 'care', 'Virological', 'methods', 'are', 'needed', 'to', 'investigate', 'the', 'etiology', 'of', 'acute', 'viral', 'infection', 'or', 'the', 'reactivation', 'of', 'a', 'latent', 'infection', 'as', 'well', 'as', 'to', 'follow', 'virus', 'load', 'in', 'antiviral', 'treatments', 'Serological', 'assays', 'are', 'also', 'used', 'for', 'screening', 'of', 'blood', 'products', 'for', 'the', 'risk', 'of', 'certain', 'chronic', 'infections', 'evaluation', 'of', 'the', 'immune', 'status', 'and', 'need', 'for', 'prophylactic', 'treatments', 'in', 'connection', 'with', 'organ', 'transplantations', 'For', 'diagnostic', 'purposes', 'the', 'following', 'approaches', 'can', 'be', 'used', 'demonstration', 'of', 'presence', 'of', 'infectious', 'virus', 'or', 'its', 'structural', 'components', 'directly', 'from', 'a', 'patient', 's', 'specimens', 'or', 'investigation', 'of', 'specific', 'antibody', 'response', 'in', 'serum', 'specimens', 'Amplification', 'techniques', 'most', 'commonly', 'polymerase', 'chain', 'reaction', 'PCR', 'is', 'currently', 'the', 'workhorse', 'of', 'nucleic', 'acid', 'testing', 'for', 'the', 'detection', 'and', 'quantitation', 'of', 'virus', 'genomes', 'Virus', 'isolation', 'is', 'used', 'to', 'demonstrate', 'infectious', 'virus', 'in', 'a', 'patient', 's', 'specimens', 'whereas', 'virus', 'antigens', 'are', 'investigated', 'by', 'antigen', 'detection', 'assays', 'Serological', 'diagnosis', 'is', 'based', 'on', 'either', 'the', 'demonstration', 'of', 'the', 'presence', 'of', 'virus', 'specific', 'IgM', 'antibodies', 'or', 'a', 'significant', 'increase', 'in', 'the', 'levels', 'and', 'or', 'avidity', 'of', 'specific', 'IgG', 'antibodies', 'Immunoassays', 'are', 'the', 'most', 'commonly', 'used', 'serological', 'assays', 'Point', 'of', 'care', 'tests', 'POC', 'tests', 'for', 'antigens', 'antibodies', 'and', 'also', 'nucleic', 'acids', 'are', 'also', 'becoming', 'more', 'and', 'more', 'common', 'in', 'diagnostic', 'use', 'In', 'order', 'to', 'reach', 'the', 'best', 'diagnostic', 'efficiency', 'for', 'each', 'patient', 'it', 'is', 'important', 'to', 'select', 'the', 'most', 'suitable', 'method', 'using', 'the', 'right', 'sample', 'collected', 'at', 'the', 'right', 'time', '']"
150122,SARS-CoV-2-IgG response is different in COVID-19 outpatients and asymptomatic contact persons,2020-07-06,J Clin Virol,https://doi.org/10.1016/j.jcv.2020.104542; https://api.elsevier.com/content/article/pii/S1386653220302845; https://www.ncbi.nlm.nih.gov/pubmed/32707511/; https://www.sciencedirect.com/science/article/pii/S1386653220302845?v=s5,"Commercially available immunoassays have been developed for sensitive and specific detection of antibodies against SARS-CoV-2. While a fast and reliable IgG response has been reported for samples from hospitalized COVID-19 patients, less is known about ambulatory patients. We evaluated the SARS-CoV-2-IgG response by the Anti-SARS-CoV-2-ELISA IgG (Euroimmun) in a defined cohort of SARS-CoV-2-PCR-confirmed outpatients and asymptomatic contact persons including 137 serum samples from PCR-confirmed outpatients (n = 111) and asymptomatic but PCR-positive contact persons (n = 26) sent to our laboratory as part of routine diagnostics for determination of SARS-CoV-2-IgG. Overall positivity rate for SARS-CoV-2-IgG was 81.1% in outpatients (irrespective of sampling before or after day 21 after onset of symptoms) but significantly lower in asymptomatic contact persons (15.4%, p < 0.0001). In contact persons without symptoms the ct values of the PCR assays were significantly higher (5 to 7 threshold cycles) than in outpatients, and ct values were significantly negative correlated to the SARS-CoV-2-IgG ratio, suggesting a lower viral load as a possible explanation for lower rate of seropositivity. In summary, our study shows that serological response to SARS-CoV-2 in outpatients including asymptomatic persons is less pronounced than in hospitalized patients. Further controlled studies are urgently needed to determine serological response in outpatients and asymptomatic persons since this is the main target population for seroepidemiological investigations.",10.1016/j.jcv.2020.104542,atmuj1ki,"['Commercially', 'available', 'immunoassays', 'have', 'been', 'developed', 'for', 'sensitive', 'and', 'specific', 'detection', 'of', 'antibodies', 'against', 'SARS', 'CoV', '2', 'While', 'a', 'fast', 'and', 'reliable', 'IgG', 'response', 'has', 'been', 'reported', 'for', 'samples', 'from', 'hospitalized', 'COVID', '19', 'patients', 'less', 'is', 'known', 'about', 'ambulatory', 'patients', 'We', 'evaluated', 'the', 'SARS', 'CoV', '2', 'IgG', 'response', 'by', 'the', 'Anti', 'SARS', 'CoV', '2', 'ELISA', 'IgG', 'Euroimmun', 'in', 'a', 'defined', 'cohort', 'of', 'SARS', 'CoV', '2', 'PCR', 'confirmed', 'outpatients', 'and', 'asymptomatic', 'contact', 'persons', 'including', '137', 'serum', 'samples', 'from', 'PCR', 'confirmed', 'outpatients', 'n', '111', 'and', 'asymptomatic', 'but', 'PCR', 'positive', 'contact', 'persons', 'n', '26', 'sent', 'to', 'our', 'laboratory', 'as', 'part', 'of', 'routine', 'diagnostics', 'for', 'determination', 'of', 'SARS', 'CoV', '2', 'IgG', 'Overall', 'positivity', 'rate', 'for', 'SARS', 'CoV', '2', 'IgG', 'was', '81', '1', 'in', 'outpatients', 'irrespective', 'of', 'sampling', 'before', 'or', 'after', 'day', '21', 'after', 'onset', 'of', 'symptoms', 'but', 'significantly', 'lower', 'in', 'asymptomatic', 'contact', 'persons', '15', '4', 'p', '0', '0001', 'In', 'contact', 'persons', 'without', 'symptoms', 'the', 'ct', 'values', 'of', 'the', 'PCR', 'assays', 'were', 'significantly', 'higher', '5', 'to', '7', 'threshold', 'cycles', 'than', 'in', 'outpatients', 'and', 'ct', 'values', 'were', 'significantly', 'negative', 'correlated', 'to', 'the', 'SARS', 'CoV', '2', 'IgG', 'ratio', 'suggesting', 'a', 'lower', 'viral', 'load', 'as', 'a', 'possible', 'explanation', 'for', 'lower', 'rate', 'of', 'seropositivity', 'In', 'summary', 'our', 'study', 'shows', 'that', 'serological', 'response', 'to', 'SARS', 'CoV', '2', 'in', 'outpatients', 'including', 'asymptomatic', 'persons', 'is', 'less', 'pronounced', 'than', 'in', 'hospitalized', 'patients', 'Further', 'controlled', 'studies', 'are', 'urgently', 'needed', 'to', 'determine', 'serological', 'response', 'in', 'outpatients', 'and', 'asymptomatic', 'persons', 'since', 'this', 'is', 'the', 'main', 'target', 'population', 'for', 'seroepidemiological', 'investigations', '']"
150922,Acute human bocavirus 1 infection in child with life-threatening bilateral bronchiolitis and right-sided pneumonia: a case report,2019-09-14,J Med Case Rep,https://www.ncbi.nlm.nih.gov/pubmed/31519214/; https://doi.org/10.1186/s13256-019-2222-5,"BACKGROUND: Human bocavirus 1 is a commonly detected human parvovirus. Many studies have shown human bocavirus 1 as a pathogen in association with acute respiratory tract infections in children. However, because human bocavirus 1 persists in the upper airways for extensive time periods after acute infection, the definition and diagnostics of acute human bocavirus 1 infection is challenging. Until now, detection of human bocavirus 1 exclusively, high viral load in respiratory samples, and viremia have been associated with a clinical picture of acute respiratory illness. There are no studies showing detection of human bocavirus 1 messenger ribonucleic acid in the peripheral blood mononuclear cells as a diagnostic marker for acute lower respiratory tract infection. CASE PRESENTATION: We report the case of a 17-month-old Latvian boy who presented in intensive care unit with acute bilateral bronchiolitis, with a history of rhinorrhea and cough for 6 days and fever for the last 2 days prior to admission, followed by severe respiratory distress and tracheal intubation. Human bocavirus 1 was the only respiratory virus detected by a qualitative multiplex polymerase chain reaction panel. For the diagnosis of acute human bocavirus 1 infection, both molecular and serological approaches were used. Human bocavirus 1 deoxyribonucleic acid (DNA) was detected simultaneously in nasopharyngeal aspirate, stool, and blood, as well as in the corresponding cell-free blood plasma by qualitative and quantitative polymerase chain reaction, revealing high DNA-copy numbers in nasopharyngeal aspirate and stool. Despite a low-load viremia, human bocavirus 1 messenger ribonucleic acid was found in the peripheral blood mononuclear cells. For detection of human bocavirus 1-specific antibodies, non-competitive immunoglobulin M and competitive immunoglobulin G enzyme immunoassays were used. The plasma was positive for both human bocavirus 1-specific immunoglobulin M and immunoglobulin G antibodies. CONCLUSIONS: The presence of human bocavirus 1 genomic DNA in blood plasma and human bocavirus 1 messenger ribonucleic acid in peripheral blood mononuclear cells together with human bocavirus 1-specific immunoglobulin M are markers of acute human bocavirus 1 infection that may cause life-threatening acute bronchiolitis.",10.1186/s13256-019-2222-5,baorf2ec,"['BACKGROUND', 'Human', 'bocavirus', '1', 'is', 'a', 'commonly', 'detected', 'human', 'parvovirus', 'Many', 'studies', 'have', 'shown', 'human', 'bocavirus', '1', 'as', 'a', 'pathogen', 'in', 'association', 'with', 'acute', 'respiratory', 'tract', 'infections', 'in', 'children', 'However', 'because', 'human', 'bocavirus', '1', 'persists', 'in', 'the', 'upper', 'airways', 'for', 'extensive', 'time', 'periods', 'after', 'acute', 'infection', 'the', 'definition', 'and', 'diagnostics', 'of', 'acute', 'human', 'bocavirus', '1', 'infection', 'is', 'challenging', 'Until', 'now', 'detection', 'of', 'human', 'bocavirus', '1', 'exclusively', 'high', 'viral', 'load', 'in', 'respiratory', 'samples', 'and', 'viremia', 'have', 'been', 'associated', 'with', 'a', 'clinical', 'picture', 'of', 'acute', 'respiratory', 'illness', 'There', 'are', 'no', 'studies', 'showing', 'detection', 'of', 'human', 'bocavirus', '1', 'messenger', 'ribonucleic', 'acid', 'in', 'the', 'peripheral', 'blood', 'mononuclear', 'cells', 'as', 'a', 'diagnostic', 'marker', 'for', 'acute', 'lower', 'respiratory', 'tract', 'infection', 'CASE', 'PRESENTATION', 'We', 'report', 'the', 'case', 'of', 'a', '17', 'month', 'old', 'Latvian', 'boy', 'who', 'presented', 'in', 'intensive', 'care', 'unit', 'with', 'acute', 'bilateral', 'bronchiolitis', 'with', 'a', 'history', 'of', 'rhinorrhea', 'and', 'cough', 'for', '6', 'days', 'and', 'fever', 'for', 'the', 'last', '2', 'days', 'prior', 'to', 'admission', 'followed', 'by', 'severe', 'respiratory', 'distress', 'and', 'tracheal', 'intubation', 'Human', 'bocavirus', '1', 'was', 'the', 'only', 'respiratory', 'virus', 'detected', 'by', 'a', 'qualitative', 'multiplex', 'polymerase', 'chain', 'reaction', 'panel', 'For', 'the', 'diagnosis', 'of', 'acute', 'human', 'bocavirus', '1', 'infection', 'both', 'molecular', 'and', 'serological', 'approaches', 'were', 'used', 'Human', 'bocavirus', '1', 'deoxyribonucleic', 'acid', 'DNA', 'was', 'detected', 'simultaneously', 'in', 'nasopharyngeal', 'aspirate', 'stool', 'and', 'blood', 'as', 'well', 'as', 'in', 'the', 'corresponding', 'cell', 'free', 'blood', 'plasma', 'by', 'qualitative', 'and', 'quantitative', 'polymerase', 'chain', 'reaction', 'revealing', 'high', 'DNA', 'copy', 'numbers', 'in', 'nasopharyngeal', 'aspirate', 'and', 'stool', 'Despite', 'a', 'low', 'load', 'viremia', 'human', 'bocavirus', '1', 'messenger', 'ribonucleic', 'acid', 'was', 'found', 'in', 'the', 'peripheral', 'blood', 'mononuclear', 'cells', 'For', 'detection', 'of', 'human', 'bocavirus', '1', 'specific', 'antibodies', 'non', 'competitive', 'immunoglobulin', 'M', 'and', 'competitive', 'immunoglobulin', 'G', 'enzyme', 'immunoassays', 'were', 'used', 'The', 'plasma', 'was', 'positive', 'for', 'both', 'human', 'bocavirus', '1', 'specific', 'immunoglobulin', 'M', 'and', 'immunoglobulin', 'G', 'antibodies', 'CONCLUSIONS', 'The', 'presence', 'of', 'human', 'bocavirus', '1', 'genomic', 'DNA', 'in', 'blood', 'plasma', 'and', 'human', 'bocavirus', '1', 'messenger', 'ribonucleic', 'acid', 'in', 'peripheral', 'blood', 'mononuclear', 'cells', 'together', 'with', 'human', 'bocavirus', '1', 'specific', 'immunoglobulin', 'M', 'are', 'markers', 'of', 'acute', 'human', 'bocavirus', '1', 'infection', 'that', 'may', 'cause', 'life', 'threatening', 'acute', 'bronchiolitis', '']"
151210,Molecular and Serological Tests for COVID-19. A Comparative Review of SARS-CoV-2 Coronavirus Laboratory and Point-of-Care Diagnostics,2020-06-26,Diagnostics (Basel),https://doi.org/10.3390/diagnostics10060434; https://www.ncbi.nlm.nih.gov/pubmed/32604919/,"Validated and accurate laboratory testing for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a crucial part of the timely management of Coronavirus Disease 2019 (COVID-19) disease, supporting the clinical decision-making process for infection control at the healthcare level and detecting asymptomatic cases. This would facilitate an appropriate treatment, a prompt isolation and consequently deceleration of the pandemic. Various laboratory tests can identify the genetic material of SARS-CoV-2 that causes COVID-19 in specimens, or specific anti-viral antibodies in blood/serum. Due to the current pandemic situation, a development of point-of-care diagnostics (POCD) allows us to substantially accelerate taking clinical decisions and implement strategic planning at the national level of preventative measures. This review summarizes and compares the available POCD and those currently under development, including quantitative reverse transcription PCR (RT-qPCR), serology immunoassays (SIAs) and protein microarray method (PMM) designed for standard and rapid COVID-19 diagnosis.",10.3390/diagnostics10060434,tb1zsuw4,"['Validated', 'and', 'accurate', 'laboratory', 'testing', 'for', 'Severe', 'Acute', 'Respiratory', 'Syndrome', 'Coronavirus', '2', 'SARS', 'CoV', '2', 'is', 'a', 'crucial', 'part', 'of', 'the', 'timely', 'management', 'of', 'Coronavirus', 'Disease', '2019', 'COVID', '19', 'disease', 'supporting', 'the', 'clinical', 'decision', 'making', 'process', 'for', 'infection', 'control', 'at', 'the', 'healthcare', 'level', 'and', 'detecting', 'asymptomatic', 'cases', 'This', 'would', 'facilitate', 'an', 'appropriate', 'treatment', 'a', 'prompt', 'isolation', 'and', 'consequently', 'deceleration', 'of', 'the', 'pandemic', 'Various', 'laboratory', 'tests', 'can', 'identify', 'the', 'genetic', 'material', 'of', 'SARS', 'CoV', '2', 'that', 'causes', 'COVID', '19', 'in', 'specimens', 'or', 'specific', 'anti', 'viral', 'antibodies', 'in', 'blood', 'serum', 'Due', 'to', 'the', 'current', 'pandemic', 'situation', 'a', 'development', 'of', 'point', 'of', 'care', 'diagnostics', 'POCD', 'allows', 'us', 'to', 'substantially', 'accelerate', 'taking', 'clinical', 'decisions', 'and', 'implement', 'strategic', 'planning', 'at', 'the', 'national', 'level', 'of', 'preventative', 'measures', 'This', 'review', 'summarizes', 'and', 'compares', 'the', 'available', 'POCD', 'and', 'those', 'currently', 'under', 'development', 'including', 'quantitative', 'reverse', 'transcription', 'PCR', 'RT', 'qPCR', 'serology', 'immunoassays', 'SIAs', 'and', 'protein', 'microarray', 'method', 'PMM', 'designed', 'for', 'standard', 'and', 'rapid', 'COVID', '19', 'diagnosis', '']"
152105,Development and Potential Usefulness of the COVID-19 Ag Respi-Strip Diagnostic Assay in a Pandemic Context,2020-05-08,Front Med (Lausanne),https://www.ncbi.nlm.nih.gov/pubmed/32574326/; https://doi.org/10.3389/fmed.2020.00225,"Introduction: COVID-19 Ag Respi-Strip, an immunochromatographic (ICT) assay for the rapid detection of SARS-CoV-2 antigen on nasopharyngeal specimen, has been developed to identify positive COVID-19 patients allowing prompt clinical and quarantine decisions. In this original research article, we describe the conception, the analytical and clinical performances as well as the risk management of implementing the COVID-19 Ag Respi-Strip in a diagnostic decision algorithm. Materials and Methods: Development of the COVID-19 Ag Respi-Strip resulted in a ready-to-use ICT assay based on a membrane technology with colloidal gold nanoparticles using monoclonal antibodies directed against the SARS-CoV and SARS-CoV-2 highly conserved nucleoprotein antigen. Four hundred observations were recorded for the analytical performance study and thirty tests were analyzed for the cross-reactivity study. The clinical performance study was performed in a retrospective multi-centric evaluation on aliquots of 328 nasopharyngeal samples. COVID-19 Ag Respi-Strip results were compared with qRT-PCR as golden standard for COVID-19 diagnostics. Results: In the analytical performance study, the reproducibility showed a between-observer disagreement of 1.7%, a robustness of 98%, an overall satisfying user friendliness and no cross-reactivity with other virus-infected nasopharyngeal samples. In the clinical performance study performed in three different clinical laboratories during the ascendant phase of the epidemiological curve, we found an overall sensitivity and specificity of 57.6 and 99.5%, respectively with an accuracy of 82.6%. The cut-off of the ICT was found at CT <22. User-friendliness analysis and risk management assessment through Ishikawa diagram demonstrate that COVID-19 Ag Respi-Strip may be implemented in clinical laboratories according to biosafety recommendations. Conclusion: The COVID-19 Ag Respi-Strip represents a promising rapid SARS-CoV-2 antigen assay for the first-line diagnosis of COVID-19 in 15 min at the peak of the pandemic. Its role in the proposed diagnostic algorithm is complementary to the currently-used molecular techniques.",10.3389/fmed.2020.00225,w3yoxhsg,"['Introduction', 'COVID', '19', 'Ag', 'Respi', 'Strip', 'an', 'immunochromatographic', 'ICT', 'assay', 'for', 'the', 'rapid', 'detection', 'of', 'SARS', 'CoV', '2', 'antigen', 'on', 'nasopharyngeal', 'specimen', 'has', 'been', 'developed', 'to', 'identify', 'positive', 'COVID', '19', 'patients', 'allowing', 'prompt', 'clinical', 'and', 'quarantine', 'decisions', 'In', 'this', 'original', 'research', 'article', 'we', 'describe', 'the', 'conception', 'the', 'analytical', 'and', 'clinical', 'performances', 'as', 'well', 'as', 'the', 'risk', 'management', 'of', 'implementing', 'the', 'COVID', '19', 'Ag', 'Respi', 'Strip', 'in', 'a', 'diagnostic', 'decision', 'algorithm', 'Materials', 'and', 'Methods', 'Development', 'of', 'the', 'COVID', '19', 'Ag', 'Respi', 'Strip', 'resulted', 'in', 'a', 'ready', 'to', 'use', 'ICT', 'assay', 'based', 'on', 'a', 'membrane', 'technology', 'with', 'colloidal', 'gold', 'nanoparticles', 'using', 'monoclonal', 'antibodies', 'directed', 'against', 'the', 'SARS', 'CoV', 'and', 'SARS', 'CoV', '2', 'highly', 'conserved', 'nucleoprotein', 'antigen', 'Four', 'hundred', 'observations', 'were', 'recorded', 'for', 'the', 'analytical', 'performance', 'study', 'and', 'thirty', 'tests', 'were', 'analyzed', 'for', 'the', 'cross', 'reactivity', 'study', 'The', 'clinical', 'performance', 'study', 'was', 'performed', 'in', 'a', 'retrospective', 'multi', 'centric', 'evaluation', 'on', 'aliquots', 'of', '328', 'nasopharyngeal', 'samples', 'COVID', '19', 'Ag', 'Respi', 'Strip', 'results', 'were', 'compared', 'with', 'qRT', 'PCR', 'as', 'golden', 'standard', 'for', 'COVID', '19', 'diagnostics', 'Results', 'In', 'the', 'analytical', 'performance', 'study', 'the', 'reproducibility', 'showed', 'a', 'between', 'observer', 'disagreement', 'of', '1', '7', 'a', 'robustness', 'of', '98', 'an', 'overall', 'satisfying', 'user', 'friendliness', 'and', 'no', 'cross', 'reactivity', 'with', 'other', 'virus', 'infected', 'nasopharyngeal', 'samples', 'In', 'the', 'clinical', 'performance', 'study', 'performed', 'in', 'three', 'different', 'clinical', 'laboratories', 'during', 'the', 'ascendant', 'phase', 'of', 'the', 'epidemiological', 'curve', 'we', 'found', 'an', 'overall', 'sensitivity', 'and', 'specificity', 'of', '57', '6', 'and', '99', '5', 'respectively', 'with', 'an', 'accuracy', 'of', '82', '6', 'The', 'cut', 'off', 'of', 'the', 'ICT', 'was', 'found', 'at', 'CT', '22', 'User', 'friendliness', 'analysis', 'and', 'risk', 'management', 'assessment', 'through', 'Ishikawa', 'diagram', 'demonstrate', 'that', 'COVID', '19', 'Ag', 'Respi', 'Strip', 'may', 'be', 'implemented', 'in', 'clinical', 'laboratories', 'according', 'to', 'biosafety', 'recommendations', 'Conclusion', 'The', 'COVID', '19', 'Ag', 'Respi', 'Strip', 'represents', 'a', 'promising', 'rapid', 'SARS', 'CoV', '2', 'antigen', 'assay', 'for', 'the', 'first', 'line', 'diagnosis', 'of', 'COVID', '19', 'in', '15', 'min', 'at', 'the', 'peak', 'of', 'the', 'pandemic', 'Its', 'role', 'in', 'the', 'proposed', 'diagnostic', 'algorithm', 'is', 'complementary', 'to', 'the', 'currently', 'used', 'molecular', 'techniques', '']"
153954,Selection and Characterization of Monoclonal Antibodies Targeting Middle East Respiratory Syndrome Coronavirus through a Human Synthetic Fab Phage Display Library Panning,2019-07-31,Antibodies (Basel),https://doi.org/10.3390/antib8030042; https://www.ncbi.nlm.nih.gov/pubmed/31544848/,"Since its first report in the Middle East in 2012, the Middle East respiratory syndrome-coronavirus (MERS-CoV) has become a global concern due to the high morbidity and mortality of individuals infected with the virus. Although the majority of MERS-CoV cases have been reported in Saudi Arabia, the overall risk in areas outside the Middle East remains significant as inside Saudi Arabia. Additional pandemics of MERS-CoV are expected, and thus novel tools and reagents for therapy and diagnosis are urgently needed. Here, we used phage display to develop novel monoclonal antibodies (mAbs) that target MERS-CoV. A human Fab phage display library was panned against the S2 subunit of the MERS-CoV spike protein (MERS-S2P), yielding three unique Fabs (S2A3, S2A6, and S2D5). The Fabs had moderate apparent affinities (Half maximal effective concentration (EC(50) = 123–421 nM) for MERS-S2P, showed no cross-reactivity to spike proteins from other CoVs, and were non-aggregating and thermostable (T(m) = 61.5–80.4 °C). Reformatting the Fabs into IgGs (Immunoglobulin Gs) greatly increased their apparent affinities (K(D) = 0.17–1.2 nM), presumably due to the effects of avidity. These apparent affinities were notably higher than that of a previously reported anti-MERS-CoV S2 reference mAb (K(D) = 8.7 nM). Furthermore, two of the three mAbs (S2A3 and S2D5) bound only MERS-CoV (Erasmus Medical Center (EMC)) and not other CoVs, reflecting their high binding specificity. However, the mAbs lacked MERS-CoV neutralizing activity. Given their high affinity, specificity, and desirable stabilities, we anticipate that these anti-MERS-CoV mAbs would be suitable reagents for developing antibody-based diagnostics in laboratory or hospital settings for point-of-care testing.",10.3390/antib8030042,1zcxw6yu,"['Since', 'its', 'first', 'report', 'in', 'the', 'Middle', 'East', 'in', '2012', 'the', 'Middle', 'East', 'respiratory', 'syndrome', 'coronavirus', 'MERS', 'CoV', 'has', 'become', 'a', 'global', 'concern', 'due', 'to', 'the', 'high', 'morbidity', 'and', 'mortality', 'of', 'individuals', 'infected', 'with', 'the', 'virus', 'Although', 'the', 'majority', 'of', 'MERS', 'CoV', 'cases', 'have', 'been', 'reported', 'in', 'Saudi', 'Arabia', 'the', 'overall', 'risk', 'in', 'areas', 'outside', 'the', 'Middle', 'East', 'remains', 'significant', 'as', 'inside', 'Saudi', 'Arabia', 'Additional', 'pandemics', 'of', 'MERS', 'CoV', 'are', 'expected', 'and', 'thus', 'novel', 'tools', 'and', 'reagents', 'for', 'therapy', 'and', 'diagnosis', 'are', 'urgently', 'needed', 'Here', 'we', 'used', 'phage', 'display', 'to', 'develop', 'novel', 'monoclonal', 'antibodies', 'mAbs', 'that', 'target', 'MERS', 'CoV', 'A', 'human', 'Fab', 'phage', 'display', 'library', 'was', 'panned', 'against', 'the', 'S2', 'subunit', 'of', 'the', 'MERS', 'CoV', 'spike', 'protein', 'MERS', 'S2P', 'yielding', 'three', 'unique', 'Fabs', 'S2A3', 'S2A6', 'and', 'S2D5', 'The', 'Fabs', 'had', 'moderate', 'apparent', 'affinities', 'Half', 'maximal', 'effective', 'concentration', 'EC', '50', '123', '421', 'nM', 'for', 'MERS', 'S2P', 'showed', 'no', 'cross', 'reactivity', 'to', 'spike', 'proteins', 'from', 'other', 'CoVs', 'and', 'were', 'non', 'aggregating', 'and', 'thermostable', 'T', 'm', '61', '5', '80', '4', 'C', 'Reformatting', 'the', 'Fabs', 'into', 'IgGs', 'Immunoglobulin', 'Gs', 'greatly', 'increased', 'their', 'apparent', 'affinities', 'K', 'D', '0', '17', '1', '2', 'nM', 'presumably', 'due', 'to', 'the', 'effects', 'of', 'avidity', 'These', 'apparent', 'affinities', 'were', 'notably', 'higher', 'than', 'that', 'of', 'a', 'previously', 'reported', 'anti', 'MERS', 'CoV', 'S2', 'reference', 'mAb', 'K', 'D', '8', '7', 'nM', 'Furthermore', 'two', 'of', 'the', 'three', 'mAbs', 'S2A3', 'and', 'S2D5', 'bound', 'only', 'MERS', 'CoV', 'Erasmus', 'Medical', 'Center', 'EMC', 'and', 'not', 'other', 'CoVs', 'reflecting', 'their', 'high', 'binding', 'specificity', 'However', 'the', 'mAbs', 'lacked', 'MERS', 'CoV', 'neutralizing', 'activity', 'Given', 'their', 'high', 'affinity', 'specificity', 'and', 'desirable', 'stabilities', 'we', 'anticipate', 'that', 'these', 'anti', 'MERS', 'CoV', 'mAbs', 'would', 'be', 'suitable', 'reagents', 'for', 'developing', 'antibody', 'based', 'diagnostics', 'in', 'laboratory', 'or', 'hospital', 'settings', 'for', 'point', 'of', 'care', 'testing', '']"
154082,Stable long‐term cultures of self‐renewing B cells and their applications,2016-02-10,Immunol Rev,https://doi.org/10.1111/imr.12395; https://www.ncbi.nlm.nih.gov/pubmed/26864105/,"Monoclonal antibodies are essential therapeutics and diagnostics in a large number of diseases. Moreover, they are essential tools in all sectors of life sciences. Although the great majority of monoclonal antibodies currently in use are of mouse origin, the use of human B cells to generate monoclonal antibodies is increasing as new techniques to tap the human B cell repertoire are rapidly emerging. Cloned lines of immortalized human B cells are ideal sources of monoclonal antibodies. In this review, we summarize our studies to the regulation of the replicative life span, differentiation, and maturation of B cells that led to the development of a platform that uses immortalization of human B cells by in vitro genetic modification for antibody development. We describe a number of human antibodies that were isolated using this platform and the application of the technique in other species. We also discuss the use of immortalized B cells as antigen‐presenting cells for the discovery of tumor neoantigens.",10.1111/imr.12395,g12r2417,"['Monoclonal', 'antibodies', 'are', 'essential', 'therapeutics', 'and', 'diagnostics', 'in', 'a', 'large', 'number', 'of', 'diseases', 'Moreover', 'they', 'are', 'essential', 'tools', 'in', 'all', 'sectors', 'of', 'life', 'sciences', 'Although', 'the', 'great', 'majority', 'of', 'monoclonal', 'antibodies', 'currently', 'in', 'use', 'are', 'of', 'mouse', 'origin', 'the', 'use', 'of', 'human', 'B', 'cells', 'to', 'generate', 'monoclonal', 'antibodies', 'is', 'increasing', 'as', 'new', 'techniques', 'to', 'tap', 'the', 'human', 'B', 'cell', 'repertoire', 'are', 'rapidly', 'emerging', 'Cloned', 'lines', 'of', 'immortalized', 'human', 'B', 'cells', 'are', 'ideal', 'sources', 'of', 'monoclonal', 'antibodies', 'In', 'this', 'review', 'we', 'summarize', 'our', 'studies', 'to', 'the', 'regulation', 'of', 'the', 'replicative', 'life', 'span', 'differentiation', 'and', 'maturation', 'of', 'B', 'cells', 'that', 'led', 'to', 'the', 'development', 'of', 'a', 'platform', 'that', 'uses', 'immortalization', 'of', 'human', 'B', 'cells', 'by', 'in', 'vitro', 'genetic', 'modification', 'for', 'antibody', 'development', 'We', 'describe', 'a', 'number', 'of', 'human', 'antibodies', 'that', 'were', 'isolated', 'using', 'this', 'platform', 'and', 'the', 'application', 'of', 'the', 'technique', 'in', 'other', 'species', 'We', 'also', 'discuss', 'the', 'use', 'of', 'immortalized', 'B', 'cells', 'as', 'antigen', 'presenting', 'cells', 'for', 'the', 'discovery', 'of', 'tumor', 'neoantigens', '']"
154549,Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation,2020-02-15,bioRxiv,https://doi.org/10.1101/2020.02.11.944462; https://www.ncbi.nlm.nih.gov/pubmed/32511295/,"The outbreak of a novel betacoronavirus (2019-nCov) represents a pandemic threat that has been declared a public health emergency of international concern. The CoV spike (S) glycoprotein is a key target for urgently needed vaccines, therapeutic antibodies, and diagnostics. To facilitate medical countermeasure (MCM) development we determined a 3.5 Å-resolution cryo-EM structure of the 2019-nCoV S trimer in the prefusion conformation. The predominant state of the trimer has one of the three receptor-binding domains (RBDs) rotated up in a receptor-accessible conformation. We also show biophysical and structural evidence that the 2019-nCoV S binds ACE2 with higher affinity than SARS-CoV S. Additionally we tested several published SARS-CoV RBD-specific monoclonal antibodies and found that they do not have appreciable binding to nCoV-2019 S, suggesting antibody cross-reactivity may be limited between the two virus RBDs. The atomic-resolution structure of 2019-nCoV S should enable rapid development and evaluation of MCMs to address the ongoing public health crisis.",10.1101/2020.02.11.944462,prqeufwg,"['The', 'outbreak', 'of', 'a', 'novel', 'betacoronavirus', '2019', 'nCov', 'represents', 'a', 'pandemic', 'threat', 'that', 'has', 'been', 'declared', 'a', 'public', 'health', 'emergency', 'of', 'international', 'concern', 'The', 'CoV', 'spike', 'S', 'glycoprotein', 'is', 'a', 'key', 'target', 'for', 'urgently', 'needed', 'vaccines', 'therapeutic', 'antibodies', 'and', 'diagnostics', 'To', 'facilitate', 'medical', 'countermeasure', 'MCM', 'development', 'we', 'determined', 'a', '3', '5', 'Å', 'resolution', 'cryo', 'EM', 'structure', 'of', 'the', '2019', 'nCoV', 'S', 'trimer', 'in', 'the', 'prefusion', 'conformation', 'The', 'predominant', 'state', 'of', 'the', 'trimer', 'has', 'one', 'of', 'the', 'three', 'receptor', 'binding', 'domains', 'RBDs', 'rotated', 'up', 'in', 'a', 'receptor', 'accessible', 'conformation', 'We', 'also', 'show', 'biophysical', 'and', 'structural', 'evidence', 'that', 'the', '2019', 'nCoV', 'S', 'binds', 'ACE2', 'with', 'higher', 'affinity', 'than', 'SARS', 'CoV', 'S', 'Additionally', 'we', 'tested', 'several', 'published', 'SARS', 'CoV', 'RBD', 'specific', 'monoclonal', 'antibodies', 'and', 'found', 'that', 'they', 'do', 'not', 'have', 'appreciable', 'binding', 'to', 'nCoV', '2019', 'S', 'suggesting', 'antibody', 'cross', 'reactivity', 'may', 'be', 'limited', 'between', 'the', 'two', 'virus', 'RBDs', 'The', 'atomic', 'resolution', 'structure', 'of', '2019', 'nCoV', 'S', 'should', 'enable', 'rapid', 'development', 'and', 'evaluation', 'of', 'MCMs', 'to', 'address', 'the', 'ongoing', 'public', 'health', 'crisis', '']"
155069,Identification of a Novel Linear B-Cell Epitope on the Nucleocapsid Protein of Porcine Deltacoronavirus,2020-01-19,Int J Mol Sci,https://www.ncbi.nlm.nih.gov/pubmed/31963776/; https://doi.org/10.3390/ijms21020648,"Porcine deltacoronavirus (PDCoV), first identified in 2012, is a swine enteropathogen now found in many countries. The nucleocapsid (N) protein, a core component of PDCoV, is essential for virus replication and is a significant candidate in the development of diagnostics for PDCoV. In this study, monoclonal antibodies (mAbs) were generated and tested for reactivity with three truncations of the full protein (N1, N2, N3) that contained partial overlaps; of the five monoclonals chosen tested, each reacted with only the N3 truncation. The antibody designated 4E88 had highest binding affinity with the N protein and was chosen for in-depth examination. The 4E88 epitope was located to amino acids 308-AKPKQQKKPKK-318 by testing the 4E88 monoclonal for reactivity with a series of N3 truncations, then the minimal epitope, 309-KPKQQKKPK-317 (designated EP-4E88), was pinpointed by testing the 4E88 monoclonal for reactivity with a series of synthetic peptides of this region. Homology analysis showed that the EP-4E88 sequence is highly conserved among PDCoV strains, and also shares high similarity with sparrow coronavirus (HKU17), Asian leopard cat coronavirus (ALCCoV), quail coronavirus (UAE-HKU30), and sparrow deltacoronavirus (SpDCoV). Of note, the PDCoV EP-4E88 sequence shared very low similarity (<22.2%) with other porcine coronaviruses (PEDV, TGEV, PRCV, SADS-CoV, PHEV), demonstrating that it is an epitope that can be used for distinguishing PDCoV and other porcine coronavirus. 3D structural analysis revealed that amino acids of EP-4E88 were in close proximity and may be exposed on the surface of the N protein.",10.3390/ijms21020648,2r101v54,"['Porcine', 'deltacoronavirus', 'PDCoV', 'first', 'identified', 'in', '2012', 'is', 'a', 'swine', 'enteropathogen', 'now', 'found', 'in', 'many', 'countries', 'The', 'nucleocapsid', 'N', 'protein', 'a', 'core', 'component', 'of', 'PDCoV', 'is', 'essential', 'for', 'virus', 'replication', 'and', 'is', 'a', 'significant', 'candidate', 'in', 'the', 'development', 'of', 'diagnostics', 'for', 'PDCoV', 'In', 'this', 'study', 'monoclonal', 'antibodies', 'mAbs', 'were', 'generated', 'and', 'tested', 'for', 'reactivity', 'with', 'three', 'truncations', 'of', 'the', 'full', 'protein', 'N1', 'N2', 'N3', 'that', 'contained', 'partial', 'overlaps', 'of', 'the', 'five', 'monoclonals', 'chosen', 'tested', 'each', 'reacted', 'with', 'only', 'the', 'N3', 'truncation', 'The', 'antibody', 'designated', '4E88', 'had', 'highest', 'binding', 'affinity', 'with', 'the', 'N', 'protein', 'and', 'was', 'chosen', 'for', 'in', 'depth', 'examination', 'The', '4E88', 'epitope', 'was', 'located', 'to', 'amino', 'acids', '308', 'AKPKQQKKPKK', '318', 'by', 'testing', 'the', '4E88', 'monoclonal', 'for', 'reactivity', 'with', 'a', 'series', 'of', 'N3', 'truncations', 'then', 'the', 'minimal', 'epitope', '309', 'KPKQQKKPK', '317', 'designated', 'EP', '4E88', 'was', 'pinpointed', 'by', 'testing', 'the', '4E88', 'monoclonal', 'for', 'reactivity', 'with', 'a', 'series', 'of', 'synthetic', 'peptides', 'of', 'this', 'region', 'Homology', 'analysis', 'showed', 'that', 'the', 'EP', '4E88', 'sequence', 'is', 'highly', 'conserved', 'among', 'PDCoV', 'strains', 'and', 'also', 'shares', 'high', 'similarity', 'with', 'sparrow', 'coronavirus', 'HKU17', 'Asian', 'leopard', 'cat', 'coronavirus', 'ALCCoV', 'quail', 'coronavirus', 'UAE', 'HKU30', 'and', 'sparrow', 'deltacoronavirus', 'SpDCoV', 'Of', 'note', 'the', 'PDCoV', 'EP', '4E88', 'sequence', 'shared', 'very', 'low', 'similarity', '22', '2', 'with', 'other', 'porcine', 'coronaviruses', 'PEDV', 'TGEV', 'PRCV', 'SADS', 'CoV', 'PHEV', 'demonstrating', 'that', 'it', 'is', 'an', 'epitope', 'that', 'can', 'be', 'used', 'for', 'distinguishing', 'PDCoV', 'and', 'other', 'porcine', 'coronavirus', '3D', 'structural', 'analysis', 'revealed', 'that', 'amino', 'acids', 'of', 'EP', '4E88', 'were', 'in', 'close', 'proximity', 'and', 'may', 'be', 'exposed', 'on', 'the', 'surface', 'of', 'the', 'N', 'protein', '']"
155422,"The Strategic Alliance between Clinical and Molecular Science in the War against SARS-CoV-2, with the Rapid-Diagnostics Test as an Indispensable Weapon for Front Line Doctors",2020-06-22,Int J Mol Sci,https://doi.org/10.3390/ijms21124446; https://www.ncbi.nlm.nih.gov/pubmed/32580529/,"Our work concerns the actual problem of spread of SARS- CoV-2 outbreak which requires fast and correct as possible answer. In current scenario, the need of rapid answer put away the imperative of proper methodology. We focus on the serogical immunoassay for diagnosis of Covid-19 as an important weapon not only for diagnostic purpose, but also for epidemiologic one. The right equilibrium between high speed, low cost and accuracy is obtained with easy-to-use decentralized point-of-care test as the colloidal gold-based immunochromatographic strip assay which detects IgM and IgG antibodies directed against SARS-CoV-2. As our aim is to evaluate the efficacy of Covid-19 rapid tests and of serological assays in real-life settings, we designed a research protocol aimed to establish how to use correctly these diagnostics, taking into account the different possible clinical and epidemiological scenarios.",10.3390/ijms21124446,zt3w9vy3,"['Our', 'work', 'concerns', 'the', 'actual', 'problem', 'of', 'spread', 'of', 'SARS', 'CoV', '2', 'outbreak', 'which', 'requires', 'fast', 'and', 'correct', 'as', 'possible', 'answer', 'In', 'current', 'scenario', 'the', 'need', 'of', 'rapid', 'answer', 'put', 'away', 'the', 'imperative', 'of', 'proper', 'methodology', 'We', 'focus', 'on', 'the', 'serogical', 'immunoassay', 'for', 'diagnosis', 'of', 'Covid', '19', 'as', 'an', 'important', 'weapon', 'not', 'only', 'for', 'diagnostic', 'purpose', 'but', 'also', 'for', 'epidemiologic', 'one', 'The', 'right', 'equilibrium', 'between', 'high', 'speed', 'low', 'cost', 'and', 'accuracy', 'is', 'obtained', 'with', 'easy', 'to', 'use', 'decentralized', 'point', 'of', 'care', 'test', 'as', 'the', 'colloidal', 'gold', 'based', 'immunochromatographic', 'strip', 'assay', 'which', 'detects', 'IgM', 'and', 'IgG', 'antibodies', 'directed', 'against', 'SARS', 'CoV', '2', 'As', 'our', 'aim', 'is', 'to', 'evaluate', 'the', 'efficacy', 'of', 'Covid', '19', 'rapid', 'tests', 'and', 'of', 'serological', 'assays', 'in', 'real', 'life', 'settings', 'we', 'designed', 'a', 'research', 'protocol', 'aimed', 'to', 'establish', 'how', 'to', 'use', 'correctly', 'these', 'diagnostics', 'taking', 'into', 'account', 'the', 'different', 'possible', 'clinical', 'and', 'epidemiological', 'scenarios', '']"
156228,Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation,2020-03-13,Science,https://www.ncbi.nlm.nih.gov/pubmed/32075877/; https://doi.org/10.1126/science.abb2507,"The outbreak of a novel coronavirus (2019-nCoV) represents a pandemic threat that has been declared a public health emergency of international concern. The CoV spike (S) glycoprotein is a key target for vaccines, therapeutic antibodies, and diagnostics. To facilitate medical countermeasure development, we determined a 3.5-angstrom-resolution cryo–electron microscopy structure of the 2019-nCoV S trimer in the prefusion conformation. The predominant state of the trimer has one of the three receptor-binding domains (RBDs) rotated up in a receptor-accessible conformation. We also provide biophysical and structural evidence that the 2019-nCoV S protein binds angiotensin-converting enzyme 2 (ACE2) with higher affinity than does severe acute respiratory syndrome (SARS)-CoV S. Additionally, we tested several published SARS-CoV RBD-specific monoclonal antibodies and found that they do not have appreciable binding to 2019-nCoV S, suggesting that antibody cross-reactivity may be limited between the two RBDs. The structure of 2019-nCoV S should enable the rapid development and evaluation of medical countermeasures to address the ongoing public health crisis.",10.1126/science.abb2507,vp96izcs,"['The', 'outbreak', 'of', 'a', 'novel', 'coronavirus', '2019', 'nCoV', 'represents', 'a', 'pandemic', 'threat', 'that', 'has', 'been', 'declared', 'a', 'public', 'health', 'emergency', 'of', 'international', 'concern', 'The', 'CoV', 'spike', 'S', 'glycoprotein', 'is', 'a', 'key', 'target', 'for', 'vaccines', 'therapeutic', 'antibodies', 'and', 'diagnostics', 'To', 'facilitate', 'medical', 'countermeasure', 'development', 'we', 'determined', 'a', '3', '5', 'angstrom', 'resolution', 'cryo', 'electron', 'microscopy', 'structure', 'of', 'the', '2019', 'nCoV', 'S', 'trimer', 'in', 'the', 'prefusion', 'conformation', 'The', 'predominant', 'state', 'of', 'the', 'trimer', 'has', 'one', 'of', 'the', 'three', 'receptor', 'binding', 'domains', 'RBDs', 'rotated', 'up', 'in', 'a', 'receptor', 'accessible', 'conformation', 'We', 'also', 'provide', 'biophysical', 'and', 'structural', 'evidence', 'that', 'the', '2019', 'nCoV', 'S', 'protein', 'binds', 'angiotensin', 'converting', 'enzyme', '2', 'ACE2', 'with', 'higher', 'affinity', 'than', 'does', 'severe', 'acute', 'respiratory', 'syndrome', 'SARS', 'CoV', 'S', 'Additionally', 'we', 'tested', 'several', 'published', 'SARS', 'CoV', 'RBD', 'specific', 'monoclonal', 'antibodies', 'and', 'found', 'that', 'they', 'do', 'not', 'have', 'appreciable', 'binding', 'to', '2019', 'nCoV', 'S', 'suggesting', 'that', 'antibody', 'cross', 'reactivity', 'may', 'be', 'limited', 'between', 'the', 'two', 'RBDs', 'The', 'structure', 'of', '2019', 'nCoV', 'S', 'should', 'enable', 'the', 'rapid', 'development', 'and', 'evaluation', 'of', 'medical', 'countermeasures', 'to', 'address', 'the', 'ongoing', 'public', 'health', 'crisis', '']"
156701,Molecular analysis of monoclonal antibodies to group variant capsular polysaccharide of Neisseria meningitidis: recurrent heavy chains and alternative light chain partners,2005-02-28,Molecular Immunology,https://www.sciencedirect.com/science/article/pii/S0161589004003359; https://api.elsevier.com/content/article/pii/S0161589004003359; https://www.ncbi.nlm.nih.gov/pubmed/15589322/,"Abstract We determined the molecular sequence of monoclonal antibodies (mAbs) to serogroups B and C capsular polysaccharides (PS) of Neisseria meningitidis. N. meningitidis infections are a leading cause of bacterial septicemia and meningitis in humans. Antibodies to PS are fundamental to host defense and diagnostics. The polysaccharide capsule of group B N. meningitidis is poorly immunogenic and thus is an important model for studying pathogen-host co-evolution through understanding the molecular basis of the host immune response. We used a modified reverse-transcriptase PCR to amplify and sequence the V-genes of murine hybridomas produced against types B and C capsular PS. Databank analysis of the sequences encoding the V-genes of type C capsular PS mAb, 4-2-C, reveal that heavy chain alleles are recurrently used to encode this specificity in mice. Interestingly, a V-gene from the same germline family also encodes the V-domain of mAbs 2-2-B, which targets the antigenically distinct serogroup B capsular PS. Somatic mutation, junctional diversity and alternative light chains collectively impart the specificity for these serologically distinct epitopes. Knowledge of the specific immunoglobulin genes used to target common bacterial virulence factors may lead to insights on pathogen-host co-evolution, and the potential use of this information in pre-symptomatic diagnosis is discussed.",10.1016/j.molimm.2004.09.002,544wa28l,"['Abstract', 'We', 'determined', 'the', 'molecular', 'sequence', 'of', 'monoclonal', 'antibodies', 'mAbs', 'to', 'serogroups', 'B', 'and', 'C', 'capsular', 'polysaccharides', 'PS', 'of', 'Neisseria', 'meningitidis', 'N', 'meningitidis', 'infections', 'are', 'a', 'leading', 'cause', 'of', 'bacterial', 'septicemia', 'and', 'meningitis', 'in', 'humans', 'Antibodies', 'to', 'PS', 'are', 'fundamental', 'to', 'host', 'defense', 'and', 'diagnostics', 'The', 'polysaccharide', 'capsule', 'of', 'group', 'B', 'N', 'meningitidis', 'is', 'poorly', 'immunogenic', 'and', 'thus', 'is', 'an', 'important', 'model', 'for', 'studying', 'pathogen', 'host', 'co', 'evolution', 'through', 'understanding', 'the', 'molecular', 'basis', 'of', 'the', 'host', 'immune', 'response', 'We', 'used', 'a', 'modified', 'reverse', 'transcriptase', 'PCR', 'to', 'amplify', 'and', 'sequence', 'the', 'V', 'genes', 'of', 'murine', 'hybridomas', 'produced', 'against', 'types', 'B', 'and', 'C', 'capsular', 'PS', 'Databank', 'analysis', 'of', 'the', 'sequences', 'encoding', 'the', 'V', 'genes', 'of', 'type', 'C', 'capsular', 'PS', 'mAb', '4', '2', 'C', 'reveal', 'that', 'heavy', 'chain', 'alleles', 'are', 'recurrently', 'used', 'to', 'encode', 'this', 'specificity', 'in', 'mice', 'Interestingly', 'a', 'V', 'gene', 'from', 'the', 'same', 'germline', 'family', 'also', 'encodes', 'the', 'V', 'domain', 'of', 'mAbs', '2', '2', 'B', 'which', 'targets', 'the', 'antigenically', 'distinct', 'serogroup', 'B', 'capsular', 'PS', 'Somatic', 'mutation', 'junctional', 'diversity', 'and', 'alternative', 'light', 'chains', 'collectively', 'impart', 'the', 'specificity', 'for', 'these', 'serologically', 'distinct', 'epitopes', 'Knowledge', 'of', 'the', 'specific', 'immunoglobulin', 'genes', 'used', 'to', 'target', 'common', 'bacterial', 'virulence', 'factors', 'may', 'lead', 'to', 'insights', 'on', 'pathogen', 'host', 'co', 'evolution', 'and', 'the', 'potential', 'use', 'of', 'this', 'information', 'in', 'pre', 'symptomatic', 'diagnosis', 'is', 'discussed', '']"
157758,Evaluation of the EDI enzyme linked immunosorbent assays for the detection of SARS-CoV-2 IgM and IgG antibodies in human plasma,2020-06-08,Clin Chim Acta,https://www.sciencedirect.com/science/article/pii/S0009898120302588?v=s5; https://doi.org/10.1016/j.cca.2020.05.047; https://api.elsevier.com/content/article/pii/S0009898120302588; https://www.ncbi.nlm.nih.gov/pubmed/32526218/,"BACKGROUND: Besides SARS-CoV-2 RT-PCR testing, serological testing is emerging as additional option in COVID-19 diagnostics. Aim of this study was to evaluate novel immunoassays for detection of SARS-CoV-2 antibodies in human plasma. METHODS: Using EDI(TM) Novel Coronavirus COVID-19 Enzyme Linked Immunosorbent Assays (ELISAs), we measured SARS-CoV-2 IgM and IgG antibodies in 64 SARS-CoV-2 RT-PCR confirmed COVID-19 patients with serial blood samples (n=104) collected at different time points from symptom onset. Blood samples from 200 healthy blood donors and 256 intensive care unit (ICU) patients collected before the COVID-19 outbreak were also used. RESULTS: The positivity rates in the COVID-19 patients were 5.9% for IgM and 2.9% for IgG ≤5 days after symptom onset; Between day 5 and day 10 the positivity rates were 37.1% for IgM and 37.1% for IgG and rose to 76.4% for IgM and 82.4% for IgG after >10-15 days. After 15-22 days the “true” positivity rates were 94.4% for IgM and 100% for IgG. The “false” positivity rates were 0.5% for IgM and 1.0% for IgG in the healthy blood donors, 1.6% for IgM and 1.2% for IgG in ICU patients. CONCLUSIONS: This study shows high “true” vs. low “false” positivity rates for the EDI(TM) SARS-CoV-2 IgM and IgG ELISAs.",10.1016/j.cca.2020.05.047,uqg2xkie,"['BACKGROUND', 'Besides', 'SARS', 'CoV', '2', 'RT', 'PCR', 'testing', 'serological', 'testing', 'is', 'emerging', 'as', 'additional', 'option', 'in', 'COVID', '19', 'diagnostics', 'Aim', 'of', 'this', 'study', 'was', 'to', 'evaluate', 'novel', 'immunoassays', 'for', 'detection', 'of', 'SARS', 'CoV', '2', 'antibodies', 'in', 'human', 'plasma', 'METHODS', 'Using', 'EDI', 'TM', 'Novel', 'Coronavirus', 'COVID', '19', 'Enzyme', 'Linked', 'Immunosorbent', 'Assays', 'ELISAs', 'we', 'measured', 'SARS', 'CoV', '2', 'IgM', 'and', 'IgG', 'antibodies', 'in', '64', 'SARS', 'CoV', '2', 'RT', 'PCR', 'confirmed', 'COVID', '19', 'patients', 'with', 'serial', 'blood', 'samples', 'n', '104', 'collected', 'at', 'different', 'time', 'points', 'from', 'symptom', 'onset', 'Blood', 'samples', 'from', '200', 'healthy', 'blood', 'donors', 'and', '256', 'intensive', 'care', 'unit', 'ICU', 'patients', 'collected', 'before', 'the', 'COVID', '19', 'outbreak', 'were', 'also', 'used', 'RESULTS', 'The', 'positivity', 'rates', 'in', 'the', 'COVID', '19', 'patients', 'were', '5', '9', 'for', 'IgM', 'and', '2', '9', 'for', 'IgG', '5', 'days', 'after', 'symptom', 'onset', 'Between', 'day', '5', 'and', 'day', '10', 'the', 'positivity', 'rates', 'were', '37', '1', 'for', 'IgM', 'and', '37', '1', 'for', 'IgG', 'and', 'rose', 'to', '76', '4', 'for', 'IgM', 'and', '82', '4', 'for', 'IgG', 'after', '10', '15', 'days', 'After', '15', '22', 'days', 'the', 'true', 'positivity', 'rates', 'were', '94', '4', 'for', 'IgM', 'and', '100', 'for', 'IgG', 'The', 'false', 'positivity', 'rates', 'were', '0', '5', 'for', 'IgM', 'and', '1', '0', 'for', 'IgG', 'in', 'the', 'healthy', 'blood', 'donors', '1', '6', 'for', 'IgM', 'and', '1', '2', 'for', 'IgG', 'in', 'ICU', 'patients', 'CONCLUSIONS', 'This', 'study', 'shows', 'high', 'true', 'vs', 'low', 'false', 'positivity', 'rates', 'for', 'the', 'EDI', 'TM', 'SARS', 'CoV', '2', 'IgM', 'and', 'IgG', 'ELISAs', '']"
158370,Rapid Isolation of Antibody from a Synthetic Human Antibody Library by Repeated Fluorescence-Activated Cell Sorting (FACS),2014-10-10,PLoS One,https://www.ncbi.nlm.nih.gov/pubmed/25303314/; https://doi.org/10.1371/journal.pone.0108225,"Antibodies and their derivatives are the most important agents in therapeutics and diagnostics. Even after the significant progress in the technology for antibody screening from huge libraries, it takes a long time to isolate an antibody, which prevents a prompt action against the spread of a disease. Here, we report a new strategy for isolating desired antibodies from a combinatorial library in one day by repeated fluorescence-activated cell sorting (FACS). First, we constructed a library of synthetic human antibody in which single-chain variable fragment (scFv) was expressed in the periplasm of Escherichia coli. After labeling the cells with fluorescent antigen probes, the highly fluorescent cells were sorted by using a high-speed cell sorter, and these cells were reused without regeneration in the next round of sorting. After repeating this sorting, the positive clones were completely enriched in several hours. Thus, we screened the library against three viral antigens, including the H1N1 influenza virus, Hepatitis B virus, and Foot-and-mouth disease virus. Finally, the potential antibody candidates, which show K(D) values between 10 and 100 nM against the target antigens, could be successfully isolated even though the library was relatively small (∼10(6)). These results show that repeated FACS screening without regeneration of the sorted cells can be a powerful method when a rapid response to a spreading disease is required.",10.1371/journal.pone.0108225,4i1grvlr,"['Antibodies', 'and', 'their', 'derivatives', 'are', 'the', 'most', 'important', 'agents', 'in', 'therapeutics', 'and', 'diagnostics', 'Even', 'after', 'the', 'significant', 'progress', 'in', 'the', 'technology', 'for', 'antibody', 'screening', 'from', 'huge', 'libraries', 'it', 'takes', 'a', 'long', 'time', 'to', 'isolate', 'an', 'antibody', 'which', 'prevents', 'a', 'prompt', 'action', 'against', 'the', 'spread', 'of', 'a', 'disease', 'Here', 'we', 'report', 'a', 'new', 'strategy', 'for', 'isolating', 'desired', 'antibodies', 'from', 'a', 'combinatorial', 'library', 'in', 'one', 'day', 'by', 'repeated', 'fluorescence', 'activated', 'cell', 'sorting', 'FACS', 'First', 'we', 'constructed', 'a', 'library', 'of', 'synthetic', 'human', 'antibody', 'in', 'which', 'single', 'chain', 'variable', 'fragment', 'scFv', 'was', 'expressed', 'in', 'the', 'periplasm', 'of', 'Escherichia', 'coli', 'After', 'labeling', 'the', 'cells', 'with', 'fluorescent', 'antigen', 'probes', 'the', 'highly', 'fluorescent', 'cells', 'were', 'sorted', 'by', 'using', 'a', 'high', 'speed', 'cell', 'sorter', 'and', 'these', 'cells', 'were', 'reused', 'without', 'regeneration', 'in', 'the', 'next', 'round', 'of', 'sorting', 'After', 'repeating', 'this', 'sorting', 'the', 'positive', 'clones', 'were', 'completely', 'enriched', 'in', 'several', 'hours', 'Thus', 'we', 'screened', 'the', 'library', 'against', 'three', 'viral', 'antigens', 'including', 'the', 'H1N1', 'influenza', 'virus', 'Hepatitis', 'B', 'virus', 'and', 'Foot', 'and', 'mouth', 'disease', 'virus', 'Finally', 'the', 'potential', 'antibody', 'candidates', 'which', 'show', 'K', 'D', 'values', 'between', '10', 'and', '100', 'nM', 'against', 'the', 'target', 'antigens', 'could', 'be', 'successfully', 'isolated', 'even', 'though', 'the', 'library', 'was', 'relatively', 'small', '10', '6', 'These', 'results', 'show', 'that', 'repeated', 'FACS', 'screening', 'without', 'regeneration', 'of', 'the', 'sorted', 'cells', 'can', 'be', 'a', 'powerful', 'method', 'when', 'a', 'rapid', 'response', 'to', 'a', 'spreading', 'disease', 'is', 'required', '']"
159826,A New Quaternary Structure Epitope on Dengue Virus Serotype 2 Is the Target of Durable Type-Specific Neutralizing Antibodies,2015-10-13,mBio,https://www.ncbi.nlm.nih.gov/pubmed/26463165/; https://doi.org/10.1128/mbio.01461-15,"Dengue virus serotype 2 (DENV2) is widespread and responsible for severe epidemics. While primary DENV2 infections stimulate serotype-specific protective responses, a leading vaccine failed to induce a similar protective response. Using human monoclonal antibodies (hMAbs) isolated from dengue cases and structure-guided design of a chimeric DENV, here we describe the major site on the DENV2 envelope (E) protein targeted by neutralizing antibodies. DENV2-specific neutralizing hMAb 2D22 binds to a quaternary structure epitope. We engineered and recovered a recombinant DENV4 that displayed the 2D22 epitope. DENV2 neutralizing antibodies in people exposed to infection or a live vaccine tracked with the 2D22 epitope on the DENV4/2 chimera. The chimera remained sensitive to DENV4 antibodies, indicating that the major neutralizing epitopes on DENV2 and -4 are at different sites. The ability to transplant a complex epitope between DENV serotypes demonstrates a hitherto underappreciated structural flexibility in flaviviruses, which could be harnessed to develop new vaccines and diagnostics.",10.1128/mbio.01461-15,8h8lwg5p,"['Dengue', 'virus', 'serotype', '2', 'DENV2', 'is', 'widespread', 'and', 'responsible', 'for', 'severe', 'epidemics', 'While', 'primary', 'DENV2', 'infections', 'stimulate', 'serotype', 'specific', 'protective', 'responses', 'a', 'leading', 'vaccine', 'failed', 'to', 'induce', 'a', 'similar', 'protective', 'response', 'Using', 'human', 'monoclonal', 'antibodies', 'hMAbs', 'isolated', 'from', 'dengue', 'cases', 'and', 'structure', 'guided', 'design', 'of', 'a', 'chimeric', 'DENV', 'here', 'we', 'describe', 'the', 'major', 'site', 'on', 'the', 'DENV2', 'envelope', 'E', 'protein', 'targeted', 'by', 'neutralizing', 'antibodies', 'DENV2', 'specific', 'neutralizing', 'hMAb', '2D22', 'binds', 'to', 'a', 'quaternary', 'structure', 'epitope', 'We', 'engineered', 'and', 'recovered', 'a', 'recombinant', 'DENV4', 'that', 'displayed', 'the', '2D22', 'epitope', 'DENV2', 'neutralizing', 'antibodies', 'in', 'people', 'exposed', 'to', 'infection', 'or', 'a', 'live', 'vaccine', 'tracked', 'with', 'the', '2D22', 'epitope', 'on', 'the', 'DENV4', '2', 'chimera', 'The', 'chimera', 'remained', 'sensitive', 'to', 'DENV4', 'antibodies', 'indicating', 'that', 'the', 'major', 'neutralizing', 'epitopes', 'on', 'DENV2', 'and', '4', 'are', 'at', 'different', 'sites', 'The', 'ability', 'to', 'transplant', 'a', 'complex', 'epitope', 'between', 'DENV', 'serotypes', 'demonstrates', 'a', 'hitherto', 'underappreciated', 'structural', 'flexibility', 'in', 'flaviviruses', 'which', 'could', 'be', 'harnessed', 'to', 'develop', 'new', 'vaccines', 'and', 'diagnostics', '']"
160092,Diagnostic Techniques: Serological and Molecular Approaches,2008-07-30,Encyclopedia of Virology,https://api.elsevier.com/content/article/pii/B9780123744104005859; https://www.sciencedirect.com/science/article/pii/B9780123744104005859,"Virus laboratory diagnostics has an increasingly important role in modern patient care. Virological methods are needed to investigate the etiology of acute viral infection or the reactivation of a latent infection, as well as to follow virus load in antiviral treatments. Serological assays are also used for screening of blood products for the risk of certain chronic infections, evaluation of the immune status, and need for prophylatic treatments in connection with organ transplantations. For diagnostic purposes the following approaches can be used: demonstration of presence of infectious virus or its structural components directly from a patient's specimens or investigation of specific antibody response in serum specimes. Virus isolation is used to demonstrate infectious virus in a patient's specimens, whereas nucleic acid amplification techniques, like polymerase chain reaction (PCR), are widely used to detect virus nucleic acids. Virus antigens are investigated by antigen detection assays. Serological diagnosis is based on either the demonstration of the presence of virus-specific IgM antibodies or a significant increase in the levels of specific IgG antibodies. Immunoassays are the most commonly used serological assays. Point-of-care tests (POC tests), both for antigens and antibodies, are also becoming more and more common in diagnostic use. In order to reach the best diagnostic efficiency for each patient it is important to select the most suitable method using the right sample collected at the right time.",10.1016/b978-012374410-4.00585-9,jg0br2ro,"['Virus', 'laboratory', 'diagnostics', 'has', 'an', 'increasingly', 'important', 'role', 'in', 'modern', 'patient', 'care', 'Virological', 'methods', 'are', 'needed', 'to', 'investigate', 'the', 'etiology', 'of', 'acute', 'viral', 'infection', 'or', 'the', 'reactivation', 'of', 'a', 'latent', 'infection', 'as', 'well', 'as', 'to', 'follow', 'virus', 'load', 'in', 'antiviral', 'treatments', 'Serological', 'assays', 'are', 'also', 'used', 'for', 'screening', 'of', 'blood', 'products', 'for', 'the', 'risk', 'of', 'certain', 'chronic', 'infections', 'evaluation', 'of', 'the', 'immune', 'status', 'and', 'need', 'for', 'prophylatic', 'treatments', 'in', 'connection', 'with', 'organ', 'transplantations', 'For', 'diagnostic', 'purposes', 'the', 'following', 'approaches', 'can', 'be', 'used', 'demonstration', 'of', 'presence', 'of', 'infectious', 'virus', 'or', 'its', 'structural', 'components', 'directly', 'from', 'a', 'patient', 's', 'specimens', 'or', 'investigation', 'of', 'specific', 'antibody', 'response', 'in', 'serum', 'specimes', 'Virus', 'isolation', 'is', 'used', 'to', 'demonstrate', 'infectious', 'virus', 'in', 'a', 'patient', 's', 'specimens', 'whereas', 'nucleic', 'acid', 'amplification', 'techniques', 'like', 'polymerase', 'chain', 'reaction', 'PCR', 'are', 'widely', 'used', 'to', 'detect', 'virus', 'nucleic', 'acids', 'Virus', 'antigens', 'are', 'investigated', 'by', 'antigen', 'detection', 'assays', 'Serological', 'diagnosis', 'is', 'based', 'on', 'either', 'the', 'demonstration', 'of', 'the', 'presence', 'of', 'virus', 'specific', 'IgM', 'antibodies', 'or', 'a', 'significant', 'increase', 'in', 'the', 'levels', 'of', 'specific', 'IgG', 'antibodies', 'Immunoassays', 'are', 'the', 'most', 'commonly', 'used', 'serological', 'assays', 'Point', 'of', 'care', 'tests', 'POC', 'tests', 'both', 'for', 'antigens', 'and', 'antibodies', 'are', 'also', 'becoming', 'more', 'and', 'more', 'common', 'in', 'diagnostic', 'use', 'In', 'order', 'to', 'reach', 'the', 'best', 'diagnostic', 'efficiency', 'for', 'each', 'patient', 'it', 'is', 'important', 'to', 'select', 'the', 'most', 'suitable', 'method', 'using', 'the', 'right', 'sample', 'collected', 'at', 'the', 'right', 'time', '']"
160222,Diagnostic accuracy of an automated chemiluminescent immunoassay for anti‐SARS‐CoV‐2 IgM and IgG antibodies: an Italian experience,2020-05-10,J Med Virol,https://www.ncbi.nlm.nih.gov/pubmed/32330291/; https://doi.org/10.1002/jmv.25932,"A pandemic of coronavirus disease 2019 (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has been spreading throughout the world. Though molecular diagnostic tests are the gold standard for COVID‐19, serological testing is emerging as a potential surveillance tool, in addition to its complementary role in COVID‐19 diagnostics. Indubitably quantitative serological testing provides greater advantages than qualitative tests but today there is still little known about serological diagnostics and what the most appropriate role quantitative tests might play. Sixty‐one COVID‐19 patients and 64 patients from a control group were tested by iFlash1800 CLIA analyzer for anti‐SARS CoV‐2 antibodies IgM and IgG. All COVID‐19 patients were hospitalized in San Giovanni di Dio Hospital (Florence, Italy) and had a positive oro/nasopharyngeal swab reverse‐transcription polymerase chain reaction result. The highest sensitivity with a very good specificity performance was reached at a cutoff value of 10.0 AU/mL for IgM and of 7.1 for IgG antibodies, hence near to the manufacturer's cutoff values of 10 AU/mL for both isotypes. The receiver operating characteristic curves showed area under the curve values of 0.918 and 0.980 for anti‐SARS CoV‐2 antibodies IgM and IgG, respectively. iFlash1800 CLIA analyzer has shown highly accurate results for the anti‐SARS‐CoV‐2 antibodies profile and can be considered an excellent tool for COVID‐19 diagnostics.",10.1002/jmv.25932,px4fe7mn,"['A', 'pandemic', 'of', 'coronavirus', 'disease', '2019', 'COVID', '19', 'caused', 'by', 'severe', 'acute', 'respiratory', 'syndrome', 'coronavirus', '2', 'SARS', 'CoV', '2', 'has', 'been', 'spreading', 'throughout', 'the', 'world', 'Though', 'molecular', 'diagnostic', 'tests', 'are', 'the', 'gold', 'standard', 'for', 'COVID', '19', 'serological', 'testing', 'is', 'emerging', 'as', 'a', 'potential', 'surveillance', 'tool', 'in', 'addition', 'to', 'its', 'complementary', 'role', 'in', 'COVID', '19', 'diagnostics', 'Indubitably', 'quantitative', 'serological', 'testing', 'provides', 'greater', 'advantages', 'than', 'qualitative', 'tests', 'but', 'today', 'there', 'is', 'still', 'little', 'known', 'about', 'serological', 'diagnostics', 'and', 'what', 'the', 'most', 'appropriate', 'role', 'quantitative', 'tests', 'might', 'play', 'Sixty', 'one', 'COVID', '19', 'patients', 'and', '64', 'patients', 'from', 'a', 'control', 'group', 'were', 'tested', 'by', 'iFlash1800', 'CLIA', 'analyzer', 'for', 'anti', 'SARS', 'CoV', '2', 'antibodies', 'IgM', 'and', 'IgG', 'All', 'COVID', '19', 'patients', 'were', 'hospitalized', 'in', 'San', 'Giovanni', 'di', 'Dio', 'Hospital', 'Florence', 'Italy', 'and', 'had', 'a', 'positive', 'oro', 'nasopharyngeal', 'swab', 'reverse', 'transcription', 'polymerase', 'chain', 'reaction', 'result', 'The', 'highest', 'sensitivity', 'with', 'a', 'very', 'good', 'specificity', 'performance', 'was', 'reached', 'at', 'a', 'cutoff', 'value', 'of', '10', '0', 'AU', 'mL', 'for', 'IgM', 'and', 'of', '7', '1', 'for', 'IgG', 'antibodies', 'hence', 'near', 'to', 'the', 'manufacturer', 's', 'cutoff', 'values', 'of', '10', 'AU', 'mL', 'for', 'both', 'isotypes', 'The', 'receiver', 'operating', 'characteristic', 'curves', 'showed', 'area', 'under', 'the', 'curve', 'values', 'of', '0', '918', 'and', '0', '980', 'for', 'anti', 'SARS', 'CoV', '2', 'antibodies', 'IgM', 'and', 'IgG', 'respectively', 'iFlash1800', 'CLIA', 'analyzer', 'has', 'shown', 'highly', 'accurate', 'results', 'for', 'the', 'anti', 'SARS', 'CoV', '2', 'antibodies', 'profile', 'and', 'can', 'be', 'considered', 'an', 'excellent', 'tool', 'for', 'COVID', '19', 'diagnostics', '']"
160366,SARS-CoV-2 Antibody Testing – Questions to be asked,2020-05-29,J Allergy Clin Immunol,https://www.ncbi.nlm.nih.gov/pubmed/32479758/; https://api.elsevier.com/content/article/pii/S0091674920307399; https://doi.org/10.1016/j.jaci.2020.05.020; https://www.sciencedirect.com/science/article/pii/S0091674920307399?v=s5,"ABSTRACT SARS-CoV-2 infection and development of COVID-19 disease presents a major healthcare challenge of global dimensions. Laboratory diagnostics of infected patients, and the assessment of immunity against the SARS-CoV-2 virus presents a major cornerstone in handling the pandemic. Currently there is an increase in demand of antibody testing and a large number of tests are already marketed or in the late stage of development. However, the interpretation of test results depends on many variables and factors, including sensitivity, specificity, potential cross-reactivity and cross-protectivity; the diagnostic value of antibodies of different isotypes, the use of antibody testing in identification of acutely ill patients or in epidemiological settings. In this article the recently established COVID-19 Task Force of the German Society for Clinical Chemistry and Laboratory Medicine (DGKL) addresses these issues based on the currently available datasets in this rapidly moving field.",10.1016/j.jaci.2020.05.020,tveeq4fj,"['ABSTRACT', 'SARS', 'CoV', '2', 'infection', 'and', 'development', 'of', 'COVID', '19', 'disease', 'presents', 'a', 'major', 'healthcare', 'challenge', 'of', 'global', 'dimensions', 'Laboratory', 'diagnostics', 'of', 'infected', 'patients', 'and', 'the', 'assessment', 'of', 'immunity', 'against', 'the', 'SARS', 'CoV', '2', 'virus', 'presents', 'a', 'major', 'cornerstone', 'in', 'handling', 'the', 'pandemic', 'Currently', 'there', 'is', 'an', 'increase', 'in', 'demand', 'of', 'antibody', 'testing', 'and', 'a', 'large', 'number', 'of', 'tests', 'are', 'already', 'marketed', 'or', 'in', 'the', 'late', 'stage', 'of', 'development', 'However', 'the', 'interpretation', 'of', 'test', 'results', 'depends', 'on', 'many', 'variables', 'and', 'factors', 'including', 'sensitivity', 'specificity', 'potential', 'cross', 'reactivity', 'and', 'cross', 'protectivity', 'the', 'diagnostic', 'value', 'of', 'antibodies', 'of', 'different', 'isotypes', 'the', 'use', 'of', 'antibody', 'testing', 'in', 'identification', 'of', 'acutely', 'ill', 'patients', 'or', 'in', 'epidemiological', 'settings', 'In', 'this', 'article', 'the', 'recently', 'established', 'COVID', '19', 'Task', 'Force', 'of', 'the', 'German', 'Society', 'for', 'Clinical', 'Chemistry', 'and', 'Laboratory', 'Medicine', 'DGKL', 'addresses', 'these', 'issues', 'based', 'on', 'the', 'currently', 'available', 'datasets', 'in', 'this', 'rapidly', 'moving', 'field', '']"
161425,Diagnostics of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) nucleocapsid antigen using chicken immunoglobulin Y,2012-03-01,Poultry Science,https://doi.org/10.3382/ps.2011-01916; https://api.elsevier.com/content/article/pii/S0032579119402265; https://www.sciencedirect.com/science/article/pii/S0032579119402265; https://www.ncbi.nlm.nih.gov/pubmed/22334738/,"Abstract The goal of this study was to develop a quantitative detection system for severe acute respiratory syndrome-associated coronavirus (SARS-CoV), targeting the nucleocapsid protein (NP), to determine the presence and degree of infection in suspected individuals. Because the NP is the viral protein shed during infection and its template mRNA is the most abundant subgenomic RNA, it is a suitable candidate for developing antibodies for diagnostic applications. In this study, we have prepared full-length SARS-CoV NP expressed in Escherichia coli and purified. Full-length NP was used for the preparation of mouse monoclonal antibody and chicken polyclonal IgY antibodies for the development of heterosandwich ELISA for early diagnostics of SARS-suspected individuals. The sensitivity of the developed heterosandwich ELISA can detect the viral antigen at 18.5 pg/mL of recombinant NP. This study describes ultrasensitive ELISA using 19B6 monoclonal antibody as the capture antibody and IgY as the detecting antibody against the most abundant SARS-CoV NP antigens. One of the most important findings was the use of inexpensive polyclonal IgY antibody to increase the sensitivity of the detection system for SARS-CoV at the picogram level. Furthermore, the immunoassay of SARS-CoV NP antigen developed could be an effective and sensitive method of diagnosing SARS-suspected individuals during a future SARS-CoV outbreak.",10.3382/ps.2011-01916,faymgnts,"['Abstract', 'The', 'goal', 'of', 'this', 'study', 'was', 'to', 'develop', 'a', 'quantitative', 'detection', 'system', 'for', 'severe', 'acute', 'respiratory', 'syndrome', 'associated', 'coronavirus', 'SARS', 'CoV', 'targeting', 'the', 'nucleocapsid', 'protein', 'NP', 'to', 'determine', 'the', 'presence', 'and', 'degree', 'of', 'infection', 'in', 'suspected', 'individuals', 'Because', 'the', 'NP', 'is', 'the', 'viral', 'protein', 'shed', 'during', 'infection', 'and', 'its', 'template', 'mRNA', 'is', 'the', 'most', 'abundant', 'subgenomic', 'RNA', 'it', 'is', 'a', 'suitable', 'candidate', 'for', 'developing', 'antibodies', 'for', 'diagnostic', 'applications', 'In', 'this', 'study', 'we', 'have', 'prepared', 'full', 'length', 'SARS', 'CoV', 'NP', 'expressed', 'in', 'Escherichia', 'coli', 'and', 'purified', 'Full', 'length', 'NP', 'was', 'used', 'for', 'the', 'preparation', 'of', 'mouse', 'monoclonal', 'antibody', 'and', 'chicken', 'polyclonal', 'IgY', 'antibodies', 'for', 'the', 'development', 'of', 'heterosandwich', 'ELISA', 'for', 'early', 'diagnostics', 'of', 'SARS', 'suspected', 'individuals', 'The', 'sensitivity', 'of', 'the', 'developed', 'heterosandwich', 'ELISA', 'can', 'detect', 'the', 'viral', 'antigen', 'at', '18', '5', 'pg', 'mL', 'of', 'recombinant', 'NP', 'This', 'study', 'describes', 'ultrasensitive', 'ELISA', 'using', '19B6', 'monoclonal', 'antibody', 'as', 'the', 'capture', 'antibody', 'and', 'IgY', 'as', 'the', 'detecting', 'antibody', 'against', 'the', 'most', 'abundant', 'SARS', 'CoV', 'NP', 'antigens', 'One', 'of', 'the', 'most', 'important', 'findings', 'was', 'the', 'use', 'of', 'inexpensive', 'polyclonal', 'IgY', 'antibody', 'to', 'increase', 'the', 'sensitivity', 'of', 'the', 'detection', 'system', 'for', 'SARS', 'CoV', 'at', 'the', 'picogram', 'level', 'Furthermore', 'the', 'immunoassay', 'of', 'SARS', 'CoV', 'NP', 'antigen', 'developed', 'could', 'be', 'an', 'effective', 'and', 'sensitive', 'method', 'of', 'diagnosing', 'SARS', 'suspected', 'individuals', 'during', 'a', 'future', 'SARS', 'CoV', 'outbreak', '']"
163335,Use of camel single-domain antibodies for the diagnosis and treatment of zoonotic diseases,2018-10-31,"Comparative Immunology, Microbiology and Infectious Diseases",https://www.ncbi.nlm.nih.gov/pubmed/30396425/; https://www.sciencedirect.com/science/article/pii/S0147957118300729; https://doi.org/10.1016/j.cimid.2018.09.009; https://api.elsevier.com/content/article/pii/S0147957118300729,"Abstract Camelids produce both conventional heterotetrameric antibodies and homodimeric heavy-chain only antibodies. The antigen-binding region of such homodimeric heavy-chain only antibodies consists of one single domain, called VHH. VHHs provide many advantages over conventional full-sized antibodies and currently used antibody-based fragments (Fab, scFv), including high specificity, stability and solubility, and small size, allowing them to recognize unusual antigenic sites and deeply penetrate tissues. Since their discovery, VHHs have been used extensively in diagnostics and therapy. In recent decades, the number of outbreaks of diseases transmissible from animals to humans has been on the rise. In this review, we evaluate the status of VHHs as diagnostic and therapeutic biomolecular agents for the detection and treatment of zoonotic diseases, such as bacterial, parasitic, and viral zoonosis. VHHs show great adaptability to inhibit or neutralize pathogenic agents for the creation of multifunctional VHH-based diagnostic and therapeutic molecules against zoonotic diseases.",10.1016/j.cimid.2018.09.009,qwdxgk4z,"['Abstract', 'Camelids', 'produce', 'both', 'conventional', 'heterotetrameric', 'antibodies', 'and', 'homodimeric', 'heavy', 'chain', 'only', 'antibodies', 'The', 'antigen', 'binding', 'region', 'of', 'such', 'homodimeric', 'heavy', 'chain', 'only', 'antibodies', 'consists', 'of', 'one', 'single', 'domain', 'called', 'VHH', 'VHHs', 'provide', 'many', 'advantages', 'over', 'conventional', 'full', 'sized', 'antibodies', 'and', 'currently', 'used', 'antibody', 'based', 'fragments', 'Fab', 'scFv', 'including', 'high', 'specificity', 'stability', 'and', 'solubility', 'and', 'small', 'size', 'allowing', 'them', 'to', 'recognize', 'unusual', 'antigenic', 'sites', 'and', 'deeply', 'penetrate', 'tissues', 'Since', 'their', 'discovery', 'VHHs', 'have', 'been', 'used', 'extensively', 'in', 'diagnostics', 'and', 'therapy', 'In', 'recent', 'decades', 'the', 'number', 'of', 'outbreaks', 'of', 'diseases', 'transmissible', 'from', 'animals', 'to', 'humans', 'has', 'been', 'on', 'the', 'rise', 'In', 'this', 'review', 'we', 'evaluate', 'the', 'status', 'of', 'VHHs', 'as', 'diagnostic', 'and', 'therapeutic', 'biomolecular', 'agents', 'for', 'the', 'detection', 'and', 'treatment', 'of', 'zoonotic', 'diseases', 'such', 'as', 'bacterial', 'parasitic', 'and', 'viral', 'zoonosis', 'VHHs', 'show', 'great', 'adaptability', 'to', 'inhibit', 'or', 'neutralize', 'pathogenic', 'agents', 'for', 'the', 'creation', 'of', 'multifunctional', 'VHH', 'based', 'diagnostic', 'and', 'therapeutic', 'molecules', 'against', 'zoonotic', 'diseases', '']"
163850,Antibody response of definitive hosts against antigens of two life stages of the neuropathogenic schistosome Trichobilharzia regenti,2015-07-28,Parasit Vectors,https://www.ncbi.nlm.nih.gov/pubmed/26216102/; https://doi.org/10.1186/s13071-015-1007-y,"BACKGROUND: The nasal avian schistosome Trichobilharzia regenti spends part of its intravertebrate period of life within the central nervous system. Migration of the parasites can be accompanied by neuromotor disorders or paralysis in natural definitive hosts (ducks) and even in laboratory mammals. Cercariae are also able to penetrate human skin and induce cercarial dermatitis. While the cellular and antibody responses against cercariae and migrating schistosomula have been investigated in mice, little is known about immune reactions in birds. This study first describes the dynamics of antibody response in infected ducks and identifies frequently recognized antigens that may serve as diagnostic markers of infection by T. regenti. METHODS: Groups of 35 domestic ducks and 10 mallards were exposed to different doses of T. regenti cercariae. Sera were collected at predefined time intervals and tested by ELISA for the presence of specific anti-cercarial IgY and IgM. Antigens recognized by the antibodies were identified on Western blots of cercariae and schistosomula. The applicability in immunodiagnostics was statistically evaluated by expression of specificity and sensitivity values for individual antigens. RESULTS: In ELISA, the levels of anti-cercarial IgM peaked on day 15 pi. Increased production of IgY associated with the later phases of infection was observed in most individuals around 20 dpi and culminated 30 dpi. The time course of antibody response did not differ among experimental groups, variations were only observed in the levels of specific IgY which depended rather on the age of ducks at the time of infection than on the infectious dose. On Western blots, 40 cercarial and 7 schistosomular antigens were recognized by IgY from infected ducks. Among them, 4 cercarial antigens of 50, 47, 32 and 19 kDa provided the most sensitive and specific reactions. CONCLUSIONS: Antigens of cercariae and schistosomula elicited distinct antibody response in ducks, which correlated positively with the age of animals at the time of infection. Several antigens originating in cercariae and fewer in schistosomula were recognized by IgY with diverse sensitivity and specificity; only a few seemed to be common to both stages. Four of them were considered as the most promising candidates for immunodiagnostics. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13071-015-1007-y) contains supplementary material, which is available to authorized users.",10.1186/s13071-015-1007-y,d2505w2z,"['BACKGROUND', 'The', 'nasal', 'avian', 'schistosome', 'Trichobilharzia', 'regenti', 'spends', 'part', 'of', 'its', 'intravertebrate', 'period', 'of', 'life', 'within', 'the', 'central', 'nervous', 'system', 'Migration', 'of', 'the', 'parasites', 'can', 'be', 'accompanied', 'by', 'neuromotor', 'disorders', 'or', 'paralysis', 'in', 'natural', 'definitive', 'hosts', 'ducks', 'and', 'even', 'in', 'laboratory', 'mammals', 'Cercariae', 'are', 'also', 'able', 'to', 'penetrate', 'human', 'skin', 'and', 'induce', 'cercarial', 'dermatitis', 'While', 'the', 'cellular', 'and', 'antibody', 'responses', 'against', 'cercariae', 'and', 'migrating', 'schistosomula', 'have', 'been', 'investigated', 'in', 'mice', 'little', 'is', 'known', 'about', 'immune', 'reactions', 'in', 'birds', 'This', 'study', 'first', 'describes', 'the', 'dynamics', 'of', 'antibody', 'response', 'in', 'infected', 'ducks', 'and', 'identifies', 'frequently', 'recognized', 'antigens', 'that', 'may', 'serve', 'as', 'diagnostic', 'markers', 'of', 'infection', 'by', 'T', 'regenti', 'METHODS', 'Groups', 'of', '35', 'domestic', 'ducks', 'and', '10', 'mallards', 'were', 'exposed', 'to', 'different', 'doses', 'of', 'T', 'regenti', 'cercariae', 'Sera', 'were', 'collected', 'at', 'predefined', 'time', 'intervals', 'and', 'tested', 'by', 'ELISA', 'for', 'the', 'presence', 'of', 'specific', 'anti', 'cercarial', 'IgY', 'and', 'IgM', 'Antigens', 'recognized', 'by', 'the', 'antibodies', 'were', 'identified', 'on', 'Western', 'blots', 'of', 'cercariae', 'and', 'schistosomula', 'The', 'applicability', 'in', 'immunodiagnostics', 'was', 'statistically', 'evaluated', 'by', 'expression', 'of', 'specificity', 'and', 'sensitivity', 'values', 'for', 'individual', 'antigens', 'RESULTS', 'In', 'ELISA', 'the', 'levels', 'of', 'anti', 'cercarial', 'IgM', 'peaked', 'on', 'day', '15', 'pi', 'Increased', 'production', 'of', 'IgY', 'associated', 'with', 'the', 'later', 'phases', 'of', 'infection', 'was', 'observed', 'in', 'most', 'individuals', 'around', '20', 'dpi', 'and', 'culminated', '30', 'dpi', 'The', 'time', 'course', 'of', 'antibody', 'response', 'did', 'not', 'differ', 'among', 'experimental', 'groups', 'variations', 'were', 'only', 'observed', 'in', 'the', 'levels', 'of', 'specific', 'IgY', 'which', 'depended', 'rather', 'on', 'the', 'age', 'of', 'ducks', 'at', 'the', 'time', 'of', 'infection', 'than', 'on', 'the', 'infectious', 'dose', 'On', 'Western', 'blots', '40', 'cercarial', 'and', '7', 'schistosomular', 'antigens', 'were', 'recognized', 'by', 'IgY', 'from', 'infected', 'ducks', 'Among', 'them', '4', 'cercarial', 'antigens', 'of', '50', '47', '32', 'and', '19', 'kDa', 'provided', 'the', 'most', 'sensitive', 'and', 'specific', 'reactions', 'CONCLUSIONS', 'Antigens', 'of', 'cercariae', 'and', 'schistosomula', 'elicited', 'distinct', 'antibody', 'response', 'in', 'ducks', 'which', 'correlated', 'positively', 'with', 'the', 'age', 'of', 'animals', 'at', 'the', 'time', 'of', 'infection', 'Several', 'antigens', 'originating', 'in', 'cercariae', 'and', 'fewer', 'in', 'schistosomula', 'were', 'recognized', 'by', 'IgY', 'with', 'diverse', 'sensitivity', 'and', 'specificity', 'only', 'a', 'few', 'seemed', 'to', 'be', 'common', 'to', 'both', 'stages', 'Four', 'of', 'them', 'were', 'considered', 'as', 'the', 'most', 'promising', 'candidates', 'for', 'immunodiagnostics', 'ELECTRONIC', 'SUPPLEMENTARY', 'MATERIAL', 'The', 'online', 'version', 'of', 'this', 'article', 'doi', '10', '1186', 's13071', '015', '1007', 'y', 'contains', 'supplementary', 'material', 'which', 'is', 'available', 'to', 'authorized', 'users', '']"
168418,Viral glycoproteins: biological role and application in diagnosis,2016-01-18,VirusDisease,https://doi.org/10.1007/s13337-015-0293-5; https://link.springer.com/content/pdf/10.1007/s13337-015-0293-5.pdf; https://www.ncbi.nlm.nih.gov/pubmed/26925438/,"The viruses that infect humans cause a huge global disease burden and produce immense challenge towards healthcare system. Glycoproteins are one of the major components of human pathogenic viruses. They have been demonstrated to have important role(s) in infection and immunity. Concomitantly high titres of antibodies against these antigenic viral glycoproteins have paved the way for development of novel diagnostics. Availability of appropriate biomarkers is necessary for advance diagnosis of infectious diseases especially in case of outbreaks. As human mobilization has increased manifold nowadays, dissemination of infectious agents became quicker that paves the need of rapid diagnostic system. In case of viral infection it is an emergency as virus spreads and mutates very fast. This review encircles the vast arena of viral glycoproteins, their importance in health and disease and their diagnostic applications.",10.1007/s13337-015-0293-5,gxu0refq,"['The', 'viruses', 'that', 'infect', 'humans', 'cause', 'a', 'huge', 'global', 'disease', 'burden', 'and', 'produce', 'immense', 'challenge', 'towards', 'healthcare', 'system', 'Glycoproteins', 'are', 'one', 'of', 'the', 'major', 'components', 'of', 'human', 'pathogenic', 'viruses', 'They', 'have', 'been', 'demonstrated', 'to', 'have', 'important', 'role', 's', 'in', 'infection', 'and', 'immunity', 'Concomitantly', 'high', 'titres', 'of', 'antibodies', 'against', 'these', 'antigenic', 'viral', 'glycoproteins', 'have', 'paved', 'the', 'way', 'for', 'development', 'of', 'novel', 'diagnostics', 'Availability', 'of', 'appropriate', 'biomarkers', 'is', 'necessary', 'for', 'advance', 'diagnosis', 'of', 'infectious', 'diseases', 'especially', 'in', 'case', 'of', 'outbreaks', 'As', 'human', 'mobilization', 'has', 'increased', 'manifold', 'nowadays', 'dissemination', 'of', 'infectious', 'agents', 'became', 'quicker', 'that', 'paves', 'the', 'need', 'of', 'rapid', 'diagnostic', 'system', 'In', 'case', 'of', 'viral', 'infection', 'it', 'is', 'an', 'emergency', 'as', 'virus', 'spreads', 'and', 'mutates', 'very', 'fast', 'This', 'review', 'encircles', 'the', 'vast', 'arena', 'of', 'viral', 'glycoproteins', 'their', 'importance', 'in', 'health', 'and', 'disease', 'and', 'their', 'diagnostic', 'applications', '']"
172232,Human Bocavirus,2014-05-16,Emerging Infectious Diseases,https://www.sciencedirect.com/science/article/pii/B9780124169753000157; https://api.elsevier.com/content/article/pii/B9780124169753000157,"Human bocavirus 1 (HBoV1), family Parvoviridae, subfamily Parvovirinae, genus Bocavirus, is a recently described respiratory virus with a worldwide distribution. It is recognized as one of the most frequently detected respiratory viruses in hospitalized children below 5 years of age and mainly detected in children between 6 and 24 months of age. The severe clinical course of HBoV1 infection can be seen in prematurely born children or children, but rarely adults, with other underlying medical conditions. The seroepidemiological studies show that most of the children are infected with HBoV1 by the age of 6 and that the IgG antibodies remain for life. The routine laboratory diagnostics of HBoV1 infections is almost exclusively based on detection of HBoV1 DNA in respiratory samples by PCR. Due to frequent coinfections with other respiratory viruses, PCR of plasma samples and detection of specific IgM might aid in determining the etiology of infection.",10.1016/b978-0-12-416975-3.00015-7,zi8mpy7h,"['Human', 'bocavirus', '1', 'HBoV1', 'family', 'Parvoviridae', 'subfamily', 'Parvovirinae', 'genus', 'Bocavirus', 'is', 'a', 'recently', 'described', 'respiratory', 'virus', 'with', 'a', 'worldwide', 'distribution', 'It', 'is', 'recognized', 'as', 'one', 'of', 'the', 'most', 'frequently', 'detected', 'respiratory', 'viruses', 'in', 'hospitalized', 'children', 'below', '5', 'years', 'of', 'age', 'and', 'mainly', 'detected', 'in', 'children', 'between', '6', 'and', '24', 'months', 'of', 'age', 'The', 'severe', 'clinical', 'course', 'of', 'HBoV1', 'infection', 'can', 'be', 'seen', 'in', 'prematurely', 'born', 'children', 'or', 'children', 'but', 'rarely', 'adults', 'with', 'other', 'underlying', 'medical', 'conditions', 'The', 'seroepidemiological', 'studies', 'show', 'that', 'most', 'of', 'the', 'children', 'are', 'infected', 'with', 'HBoV1', 'by', 'the', 'age', 'of', '6', 'and', 'that', 'the', 'IgG', 'antibodies', 'remain', 'for', 'life', 'The', 'routine', 'laboratory', 'diagnostics', 'of', 'HBoV1', 'infections', 'is', 'almost', 'exclusively', 'based', 'on', 'detection', 'of', 'HBoV1', 'DNA', 'in', 'respiratory', 'samples', 'by', 'PCR', 'Due', 'to', 'frequent', 'coinfections', 'with', 'other', 'respiratory', 'viruses', 'PCR', 'of', 'plasma', 'samples', 'and', 'detection', 'of', 'specific', 'IgM', 'might', 'aid', 'in', 'determining', 'the', 'etiology', 'of', 'infection', '']"
175202,IgY: A promising antibody for use in immunodiagnostic and in immunotherapy,2010-06-15,Veterinary Immunology and Immunopathology,https://www.ncbi.nlm.nih.gov/pubmed/20083313/; https://www.sciencedirect.com/science/article/pii/S016524271000005X; https://api.elsevier.com/content/article/pii/S016524271000005X; https://doi.org/10.1016/j.vetimm.2009.12.011,"Abstract Immunoglobulin IgY is the major antibody produced by chickens (Gallus domesticus). After their V-C gene is rearranged in B cells, IgY is continually synthesized, excreted into the blood and transferred to the egg yolk, where it is accumulated. IgY is produced by hens to provide their offspring with an effective humoral immunity against the commonest avian pathogens until full maturation of their own immune system. In this review we aim to give an overview about the generation, structure, properties of IgY, as well as the advantages of chicken antibodies use over mammalian antibodies in immunodiagnostics and immunotherapy.",10.1016/j.vetimm.2009.12.011,igv2wl97,"['Abstract', 'Immunoglobulin', 'IgY', 'is', 'the', 'major', 'antibody', 'produced', 'by', 'chickens', 'Gallus', 'domesticus', 'After', 'their', 'V', 'C', 'gene', 'is', 'rearranged', 'in', 'B', 'cells', 'IgY', 'is', 'continually', 'synthesized', 'excreted', 'into', 'the', 'blood', 'and', 'transferred', 'to', 'the', 'egg', 'yolk', 'where', 'it', 'is', 'accumulated', 'IgY', 'is', 'produced', 'by', 'hens', 'to', 'provide', 'their', 'offspring', 'with', 'an', 'effective', 'humoral', 'immunity', 'against', 'the', 'commonest', 'avian', 'pathogens', 'until', 'full', 'maturation', 'of', 'their', 'own', 'immune', 'system', 'In', 'this', 'review', 'we', 'aim', 'to', 'give', 'an', 'overview', 'about', 'the', 'generation', 'structure', 'properties', 'of', 'IgY', 'as', 'well', 'as', 'the', 'advantages', 'of', 'chicken', 'antibodies', 'use', 'over', 'mammalian', 'antibodies', 'in', 'immunodiagnostics', 'and', 'immunotherapy', '']"
175868,Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation,2020-06-15,J Clin Virol,https://www.ncbi.nlm.nih.gov/pubmed/32563180/; https://api.elsevier.com/content/article/pii/S1386653220302547; https://doi.org/10.1016/j.jcv.2020.104512; https://www.sciencedirect.com/science/article/pii/S1386653220302547?v=s5,"There is an urgent need for reliable high-throughput serological assays for the management of the ongoing COVID-19 pandemic. Preferably, the performance of serological tests for a novel virus should be determined with clinical specimens against a gold standard, i.e. virus neutralisation. We compared the performance of six commercial immunoassays for the detection of SARS-CoV-2 IgG, IgA and IgM antibodies, including four automated assays [Abbott SARS-COV-2 IgG (CE marked), Diasorin Liaison® SARS-CoV-2 S1/S2 IgG (research use only, RUO), and Euroimmun SARS-CoV-2 IgG and IgA (CE marked)], and two rapid lateral flow (immunocromatographic) tests [Acro Biotech 2019-nCoV IgG/IgM (CE marked) and Xiamen Biotime Biotechnology SARS-CoV-2 IgG/IgM (CE marked)] with a microneutralisation test (MNT). Two specimen panels from serum samples sent to Helsinki University Hospital Laboratory (HUSLAB) were compiled: the patient panel (N=70) included sera from PCR confirmed COVID-19 patients, and the negative panel (N=81) included sera sent for screening of autoimmune diseases and respiratory virus antibodies in 2018 and 2019. The MNT was carried out for all COVID-19 samples (70 serum samples, 62 individuals) and for 53 samples from the negative panel. Forty-one out of 62 COVID-19 patients showed neutralising antibodies.The specificity and sensitivity values of the commercial tests against MNT, respectively, were as follows: 95.1%/80.5% (Abbott Architect SARS-CoV-2 IgG), 94.9%/43.8% (Diasorin Liaison SARS-CoV-2 IgG; RUO), 68.3%/87.8% (Euroimmun SARS-CoV-2 IgA), 86.6%/70.7% (Euroimmun SARS-CoV-2 IgG), 74.4%/56.1% (Acro 2019-nCoV IgG), 69.5%/46.3% (Acro 2019-nCoV IgM), 97.5%/71.9% (Xiamen Biotime SARS-CoV-2 IgG), and 88.8%/81.3% (Xiamen Biotime SARS-CoV-2 IgM). This study shows variable performance values. Laboratories should carefully consider their testing process, such as a two-tier approach, in order to optimize the overall performance of SARS- CoV-2 serodiagnostics.",10.1016/j.jcv.2020.104512,hc7gagnq,"['There', 'is', 'an', 'urgent', 'need', 'for', 'reliable', 'high', 'throughput', 'serological', 'assays', 'for', 'the', 'management', 'of', 'the', 'ongoing', 'COVID', '19', 'pandemic', 'Preferably', 'the', 'performance', 'of', 'serological', 'tests', 'for', 'a', 'novel', 'virus', 'should', 'be', 'determined', 'with', 'clinical', 'specimens', 'against', 'a', 'gold', 'standard', 'i', 'e', 'virus', 'neutralisation', 'We', 'compared', 'the', 'performance', 'of', 'six', 'commercial', 'immunoassays', 'for', 'the', 'detection', 'of', 'SARS', 'CoV', '2', 'IgG', 'IgA', 'and', 'IgM', 'antibodies', 'including', 'four', 'automated', 'assays', 'Abbott', 'SARS', 'COV', '2', 'IgG', 'CE', 'marked', 'Diasorin', 'Liaison', 'SARS', 'CoV', '2', 'S1', 'S2', 'IgG', 'research', 'use', 'only', 'RUO', 'and', 'Euroimmun', 'SARS', 'CoV', '2', 'IgG', 'and', 'IgA', 'CE', 'marked', 'and', 'two', 'rapid', 'lateral', 'flow', 'immunocromatographic', 'tests', 'Acro', 'Biotech', '2019', 'nCoV', 'IgG', 'IgM', 'CE', 'marked', 'and', 'Xiamen', 'Biotime', 'Biotechnology', 'SARS', 'CoV', '2', 'IgG', 'IgM', 'CE', 'marked', 'with', 'a', 'microneutralisation', 'test', 'MNT', 'Two', 'specimen', 'panels', 'from', 'serum', 'samples', 'sent', 'to', 'Helsinki', 'University', 'Hospital', 'Laboratory', 'HUSLAB', 'were', 'compiled', 'the', 'patient', 'panel', 'N', '70', 'included', 'sera', 'from', 'PCR', 'confirmed', 'COVID', '19', 'patients', 'and', 'the', 'negative', 'panel', 'N', '81', 'included', 'sera', 'sent', 'for', 'screening', 'of', 'autoimmune', 'diseases', 'and', 'respiratory', 'virus', 'antibodies', 'in', '2018', 'and', '2019', 'The', 'MNT', 'was', 'carried', 'out', 'for', 'all', 'COVID', '19', 'samples', '70', 'serum', 'samples', '62', 'individuals', 'and', 'for', '53', 'samples', 'from', 'the', 'negative', 'panel', 'Forty', 'one', 'out', 'of', '62', 'COVID', '19', 'patients', 'showed', 'neutralising', 'antibodies', 'The', 'specificity', 'and', 'sensitivity', 'values', 'of', 'the', 'commercial', 'tests', 'against', 'MNT', 'respectively', 'were', 'as', 'follows', '95', '1', '80', '5', 'Abbott', 'Architect', 'SARS', 'CoV', '2', 'IgG', '94', '9', '43', '8', 'Diasorin', 'Liaison', 'SARS', 'CoV', '2', 'IgG', 'RUO', '68', '3', '87', '8', 'Euroimmun', 'SARS', 'CoV', '2', 'IgA', '86', '6', '70', '7', 'Euroimmun', 'SARS', 'CoV', '2', 'IgG', '74', '4', '56', '1', 'Acro', '2019', 'nCoV', 'IgG', '69', '5', '46', '3', 'Acro', '2019', 'nCoV', 'IgM', '97', '5', '71', '9', 'Xiamen', 'Biotime', 'SARS', 'CoV', '2', 'IgG', 'and', '88', '8', '81', '3', 'Xiamen', 'Biotime', 'SARS', 'CoV', '2', 'IgM', 'This', 'study', 'shows', 'variable', 'performance', 'values', 'Laboratories', 'should', 'carefully', 'consider', 'their', 'testing', 'process', 'such', 'as', 'a', 'two', 'tier', 'approach', 'in', 'order', 'to', 'optimize', 'the', 'overall', 'performance', 'of', 'SARS', 'CoV', '2', 'serodiagnostics', '']"
177418,Towards Detection and Diagnosis of Ebola Virus Disease at Point-of-Care,2016-01-01,Biosensors and Bioelectronics,https://api.elsevier.com/content/article/pii/S0956566315303651; https://doi.org/10.1016/j.bios.2015.08.040; https://www.ncbi.nlm.nih.gov/pubmed/26319169/; http://europepmc.org/articles/pmc4601610?pdf=render; https://www.sciencedirect.com/science/article/pii/S0956566315303651,"Ebola outbreak-2014 (mainly Zaire strain related Ebola virus) has been declared most widely spread deadly persistent epidemic due to unavailability of rapid diagnostic, detection, and therapeutics. Ebola virus disease (EVD), a severe viral hemorrhagic fever syndrome caused by Ebola virus (EBOV) is transmitted by direct contact with the body fluids of infected person and objects contaminated with virus or infected animals. World Health Organization (WHO) has declared EVD epidemic as public health emergency of international concern with severe global economic burden. At fatal EBOV infection stage, patients usually die before the antibody response. Currently, rapid blood tests to diagnose EBOV infection include the antigen or antibodies capture using ELISA and RNA detection using RT/Q-PCR within 3–10 days after the onset of symptoms. Moreover, few nanotechnology-based colorimetric and paper-based immunoassay methods have been recently reported to detect Ebola virus. Unfortunately, these methods are limited to laboratory only. As state-of-the art (SoA) diagnostics time to confirm Ebola infection, varies from 6 hours to about 3 days, it causes delay in therapeutic approaches. Thus developing a cost-effective, rapid, sensitive, and selective sensor to detect EVD at point-of-care (POC) is certainly worth exploring to establish rapid diagnostics to decide therapeutics. This review highlights SoA of Ebola diagnostics and also a call to develop rapid, selective and sensitive POC detection of EBOV for global health care. We propose that adopting miniaturized electrochemical EBOV immunosensing can detect virus level at pM concentration within ~40 minute compared to 3 days of ELISA test at nM levels.",10.1016/j.bios.2015.08.040,yrqcyboo,"['Ebola', 'outbreak', '2014', 'mainly', 'Zaire', 'strain', 'related', 'Ebola', 'virus', 'has', 'been', 'declared', 'most', 'widely', 'spread', 'deadly', 'persistent', 'epidemic', 'due', 'to', 'unavailability', 'of', 'rapid', 'diagnostic', 'detection', 'and', 'therapeutics', 'Ebola', 'virus', 'disease', 'EVD', 'a', 'severe', 'viral', 'hemorrhagic', 'fever', 'syndrome', 'caused', 'by', 'Ebola', 'virus', 'EBOV', 'is', 'transmitted', 'by', 'direct', 'contact', 'with', 'the', 'body', 'fluids', 'of', 'infected', 'person', 'and', 'objects', 'contaminated', 'with', 'virus', 'or', 'infected', 'animals', 'World', 'Health', 'Organization', 'WHO', 'has', 'declared', 'EVD', 'epidemic', 'as', 'public', 'health', 'emergency', 'of', 'international', 'concern', 'with', 'severe', 'global', 'economic', 'burden', 'At', 'fatal', 'EBOV', 'infection', 'stage', 'patients', 'usually', 'die', 'before', 'the', 'antibody', 'response', 'Currently', 'rapid', 'blood', 'tests', 'to', 'diagnose', 'EBOV', 'infection', 'include', 'the', 'antigen', 'or', 'antibodies', 'capture', 'using', 'ELISA', 'and', 'RNA', 'detection', 'using', 'RT', 'Q', 'PCR', 'within', '3', '10', 'days', 'after', 'the', 'onset', 'of', 'symptoms', 'Moreover', 'few', 'nanotechnology', 'based', 'colorimetric', 'and', 'paper', 'based', 'immunoassay', 'methods', 'have', 'been', 'recently', 'reported', 'to', 'detect', 'Ebola', 'virus', 'Unfortunately', 'these', 'methods', 'are', 'limited', 'to', 'laboratory', 'only', 'As', 'state', 'of', 'the', 'art', 'SoA', 'diagnostics', 'time', 'to', 'confirm', 'Ebola', 'infection', 'varies', 'from', '6', 'hours', 'to', 'about', '3', 'days', 'it', 'causes', 'delay', 'in', 'therapeutic', 'approaches', 'Thus', 'developing', 'a', 'cost', 'effective', 'rapid', 'sensitive', 'and', 'selective', 'sensor', 'to', 'detect', 'EVD', 'at', 'point', 'of', 'care', 'POC', 'is', 'certainly', 'worth', 'exploring', 'to', 'establish', 'rapid', 'diagnostics', 'to', 'decide', 'therapeutics', 'This', 'review', 'highlights', 'SoA', 'of', 'Ebola', 'diagnostics', 'and', 'also', 'a', 'call', 'to', 'develop', 'rapid', 'selective', 'and', 'sensitive', 'POC', 'detection', 'of', 'EBOV', 'for', 'global', 'health', 'care', 'We', 'propose', 'that', 'adopting', 'miniaturized', 'electrochemical', 'EBOV', 'immunosensing', 'can', 'detect', 'virus', 'level', 'at', 'pM', 'concentration', 'within', '40', 'minute', 'compared', 'to', '3', 'days', 'of', 'ELISA', 'test', 'at', 'nM', 'levels', '']"
180216,In silico approach toward the identification of unique peptides from viral protein infection: Application to COVID-19,2020-04-10,bioRxiv,https://doi.org/10.1101/2020.03.08.980383,"We describe a method for rapid in silico selection of diagnostic peptides from newly described viral pathogens and applied this approach to SARS-CoV-2/COVID-19. This approach is multi-tiered, beginning with compiling the theoretical protein sequences from genomic derived data. In the case of SARS-CoV-2 we begin with 496 peptides that would be produced by proteolytic digestion of the viral proteins. To eliminate peptides that would cause cross-reactivity and false positives we remove peptides from consideration that have sequence homology or similar chemical characteristics using a progressively larger database of background peptides. Using this pipeline, we can remove 47 peptides from consideration as diagnostic due to the presence of peptides derived from the human proteome. To address the complexity of the human microbiome, we describe a method to create a database of all proteins of relevant abundance in the saliva microbiome. By utilizing a protein-based approach to the microbiome we can more accurately identify peptides that will be problematic in COVID-19 studies which removes 12 peptides from consideration. To identify diagnostic peptides, another 7 peptides are flagged for removal following comparison to the proteome backgrounds of viral and bacterial pathogens of similar clinical presentation. By aligning the protein sequences of SARS-CoV-2 field isolates deposited to date we can identify peptides for removal due to their presence in highly variable regions that may lead to false negatives as the pathogen evolves. We provide maps of these regions and highlight 3 peptides that should be avoided as potential diagnostic or vaccine targets. Finally, we leverage publicly deposited proteomics data from human cells infected with SARS-CoV-2, as well as a second study with the closely related MERS-CoV to identify the two proteins of highest abundance in human infections. The resulting final list contains the 24 peptides most unique and diagnostic of SARS-CoV-2 infections. These peptides represent the best targets for the development of antibodies are clinical diagnostics. To demonstrate one application of this we model peptide fragmentation using a deep learning tool to rapidly generate targeted LCMS assays and data processing method for detecting CoVID-19 infected patient samples. Graphical Abstract",10.1101/2020.03.08.980383,te049lxh,"['We', 'describe', 'a', 'method', 'for', 'rapid', 'in', 'silico', 'selection', 'of', 'diagnostic', 'peptides', 'from', 'newly', 'described', 'viral', 'pathogens', 'and', 'applied', 'this', 'approach', 'to', 'SARS', 'CoV', '2', 'COVID', '19', 'This', 'approach', 'is', 'multi', 'tiered', 'beginning', 'with', 'compiling', 'the', 'theoretical', 'protein', 'sequences', 'from', 'genomic', 'derived', 'data', 'In', 'the', 'case', 'of', 'SARS', 'CoV', '2', 'we', 'begin', 'with', '496', 'peptides', 'that', 'would', 'be', 'produced', 'by', 'proteolytic', 'digestion', 'of', 'the', 'viral', 'proteins', 'To', 'eliminate', 'peptides', 'that', 'would', 'cause', 'cross', 'reactivity', 'and', 'false', 'positives', 'we', 'remove', 'peptides', 'from', 'consideration', 'that', 'have', 'sequence', 'homology', 'or', 'similar', 'chemical', 'characteristics', 'using', 'a', 'progressively', 'larger', 'database', 'of', 'background', 'peptides', 'Using', 'this', 'pipeline', 'we', 'can', 'remove', '47', 'peptides', 'from', 'consideration', 'as', 'diagnostic', 'due', 'to', 'the', 'presence', 'of', 'peptides', 'derived', 'from', 'the', 'human', 'proteome', 'To', 'address', 'the', 'complexity', 'of', 'the', 'human', 'microbiome', 'we', 'describe', 'a', 'method', 'to', 'create', 'a', 'database', 'of', 'all', 'proteins', 'of', 'relevant', 'abundance', 'in', 'the', 'saliva', 'microbiome', 'By', 'utilizing', 'a', 'protein', 'based', 'approach', 'to', 'the', 'microbiome', 'we', 'can', 'more', 'accurately', 'identify', 'peptides', 'that', 'will', 'be', 'problematic', 'in', 'COVID', '19', 'studies', 'which', 'removes', '12', 'peptides', 'from', 'consideration', 'To', 'identify', 'diagnostic', 'peptides', 'another', '7', 'peptides', 'are', 'flagged', 'for', 'removal', 'following', 'comparison', 'to', 'the', 'proteome', 'backgrounds', 'of', 'viral', 'and', 'bacterial', 'pathogens', 'of', 'similar', 'clinical', 'presentation', 'By', 'aligning', 'the', 'protein', 'sequences', 'of', 'SARS', 'CoV', '2', 'field', 'isolates', 'deposited', 'to', 'date', 'we', 'can', 'identify', 'peptides', 'for', 'removal', 'due', 'to', 'their', 'presence', 'in', 'highly', 'variable', 'regions', 'that', 'may', 'lead', 'to', 'false', 'negatives', 'as', 'the', 'pathogen', 'evolves', 'We', 'provide', 'maps', 'of', 'these', 'regions', 'and', 'highlight', '3', 'peptides', 'that', 'should', 'be', 'avoided', 'as', 'potential', 'diagnostic', 'or', 'vaccine', 'targets', 'Finally', 'we', 'leverage', 'publicly', 'deposited', 'proteomics', 'data', 'from', 'human', 'cells', 'infected', 'with', 'SARS', 'CoV', '2', 'as', 'well', 'as', 'a', 'second', 'study', 'with', 'the', 'closely', 'related', 'MERS', 'CoV', 'to', 'identify', 'the', 'two', 'proteins', 'of', 'highest', 'abundance', 'in', 'human', 'infections', 'The', 'resulting', 'final', 'list', 'contains', 'the', '24', 'peptides', 'most', 'unique', 'and', 'diagnostic', 'of', 'SARS', 'CoV', '2', 'infections', 'These', 'peptides', 'represent', 'the', 'best', 'targets', 'for', 'the', 'development', 'of', 'antibodies', 'are', 'clinical', 'diagnostics', 'To', 'demonstrate', 'one', 'application', 'of', 'this', 'we', 'model', 'peptide', 'fragmentation', 'using', 'a', 'deep', 'learning', 'tool', 'to', 'rapidly', 'generate', 'targeted', 'LCMS', 'assays', 'and', 'data', 'processing', 'method', 'for', 'detecting', 'CoVID', '19', 'infected', 'patient', 'samples', 'Graphical', 'Abstract']"
181247,Single B cell antibody technologies,2011-04-05,N Biotechnol,https://www.sciencedirect.com/science/article/pii/S1871678411000768; https://www.ncbi.nlm.nih.gov/pubmed/21473940/; https://api.elsevier.com/content/article/pii/S1871678411000768; https://doi.org/10.1016/j.nbt.2011.03.014,"Monoclonal antibodies (mAbs) are arguably the most significant class of biologics for use as pharmaceuticals and diagnostics. Many technological concepts exist for the generation and identification of therapeutically relevant mAbs, including the isolation and cloning of immunoglobulin (Ig) encoding genes from single B-lineage cells. This review summarizes various single B cell approaches and describes their use for the discovery of mAbs with potential therapeutic values or in basic research.",10.1016/j.nbt.2011.03.014,1j3s95gw,"['Monoclonal', 'antibodies', 'mAbs', 'are', 'arguably', 'the', 'most', 'significant', 'class', 'of', 'biologics', 'for', 'use', 'as', 'pharmaceuticals', 'and', 'diagnostics', 'Many', 'technological', 'concepts', 'exist', 'for', 'the', 'generation', 'and', 'identification', 'of', 'therapeutically', 'relevant', 'mAbs', 'including', 'the', 'isolation', 'and', 'cloning', 'of', 'immunoglobulin', 'Ig', 'encoding', 'genes', 'from', 'single', 'B', 'lineage', 'cells', 'This', 'review', 'summarizes', 'various', 'single', 'B', 'cell', 'approaches', 'and', 'describes', 'their', 'use', 'for', 'the', 'discovery', 'of', 'mAbs', 'with', 'potential', 'therapeutic', 'values', 'or', 'in', 'basic', 'research', '']"
182816,The role of interleukin-12 in the heavy metal-elicited immunomodulation: relevance of various evaluation methods,2008-11-06,J Occup Med Toxicol,https://www.ncbi.nlm.nih.gov/pubmed/18990205/; https://doi.org/10.1186/1745-6673-3-25,"BACKGROUND: Increasing evidence exists that heavy metals modulate T helper cell (Th) responses and thereby elicit various pathological manifestation. Interleukin (IL)-12, a crucial innate cytokine, was found to be regulated by such xenobiotic agents. This study aimed at testing whether IL-12 profiles may be indicative of heavy metals-induced immunomodulation. METHODS: Human immunocompetent cells, activated either by monoclonal antibodies or heat-killed Salmonella enterica, were cultured in the absence or presence of cadmium (Cd) acetate or mercuric (Hg) chloride. In vivo experiments were set up where BALB/c mice were exposed to sub-lethal doses of Cd or Hg salts for 3 or 5 weeks. Cytotoxicity was assessed by MTT-reduction assay. Modulation of cytokine profiles was evaluated by enzyme-linked immunosorbent assay (ELISA), cytometric bead-based array (CBA) and real-time polymerase chain reaction (RT-PCR); the relevance of these methods of cytokine quantification was explored. RESULTS: Modulation of IL-12 profiles in Cd- or Hg-exposed human PBMC was dose-dependent and significantly related to IFN-γ levels as well as to the Th1- or Th2-polarized responses. Similarly, skewing the Th1/Th2 ratios in vivo correlated significantly with up- or down-regulation of IL-12 levels in both cases of investigated metals. CONCLUSION: It can be inferred that: (i) IL-12 profiles alone may represent a relevant indicator of heavy metal-induced immune modulation; (ii) evaluating cytokine profiles by CBA is relevant and can adequately replace other methods such as ELISA and RT-PCR in basic research as well as in immune diagnostics; and (iii) targeting IL-12 in therapeutic approaches may be promising to modify Th1/Th2-associated immune disorders.",10.1186/1745-6673-3-25,j74a3j5w,"['BACKGROUND', 'Increasing', 'evidence', 'exists', 'that', 'heavy', 'metals', 'modulate', 'T', 'helper', 'cell', 'Th', 'responses', 'and', 'thereby', 'elicit', 'various', 'pathological', 'manifestation', 'Interleukin', 'IL', '12', 'a', 'crucial', 'innate', 'cytokine', 'was', 'found', 'to', 'be', 'regulated', 'by', 'such', 'xenobiotic', 'agents', 'This', 'study', 'aimed', 'at', 'testing', 'whether', 'IL', '12', 'profiles', 'may', 'be', 'indicative', 'of', 'heavy', 'metals', 'induced', 'immunomodulation', 'METHODS', 'Human', 'immunocompetent', 'cells', 'activated', 'either', 'by', 'monoclonal', 'antibodies', 'or', 'heat', 'killed', 'Salmonella', 'enterica', 'were', 'cultured', 'in', 'the', 'absence', 'or', 'presence', 'of', 'cadmium', 'Cd', 'acetate', 'or', 'mercuric', 'Hg', 'chloride', 'In', 'vivo', 'experiments', 'were', 'set', 'up', 'where', 'BALB', 'c', 'mice', 'were', 'exposed', 'to', 'sub', 'lethal', 'doses', 'of', 'Cd', 'or', 'Hg', 'salts', 'for', '3', 'or', '5', 'weeks', 'Cytotoxicity', 'was', 'assessed', 'by', 'MTT', 'reduction', 'assay', 'Modulation', 'of', 'cytokine', 'profiles', 'was', 'evaluated', 'by', 'enzyme', 'linked', 'immunosorbent', 'assay', 'ELISA', 'cytometric', 'bead', 'based', 'array', 'CBA', 'and', 'real', 'time', 'polymerase', 'chain', 'reaction', 'RT', 'PCR', 'the', 'relevance', 'of', 'these', 'methods', 'of', 'cytokine', 'quantification', 'was', 'explored', 'RESULTS', 'Modulation', 'of', 'IL', '12', 'profiles', 'in', 'Cd', 'or', 'Hg', 'exposed', 'human', 'PBMC', 'was', 'dose', 'dependent', 'and', 'significantly', 'related', 'to', 'IFN', 'γ', 'levels', 'as', 'well', 'as', 'to', 'the', 'Th1', 'or', 'Th2', 'polarized', 'responses', 'Similarly', 'skewing', 'the', 'Th1', 'Th2', 'ratios', 'in', 'vivo', 'correlated', 'significantly', 'with', 'up', 'or', 'down', 'regulation', 'of', 'IL', '12', 'levels', 'in', 'both', 'cases', 'of', 'investigated', 'metals', 'CONCLUSION', 'It', 'can', 'be', 'inferred', 'that', 'i', 'IL', '12', 'profiles', 'alone', 'may', 'represent', 'a', 'relevant', 'indicator', 'of', 'heavy', 'metal', 'induced', 'immune', 'modulation', 'ii', 'evaluating', 'cytokine', 'profiles', 'by', 'CBA', 'is', 'relevant', 'and', 'can', 'adequately', 'replace', 'other', 'methods', 'such', 'as', 'ELISA', 'and', 'RT', 'PCR', 'in', 'basic', 'research', 'as', 'well', 'as', 'in', 'immune', 'diagnostics', 'and', 'iii', 'targeting', 'IL', '12', 'in', 'therapeutic', 'approaches', 'may', 'be', 'promising', 'to', 'modify', 'Th1', 'Th2', 'associated', 'immune', 'disorders', '']"
183520,Die Virologie von SARS-CoV-2,2020-07-23,Internist (Berl),https://doi.org/10.1007/s00108-020-00853-6; https://www.ncbi.nlm.nih.gov/pubmed/32705298/,"The new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has far reaching effects on society, the economy and medical treatment. It is all the more important to understand the characteristics of the virus and to utilize them diagnostically, therapeutically and epidemiologically. This article firstly elucidates the medical importance of coronaviruses in general. Then angiotensin-converting enzyme 2 (ACE2) as the binding site of SARS-CoV‑2 and the possible influence on the disease susceptibility are explained. The gold standard for detection of an active SARS-CoV‑2 infection is the direct detection of the pathogen with nucleic acid amplification techniques. At the onset of symptoms, a swab of the upper airway is especially suitable due to the high viral burden. At a later stage direct detection can be achieved in samples from the lower airway or a stool or anal swab. Antigen or antibody tests cannot replace the direct detection of the pathogen; however, the detection of immunoglobulin G antibodies are of special interest for epidemiological questions (seroconversion time of sometimes several weeks). The plaque reduction neutralization test exclusively detects antibodies which neutralize viruses but the procedure is complicated. In addition, the importance of these antibodies with respect to immunity against a second infection is uncertain. Thanks to modern techniques thousands of SARS-CoV‑2 sequences are already available, which show a genomic variability. The D614G mutation in the S spikes seems to cause a higher infectiosity. Mutations can impair the diagnostics and treatment, which makes monitoring necessary.",10.1007/s00108-020-00853-6,4rx9ii1j,"['The', 'new', 'severe', 'acute', 'respiratory', 'syndrome', 'coronavirus', '2', 'SARS', 'CoV', '2', 'has', 'far', 'reaching', 'effects', 'on', 'society', 'the', 'economy', 'and', 'medical', 'treatment', 'It', 'is', 'all', 'the', 'more', 'important', 'to', 'understand', 'the', 'characteristics', 'of', 'the', 'virus', 'and', 'to', 'utilize', 'them', 'diagnostically', 'therapeutically', 'and', 'epidemiologically', 'This', 'article', 'firstly', 'elucidates', 'the', 'medical', 'importance', 'of', 'coronaviruses', 'in', 'general', 'Then', 'angiotensin', 'converting', 'enzyme', '2', 'ACE2', 'as', 'the', 'binding', 'site', 'of', 'SARS', 'CoV', '2', 'and', 'the', 'possible', 'influence', 'on', 'the', 'disease', 'susceptibility', 'are', 'explained', 'The', 'gold', 'standard', 'for', 'detection', 'of', 'an', 'active', 'SARS', 'CoV', '2', 'infection', 'is', 'the', 'direct', 'detection', 'of', 'the', 'pathogen', 'with', 'nucleic', 'acid', 'amplification', 'techniques', 'At', 'the', 'onset', 'of', 'symptoms', 'a', 'swab', 'of', 'the', 'upper', 'airway', 'is', 'especially', 'suitable', 'due', 'to', 'the', 'high', 'viral', 'burden', 'At', 'a', 'later', 'stage', 'direct', 'detection', 'can', 'be', 'achieved', 'in', 'samples', 'from', 'the', 'lower', 'airway', 'or', 'a', 'stool', 'or', 'anal', 'swab', 'Antigen', 'or', 'antibody', 'tests', 'cannot', 'replace', 'the', 'direct', 'detection', 'of', 'the', 'pathogen', 'however', 'the', 'detection', 'of', 'immunoglobulin', 'G', 'antibodies', 'are', 'of', 'special', 'interest', 'for', 'epidemiological', 'questions', 'seroconversion', 'time', 'of', 'sometimes', 'several', 'weeks', 'The', 'plaque', 'reduction', 'neutralization', 'test', 'exclusively', 'detects', 'antibodies', 'which', 'neutralize', 'viruses', 'but', 'the', 'procedure', 'is', 'complicated', 'In', 'addition', 'the', 'importance', 'of', 'these', 'antibodies', 'with', 'respect', 'to', 'immunity', 'against', 'a', 'second', 'infection', 'is', 'uncertain', 'Thanks', 'to', 'modern', 'techniques', 'thousands', 'of', 'SARS', 'CoV', '2', 'sequences', 'are', 'already', 'available', 'which', 'show', 'a', 'genomic', 'variability', 'The', 'D614G', 'mutation', 'in', 'the', 'S', 'spikes', 'seems', 'to', 'cause', 'a', 'higher', 'infectiosity', 'Mutations', 'can', 'impair', 'the', 'diagnostics', 'and', 'treatment', 'which', 'makes', 'monitoring', 'necessary', '']"
184720,Antibody-profiling technologies for studying humoral responses to infectious agents,2010-06-01,Expert Review of Vaccines,http://europepmc.org/articles/pmc3417761?pdf=render; https://www.ncbi.nlm.nih.gov/pubmed/20518713/; https://doi.org/10.1586/erv.10.50,"Analyses of humoral responses against different infectious agents are critical for infectious disease diagnostics, understanding pathogenic mechanisms, and the development and monitoring of vaccines. While ELISAs are often used to measure antibody responses to one or several targets, new antibody-profiling technologies, such as protein microarrays, can now evaluate antibody responses to hundreds, or even thousands, of recombinant antigens at one time. These large-scale studies have uncovered new antigenic targets, provided new insights into vaccine research and yielded an overview of immunoreactivity against almost the entire proteome of certain pathogens. However, solid-phase antigen arrays also have drawbacks that limit the type of information obtained, including suboptimal detection of conformational epitopes, high backgrounds due to impure antigens and a narrow dynamic range of detection. We have developed a solution-phase antibody-profiling technology, luciferase immunoprecipitation systems (LIPS), which harnesses light-emitting recombinant antigen fusion proteins to quantitatively measure patient antibody titers. Owing to the highly linear light output of the luciferase reporter, some antibodies can be detected without serum dilution in a dynamic range of detection often spanning seven orders of magnitude. When LIPS is applied iteratively with multiple target antigens, a high-definition antibody profile is obtained. Here, we discuss the application of these different antibody-profiling technologies and their associated limitations with particular emphasis on protein microarrays. We also describe LIPS in detail and discuss several clinically relevant uses of the technology. Together, these new technologies offer new tools for understanding humoral responses to known and emerging infectious agents.",10.1586/erv.10.50,1evsmqw6,"['Analyses', 'of', 'humoral', 'responses', 'against', 'different', 'infectious', 'agents', 'are', 'critical', 'for', 'infectious', 'disease', 'diagnostics', 'understanding', 'pathogenic', 'mechanisms', 'and', 'the', 'development', 'and', 'monitoring', 'of', 'vaccines', 'While', 'ELISAs', 'are', 'often', 'used', 'to', 'measure', 'antibody', 'responses', 'to', 'one', 'or', 'several', 'targets', 'new', 'antibody', 'profiling', 'technologies', 'such', 'as', 'protein', 'microarrays', 'can', 'now', 'evaluate', 'antibody', 'responses', 'to', 'hundreds', 'or', 'even', 'thousands', 'of', 'recombinant', 'antigens', 'at', 'one', 'time', 'These', 'large', 'scale', 'studies', 'have', 'uncovered', 'new', 'antigenic', 'targets', 'provided', 'new', 'insights', 'into', 'vaccine', 'research', 'and', 'yielded', 'an', 'overview', 'of', 'immunoreactivity', 'against', 'almost', 'the', 'entire', 'proteome', 'of', 'certain', 'pathogens', 'However', 'solid', 'phase', 'antigen', 'arrays', 'also', 'have', 'drawbacks', 'that', 'limit', 'the', 'type', 'of', 'information', 'obtained', 'including', 'suboptimal', 'detection', 'of', 'conformational', 'epitopes', 'high', 'backgrounds', 'due', 'to', 'impure', 'antigens', 'and', 'a', 'narrow', 'dynamic', 'range', 'of', 'detection', 'We', 'have', 'developed', 'a', 'solution', 'phase', 'antibody', 'profiling', 'technology', 'luciferase', 'immunoprecipitation', 'systems', 'LIPS', 'which', 'harnesses', 'light', 'emitting', 'recombinant', 'antigen', 'fusion', 'proteins', 'to', 'quantitatively', 'measure', 'patient', 'antibody', 'titers', 'Owing', 'to', 'the', 'highly', 'linear', 'light', 'output', 'of', 'the', 'luciferase', 'reporter', 'some', 'antibodies', 'can', 'be', 'detected', 'without', 'serum', 'dilution', 'in', 'a', 'dynamic', 'range', 'of', 'detection', 'often', 'spanning', 'seven', 'orders', 'of', 'magnitude', 'When', 'LIPS', 'is', 'applied', 'iteratively', 'with', 'multiple', 'target', 'antigens', 'a', 'high', 'definition', 'antibody', 'profile', 'is', 'obtained', 'Here', 'we', 'discuss', 'the', 'application', 'of', 'these', 'different', 'antibody', 'profiling', 'technologies', 'and', 'their', 'associated', 'limitations', 'with', 'particular', 'emphasis', 'on', 'protein', 'microarrays', 'We', 'also', 'describe', 'LIPS', 'in', 'detail', 'and', 'discuss', 'several', 'clinically', 'relevant', 'uses', 'of', 'the', 'technology', 'Together', 'these', 'new', 'technologies', 'offer', 'new', 'tools', 'for', 'understanding', 'humoral', 'responses', 'to', 'known', 'and', 'emerging', 'infectious', 'agents', '']"
185638,Generation and characterization of a monoclonal antibody against MERS-CoV targeting the spike protein using a synthetic peptide epitope-CpG-DNA-liposome complex,2019-06-30,BMB Rep,https://www.ncbi.nlm.nih.gov/pubmed/30355437/,"Middle East respiratory syndrome coronavirus (MERS-CoV) uses the spike (S) glycoprotein to recognize and enter target cells. In this study, we selected two epitope peptide sequences within the receptor binding domain (RBD) of the MERS-CoV S protein. We used a complex consisting of the epitope peptide of the MERS-CoV S protein and CpG-DNA encapsulated in liposome complex to immunize mice, and produced the monoclonal antibodies 506-2G10G5 and 492-1G10E4E2. The western blotting data showed that both monoclonal antibodies detected the S protein and immunoprecipitated the native form of the S protein. Indirect immunofluorescence and confocal analysis suggested strong reactivity of the antibodies towards the S protein of MERS-CoV virus infected Vero cells. Furthermore, the 506-2G10G5 monoclonal antibody significantly reduced plaque formation in MERS-CoV infected Vero cells compared to normal mouse IgG and 492-1G10E4E2. Thus, we successfully produced a monoclonal antibody directed against the RBD domain of the S protein which could be used in the development of diagnostics and therapeutic applications in the future.",10.5483/bmbrep.2019.52.6.185,n7ehxulc,"['Middle', 'East', 'respiratory', 'syndrome', 'coronavirus', 'MERS', 'CoV', 'uses', 'the', 'spike', 'S', 'glycoprotein', 'to', 'recognize', 'and', 'enter', 'target', 'cells', 'In', 'this', 'study', 'we', 'selected', 'two', 'epitope', 'peptide', 'sequences', 'within', 'the', 'receptor', 'binding', 'domain', 'RBD', 'of', 'the', 'MERS', 'CoV', 'S', 'protein', 'We', 'used', 'a', 'complex', 'consisting', 'of', 'the', 'epitope', 'peptide', 'of', 'the', 'MERS', 'CoV', 'S', 'protein', 'and', 'CpG', 'DNA', 'encapsulated', 'in', 'liposome', 'complex', 'to', 'immunize', 'mice', 'and', 'produced', 'the', 'monoclonal', 'antibodies', '506', '2G10G5', 'and', '492', '1G10E4E2', 'The', 'western', 'blotting', 'data', 'showed', 'that', 'both', 'monoclonal', 'antibodies', 'detected', 'the', 'S', 'protein', 'and', 'immunoprecipitated', 'the', 'native', 'form', 'of', 'the', 'S', 'protein', 'Indirect', 'immunofluorescence', 'and', 'confocal', 'analysis', 'suggested', 'strong', 'reactivity', 'of', 'the', 'antibodies', 'towards', 'the', 'S', 'protein', 'of', 'MERS', 'CoV', 'virus', 'infected', 'Vero', 'cells', 'Furthermore', 'the', '506', '2G10G5', 'monoclonal', 'antibody', 'significantly', 'reduced', 'plaque', 'formation', 'in', 'MERS', 'CoV', 'infected', 'Vero', 'cells', 'compared', 'to', 'normal', 'mouse', 'IgG', 'and', '492', '1G10E4E2', 'Thus', 'we', 'successfully', 'produced', 'a', 'monoclonal', 'antibody', 'directed', 'against', 'the', 'RBD', 'domain', 'of', 'the', 'S', 'protein', 'which', 'could', 'be', 'used', 'in', 'the', 'development', 'of', 'diagnostics', 'and', 'therapeutic', 'applications', 'in', 'the', 'future', '']"
188545,Validation of a SARS-CoV-2 spike protein ELISA for use in contact investigations and sero-surveillance,2020-04-25,bioRxiv,https://doi.org/10.1101/2020.04.24.057323; https://www.ncbi.nlm.nih.gov/pubmed/32511332/,"Since emergence of SARS-CoV-2 in late 2019, there has been a critical need to understand prevalence, transmission patterns, to calculate the burden of disease and case fatality rates. Molecular diagnostics, the gold standard for identifying viremic cases, are not ideal for determining true case counts and rates of asymptomatic infection. Serological detection of SARS-CoV-2 specific antibodies can contribute to filling these knowledge gaps. In this study, we describe optimization and validation of a SARS-CoV-2-specific-enzyme linked immunosorbent assay (ELISA) using the prefusion-stabilized form of the spike protein [1]. We performed receiver operator characteristic (ROC) analyses to define the specificities and sensitivities of the optimized assay and examined cross reactivity with immune sera from persons confirmed to have had infections with other coronaviruses. These assays will be used to perform contact investigations and to conduct large-scale, cross sectional surveillance to define disease burden in the population.",10.1101/2020.04.24.057323,4070r4fc,"['Since', 'emergence', 'of', 'SARS', 'CoV', '2', 'in', 'late', '2019', 'there', 'has', 'been', 'a', 'critical', 'need', 'to', 'understand', 'prevalence', 'transmission', 'patterns', 'to', 'calculate', 'the', 'burden', 'of', 'disease', 'and', 'case', 'fatality', 'rates', 'Molecular', 'diagnostics', 'the', 'gold', 'standard', 'for', 'identifying', 'viremic', 'cases', 'are', 'not', 'ideal', 'for', 'determining', 'true', 'case', 'counts', 'and', 'rates', 'of', 'asymptomatic', 'infection', 'Serological', 'detection', 'of', 'SARS', 'CoV', '2', 'specific', 'antibodies', 'can', 'contribute', 'to', 'filling', 'these', 'knowledge', 'gaps', 'In', 'this', 'study', 'we', 'describe', 'optimization', 'and', 'validation', 'of', 'a', 'SARS', 'CoV', '2', 'specific', 'enzyme', 'linked', 'immunosorbent', 'assay', 'ELISA', 'using', 'the', 'prefusion', 'stabilized', 'form', 'of', 'the', 'spike', 'protein', '1', 'We', 'performed', 'receiver', 'operator', 'characteristic', 'ROC', 'analyses', 'to', 'define', 'the', 'specificities', 'and', 'sensitivities', 'of', 'the', 'optimized', 'assay', 'and', 'examined', 'cross', 'reactivity', 'with', 'immune', 'sera', 'from', 'persons', 'confirmed', 'to', 'have', 'had', 'infections', 'with', 'other', 'coronaviruses', 'These', 'assays', 'will', 'be', 'used', 'to', 'perform', 'contact', 'investigations', 'and', 'to', 'conduct', 'large', 'scale', 'cross', 'sectional', 'surveillance', 'to', 'define', 'disease', 'burden', 'in', 'the', 'population', '']"
189471,Profiling the IgOme: Meeting the challenge,2014-01-21,FEBS Letters,https://www.sciencedirect.com/science/article/pii/S0014579313008259; https://api.elsevier.com/content/article/pii/S0014579313008259; https://www.ncbi.nlm.nih.gov/pubmed/24239539/; https://doi.org/10.1016/j.febslet.2013.11.005,"Abstract The entire repertoire of antibodies in our serum, the IgOme, is a historical record of our past experiences and a reflection of our immune status at any given moment. Understanding the dynamics of the IgOme and how the diversity and specificities of serum antibodies change in response to disease and maintenance of homeostasis can directly impact the ability to design and develop novel vaccines, diagnostics and therapeutics. Here we review both direct and indirect methodologies that are being developed to map the complexity and specificities of the antibodies in polyclonal serum – the IgOme.",10.1016/j.febslet.2013.11.005,qrot4o69,"['Abstract', 'The', 'entire', 'repertoire', 'of', 'antibodies', 'in', 'our', 'serum', 'the', 'IgOme', 'is', 'a', 'historical', 'record', 'of', 'our', 'past', 'experiences', 'and', 'a', 'reflection', 'of', 'our', 'immune', 'status', 'at', 'any', 'given', 'moment', 'Understanding', 'the', 'dynamics', 'of', 'the', 'IgOme', 'and', 'how', 'the', 'diversity', 'and', 'specificities', 'of', 'serum', 'antibodies', 'change', 'in', 'response', 'to', 'disease', 'and', 'maintenance', 'of', 'homeostasis', 'can', 'directly', 'impact', 'the', 'ability', 'to', 'design', 'and', 'develop', 'novel', 'vaccines', 'diagnostics', 'and', 'therapeutics', 'Here', 'we', 'review', 'both', 'direct', 'and', 'indirect', 'methodologies', 'that', 'are', 'being', 'developed', 'to', 'map', 'the', 'complexity', 'and', 'specificities', 'of', 'the', 'antibodies', 'in', 'polyclonal', 'serum', 'the', 'IgOme', '']"
191707,Recombinant antibodies for diagnostics and therapy against pathogens and toxins generated by phage display,2016-06-21,Proteomics Clin Appl,https://www.ncbi.nlm.nih.gov/pubmed/27198131/; https://doi.org/10.1002/prca.201600002,"Antibodies are valuable molecules for the diagnostic and treatment of diseases caused by pathogens and toxins. Traditionally, these antibodies are generated by hybridoma technology. An alternative to hybridoma technology is the use of antibody phage display to generate recombinant antibodies. This in vitro technology circumvents the limitations of the immune system and allows—in theory—the generation of antibodies against all conceivable molecules. Phage display technology enables obtaining human antibodies from naïve antibody gene libraries when either patients are not available or immunization is not ethically feasible. On the other hand, if patients or immunized/infected animals are available, it is common to construct immune phage display libraries to select in vivo affinity‐matured antibodies. Because the phage packaged DNA sequence encoding the antibodies is directly available, the antibodies can be smoothly engineered according to the requirements of the final application. In this review, an overview of phage display derived recombinant antibodies against bacterial, viral, and eukaryotic pathogens as well as toxins for diagnostics and therapy is given.",10.1002/prca.201600002,yblzopc3,"['Antibodies', 'are', 'valuable', 'molecules', 'for', 'the', 'diagnostic', 'and', 'treatment', 'of', 'diseases', 'caused', 'by', 'pathogens', 'and', 'toxins', 'Traditionally', 'these', 'antibodies', 'are', 'generated', 'by', 'hybridoma', 'technology', 'An', 'alternative', 'to', 'hybridoma', 'technology', 'is', 'the', 'use', 'of', 'antibody', 'phage', 'display', 'to', 'generate', 'recombinant', 'antibodies', 'This', 'in', 'vitro', 'technology', 'circumvents', 'the', 'limitations', 'of', 'the', 'immune', 'system', 'and', 'allows', 'in', 'theory', 'the', 'generation', 'of', 'antibodies', 'against', 'all', 'conceivable', 'molecules', 'Phage', 'display', 'technology', 'enables', 'obtaining', 'human', 'antibodies', 'from', 'naïve', 'antibody', 'gene', 'libraries', 'when', 'either', 'patients', 'are', 'not', 'available', 'or', 'immunization', 'is', 'not', 'ethically', 'feasible', 'On', 'the', 'other', 'hand', 'if', 'patients', 'or', 'immunized', 'infected', 'animals', 'are', 'available', 'it', 'is', 'common', 'to', 'construct', 'immune', 'phage', 'display', 'libraries', 'to', 'select', 'in', 'vivo', 'affinity', 'matured', 'antibodies', 'Because', 'the', 'phage', 'packaged', 'DNA', 'sequence', 'encoding', 'the', 'antibodies', 'is', 'directly', 'available', 'the', 'antibodies', 'can', 'be', 'smoothly', 'engineered', 'according', 'to', 'the', 'requirements', 'of', 'the', 'final', 'application', 'In', 'this', 'review', 'an', 'overview', 'of', 'phage', 'display', 'derived', 'recombinant', 'antibodies', 'against', 'bacterial', 'viral', 'and', 'eukaryotic', 'pathogens', 'as', 'well', 'as', 'toxins', 'for', 'diagnostics', 'and', 'therapy', 'is', 'given', '']"
193659,A line immunoassay utilizing recombinant nucleocapsid proteins for detection of antibodies to human coronaviruses,2008-05-31,Diagnostic Microbiology and Infectious Disease,https://www.sciencedirect.com/science/article/pii/S0732889307005883; https://api.elsevier.com/content/article/pii/S0732889307005883; https://www.ncbi.nlm.nih.gov/pubmed/18191362/; https://doi.org/10.1016/j.diagmicrobio.2007.12.002,"Abstract Most coronaviruses infecting humans cause mild diseases, whereas severe acute respiratory syndrome (SARS)-associated coronavirus is an extremely dangerous pathogen. Here, we report the development of a serologic assay for detection of antibodies to human coronaviruses (HCoVs) based on recombinant nucleocapsid (N) proteins of all known pathogenic strains (229E, NL63, OC43, HKU1, SARS). The novel immunoassay is highly useful for epidemiologic surveys, where use of nucleic acid diagnostics often is limited. Purified recombinant antigens were immobilized on nitrocellulose membranes and applied in a line immunoassay, which allows rapid detection of antibodies to 5 different HCoVs in a single experiment. For assay evaluation, serum samples from persons infected with 229E or OC43 (acute/convalescent), recovered SARS patients and healthy donors were analyzed. Screening for nucleocapsid (N)-specific immunoglobulin G (IgG) in convalescent sera reached 100% sensitivity. With this new technique, we found that recently identified NL63 and HKU1 contribute significantly to the overall spectrum of coronavirus infections. Possibly, cross-reactive antibody responses were observed using 229E and OC43 serum pairs. However, the potential of this assay could clearly be demonstrated employing SARS-positive serum samples, where nonspecific binding to nucleocapsids of other HCoVs was not observed. This coronavirus strain-specific line immunoassay represents a powerful tool for serologic diagnostics.",10.1016/j.diagmicrobio.2007.12.002,m400cal3,"['Abstract', 'Most', 'coronaviruses', 'infecting', 'humans', 'cause', 'mild', 'diseases', 'whereas', 'severe', 'acute', 'respiratory', 'syndrome', 'SARS', 'associated', 'coronavirus', 'is', 'an', 'extremely', 'dangerous', 'pathogen', 'Here', 'we', 'report', 'the', 'development', 'of', 'a', 'serologic', 'assay', 'for', 'detection', 'of', 'antibodies', 'to', 'human', 'coronaviruses', 'HCoVs', 'based', 'on', 'recombinant', 'nucleocapsid', 'N', 'proteins', 'of', 'all', 'known', 'pathogenic', 'strains', '229E', 'NL63', 'OC43', 'HKU1', 'SARS', 'The', 'novel', 'immunoassay', 'is', 'highly', 'useful', 'for', 'epidemiologic', 'surveys', 'where', 'use', 'of', 'nucleic', 'acid', 'diagnostics', 'often', 'is', 'limited', 'Purified', 'recombinant', 'antigens', 'were', 'immobilized', 'on', 'nitrocellulose', 'membranes', 'and', 'applied', 'in', 'a', 'line', 'immunoassay', 'which', 'allows', 'rapid', 'detection', 'of', 'antibodies', 'to', '5', 'different', 'HCoVs', 'in', 'a', 'single', 'experiment', 'For', 'assay', 'evaluation', 'serum', 'samples', 'from', 'persons', 'infected', 'with', '229E', 'or', 'OC43', 'acute', 'convalescent', 'recovered', 'SARS', 'patients', 'and', 'healthy', 'donors', 'were', 'analyzed', 'Screening', 'for', 'nucleocapsid', 'N', 'specific', 'immunoglobulin', 'G', 'IgG', 'in', 'convalescent', 'sera', 'reached', '100', 'sensitivity', 'With', 'this', 'new', 'technique', 'we', 'found', 'that', 'recently', 'identified', 'NL63', 'and', 'HKU1', 'contribute', 'significantly', 'to', 'the', 'overall', 'spectrum', 'of', 'coronavirus', 'infections', 'Possibly', 'cross', 'reactive', 'antibody', 'responses', 'were', 'observed', 'using', '229E', 'and', 'OC43', 'serum', 'pairs', 'However', 'the', 'potential', 'of', 'this', 'assay', 'could', 'clearly', 'be', 'demonstrated', 'employing', 'SARS', 'positive', 'serum', 'samples', 'where', 'nonspecific', 'binding', 'to', 'nucleocapsids', 'of', 'other', 'HCoVs', 'was', 'not', 'observed', 'This', 'coronavirus', 'strain', 'specific', 'line', 'immunoassay', 'represents', 'a', 'powerful', 'tool', 'for', 'serologic', 'diagnostics', '']"
195556,Electrochemical biosensors for pathogen detection,2020-07-01,Biosensors and Bioelectronics,https://api.elsevier.com/content/article/pii/S0956566320302116; https://www.sciencedirect.com/science/article/pii/S0956566320302116; https://doi.org/10.1016/j.bios.2020.112214; https://www.ncbi.nlm.nih.gov/pubmed/32364936/,"Abstract Recent advances in electrochemical biosensors for pathogen detection are reviewed. Electrochemical biosensors for pathogen detection are broadly reviewed in terms of transduction elements, biorecognition elements, electrochemical techniques, and biosensor performance. Transduction elements are discussed in terms of electrode material and form factor. Biorecognition elements for pathogen detection, including antibodies, aptamers, and imprinted polymers, are discussed in terms of availability, production, and immobilization approach. Emerging areas of electrochemical biosensor design are reviewed, including electrode modification and transducer integration. Measurement formats for pathogen detection are classified in terms of sample preparation and secondary binding steps. Applications of electrochemical biosensors for the detection of pathogens in food and water safety, medical diagnostics, environmental monitoring, and bio-threat applications are highlighted. Future directions and challenges of electrochemical biosensors for pathogen detection are discussed, including wearable and conformal biosensors, detection of plant pathogens, multiplexed detection, reusable biosensors for process monitoring applications, and low-cost, disposable biosensors.",10.1016/j.bios.2020.112214,cxa2ugap,"['Abstract', 'Recent', 'advances', 'in', 'electrochemical', 'biosensors', 'for', 'pathogen', 'detection', 'are', 'reviewed', 'Electrochemical', 'biosensors', 'for', 'pathogen', 'detection', 'are', 'broadly', 'reviewed', 'in', 'terms', 'of', 'transduction', 'elements', 'biorecognition', 'elements', 'electrochemical', 'techniques', 'and', 'biosensor', 'performance', 'Transduction', 'elements', 'are', 'discussed', 'in', 'terms', 'of', 'electrode', 'material', 'and', 'form', 'factor', 'Biorecognition', 'elements', 'for', 'pathogen', 'detection', 'including', 'antibodies', 'aptamers', 'and', 'imprinted', 'polymers', 'are', 'discussed', 'in', 'terms', 'of', 'availability', 'production', 'and', 'immobilization', 'approach', 'Emerging', 'areas', 'of', 'electrochemical', 'biosensor', 'design', 'are', 'reviewed', 'including', 'electrode', 'modification', 'and', 'transducer', 'integration', 'Measurement', 'formats', 'for', 'pathogen', 'detection', 'are', 'classified', 'in', 'terms', 'of', 'sample', 'preparation', 'and', 'secondary', 'binding', 'steps', 'Applications', 'of', 'electrochemical', 'biosensors', 'for', 'the', 'detection', 'of', 'pathogens', 'in', 'food', 'and', 'water', 'safety', 'medical', 'diagnostics', 'environmental', 'monitoring', 'and', 'bio', 'threat', 'applications', 'are', 'highlighted', 'Future', 'directions', 'and', 'challenges', 'of', 'electrochemical', 'biosensors', 'for', 'pathogen', 'detection', 'are', 'discussed', 'including', 'wearable', 'and', 'conformal', 'biosensors', 'detection', 'of', 'plant', 'pathogens', 'multiplexed', 'detection', 'reusable', 'biosensors', 'for', 'process', 'monitoring', 'applications', 'and', 'low', 'cost', 'disposable', 'biosensors', '']"
200237,Monoclonal Antibodies and Antibody Like Fragments Derived from Immunised Phage Display Libraries,2018-03-17,Recombinant Antibodies for Infectious Diseases,https://doi.org/10.1007/978-3-319-72077-7_6; https://www.ncbi.nlm.nih.gov/pubmed/29549637/,"Morbidity and mortality associated with infectious diseases are always on the rise, especially in poorer countries and in the aging population. The inevitable, but unpredictable emergence of new infectious diseases has become a global threat. HIV/AIDS, severe acute respiratory syndrome (SARS), and the more recent H1N1 influenza are only a few of the numerous examples of emerging infectious diseases in the modern era. However despite advances in diagnostics, therapeutics and vaccines, there is need for more specific, efficacious, cost-effective and less toxic treatment and preventive drugs. In this chapter, we discuss a powerful combinatorial technology in association with animal immunisation that is capable of generating biologic drugs with high affinity, efficacy and limited off-site toxicity, and diagnostic tools with great precision. Although time consuming, immunisation still remains the preferred route for the isolation of high-affinity antibodies and antibody-like fragments. Phage display is a molecular diversity technology that allows the presentation of large peptide and protein libraries on the surface of filamentous phage. The selection of binding fragments from phage display libraries has proven significant for routine isolation of invaluable peptides, antibodies, and antibody-like domains for diagnostic and therapeutic applications. Here we highlight the many benefits of combining immunisation with phage display in combating infectious diseases, and how our knowledge of antibody engineering has played a crucial role in fully exploiting these platforms in generating therapeutic and diagnostic biologics towards antigenic targets of infectious organisms.",10.1007/978-3-319-72077-7_6,fxs31d66,"['Morbidity', 'and', 'mortality', 'associated', 'with', 'infectious', 'diseases', 'are', 'always', 'on', 'the', 'rise', 'especially', 'in', 'poorer', 'countries', 'and', 'in', 'the', 'aging', 'population', 'The', 'inevitable', 'but', 'unpredictable', 'emergence', 'of', 'new', 'infectious', 'diseases', 'has', 'become', 'a', 'global', 'threat', 'HIV', 'AIDS', 'severe', 'acute', 'respiratory', 'syndrome', 'SARS', 'and', 'the', 'more', 'recent', 'H1N1', 'influenza', 'are', 'only', 'a', 'few', 'of', 'the', 'numerous', 'examples', 'of', 'emerging', 'infectious', 'diseases', 'in', 'the', 'modern', 'era', 'However', 'despite', 'advances', 'in', 'diagnostics', 'therapeutics', 'and', 'vaccines', 'there', 'is', 'need', 'for', 'more', 'specific', 'efficacious', 'cost', 'effective', 'and', 'less', 'toxic', 'treatment', 'and', 'preventive', 'drugs', 'In', 'this', 'chapter', 'we', 'discuss', 'a', 'powerful', 'combinatorial', 'technology', 'in', 'association', 'with', 'animal', 'immunisation', 'that', 'is', 'capable', 'of', 'generating', 'biologic', 'drugs', 'with', 'high', 'affinity', 'efficacy', 'and', 'limited', 'off', 'site', 'toxicity', 'and', 'diagnostic', 'tools', 'with', 'great', 'precision', 'Although', 'time', 'consuming', 'immunisation', 'still', 'remains', 'the', 'preferred', 'route', 'for', 'the', 'isolation', 'of', 'high', 'affinity', 'antibodies', 'and', 'antibody', 'like', 'fragments', 'Phage', 'display', 'is', 'a', 'molecular', 'diversity', 'technology', 'that', 'allows', 'the', 'presentation', 'of', 'large', 'peptide', 'and', 'protein', 'libraries', 'on', 'the', 'surface', 'of', 'filamentous', 'phage', 'The', 'selection', 'of', 'binding', 'fragments', 'from', 'phage', 'display', 'libraries', 'has', 'proven', 'significant', 'for', 'routine', 'isolation', 'of', 'invaluable', 'peptides', 'antibodies', 'and', 'antibody', 'like', 'domains', 'for', 'diagnostic', 'and', 'therapeutic', 'applications', 'Here', 'we', 'highlight', 'the', 'many', 'benefits', 'of', 'combining', 'immunisation', 'with', 'phage', 'display', 'in', 'combating', 'infectious', 'diseases', 'and', 'how', 'our', 'knowledge', 'of', 'antibody', 'engineering', 'has', 'played', 'a', 'crucial', 'role', 'in', 'fully', 'exploiting', 'these', 'platforms', 'in', 'generating', 'therapeutic', 'and', 'diagnostic', 'biologics', 'towards', 'antigenic', 'targets', 'of', 'infectious', 'organisms', '']"
200837,Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients,2020-06-01,Nat Commun,https://www.ncbi.nlm.nih.gov/pubmed/32483236/; https://doi.org/10.1038/s41467-020-16638-2,"Given the ongoing SARS-CoV-2 pandemic, identification of immunogenic targets against the coronavirus spike glycoprotein will provide crucial advances towards the development of sensitive diagnostic tools and potential vaccine candidate targets. In this study, using pools of overlapping linear B-cell peptides, we report two IgG immunodominant regions on SARS-CoV-2 spike glycoprotein that are recognised by sera from COVID-19 convalescent patients. Notably, one is specific to SARS-CoV-2, which is located in close proximity to the receptor binding domain. The other region, which is localised at the fusion peptide, could potentially function as a pan-SARS target. Functionally, antibody depletion assays demonstrate that antibodies targeting these immunodominant regions significantly alter virus neutralisation capacities. Taken together, identification and validation of these neutralising B-cell epitopes will provide insights towards the design of diagnostics and vaccine candidates against this high priority coronavirus.",10.1038/s41467-020-16638-2,p9u6rlue,"['Given', 'the', 'ongoing', 'SARS', 'CoV', '2', 'pandemic', 'identification', 'of', 'immunogenic', 'targets', 'against', 'the', 'coronavirus', 'spike', 'glycoprotein', 'will', 'provide', 'crucial', 'advances', 'towards', 'the', 'development', 'of', 'sensitive', 'diagnostic', 'tools', 'and', 'potential', 'vaccine', 'candidate', 'targets', 'In', 'this', 'study', 'using', 'pools', 'of', 'overlapping', 'linear', 'B', 'cell', 'peptides', 'we', 'report', 'two', 'IgG', 'immunodominant', 'regions', 'on', 'SARS', 'CoV', '2', 'spike', 'glycoprotein', 'that', 'are', 'recognised', 'by', 'sera', 'from', 'COVID', '19', 'convalescent', 'patients', 'Notably', 'one', 'is', 'specific', 'to', 'SARS', 'CoV', '2', 'which', 'is', 'located', 'in', 'close', 'proximity', 'to', 'the', 'receptor', 'binding', 'domain', 'The', 'other', 'region', 'which', 'is', 'localised', 'at', 'the', 'fusion', 'peptide', 'could', 'potentially', 'function', 'as', 'a', 'pan', 'SARS', 'target', 'Functionally', 'antibody', 'depletion', 'assays', 'demonstrate', 'that', 'antibodies', 'targeting', 'these', 'immunodominant', 'regions', 'significantly', 'alter', 'virus', 'neutralisation', 'capacities', 'Taken', 'together', 'identification', 'and', 'validation', 'of', 'these', 'neutralising', 'B', 'cell', 'epitopes', 'will', 'provide', 'insights', 'towards', 'the', 'design', 'of', 'diagnostics', 'and', 'vaccine', 'candidates', 'against', 'this', 'high', 'priority', 'coronavirus', '']"
203648,Immunological properties of gold nanoparticles,2017-03-01,Chem Sci,https://doi.org/10.1039/c6sc03631g; https://www.ncbi.nlm.nih.gov/pubmed/28451297/,"In the past decade, gold nanoparticles have attracted strong interest from the nanobiotechnological community owing to the significant progress made in robust and easy-to-make synthesis technologies, in surface functionalization, and in promising biomedical applications. These include bioimaging, gene diagnostics, analytical sensing, photothermal treatment of tumors, and targeted delivery of various biomolecular and chemical cargos. For the last-named application, gold nanoparticles should be properly fabricated to deliver the cargo into the targeted cells through effective endocytosis. In this review, we discuss recent progress in understanding the selective penetration of gold nanoparticles into immune cells. The interaction of gold nanoparticles with immune cell receptors is discussed. As distinct from other published reviews, we present a summary of the immunological properties of gold nanoparticles. This review also summarizes what is known about the application of gold nanoparticles as an antigen carrier and adjuvant in immunization for the preparation of antibodies in vivo. For each of the above topics, the basic principles, recent advances, and current challenges are discussed. Thus, this review presents a detailed analysis of data on interaction of gold nanoparticles with immune cells. Emphasis is placed on the systematization of data over production of antibodies by using gold nanoparticles and adjuvant properties of gold nanoparticles. Specifically, we start our discussion with current data on interaction of various gold nanoparticles with immune cells. The next section describes existing technologies to improve production of antibodies in vivo by using gold nanoparticles conjugated with specific ligands. Finally, we describe what is known about adjuvant properties of bare gold or functionalized nanoparticles. In the Conclusion section, we present a short summary of reported data and some challenges and perspectives.",10.1039/c6sc03631g,yga5omv7,"['In', 'the', 'past', 'decade', 'gold', 'nanoparticles', 'have', 'attracted', 'strong', 'interest', 'from', 'the', 'nanobiotechnological', 'community', 'owing', 'to', 'the', 'significant', 'progress', 'made', 'in', 'robust', 'and', 'easy', 'to', 'make', 'synthesis', 'technologies', 'in', 'surface', 'functionalization', 'and', 'in', 'promising', 'biomedical', 'applications', 'These', 'include', 'bioimaging', 'gene', 'diagnostics', 'analytical', 'sensing', 'photothermal', 'treatment', 'of', 'tumors', 'and', 'targeted', 'delivery', 'of', 'various', 'biomolecular', 'and', 'chemical', 'cargos', 'For', 'the', 'last', 'named', 'application', 'gold', 'nanoparticles', 'should', 'be', 'properly', 'fabricated', 'to', 'deliver', 'the', 'cargo', 'into', 'the', 'targeted', 'cells', 'through', 'effective', 'endocytosis', 'In', 'this', 'review', 'we', 'discuss', 'recent', 'progress', 'in', 'understanding', 'the', 'selective', 'penetration', 'of', 'gold', 'nanoparticles', 'into', 'immune', 'cells', 'The', 'interaction', 'of', 'gold', 'nanoparticles', 'with', 'immune', 'cell', 'receptors', 'is', 'discussed', 'As', 'distinct', 'from', 'other', 'published', 'reviews', 'we', 'present', 'a', 'summary', 'of', 'the', 'immunological', 'properties', 'of', 'gold', 'nanoparticles', 'This', 'review', 'also', 'summarizes', 'what', 'is', 'known', 'about', 'the', 'application', 'of', 'gold', 'nanoparticles', 'as', 'an', 'antigen', 'carrier', 'and', 'adjuvant', 'in', 'immunization', 'for', 'the', 'preparation', 'of', 'antibodies', 'in', 'vivo', 'For', 'each', 'of', 'the', 'above', 'topics', 'the', 'basic', 'principles', 'recent', 'advances', 'and', 'current', 'challenges', 'are', 'discussed', 'Thus', 'this', 'review', 'presents', 'a', 'detailed', 'analysis', 'of', 'data', 'on', 'interaction', 'of', 'gold', 'nanoparticles', 'with', 'immune', 'cells', 'Emphasis', 'is', 'placed', 'on', 'the', 'systematization', 'of', 'data', 'over', 'production', 'of', 'antibodies', 'by', 'using', 'gold', 'nanoparticles', 'and', 'adjuvant', 'properties', 'of', 'gold', 'nanoparticles', 'Specifically', 'we', 'start', 'our', 'discussion', 'with', 'current', 'data', 'on', 'interaction', 'of', 'various', 'gold', 'nanoparticles', 'with', 'immune', 'cells', 'The', 'next', 'section', 'describes', 'existing', 'technologies', 'to', 'improve', 'production', 'of', 'antibodies', 'in', 'vivo', 'by', 'using', 'gold', 'nanoparticles', 'conjugated', 'with', 'specific', 'ligands', 'Finally', 'we', 'describe', 'what', 'is', 'known', 'about', 'adjuvant', 'properties', 'of', 'bare', 'gold', 'or', 'functionalized', 'nanoparticles', 'In', 'the', 'Conclusion', 'section', 'we', 'present', 'a', 'short', 'summary', 'of', 'reported', 'data', 'and', 'some', 'challenges', 'and', 'perspectives', '']"
203913,Analysis and prediction of protective continuous B-cell epitopes on pathogen proteins,2008-01-07,Immunome Res,https://doi.org/10.1186/1745-7580-4-1; https://www.ncbi.nlm.nih.gov/pubmed/18179690/,"BACKGROUND: The application of peptide based diagnostics and therapeutics mimicking part of protein antigen is experiencing renewed interest. So far selection and design rationale for such peptides is usually driven by T-cell epitope prediction, available experimental and modelled 3D structure, B-cell epitope predictions such as hydrophilicity plots or experience. If no structure is available the rational selection of peptides for the production of functionally altering or neutralizing antibodies is practically impossible. Specifically if many alternative antigens are available the reduction of required synthesized peptides until one successful candidate is found is of central technical interest. We have investigated the integration of B-cell epitope prediction with the variability of antigen and the conservation of patterns for post-translational modification (PTM) prediction to improve over state of the art in the field. In particular the application of machine-learning methods shows promising results. RESULTS: We find that protein regions leading to the production of functionally altering antibodies are often characterized by a distinct increase in the cumulative sum of three presented parameters. Furthermore the concept to maximize antigenicity, minimize variability and minimize the likelihood of post-translational modification for the identification of relevant sites leads to biologically interesting observations. Primarily, for about 50% of antigen the approach works well with individual area under the ROC curve (AROC) values of at least 0.65. On the other hand a significant portion reveals equivalently low AROC values of < = 0.35 indicating an overall non-Gaussian distribution. While about a third of 57 antigens are seemingly intangible by our approach our results suggest the existence of at least two distinct classes of bioinformatically detectable epitopes which should be predicted separately. As a side effect of our study we present a hand curated dataset for the validation of protectivity classification. Based on this dataset machine-learning methods further improve predictive power to a class separation in an equilibrated dataset of up to 83%. CONCLUSION: We present a computational method to automatically select and rank peptides for the stimulation of potentially protective or otherwise functionally altering antibodies. It can be shown that integration of variability, post-translational modification pattern conservation and B-cell antigenicity improve rational selection over random guessing. Probably more important, we find that for about 50% of antigen the approach works substantially better than for the overall dataset of 57 proteins. Essentially as a side effect our method optimizes for presumably best applicable peptides as they tend to be likely unmodified and as invariable as possible which is answering needs in diagnosis and treatment of pathogen infection. In addition we show the potential for further improvement by the application of machine-learning methods, in particular Random Forests.",10.1186/1745-7580-4-1,ml2luc1t,"['BACKGROUND', 'The', 'application', 'of', 'peptide', 'based', 'diagnostics', 'and', 'therapeutics', 'mimicking', 'part', 'of', 'protein', 'antigen', 'is', 'experiencing', 'renewed', 'interest', 'So', 'far', 'selection', 'and', 'design', 'rationale', 'for', 'such', 'peptides', 'is', 'usually', 'driven', 'by', 'T', 'cell', 'epitope', 'prediction', 'available', 'experimental', 'and', 'modelled', '3D', 'structure', 'B', 'cell', 'epitope', 'predictions', 'such', 'as', 'hydrophilicity', 'plots', 'or', 'experience', 'If', 'no', 'structure', 'is', 'available', 'the', 'rational', 'selection', 'of', 'peptides', 'for', 'the', 'production', 'of', 'functionally', 'altering', 'or', 'neutralizing', 'antibodies', 'is', 'practically', 'impossible', 'Specifically', 'if', 'many', 'alternative', 'antigens', 'are', 'available', 'the', 'reduction', 'of', 'required', 'synthesized', 'peptides', 'until', 'one', 'successful', 'candidate', 'is', 'found', 'is', 'of', 'central', 'technical', 'interest', 'We', 'have', 'investigated', 'the', 'integration', 'of', 'B', 'cell', 'epitope', 'prediction', 'with', 'the', 'variability', 'of', 'antigen', 'and', 'the', 'conservation', 'of', 'patterns', 'for', 'post', 'translational', 'modification', 'PTM', 'prediction', 'to', 'improve', 'over', 'state', 'of', 'the', 'art', 'in', 'the', 'field', 'In', 'particular', 'the', 'application', 'of', 'machine', 'learning', 'methods', 'shows', 'promising', 'results', 'RESULTS', 'We', 'find', 'that', 'protein', 'regions', 'leading', 'to', 'the', 'production', 'of', 'functionally', 'altering', 'antibodies', 'are', 'often', 'characterized', 'by', 'a', 'distinct', 'increase', 'in', 'the', 'cumulative', 'sum', 'of', 'three', 'presented', 'parameters', 'Furthermore', 'the', 'concept', 'to', 'maximize', 'antigenicity', 'minimize', 'variability', 'and', 'minimize', 'the', 'likelihood', 'of', 'post', 'translational', 'modification', 'for', 'the', 'identification', 'of', 'relevant', 'sites', 'leads', 'to', 'biologically', 'interesting', 'observations', 'Primarily', 'for', 'about', '50', 'of', 'antigen', 'the', 'approach', 'works', 'well', 'with', 'individual', 'area', 'under', 'the', 'ROC', 'curve', 'AROC', 'values', 'of', 'at', 'least', '0', '65', 'On', 'the', 'other', 'hand', 'a', 'significant', 'portion', 'reveals', 'equivalently', 'low', 'AROC', 'values', 'of', '0', '35', 'indicating', 'an', 'overall', 'non', 'Gaussian', 'distribution', 'While', 'about', 'a', 'third', 'of', '57', 'antigens', 'are', 'seemingly', 'intangible', 'by', 'our', 'approach', 'our', 'results', 'suggest', 'the', 'existence', 'of', 'at', 'least', 'two', 'distinct', 'classes', 'of', 'bioinformatically', 'detectable', 'epitopes', 'which', 'should', 'be', 'predicted', 'separately', 'As', 'a', 'side', 'effect', 'of', 'our', 'study', 'we', 'present', 'a', 'hand', 'curated', 'dataset', 'for', 'the', 'validation', 'of', 'protectivity', 'classification', 'Based', 'on', 'this', 'dataset', 'machine', 'learning', 'methods', 'further', 'improve', 'predictive', 'power', 'to', 'a', 'class', 'separation', 'in', 'an', 'equilibrated', 'dataset', 'of', 'up', 'to', '83', 'CONCLUSION', 'We', 'present', 'a', 'computational', 'method', 'to', 'automatically', 'select', 'and', 'rank', 'peptides', 'for', 'the', 'stimulation', 'of', 'potentially', 'protective', 'or', 'otherwise', 'functionally', 'altering', 'antibodies', 'It', 'can', 'be', 'shown', 'that', 'integration', 'of', 'variability', 'post', 'translational', 'modification', 'pattern', 'conservation', 'and', 'B', 'cell', 'antigenicity', 'improve', 'rational', 'selection', 'over', 'random', 'guessing', 'Probably', 'more', 'important', 'we', 'find', 'that', 'for', 'about', '50', 'of', 'antigen', 'the', 'approach', 'works', 'substantially', 'better', 'than', 'for', 'the', 'overall', 'dataset', 'of', '57', 'proteins', 'Essentially', 'as', 'a', 'side', 'effect', 'our', 'method', 'optimizes', 'for', 'presumably', 'best', 'applicable', 'peptides', 'as', 'they', 'tend', 'to', 'be', 'likely', 'unmodified', 'and', 'as', 'invariable', 'as', 'possible', 'which', 'is', 'answering', 'needs', 'in', 'diagnosis', 'and', 'treatment', 'of', 'pathogen', 'infection', 'In', 'addition', 'we', 'show', 'the', 'potential', 'for', 'further', 'improvement', 'by', 'the', 'application', 'of', 'machine', 'learning', 'methods', 'in', 'particular', 'Random', 'Forests', '']"
204163,Diagnostics for SARS-CoV-2 detection: A comprehensive review of the FDA-EUA COVID-19 testing landscape,2020-07-18,Biosens Bioelectron,https://www.sciencedirect.com/science/article/pii/S0956566320304486?v=s5; https://doi.org/10.1016/j.bios.2020.112454; https://api.elsevier.com/content/article/pii/S0956566320304486,"The rapidly spreading outbreak of COVID-19 disease is caused by the SARS-CoV-2 virus, first reported in December 2019 in Wuhan, China. As of June 17, 2020, this virus has infected over 8.2 million people but ranges in symptom severity, making it difficult to assess its overall infection rate. There is a need for rapid and accurate diagnostics to better monitor and prevent the spread of COVID-19. In this review, we present and evaluate two main types of diagnostics with FDA-EUA status for COVID-19: nucleic acid testing for detection of SARS-CoV-2 RNA, and serological assays for detection of SARS-CoV-2 specific IgG and IgM patient antibodies, along with the necessary sample preparation for accurate diagnoses. In particular, we cover and compare tests such as the CDC 2019-nCoV RT-PCR Diagnostic Panel, Cellex's qSARS-CoV-2 IgG/IgM Rapid Test, and point-of-care tests such as Abbott's ID NOW COVID-19 Test. Antibody testing is especially important in understanding the prevalence of the virus in the community and to identify those who have gained immunity. We conclude by highlighting the future of COVID-19 diagnostics, which include the need for quantitative testing and the development of emerging biosensors as point-of-care tests.",10.1016/j.bios.2020.112454,3ejychjf,"['The', 'rapidly', 'spreading', 'outbreak', 'of', 'COVID', '19', 'disease', 'is', 'caused', 'by', 'the', 'SARS', 'CoV', '2', 'virus', 'first', 'reported', 'in', 'December', '2019', 'in', 'Wuhan', 'China', 'As', 'of', 'June', '17', '2020', 'this', 'virus', 'has', 'infected', 'over', '8', '2', 'million', 'people', 'but', 'ranges', 'in', 'symptom', 'severity', 'making', 'it', 'difficult', 'to', 'assess', 'its', 'overall', 'infection', 'rate', 'There', 'is', 'a', 'need', 'for', 'rapid', 'and', 'accurate', 'diagnostics', 'to', 'better', 'monitor', 'and', 'prevent', 'the', 'spread', 'of', 'COVID', '19', 'In', 'this', 'review', 'we', 'present', 'and', 'evaluate', 'two', 'main', 'types', 'of', 'diagnostics', 'with', 'FDA', 'EUA', 'status', 'for', 'COVID', '19', 'nucleic', 'acid', 'testing', 'for', 'detection', 'of', 'SARS', 'CoV', '2', 'RNA', 'and', 'serological', 'assays', 'for', 'detection', 'of', 'SARS', 'CoV', '2', 'specific', 'IgG', 'and', 'IgM', 'patient', 'antibodies', 'along', 'with', 'the', 'necessary', 'sample', 'preparation', 'for', 'accurate', 'diagnoses', 'In', 'particular', 'we', 'cover', 'and', 'compare', 'tests', 'such', 'as', 'the', 'CDC', '2019', 'nCoV', 'RT', 'PCR', 'Diagnostic', 'Panel', 'Cellex', 's', 'qSARS', 'CoV', '2', 'IgG', 'IgM', 'Rapid', 'Test', 'and', 'point', 'of', 'care', 'tests', 'such', 'as', 'Abbott', 's', 'ID', 'NOW', 'COVID', '19', 'Test', 'Antibody', 'testing', 'is', 'especially', 'important', 'in', 'understanding', 'the', 'prevalence', 'of', 'the', 'virus', 'in', 'the', 'community', 'and', 'to', 'identify', 'those', 'who', 'have', 'gained', 'immunity', 'We', 'conclude', 'by', 'highlighting', 'the', 'future', 'of', 'COVID', '19', 'diagnostics', 'which', 'include', 'the', 'need', 'for', 'quantitative', 'testing', 'and', 'the', 'development', 'of', 'emerging', 'biosensors', 'as', 'point', 'of', 'care', 'tests', '']"
204787,Aptamers in Diagnostics and Treatment of Viral Infections,2015-02-16,Viruses,https://www.ncbi.nlm.nih.gov/pubmed/25690797/; https://doi.org/10.3390/v7020751,"Aptamers are in vitro selected DNA or RNA molecules that are capable of binding a wide range of nucleic and non-nucleic acid molecules with high affinity and specificity. They have been conducted through the process known as SELEX (Systematic Evolution of Ligands by Exponential Enrichment). It serves to reach specificity and considerable affinity to target molecules, including those of viral origin, both proteins and nucleic acids. Properties of aptamers allow detecting virus infected cells or viruses themselves and make them competitive to monoclonal antibodies. Specific aptamers can be used to interfere in each stage of the viral replication cycle and also inhibit its penetration into cells. Many current studies have reported possible application of aptamers as a treatment or diagnostic tool in viral infections, e.g., HIV (Human Immunodeficiency Virus), HBV (Hepatitis B Virus), HCV (Hepatitis C Virus), SARS (Severe Acute Respiratory Syndrome), H5N1 avian influenza and recently spread Ebola. This review presents current developments of using aptamers in the diagnostics and treatment of viral diseases.",10.3390/v7020751,2hj8zzdh,"['Aptamers', 'are', 'in', 'vitro', 'selected', 'DNA', 'or', 'RNA', 'molecules', 'that', 'are', 'capable', 'of', 'binding', 'a', 'wide', 'range', 'of', 'nucleic', 'and', 'non', 'nucleic', 'acid', 'molecules', 'with', 'high', 'affinity', 'and', 'specificity', 'They', 'have', 'been', 'conducted', 'through', 'the', 'process', 'known', 'as', 'SELEX', 'Systematic', 'Evolution', 'of', 'Ligands', 'by', 'Exponential', 'Enrichment', 'It', 'serves', 'to', 'reach', 'specificity', 'and', 'considerable', 'affinity', 'to', 'target', 'molecules', 'including', 'those', 'of', 'viral', 'origin', 'both', 'proteins', 'and', 'nucleic', 'acids', 'Properties', 'of', 'aptamers', 'allow', 'detecting', 'virus', 'infected', 'cells', 'or', 'viruses', 'themselves', 'and', 'make', 'them', 'competitive', 'to', 'monoclonal', 'antibodies', 'Specific', 'aptamers', 'can', 'be', 'used', 'to', 'interfere', 'in', 'each', 'stage', 'of', 'the', 'viral', 'replication', 'cycle', 'and', 'also', 'inhibit', 'its', 'penetration', 'into', 'cells', 'Many', 'current', 'studies', 'have', 'reported', 'possible', 'application', 'of', 'aptamers', 'as', 'a', 'treatment', 'or', 'diagnostic', 'tool', 'in', 'viral', 'infections', 'e', 'g', 'HIV', 'Human', 'Immunodeficiency', 'Virus', 'HBV', 'Hepatitis', 'B', 'Virus', 'HCV', 'Hepatitis', 'C', 'Virus', 'SARS', 'Severe', 'Acute', 'Respiratory', 'Syndrome', 'H5N1', 'avian', 'influenza', 'and', 'recently', 'spread', 'Ebola', 'This', 'review', 'presents', 'current', 'developments', 'of', 'using', 'aptamers', 'in', 'the', 'diagnostics', 'and', 'treatment', 'of', 'viral', 'diseases', '']"
